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Nile tilapia, Oreochromis niloticus, is one of the most important farmed fish globally. One 
of the most serious bacterial diseases constraining global tilapia production is 
Francisellosis caused by Francisella noatunensis subsp. orientalis (Fno). Although 
outbreaks of Fno are increasing worldwide, there are no licenced commercial vaccines to 
prevent the disease for use on tilapia farms. Thus, the current treatment of choice is the use 
of antibiotics combined with increasing water temperature up to 30°C. Studies 
investigating the diversity of circulating Fno isolates and the immune response of tilapia 
elicited by vaccination against piscine francisellosis are lacking. In addition, the current 
conventional and molecular tools used for detection of Fno have many drawbacks, making 
detection of Fno a challenging process.  
  In this study, five clinical isolates of Fno from diverse geographical locations (UK, 
Costa Rica, Mexico, Japan and Austria), previously characterised by morphology, 
genotype, antimicrobial susceptibility and virulence, were used in a proteomic study. The 
whole proteomic cell profile of the five isolates were homogenous by one-dimension 
sodium dodecyl polyacrylamide gel electrophoresis (1D-SDS-PAGE), while minor 
differences in the intensity of 15 proteins between the strains were observed by two-
dimension SDS-PAGE (2DE), including some important virulence related proteins. The 
UK isolate was the most significantly different isolate when compared to the other Fno 
isolates in the current study. The Fno UK isolate had significantly higher abundance of 
10/15 of the significantly expressed proteins including four of the essential pathogenicity 
and virulence related proteins (IglC, GroEL, DnaK, ClpB) compared to the other used Fno 
isolates. The antigenic profiles of the five Fno isolates were studied by 1D western 
blotting using tilapia hyper immune sera which recognised an immunodominant band of a 
molecular weight of ~ 17-28 kDa in all tested Fno isolates. Liquid chromatography-
electrospray ionization-tandem mass spectrometry (LC/ESI/MS/MS) identified 47 proteins 
in this antigenic band. Some of the identified proteins are associated with Fno 
pathogenicity. 2D western blot analysis of the vaccine isolate (Fno UK) revealed 
differential antigen recognition between sera from vaccinated and non-vaccinated fish 
following experimental challenge (26 antigenic spots recognised by sera from vaccinated 
fish; 31 antigenic spots recognised by sera from vaccinated and challenged fish and 30 
antigenic spots recognised by non-vaccinated and challenged fish). The identity of these 
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proteins was determined by matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF-MS) and some of them are known Francisella virulence 
related proteins. Bioinformatics analyses revealed diverse categories of proteins with high 
biological functions, however the vast majority of these proteins are involved in energy 
production and metabolic pathways of the bacteria. This detailed analysis will facilitate the 
development of cross-strain protective subunit Fno vaccines and antigen-targeted Fno 
diagnostics. 
The outer membrane proteins (OMPs) of the same five Fno isolates were extracted 
using the ionic detergent sarkosyl. The OMP fraction of the different isolates were 
separated via 1D-SDS PAGE and the digested peptides of the UK isolate were analysed by 
LC/ESI/MS/MS. High degree of similarity was observed in the OMP profile of the five 
Fno isolates with an abundant protein band at 17-28 kDa, which was found to be antigenic 
by 1D western blot using convalescent tilapia sera. LC/ESI/MS/MS analysis of the OMPs 
of the Fno UK isolate identified 239 proteins, including 44 proteins in the antigenic band 
(17-28 kDa). Comparison between the proteins identified in the immunogenic band of 
whole cell lysate and OMP fraction of the Fno UK isolate showed 30 common proteins 
between the two preparations, 17 proteins were identified only in the whole cell extract 
and 14 were identified only in OMP fraction. Outer membrane proteins (e.g. Omp-A), 
virulence related proteins such (e.g. IglC) and other stress related proteins (e.g. AhpC/TSA 
family peroxiredoxin) were more abundant in the OMP fraction than the whole cell lysate. 
In silico analysis enabled prediction of the function and location of the OMPs identified by 
Mass-spectrometry. The findings of this study provide preliminary data on bacterial 
surface proteins that exist in direct contact with the host immune defence during infection 
and offering an insight into their potential role as novel targets for Fno diagnostics and 
vaccine development.  
The efficacy of an injectable whole cell oil-adjuvanted vaccine was evaluated 
against challenge with heterologous Fno isolates in Nile tilapia, Oreochromis niloticus. 
Three duplicate groups of 130 healthy Nile tilapia (~15 g) were intraperitoneally (i.p.) 
injected with the vaccine, adjuvant-alone or PBS followed by an i.p. challenge with three 
Fno isolates from geographically distinct locations. The vaccine provided significant 
protection to all immunised tilapia groups with a significantly higher relative percent 
survival (RPS) of 82.3% against homologous challenge, compared to 69.8% and 65.9% 
Abstract 
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after heterologous challenge. Protection correlated with significantly elevated specific 
antibody responses and western blot analysis demonstrated cross-isolate antigenicity with 
sera from fish post-vaccination and post-challenge. Moreover, a significantly lower 
bacterial burden was detected by quantitative real-time polymerase chain reaction (qPCR) 
in conjunction with significantly greater expression of IgM, IL-1β, TNF-a and MHCII 72 
hours post-vaccination (hpv) in spleen samples from vaccinated tilapia compared to those 
of adjuvant-alone and control fish. The latter results suggested stimulation of protective 
immune responses following vaccination.  
In addition, a whole cell formalin killed autogenous immersion vaccine against Fno 
was developed using the same isolate used for the injectable vaccine. Duplicate tanks of 35 
tilapia fry were immersed in the vaccine or in sterile Modified Muller Hinton broth 
(MMHB) diluted in tank water (1:10 dilution) for 30 s and at 30 days post-vaccination 
(dpv), all fish groups were immersion challenged with the homologous Fno isolate and 
monitored for 21 days. A moderate RPS of 43.7% was provided by the vaccine. Serum 
IgM levels were below the threshold in 30 % of the vaccinated fry 30 dpv. Also, the IgM 
levels of the vaccinated fry were not significantly different from control fry 21 days-post 
challenge.  
A recombinase polymerase amplification (RPA) assay was developed and 
validated for rapid detection of Fno. The RPA reaction was performed at a constant 
temperature of 42°C for 20 min. The RPA assay was performed using a quantitative 
plasmid standard containing a unique Fno gene sequence. Validation of the assay was 
performed not only by using DNA from Fno, closely related Francisella species and other 
common bacterial pathogens in fish farms, but also by screening 78 Nile tilapia and 5 
water samples collected from UK and Thailand. All results were compared with those 
obtained by previously established real-time qPCR. The developed RPA showed high 
specificity in detection of Fno with no cross-detection of either the closely related 
Francisella spp. or the other species of bacteria tested. The Fno-RPA performance was 
highly comparable to the published qPCR with detection limits at 15 and 11 DNA 
molecules detected, respectively. The Fno-RPA was rapid, giving results in approximately 
6 min in contrast to the qPCR that required approximately 90 min to reach the same 
detection limits. Moreover, the RPA was more tolerant to reaction inhibitors than qPCR 
when tested with field samples. The fast reaction, simplicity, cost-effectiveness, sensitivity 
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and specificity make the RPA an attractive diagnostic tool that will contribute to control 
the infection through prompt on-site detection of Fno. 
The overall results of this study indicated that Fno isolates from different origins 
share a high degree of homology in their proteomic and antigenic profile. Proteomic 
characterisation data of Fno isolates has contributed to understanding the diversity of Fno 
isolates and assisted in identifying suitable candidates for developing an effective Fno 
vaccine. Moreover, this study has proven the efficacy of a cross protective Fno injection 
vaccine in tilapia fingerlings, with further optimisation needed for immersion vaccination 
of fry, and given insights into the immune response of tilapia to vaccination against 
francisellosis. In addition, it provided a rapid, sensitive, specific and robust molecular tool 
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1.1. Tilapia aquaculture 
1.1.1. History of tilapia aquaculture 
Tilapia is the common name for nearly a hundred species of freshwater and some brackish 
water fish belonging to the Cichilidae family. This large family of tropical fish is widely 
distributed throughout waters of Africa, the Middle East, coastal India, South East Asia, 
Central and South America. Although they are exotic to the USA, populations of tilapia 
are now established in Arizona, California, Hawaii, Florida, Nevada, North Carolina, and 
Texas. The tribe “Tilapiini”, to which tilapias belong, emerged from Africa and Palestine 
(Jordan and coastal rivers), however, they have now been distributed worldwide. The most 
valuable commercial species are the Mozambique or Java tilapia (Oreochromis 
mossambicus), blue tilapia (Oreochromis aureus), Nile tilapia (Oreochromis niloticus), 
Zanzibar or Wami tilapia (Oreochromis hornorum), and the red-belly tilapia (Oreochromis 
zilli) (Sell, 1993; Chapman, 2009). 
 The culture of tilapia (especially Nile tilapia) can be traced back to ancient 
Egyptian times as depicted on bas-relief from Egyptian tombs dating over 4000 years ago, 
which showed the fish held in ornamental ponds. While significant worldwide distribution 
of tilapia, primarily O. mossambicus, occurred during the 1940s and 1950s, distribution of 
the more desirable Nile tilapia occurred during the 1960s up to the 1980s. Nile tilapia from 
Japan were introduced to Thailand in 1965, from where they were exported to the 
Philippines. Tilapia were introduced from the Ivory Coast to Brazil in 1971 from where 
they were exported to the United States in 1974 and in 1978 Nile tilapia were introduced to 
China (FAO, cultured aquatic species information programme, Oreochromis niloticus, 
(Linnaeus, 1758)). Currently, China is the top tilapia producer with production of 1.8 
million tonnes, whilst production ranges from 57,000 – 1.1 million tonnes throughout 
Asia, South America and Africa. The top ten producers are shown in Figure 1.1. 
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Nile tilapia were the major cultured species of tilapia between 1956-2002 
representing 80% of total tilapia production, followed by Mozambique tilapia (3.6%). 
Besides the previously mentioned species, a minor contribution to tilapia production 
occurs in different countries for three spotted tilapia: blue tilapia, red breast tilapia and 
long fin tilapia (El-Sayed, 2006). Recently, Nile tilapia and hybrid red tilapia represent the 
most common species of tilapia used in aquaculture (Alston, 2009), where Nile tilapia 
ranks 6th among the most important cultured species, providing food, jobs and domestic 
and export industries for many people globally. The global production of tilapia was 
estimated to be 5.67 million tons with a value of USD ~ 7.5 billion in 2015 and is expected 
to reach 7.3 million tons by 2030 (FAO, 2017).  
 The wide use of tilapia in aquaculture can be attributed to many factors, including 
general hardiness, high tolerance to adverse environmental conditions, resistance to 
disease and their ability to withstand low oxygen conditions and a wide range of salinity 
(El-Sayed, 2006). Moreover, tilapia can grow and survive on a wide range of natural and 
artificial feeds, convert food efficiently, grow at a relatively fast rate and are attractive to a 
wide range of consumers due to their low cost and protein-rich meat (Ng and Romano, 
2013). Furthermore, tilapia can be grown in a variety of culture systems ranging from 
simple systems with little infrastructure to more intensive and complex systems. Their 
uncomplicated biology, feeding and veterinary requirements have made them a favoured 
species for aquaculture (El-Sayed, 2006).  
1.1.2. Production of tilapia on farms 
The tilapia production cycle consists of three main stages, (i) spawning and hatchery stage: 
which includes spawning of the brood fish, fertilization by males and incubation of the 
fertilized eggs collected from the mouth of brood female till hatching new stock of fry, (ii) 
nursery stage: which includes production of fingerlings from the newly hatched fry, and 
(iii) grow-out stage: that includes rearing of fingerlings till reaching the desired marketable 
size (Little et al., 2003). The production cycle of farmed tilapia in most of the tropical 
regions takes 4- 6 months (Liu et al., 2016), however, it may be extended to 8- 9 months to 
produce larger marketable size fish (> 700 g). The production cycle of tilapia on farms is 
shown in Figure 1.2. 
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1.1.3. Diseases in tilapia aquaculture 
Infectious diseases represent one of the major constraints to development of aquaculture 
world-wide. Diseases caused serious economic losses to finfish aquaculture globally that 
were estimated at US $ 1.05 to US $ 9.58 billion per year (Shinn et al., 2015). Diseases in 
fish not only cause mortality and morbidity, but also reduce market value, growth 
performance and feed conversion in fish. In addition, costs of purchasing chemicals and 
medicines to treat these diseases represent a significant issue to the aquaculture industry 
(Paul, 2014).  
With extensive tilapia farming, these fish have shown high resistance to infection 
when reared under properly controlled and managed conditions ensuring good water 
quality, suitable temperatures and proper husbandry practices. In contrast, as a result of 
intensification of culture systems (ponds, cages, raceways or recirculating systems), poor 
water quality and adverse environmental conditions, especially water temperature or 
improper handling, have exacerbated the impact of diseases (Plumb and Larry, 2010).  
Tilapia aquaculture has been affected by a diverse pool of diseases caused by viral, 
bacterial, parasitic and fungal pathogens (Shlapobersky et al., 2010), of which the bacterial 
diseases constitute the most significant threat to the future growth and sustainability of 
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Table 1.1. Major pathogens in tilapia aquaculture 








1- Aeromonas hydrophila 
2- Edwardisella tarda 
3- Flavobacterium columnare 
4- Francisella noatunensis subsp. orientalis 
(Fno) 
5- Lactococcus garvieae 
6- Plesiomonas spp. 
7- Pseudomonas spp. 
 
8- Streptococcus agalactiae, S. iniae 
 
9- Vibrio spp. 
Maluping et al., (2005) 
Soto et al., (2012b)  
Eissa et al., (2010) 
Soto et al., (2009a) 
 
Evans et al., (2009) 
Maluping et al., (2005) 
Thomas et al., 2014  
Pereira et al., (2010) 
Shoemaker et al., 2001 
 






2-Iridovirus (Spinning tilapia syndrome)  
3-Nodavirus (Viral Nervous Necrosis, VNN 
or viral encephalopathy and retinopathy 
(VER)) 
4-Tilapia Lake virus (TiLV) 
Ariel and Owens, (1997) 
ShaoWen et al., (2003) 
Shlapobersky et al., 
(2010) 
Sinyakov et al., (2011) 
Nicholson et al., (2017) 
Behera et al., (2018) 





1- Amyloodinium ocellatum  
2- Cymothoa spp.  
3- Diplostomum compactum  
4- Icthyophthirius multifilis 
5- Piscinoodinium pillulare  
6- Spironucleus spp.  
7- Trichodina spp.  
 
El-Dien and Abdel-
Gaber, (2009)  
Abd El-Galil and 
Aboelhadid, (2012) 









1.1.4. Francisellosis in tilapia 
1.1.4.1. Taxonomy of the aetiological agent 
Francisella is an intracellular bacterium belonging to class Gammaproteobacteria, 
order Thiotrichales and it represents the family Francisellaceae with the newly classified 
Allofrancisella genus (Colquhoun and Duodu, 2011; Qu et al., 2016). Francisella genus 
includes many species and subspecies of clinical importance to humans (Oyston et al., 
2005; Foley and Nieto, 2010), terrestrial animals (Cora et al., 2010; Hotta et al., 2016) and 
fish (Colquhoun et al., 2014). In humans, the most important Francisella species are F. 
tularensis (Ft) that causes tularemia which is a fatal disease that has been categorised as a 
potential bioweapon due to high infectivity and multiple infection routes (Keim et al., 
2007), and F. philomiragia (Fp) that also affects other animals causing a serious 
granulomatous disease (Hollis et al., 1989). Francisella tularensis includes four 
subspecies, F. tularensis subsp. tularensis, F. tularensis subsp. mediasiatica, F. tularensis 
subsp. holarctica and F. tularensis subsp. novicida (Oyston et al., 2005; Foley and Nieto, 
2010). In aquatic organisms, francisellosis is mainly caused by F. noatunensis subsp. 
noatunensis (Fnn) in cold water fish species, F. noatunensis subsp. orientalis (Fno) in 
warm water fish species or F. halioticida (Fh) in mollusca (Colquhoun and Duodu, 2011). 
Recently, a novel strain of Francisella was isolated from cultured spotted rose snapper 
(Lutjanus guttatus) in Central America and recognised as Francisella marina sp. nov. 
based on its phenotypic and genotypic differences from other Francisella spp. (Soto et al., 
2018)   
Fno is a Gram negative, encapsulated, pleomorphic or cocco-bacilli, non-motile 
bacterium ranging from 0.7 – 1.7 µm (0.57± 0.1 µm x 0.8 ± 0.2 µm) (Figure 1.3A) (Mauel 
et al., 2005; Mikalsen and Colquhoun, 2009). It is a fastidious, slow growing aquatic 
pathogen that cannot be cultured on ordinary media commonly used in bacteriological 
diagnosis of fish pathogens but requires high levels of cysteine and glucose to grow 
(Colquhoun and Duodu, 2011). It is strictly aerobic, and the optimum incubation 
temperature is in the range of 22- 28°C (maximum 30°C), where it takes 3- 4 days for 
growth, but it cannot grow at 37°C (Soto et al., 2009a). The colonies appear convex, 
smooth, semi-translucent mucoid grey, pale white, green or even bluish with a maximum 
diameter of 1mm (Figure 1.3B).  
 
                                                                                                                      Chapter One 
 
 














Figure 1.3. Morphological and cultural characters of Fno. (A) Gram-negative cocco-
bacilli Fno isolated from infected Nile tilapia spleen, LM 100x. (B) colony morphology 
of Fno on CHAH. The colonies appear convex, smooth, semi-translucent mucoid grey 








Studies on Francisella pathogenesis have revealed that these bacteria have various 
mechanisms that facilitate their ability to survive and replicate not only in the 
extracellualar environment but also inside eukaryotic cell, in particular those cells 
belonging to monocytes or macrophage lineage or other cells like neutrophils and B-cells 
(Soto et al., 2010b; Furevik et al., 2011; Vestik et al., 2012 Celli and Zahrt, 2013; Brudal 
et al., 2014; Lagos et al., 2017). In tilapia and zebra fish (Danio rerio), head kidney 
derived macrophages (HKDM) represent the primary dwelling for Fno, where it can 
replicate within 72 hours post-infection (hpi), inducing inhibition of phagocytic activity, 
apoptosis, cytotoxicity and can also resist serum killing activity (Soto et al., 2010a; Lagos 
et al., 2017). The localisation of Francisella in phagosomes induces alteration in 
phagosomal maturation, causing arresting of the phagosome in the late maturation stage 
(Lai et al., 2001; Clemens et al., 2004). Once the bacteria are engulfed by host cell 
phagosomes, the phagosomal membrane is disrupted allowing escape of the bacteria into 
the cytoplasm and giving opportunity for massive multiplication (Golovliov et al., 2003). 
Furthermore, Francisella decrease the acidity of the phagosome by recruitment of vacuolar 
ATPase that exacerbates weakness of the invaded cells that can then be easily disrupted 
and facilitate escape of the bacteria to adjacent cells or into the cytoplasm, where the 
bacteria can replicate to produce high numbers of bacterial cells (Golovliov et al., 2003; 
Huynh and Grinstein, 2007). The process of recognition of the bacterial pathogen 
associated molecular patterns (PAMPs) by toll-like receptors (TLRs) orchestrates the 
caspase-1 activity that in turn triggers release of pro-inflammatory cytokines including IL-
1 b and IL-18 and consequently cell death (Celli and Zahrt, 2013).  
The main promoter of Francisella virulence and intracellular survival machinery is 
the iglABCD operon which is found as part of the 30 Kb pathogenicity island (also known 
as Francisella pathogenicity island or FPI) that has been identified in all reported 
Francisella spp. genomes (Sjödin et al., 2012; Sridhar et al., 2012; Celli and Zahrt, 2013).  
This important locus in FPI with the help of other determinant factors (e.g. MglA and 
MglB) was reported to encode a type six secretion system (T6SS) that orchestrates 
entrance, survival and proliferation of Francisella within host cells (Brotcke et al., 2006, 
Santic e al, 2005; 2006; de Bruin et al., 2007; Nano and Schmerk, 2007; Chong et al., 
2008). Studies have revealed that any mutation in the core components of T6SS system 
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will adversely affect the ability of the bacterium to escape the phagosome and replicate 
intracellularly (Bröms et al., 2012a;b). Nevertheless, comparison of the iglABCD operon 
DNA sequence revealed that F. noatunensis subsp. orientalis had percentage identities of 
94% and 83% with F. philomiragia subsp. philomiragia and F. tularensis subsp. novicida, 
respectively (Soto et al., 2009b).  
The roles and functions of the genes of the FPI and their regulators in Fno are not 
fully understood and most of our understanding of these genes comes from studies on 
human parasitic Francisella including F. novicida and F. tularensis (Nano et al.,2004; 
Chou et al., 2013). In addition, there is little information available about the effect of 
mutation of FPI components on virulence of Fno. The iglC gene is one of the highly 
expressed genes during the intracellular growth phase of Francisella (Nano and Schemark, 
2007). It has been found that iglC is important in Fno for induction of disease and 
intramacrophage survival in tilapia (Soto et al., 2009b; 2010b). Mutation of the iglC gene 
impeded Fno replication, cytotoxicity and apoptosis to tilapia HKDM, but did not affect 
complement lysis activity. Survival rates of 50 % and 100% were reported after immersion 
challenge with Fno wild type and Fno-iglC mutant strains, respectively (Soto et al., 2009b, 
2010a). PdpA is one of the genes that had been described in Fno FPI (Hansen et al., 2013). 
In F. tularensis it is involved in intreacellular growth and survival (Schmerk et al., 2009), 
however, its role in Fno is unknown. Mutation of pathogenicity determinant protein A 
gene (pdpA) opposed Fno virulence in a zebrafish model, Dario rerio (Hansen et al., 
2013). In addition, two Fno-pdpA mutant strains showed higher LD50 (>2×106 CFU/mL) 
and lower resistance to oxidative stress using hydrogen peroxide (H2O2) compared to the 
wild type that displayed lower LD50 (891 CFU/mL) and more resistance to killing by H2O2 
in an immersion challenge in hybrid red tilapia (Farrell, 2015). This study suggested that 
pdpA gene may contribute to the virulence of Fno, however, further studies are required to 
investigate this hypothesis.   
Little is known of the immunopathological response of Francisellosis in fish. The 
lipo-oligo-polysaccharide residues (LOP-antigens) in the cell wall of Francisella play an 
important role in its interaction with innate immune elements by enabling the bacterial 
cells to impede recognition by host antibodies, complement or TLRs and dampen the pro-
inflammatory responses (Chase et al., 2009; Zarrella et al., 2011). The lipo-





challenging of macrophages in cod. Upregulation of IL-10 indicates stimulation of helper 
T-cell type 2 (Th2) response (Bakkemo et al., 2011). One of the key factors for 
Francisella virulence is their ability to disrupt reactive oxygen species (ROS) generation 
following phagocytosis by inhibition of NADPH oxidase that limits the activity of 
phagocytes (e.g. polymorphonuclear cells (PMNs), monocytes) and fosters the survival of 
Francisella (Celli and Zahrt, 2013). Moreover, previous studies reported that Francisella 
requires iron (Fe) for maintenance and growth and consequently virulence. Francisella 
genome contains certain regions (fsL locus and fopA locus), which encode components for 
production, release and capture of polycarboxylate siderophores responsible for uptake of 
ferric ions (Sullivan et al., 2006).  
1.1.4.3. Epizootiology, risk factors and transmission  
Francisellosis is a highly epizootic disease of tilapia species that can be found in all sizes 
and stages, ranging from small fingerlings to adult broodstock. Morbidity rates of 100% 
and mortality rates ranging from 5 to 95% were reported in cultured Nile tilapia reflecting 
the scale of the disease as a major threat to global tilapia farming (Colquhoun and Duodu, 
2011; Ortega et al., 2016; Sebastião et al., 2017). The disease is characterised by high 
infectivity where as few as 23 colony forming units (CFU) of Fno could induce the disease 
by intraperitoneal injection in tilapia (Soto et al., 2009b) and 32 CFU of F. halioticida 
caused 100% mortality by intramuscular injection in abalone (Kamaishi et al., 2010).  
There are many factors that favour the occurrence of francisellosis in tilapia and 
other warm water fish species. Water temperature is considered a determining factor in 
initiation of the clinical symptoms and provokes mortality rates in the affected fish (Mauel 
et al., 2007). The disease frequently occurs in cooler months (October to April) in which 
the low temperature exacerbates stress and consequently increases the chance of disease 
incidence. The favourable temperature for occurrence of Fno is between 21.5°C to 26.5°C. 
(Mauel et al., 2005; Colquhoun and Duodu, 2011). In an experimental challenge, the 
disease could be established either by i.p. injection or immersion at temperatures of 23-
25°C (Soto et al., 2009a; 2013b). Soto et al. (2012a) reported that fish maintained at 25°C 
showed considerably higher mortality rates (66.6 ± 11.8 %) and splenic bacterial burden 
(5.26 ± 0.6 log CFU/mg of spleen) after 2 weeks of immersion challenge with Fno in 
contrast with fish maintained at 30°C which showed lower mortality (46.6 ± 7.20 %) and 
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lower bacterial splenic concentration (3.15 ± 0.9 log CFU/mg of spleen). In addition, 
stocking density has an obvious effect on the incidence of Fno, where transmission of the 
disease was significant on tilapia farms with elevated biomass within the system, that 
consequently increases the level of waste and favours the horizontal transmission by 
greater contact between fish (Jeffery et al., 2010, Ortega et al., 2016). Fish stress by 
constant handling was also reported as a predisposing factor for the occurrence of Fno in 
farmed tilapia (Mauel et al., 2003; 2007; Soto et al., 2009a; Ortega et al., 2016).  
The horizontal mode of transmission of francisellosis in tilapia is considered the 
most common route of infection either by water borne transmission or direct contact 
between infected and/or dead fish and healthy fish (Mauel et al., 2003; Soto et al., 2009a; 
Jeffery et al., 2010). Recently, it was found that vertical transmission of Fno through 
gametes can occur, where Fno was detected in 6/10 crossed families using Loop Mediated 
Isothermal Amplification (LAMP) in milt, roe, fertilised and non-fertilised eggs at 
different developmental stages of tilapia after in vitro fertilisation (Pradeep et al., 2016). In 
addition, detection of Fno was reported in gonads of non-symptomatic tilapia, indicating 
its ability to transmit vertically from infected broodstock to their off-spring (Soto et al., 
2013b; Pradeep et al., 2016). Asymptomatic carrier farmed, or ornamental fish have been 
suggested to play a role in transmission of Francisella species. This finding was 
exemplified in detection of Fno in farmed tilapia and Indo-Pacific reef fish such as fairy 
wrasses (Cirrhilabrus spp.) and blue-green damselfish (Chromis viridis) in USA, where 
importing of either farmed tilapia fry or other ornamental cichlids could establish the 
infection in these susceptible hosts (Soto et al., 2011a; Camus et al., 2013).       
1.1.4.4. Host range and geographical distribution 
Piscine francisellosis has emerged as a significant problem in a wide range of hosts 
(Colquhoun and Duodu 2011). Until now, there is no definite list of susceptible hosts or 
vectors for piscine francisellosis. The disease has so far been recorded in fresh and marine 
water, wild and cultured fish and vertebrate and non-vertebrate aquatic species. The 




























Figure 1.4. A schematic map of the world distribution of piscine francisellosis.   
 
Francisella noatunensis subsp. orientalis
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 Previous studies have demonstrated that fish francisellosis can be attributed to 
either Francisella noatunensis subsp. orientalis (Fno) that affects mainly warm water fish 
or Francisella noatunensis subsp. noatunensis (Fnn) that affects mainly cold-water fish 
(Ostland et al., 2006; Mikalsen and Colquhoun, 2009; Ottem et al., 2009; Colquhoun et 
al., 2014). Fnn had been identified in the North Sea and northern Atlantic area, where it 
was recovered from wild and farmed Atlantic Cod (Gadus morhua) in Norway (Nylund et 
al., 2006; Olsen et al., 2006; Mikalsen et al., 2007; Ottem et al., 2007, 2008) and in wild-
caught adult Celtic sea Atlantic cod and juveniles reared in captivity in Ireland (Ruane et 
al., 2015). It was also identified in cultured Atlantic salmon (Salmo salar) in Chile 
(Birkbeck et al., 2007; Bohle et al., 2009). Fno has been identified in many warm water 
fish, however tilapia species are the most affected with outbreaks reported in many 
localities worldwide, such as Taiwan (Chen et al., 1994; Hseih et al., 2006), continental 
United States including Hawaii (Mauel et al., 2003; Soto et al., 2013a), Florida, California 
and south Carolina (Mauel et al., 2005), Latin America (Mauel et al., 2007), Costa Rica 
(Soto et al., 2009a), U.K. (Jeffery et al., 2010), Thailand (Nguyen et al., 2016), China 
(Qiang et al., 2016), Brazil (Leal et al., 2014; Sebastião et al., 2017; Rodrigues et al., 
2017) and Mexico (Ortega et al., 2016). Spotted rose snapper (Lutijanus guttatus) cultured 
in Pacific coast of Central Americas was recently found to be susceptible to a novel strain 
of Francisella spp. proposed as Francisella marina sp. nov. The diseased fish showed 
non-specific external signs, severe granulomatous inflammation and mortality was 
estimated at 3-8 % (Soto et al., 2018).    
 Moreover, Fno has been transmitted through the ornamental fish trading between 
countries, where it was isolated from Indo-Pacific reef fish imported from Asia to the 
United States (Camus et al., 2013), French grunt (Haemulon flavolineatum) and the Caesar 
grunt (Haemulon carbonarium) in Florida, USA (Soto et al., 2014b) and Ornamental 
African cichlids in Austria (Lewisch et al., 2014). Outbreaks of francisellosis were seldom 
detected in cultured hybrid striped bass (Morone chrysops x M. saxatilis) in USA (Ostland 
et al., 2006) and three-line Grunt (Parapristipoma trilineatum) in Japan where it caused 
mass mortality among cultured stocks (Fukuda et al., 2002; Kamaishi et al., 2005). In 
shellfish, francisellosis was recorded in two farmed species of giant abalone Haliotis 
gigantea and Haliotis discus in Japan and the causative pathogen was classified as 





bacterial isolates resulted in a very high mortality (98.6%) confirming the suspected 
susceptibility of abalone and other bivalves to francisellosis (Brevik et al. 2011a).  
Studies of the susceptibility of other fish species to francisellosis have been 
performed. Lewish et al. (2016) performed intraperitoneal (i.p.) challenge using Fno at 
doses of 2 × 106 CFU/mL, 2 × 107 CFU/mL and 2 × 108 CFU/mL in sun fish (Lepomis 
giobosus) and common carp (Cyprinus carpio). Interestingly, the sun fish were susceptible 
to the infection, where mild splenomegaly and renomegally were observed and the highest 
mortality reached 56.1 % after 96 hpi, while the carp were resistant. PCR analysis showed 
positive results in 63.8 % and 12.2 % in the challenged sun fish and carp, respectively. In a 
similar experiment, Fno was i.p. injected at a dose of 1.5 × 106 CFU/mL into striped 
catfish (Pangasianodon hypophthalmus) and carp. Both fishes were resistant with no 
mortalities or histopathological features of francisellosis. Paradoxically, 50 % and 100 % 
of the surviving striped catfish and carp were positive for Fno by PCR, respectively (Dong 
et al., 2016b).  
1.1.4.5. Genetic diversity of fish Francisella 
Analysis of the 16S rRNA gene sequence of Francisella isolates retrieved from 
different fish species revealed that these isolates can fall into two distinct clades. Clade I 
represented by Fnn, which was found in conjunction with disease in Norwegian cod and 
Chilean salmon and Clade II represented by Fno, which induces the disease in tilapia spp., 
ornamental cichlids and three-line grunt. These studies showed that the fish-pathogenic 
Francisella members share a high degree of homology with F. philomiragia (Fp) which 
induces disease in immunocompromised humans and other animals (Birkbeck et. al., 
2011). The average nucleotide identity (ANI) of DNA sequence of Fno with that of F. 
philomiragia was found to be up to 98.6 % and for Fnn it was 99.3 % based on the 16S 
rRNA gene sequence, and 92.9-99 % based on similarities in other nucleotide sequences 
from 5 housekeeping genes including groEL, pgm, shdA, rpoA and rpoB (Mikalsen and 
Colquhoun, 2009; Mikalsen et al., 2007). Furthermore, comparison between Fnn isolates 
from Norwegian cod and Chilean salmon revealed that the percentage identity of 16S 
rRNA gene sequences was about 99.8% (Birkbeck et al., 2011) and the nucleotide 
percentage identity of six housekeeping genes was 99.5 %. Sequencing of the 16S rRNA 
gene and housekeeping genes of Francisella retrieved from Giant abalone in Japan and 
comparisons with genes of F. philomiragia and F. noatunensis subsp. noatunensis showed 
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that it was genetically different, with percentage identities of 49.2% with F. philomiragia 
and 61% with F. noatunensis subsp. noatunensis, respectively. Thus, it was established as 
a new species under the name F. halioticida sp. nov. (Brevik et al., 2011a).    
In addition, Brevik et al. (2011b) used multi-locus variable number of tandem 
repeats (VNTR) analysis (MLVA) to study the genetic diversity of Francisella sp. isolates 
including 22 isolates of F. noatunensis subsp. noatunensis retrieved from Norwegian 
farmed cod (n= 17), Norwegian wild cod (n= 4) and Chilean farmed salmon (n= 1), 4 
isolates of F. noatunensis subsp. orientalis retrieved from Indonesian farmed Nile tilapia 
(n= 3) and Japanese three-line grunt, P. trilineatum (n= 1) and 7 isolates of F. 
philomiragia from human (n= 3), water (n= 1) and aquatic mammals (n= 3). A sequence-
based system was performed on seven VNTR-loci and the results indicated a low allelic 
diversity in isolates retrieved from francisellosis outbreaks in cultured fish, and only two 
allelic profiles were seen in wild fish. Isolates from infected Chilean salmon showed 
differences in 6 out of 7 markers from those in infected Norwegian cod strains, which 
reflected the differences in their geographical and ecological origins and also in their host 
divergence. Moreover, the allelic profiles of Fno and Fp isolates were unique and easily 
separated. An improved simplified MLVA targetting five highly polymorphic VNTR loci 
in a single multiplex PCR was developed by Duodu et al. (2013) that resulted in 
identification of at least 13 allelic profiles of 91 isolates of Fnn from Atlantic cod in 
Norway. The data obtained from the MLVA showed that the source of francisellosis in 
cultured cod could be of human origin and provides a promising tool for typing of Fnn and 
studying francisellosis epizootics in fish.   
In a similar study, the genetic fingerprinting of 62 locally isolated Fno isolates 
retrieved from natural outbreaks in Nile tilapia cage farms in Brazil between 2012-2013 
were studied by repetitive element palindromic polymerase chain reaction (REP-PCR) and 
results showed that all the isolates were clonally related, despite being collected from 
different locations (Leal et al., 2014). Recently, Ramirez-Paredes et al. (2017b) performed 
phylogenetic analyses of 5 Fno isolates from different locations using 11 house-keeping 
and core genes (16SrRNA,16SrRNA-23S rRNA intergenic spacer (ITS), 23S rRNA, mdh, 
dnaA, mutS, prfB, putA, rpoA, rpoB, tpiA), where they reported sequence percentage 
identities between 99-100 %. The newly identified Francisella marina sp. nov showed 





comparison, multi-locus sequence typing analysis (MLSA) of selected house-keeping 
genes (DnaK, gyrB, muts, pgm, pyrfB, rpoB, sodB) and REP-PCR. The 16S rRNA 
sequence of the novel isolate showed 99% homology to a Francisella sp. (Francisella sp. 
isolate TX077308) isolated from sea water in Gulf of Mexico (Peterson et al., 2009), while 
it showed < 99% similarity to the other validated fish, human and environmental 
Francisella spp. The REP-PCR confirmed the 16S rRNA sequence comparison and MLSA 
showed that the novel Francisella isolate retrieved from red snapper formed a discrete 
phyletic haplogroup close to Fno, Fnn and Fp cluster and far from the Ft subspecies 
cluster. The results of this analysis indicated that this novel isolate represents a distinctive 
divergent species with in the genus Francisella (Soto et al., 2018). 
1.1.4.6. Clinical and post-mortem findings of francisellosis in tilapia 
 Francisellosis in tilapia is a severe disease that can be present in all forms, acute, 
subacute and chronic, according to many factors including environmental conditions, size 
and susceptibility of the host. During an epizootic episode, mortality was reported up to 
95%, especially with low water temperature and bad water quality (Mauel et al., 2007). 
The disease is recognised in farmed tilapia in different developmental stages including 
larvae, juveniles or adults and the clinical and post-mortem signs are similar in most cases 
(Ortega et al., 2016; Sebastião et al., 2017). Infected fish show non-specific clinical signs 
including lethargy, erratic swimming - either vertical or circling with floating at the 
surface - and crowding towards the centre of the pond or the tank. Loss of appetite, 
exophthalmia and variable degrees of ascites also commonly occur, and skin appears 
ulcerated with petechial haemorrhages or scattered cutaneous lesions on the abdomen and 
in or around the fin with loss of scales in some cases. Upon necropsy, fish gills appear 
pale, patchy white or red and gills and/or skin parasites were also reported such as 
monogenean parasites or Trichodina spp. in association with Fno infection in tilapia. The 
characteristic lesions of francisellosis in fish include enlargement of most of the internal 
organs, especially head kidney where tissue size increases by approximately 5-50 fold and 
the appearance of focal or diffused whitish nodules of about 1-5 mm may appear that 
might have a shallow hole in their centre (ring shape foci) filled with clear serous fluid and 
appear as cyst-like lesions in other cases. The abdominal cavity often contains clear watery 
fluid and the gastro-intestinal tract is devoid of any feed. External muscles show black 
granulomatous lesions ranging from pin-point to large sized lesions (≥ 3cm). The presence 
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of nodules in the brain is only observed in exceptional cases of severe infection. 
Mesenteries are also irregularly thickened with multiple nodules and adhesion to the 
adjacent viscera (Mauel et al., 2007; Soto et al., 2009b, 2011a; Jeffery et al., 2010; Camus 






















Figure 1.5. Clinical and post mortem signs of francisellosis in tilapia. [A] ulceration 
around mouth (dashed arrows), [B] abdominal distension as a result of ascites (a), [C] 
white nodules on spleen (S) and head kidney (HK) and [D] massive enlargement of 







1.1.4.7. Histopathological findings of francisellosis in tilapia 
The most typical lesion of piscine francisellosis in fish is massive granulomatous 
reaction in internal organs with spleen and head kidney being the most affected tissues 
(Figure 1.6). The granuloma is characterised by central areas of necrosis and\or vacuolated 
foamy macrophages mixed with very few neutrophils and sometimes there are multifocal 
areas of eosinophilic, basophilic or mononuclear cell infiltration and the overall structures 
are surrounded by a fine fibrous capsule and small cuffs of lymphocytes. The vacuolated 
cells show variable numbers of small pleomorphic, Gram-negative coccobacilli and 
pyknosis was also observed. With the massive inflammatory response in the spleen, 
necrotic tissue and inflammatory cells replace the normal splenic parenchyma architecture 
(Colquhoun and Doudu, 2011).  
Gills of Fno-infected fish reveal massive hyperplasia with lamellar fusion, loss of 
the inter-lamellar spaces and increased number of mucous cells. The heart shows a mild to 
severe epicarditis and endocarditis with endothelial hypertrophy and hyperplasia in the 
atrium and myocardial fibre fragmentation, while the stomach and intestine exhibit chronic 
inflammatory cell infiltration and necrosis in the lamina propria and submucosa. 
Necrotising vasculitis with the formation of fibrin thrombi and mild focal infiltration of 
inflammatory cells with cytoplasmic vacuolation are rarely seen in the brain, pancreas, 
ovary and testes. The lesions in the liver are mainly concentrated in the hepatic 
parenchyma that shows a granulomatous reaction surrounded by macrophages and necrotic 
tissue. Skin samples exhibit necrosis and chronic inflammatory cell infiltration in muscle 
fibers and epidermis that are lost in some infected fish. In severely infected tilapia, 
systemic infection extends to the brain and eyes which show macrophage infiltration in 
meninges and choroid gland, respectively (Mauel et al., 2007; Soto et al., 2009a, 2011a; 
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Figure 1.6. Pathological features of francisellosis in tilapia. Coalescent granulomas (g) 
replacing the majority of normal splenic parenchyma [Plate A] (H&E, 20x). Multifocal, 
round, well demarcated granulomas (solid arrows) with necrotic material in the centre (n) 
and epithelioid and melano macrophage infiltration of varying size (dotted arrows) in head 
kidney [Plate B] and spleen [Plate C], (H&E, 40x). Extensive hyperplasia and fusion of 
secondary lamellae (solid arrow) with mild infestation with epitheliocystis-like inclusions 







1.1.4.8. Clinical pathology of francisellosis in tilapia 
Data on the clinical pathology of Fno-infected tilapia is scarce. Examination of 
blood samples from infected fishes revealed that there was a significant decrease in the 
haematocrit values with neutrophilia, low numbers of monocytes and total lipid values. 
Moreover, cytological examination of blood smears stained with Geimsa revealed variable 
numbers of pleomorphic bacteria in macrophages or free in serum (Chen et al., 1994; 
Mauel et al., 2003, 2005). 
1.1.4.9. Fish immune response and interaction with Fno 
The genus Francisella includes various members that all share characteristics of an 
intracellular life cycle in different hosts including mammals, fish and mollusca (Soto et al., 
2010b). Extensive research has been done on understanding the bacterial factors involved 
in survival and proliferation of Francisella spp. within their target host cell, however, the 
genetic basis of these mechanisms is still not fully understood (Celli and Zahrt, 2013).  
An immune system within any organism is a combination of cellular and humoral 
components that are responsible for detection of various agents, including microorganisms 
(viruses, bacteria and parasites), toxins or malignant cells, protection against diseases and 
distinguish them from the host’s normal tissues in response to endogenous or exogenous 
stimuli (Rauta et al., 2012; Biller-Takahashi and Urbinati, 2014). As in other vertebrates, 
fish possess both innate and adaptive immune responses. The innate immune response 
represents the earliest basic immune strategy in all living organisms, where it shares 
common criteria of non-specificity and rapid response (Tort et al., 2003). In fish, spleen 
and head kidney are integral constituents of the immune system. Unlike other vertebrates, 
including mammals and other terrestrial animals, the kidney in fish serves as a 
hemopoietic, immune-endocrine and secretory functioning organ (Zapata et al., 1996; 
Castro and Taffala, 2015). In teleost fish, the kidney is anatomically differentiated into two 
compartments, head kidney (also known as anterior kidney or pronephros) and posterior 
kidney (also known as trunk kidney). The head kidney is the active part of the kidney 
which consists of hematopoietic, lymphoid and endocrine tissue and serves as the main 
factory for blood cells that are synthesized in its interlobular tissues (Castro and Taffala, 
2015). In addition, it actively performs essential immune functions, including the 
production of antibodies via plasma cells and proliferated B-cells (Secombes and Wang, 
2012), phagocytosis (Dannevig et al., 1994) and is responsible for the formation of 
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immune memory via melano-macrophage centres (Tsuji et al., 1990) and antigen 
processing (Kaattari and Irwin, 1985). Paradoxically, the trunk kidney performs an 
excretory function (Secombes and Wang, 2012).  
The spleen in teleost fish follows the same anatomical and functional scheme as 
other terrestrial mammals. The white pulp and red pulp in the fish spleen are mainly 
involved in blood filtration, destruction of aged blood cells, antigen presentation and 
antibody production (Zapata et al., 1996; Secombes and Wang, 2015; Castro and Taffala, 
2015). Interestingly, the spleen and head kidney are the most targeted organs for pathogen 
invasion following Fno infection (Soto et al., 2009a), where they exhibit the most 
significant lesions. These organs have been used as appropriate sample tissues for a 
number of applications including, detection and quantification of the pathogen in various 
infected fish species (Brudal et al., 2014; Sebastião et al., 2017; Rodrigues et al., 2017), 
evaluation of antibiotics efficacy (Soto et al., 2014b) and evaluation of vaccine efficacy 
(Brudal et al., 2015; Lagos et al., 2017) against fish pathogenic Francisella spp.  
Cytokines play an essential role in the immediate and early immune response of 
fish to bacterial infection via various mechanisms such as lymphocytic activation and 
boosting phagocytosis and apoptosis (Reyes-Cerpa et al., 2013). The expression of 
inflammatory cytokine related genes including interleukins, interferons and tumour 
necrosis factor after Francisella infection has been extensively investigated to elucidate 
the dynamics of response to the disease in various fish hosts.   
Interleukins (ILs) represent a class of cytokines that are mainly synthesized by 
CD4+ T-helper cells, macrophages, monocytes and endothelial cells (Secombes et al., 
2011). Interleukins are involved in controlling the differentiation and development of T 
cells (e.g. Th1, Th2, TREG and Th17 subsets) and B-cells (Brocker et al., 2010; Holt et 
al., 2010). IL-1b is one of the commonly expressed cytokines in various teleosts including 
salmonids, cyprinids, gadoids, periciforms and anguilliforms (Secombes et al., 2011). It is 
a constitutive inflammatory mediator produced by macrophages in response to infection 
(Tort et al., 2003) and Komatsu et al. (2009) reported that IL-1b  is affiliated with bacterial 
invasion and colonisation. IL-1b was upregulated in splenic cells of Nile tilapia 24 and 96 
hpi with 0.8 × 105 CFU/fish of Fno (Jantrakajorn and Wongtavatchai, 2016). IL-1b 
transcription level was also significantly increased in kidney cells of adult zebra fish 





(dpv) compared to control fish, with a slight increase at 7 dpv and 21 dpv, while no 
significant difference was observed in the expression levels between vaccinated and 
control fish 1 and 7 days post-challenge (dpc) with 1 × 106 CFU/fish of Fno (Lagos et al., 
2017). Brudal et al. (2014) reported increased transcription level of IL-1b in zebra fish 
embryos injected with fluorescently labelled Fno, Fnn and F. tularensis subsp. novicida at 
22, 28 and 32 °C. In addition, up-regulation of IL-1b was reported in the spleen of Atlantic 
cod after 3 hpi with Fnn (Bakkemo et al., 2011) and in zebra fish at 6 and 24 hpi with 
Francisella sp. (Vojtech et al., 2009). Paradoxically, down regulation of IL-1b was 
reported after 2-24 hpi with Fnn and absence of expression by 48 hpi was also reported in 
Atlantic cod (Bakkemo et al., 2011). 
Interferons (IFNs) are known by their anti-viral activity in vertebrates, where they 
are divided into three families: IFN I, IFN II and IFN III, which were identified based on 
their specific receptors, cellular origin, genomic structure and their induced immune 
response. In teleost fish, two of the three recognised families are present and constitute the 
antiviral defence mechanism (Zou and Secombes, 2011). In addition, Type I IFN is further 
divided to two distinct sub classes based on cysteine residues and were reported to be 
released by any kind of cells as result of viral invasion (Boehm et al., 1997; Zou and 
Secombes, 2011). Type II IFN, on the other hand is mainly advocated to cell-mediated 
immunity and produced by activated T-cells and natural killer cells (NK- cells) in response 
to intracellular pathogens (e.g. intracellular virus or bacteria). Two members were 
described in the latter type including the mammalian homologue IFN-g and a fish specific 
member known as IFN-g -related molecule (IFN-g rel) (Boehm et al., 1997; Zou and 
Secombes, 2011). In zebra fish injected with an Fno-derived OMV vaccine, only the IFN-I 
transcription level but not IFN-II was higher than control fish at 1 dpv and decreased by 7 
dpv then interestingly elevated at 21 dpv (Lagos et al., 2017).  
Tumor necrosis factor (TNF) is a key factor in the body’s immune response to 
tumor cells, bacteria and virus with a vital role in both acute reactions and systemic 
inflammation. In fish, TNF-a is a well-known pro-inflammatory mediator that has been 
cloned in various fish species (Hirono et al., 2000; Bobe and Goetz, 2001; Laing et al., 
2001; Castillo et al., 2002). It promotes cell proliferation, differentiation, necrosis, 
apoptosis and promotion of the other cytokines. In addition, it moderates effective anti-
microbial responses in the form of induced apoptosis, infected cell killing, suppression of 
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intracellular pathogen replication and increased transcription of various immune-related 
genes (Reyes-Cerpa et al., 2013). TNF-a was upregulated in spleen cells of Nile tilapia 6 
hpi with Fno and was maintained at a high level also at 24-96 hpi (Jantrakajorn and 
Wongtavatchai, 2016). Furthermore, the transcription level of TNF-a was significantly 
higher in zebra fish larvae after 6 hpi with Francisella sp., however, lower levels were 
noted at 12 hpi before increasing again after 24 hpi. (Vojtech et al., 2009). The kidney of 
zebra fish adults vaccinated with Fno-derived OMVs exhibited down-regulation of TNF-a 
1-21 dpv, which then showed significant up-regulation 1 dpc of Fno (Lagos et al., 2017). 
In contrast, zebra fish larvae showed upregulation of TNF-a 48 hpi with Fno and F. 
tularensis subsp. novicida and 7 dpc with Fnn (Brudal et al., 2014).     
Transforming growth factor (TGF) is described as a pleiotropic cytokine that 
performs multi-purpose immune-related functions including cell development, 
proliferation, differentiation and regulation of the survival of leukocytes of various origins 
such as lymphocytes, dendritic cells, natural killer cells, macrophages and granulocytes (Li 
and Flavell, 2006; Li et al., 2008). In fish, there is little information about the function of 
TGF-b1 compared to the mammalian homologues, which are well-described as immune-
suppressive cytokines (Saxena et al., 2008) that are mainly involved in harmonising 
immune tolerance and auto-immunity inhibition via their effect on T-cells (Lio and 
Flavell, 2008; Li et al., 2006; Wan et al., 2007). However, recent studies in gold fish 
(Haddad et al., 2008), carp (Yang et al., 2012) and red sea bream (Cai et al., 2010) suggest 
that TGF-b1 in teleosts exhibits the same immune-suppressive effect on leukocytes as seen 
in mammals. Jantrakajorn and Wongtavatchai (2016) reported tissue damage and increased 
granuloma formation in the spleen of Fno-infected tilapia accompanied with down 
regulation of TGF-b.  
At a cellular level, Francisella spp. have shown high adaptatability to various host 
cell types including macrophages, dendritic cells, polymorpho-nuclear neutrophils in 
mammals (McCaffery and Allen, 2006; Hall et al., 2008), as well as in tilapia (Soto et al., 
2010b), Atlantic cod (Gjessing et al., 2011) and zebrafish (Vojtech et al., 2009; Brudal et 
al., 2014, 2015). In fish, macrophages are the most involved immune cells in Fno 
infection, in which the bacterium can replicate, avoid phagolysosome activities and egress 
to the cytosol to infect more cells. This was exemplified by the ability of Fno to inhabit the 





and macrophage-promotor expressed gene (mpeg1.1 promoter) was the most upregulated 
cell-marker following Fno infection (Lagos et al., 2017). In a similar experiment, Brudal 
et al. (2014) showed the uptake of Fno, Fnn and F. tularensis subsp. novicida using 
enhanced green fluorescent protein-labelled macrophages or neutrophils in transgenic 
zebra fish cell lines after microinjection with these three pathogens, with macrophage 
uptake being more efficient leading to aggregation of more bacterial cells. In addition, 
wild type Fno maintained its ability to invade, survive and multiply within the milieu of 
tilapia head kidney-derived macrophages (HKDM) inducing apoptosis after activation of 
caspase 3 and 7, while a mutant strain of this bacteria lacking iglC gene was defective for 
all these activities (Soto et al., 2010b).  
The adaptive or acquired immune response is the second component of the immune 
system that performs a significant role in protection against pathogens (Ellis, 2001; Swain, 
2006). Unlike the innate immune response, the acquired immune mechanism is very 
specific, highly complex and represents the key element of immune system that provides 
protection after vaccination. The teleost adaptive immune response is comparable to that 
of higher vertebrates. It has the ability to generate memory cells (cell mediated immunity) 
such as T and B lymphocytes and specific soluble and membrane-bound receptors 
(humoral immunity) including B and T-cell receptors (BCR and TCR) and 
immunoglobulins (Igs) which enable fast and efficient elimination of the specific fish 
pathogen upon re-encountering them (Thompson, 2017).       
Antibody mediated immunity is a fundamental arm of the fish immune system. In 
teleost fish, the humoral immune response is relatively less advanced due to its limited 
immunoglobulin isotype diversity (Pilstorm and Bengten, 1996). To date, three major 
isotypes of immunoglobulin have been discovered in fish, IgM, IgD, IgT/IgZ, of which 
IgM was the first to be discovered and is the main antibody isotype in teleosts (Castro and 
Tafalla, 2015). More information is still needed relating to IgD and IgT/IgZ to be able to 
understand the role of their B-cell precursors (i.e. IgT positive and IgD positive B-cell 
population) within mucosal surfaces (Zhang et al., 2010; Castro and Tafalla, 2015). 
Nevertheless, the synergistic effect of antibodies, cytokines and immune cells, including 
phagocytes, generally enables effective clearance of intracellular pathogens (Lagos et al., 
2017). The antibody-mediated immunity was shown to be critical against francisellosis in 
experimentally infected Nile tilapia fingerlings. Vaccination with live attenuated Fno 
                                                                                                                      Chapter One 
 
 
  27 
vaccine could produce specific antibodies that were detected in serum by ELISA and 
successfully protected the fish against a subsequent immersion challenge with a lethal dose 
of F. asiatica (Soto et al., 2011b). In addition, IgM was upregulated in zebra fish post-
immunisation with Fno-derived OMVs at 7 and 21 dpv and 1 dpc, suggesting activation of 
cell mediated responses by stimulation of B-cells. Moreover, a significantly high serum 
antibody response was reported in both vaccinated and non-vaccinated zebra fish at 21 dpc 
with Fno, suggesting the activation of humoral immune responses by increased production 
of antibodies against Fno infection following the decrease of IgM level at 21 dpv (Lagos et 
al., 2017).  
1.1.4.10. Diagnosis of francisellosis in tilapia 
Detection of Fno in fish is a challenging process, due to its fastidious intracellular nature 
and the relatively low number of bacterial cells required to induce the disease (Soto et al., 
2009a). With the increasing number of cases of francisellosis, various tools have been 
developed for isolation and identification of Fno from infected fish, including 
conventional culture, molecular assays, and antibody-based / immunological techniques 
(Soto et al., 2010a).  
A. Bacterial isolation on bacteriological media and cell culture  
Diagnosis of Fno by bacterial isolation on culture media has been previously reported 
using various culture media. Cysteine heart agar medium supplemented with 1% bovine 
haemoglobin (CHAH) is the gold standard media used for isolation of piscine Francisella 
including Fno (Kamaichi et al., 2005; Soto et al., 2009a, 2011a, 2014; Nguyen et al., 
2016; Lewish et al., 2016; Ortega et al., 2016). Other media have also been used such as 
Muller Hinton base supplemented with 3% foetal bovine serum, glucose 1% and cysteine 
0.1% (Soto et al., 2009a), Cysteine heart agar medium supplemented with sheep blood 
(Mikalsen and Colquhoun, 2009) and Thayer-Martin agar (Hseih et al., 2006). The 
optimum temperature for in vitro growth of Fno ranged from 25-28°C, with growth 
inhibited at 35-37°C (Soto et al., 2009a). This temperature-dependent growth is a hallmark 
in the differential diagnosis of Fno from either closely related fish pathogenic Francisella 
spp. or human and environmental Francisella spp. In addition, Fno isolated from infected 
tilapia was successfully cultured in CHSE-214 cells resulting in cytopathic effect after 5-7 





(Ostland et al., 2006; Jeffery et al., 2010). The sensitivity of bacteriological culture for 
detection of Fno in carrier farmed tilapia has been tested, where the median sensitivity 
value was determined as 1.6% (Assis et al., 2016). There are a number of issues using 
conventional culturing methods for the isolation of Francisella spp. from infected fish 
tissues including outcompeting overgrowth by other concomitant bacteria (Colquhoun and 
Duodu, 2011), the requirement for homogenisation of tissues and the possibility of false 
negative results (Soto et al., 2010a). 
B. Biochemical and phenotypic identification 
a. Biochemical tests 
Fish pathogenic Francisella spp. were reported to be biochemically non-reactive and there 
is a lack of reliable tests to differentiate between them, or even with the other members of 
the Francisella genus (Colquhoun and Duodu, 2011). There are some commercially 
available kits for identifying the phenotypic profile of piscine Francisella spp., however, 
they have resulted in weak reactions, which can be difficult to interpret (Mikalsen and 
Colquhoun, 2009). The bacteria show positive citrate, Voges-Proskauer and gelatinase 
reactions by API20 E, and only 8 out of 20 positive enzymatic reactions (acid phosphatase, 
naphthol-AS-BI-phosphohydrolase, esterase lipase, alkaline phosphatase, esterase, lipase, 
 a-chymotrypsin and b-galactosidase) with APIzyme kit (Ramirez-Paredes et al., 2017b).  
b. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis 
(MALDI-TOF-MS) 
Matrix assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF 
MS) has recently emerged as a potential tool for microbial identification and diagnosis. In 
MALDI-TOF-MS, the sample for analysis is prepared by mixing with a solution of an 
energy-absorbent, organic compound called matrix. When the matrix crystallizes on 
drying, the sample entrapped within the matrix also co-crystallizes. The sample within the 
matrix is ionized in an automated mode with a laser beam. Desorption and ionization with 
the laser beam generate singly protonated ions from analytes in the sample. The protonated 
ions are then accelerated at a fixed potential, where the are separated from each other on 
the basis of their mass-to-charge ratio (m/z). The charged analytes are then detected and 
measured using different types of mass analyzers including time of flight (TOF) analyser, 
that is commonly used for microbiological applications. During MALDI-TOF analysis, the 
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m/z ratio of an ion is measured by determining the time required for it to travel the length 
of the flight tube. Identification of microbes by MALDI-TOF-MS is done by either 
peptide-mass fingerprintings (PMFs) matching via comparing the MS spectrum of the 
unknown microbial isolates with the MS spectra of known microbial isolates contained in 
the database or by matching the masses of biomarkers of the unknown organism with the 
proteome database (Singhal et al., 2015). MALDI-TOF-MS was recently used to identify 
novel isolates of Francisella sp. retrieved from diseased red snapper cultured in Central 
America. The spectra obtained for the proteins of the novel isolate enabled its 
differentiation from other validated Francisella spp. including Fno, Fp and Ft. The spectra 
analysis showed that the new isolate was more similar to Fno than Fp and Ft (Soto et al., 
2018).  
C. Histopathological examination 
Histopathology is a powerful tool for diagnosis of many fish diseases by determination of 
tissue changes resulting from infectious or non-infectious etiologies. It was extensively 
used to describe the pathological features of francisellosis in formalin fixed paraffin 
embedded tissues, particularly in head kidney and spleen (Fukuda et al., 2002, Soto et al., 
2009a, 2011a, 2013a, 2014b; Nguyen et al., 2016; Qiang et al., 2016; Ramirez-Paredes et 
al., 2017b). The most common pathological feature in most cases is an extensive 
granulomatous inflammation with multi-organ granulomas (Colquhoun and Duodu, 2011). 
The granuloma is usually infiltrated by foamy macrophages, fibroblasts and leukocytes 
(Mauel et al., 2007; Nylund et al., 2006) and may show necrotic or liquefied centres (Soto 
et al., 2014b) or bacterial colonisation in severe cases (Nylund et al., 2006). 
D. Molecular diagnosis 
The use of molecular diagnostic tools for Fno offers an alternative to the problems 
associated with culture of this fastidious pathogen.  
a. Conventional Francisella genus specific polymerase chain reaction (PCR)  
The use of Francisella genus-specific PCR primers targeting the 16S rRNA gene sequence 
followed by sequencing of the PCR product has been successfully implemented to 
diagnose cases of Fno in various hosts including tilapia (Hseih et al., 2006; Mauel et al., 
2007; Soto et al., 2009a; Nguyen et al., 2016; Qiang et al., 2016; Ortega et al., 2016; 





striped-bass (Ostland et al., 2006). However, the disadvantages of conventional PCR, 
including limited sensitivity and inability to differentiate between Francisella members on 
the species level or of subspecies, limits its usage in piscine francisellosis diagnosis.       
b. Fno specific real-time PCR  
Real-time PCR involves monitoring of PCR amplification by measuring fluorescence 
during the exponential phase of the reaction. Non-specific DNA binding dyes, which emit 
fluorescence upon binding to double-stranded DNA, such as SYBRGreen®, enable 
determination of the presence or absence of an amplicon, without giving any information 
on the precise nature of the product (Kim et al., 2017). Improved accuracy of molecular 
tests for Fno detection and identification in tilapia and other susceptible species has been 
achieved using real-time PCR, alleviating the disadvantages of conventional PCR which 
depends on the results of agarose gel electrophoresis of endpoint reaction products. A 
TaqMan real-time PCR assay was developed by Soto et al. (2010a) targeting the iglC gene 
from Francisella strains isolated from Nile tilapia. The higher sensitivity of this assay (~25 
genomic equivalents) could differentiate between Francisella isolates retrieved from 
infected tilapia and cod based on the sequence of the iglC gene as the sequence homology 
of that gene between Fno and Fnn was only ~ 90%. This assay has also successfully been 
used to diagnose Fno outbreaks in Brazil (Leal et al., 2016; Sebastião et al., 2017) and 
Mexico (Ortega et al., 2016). With the recent availability of the whole genome sequences 
of fish Francisella isolates, a real-time PCR targeting specific genomic regions in Fno and 
Fnn could be used to identify and differentiate between both isolates with high specificity 
and sensitivity which represents a powerful tool for molecular diagnosis of the known fish 
Francisella strains (Duodu et al., 2012).  
c. Duplex-PCR  
Multiplex PCR technology, including duplex PCR, is another type of molecular tools that 
was first developed by Chamberlain et al. (1988) and includes amplification of more than 
one target of interest in a PCR using multiple pairs of primers, resulting in specific 
amplicons of different sizes for the target organisms. Recently, a duplex PCR targeting 
16S rRNA and a unique hypothetical gene sequence in Fno was developed that gave high 
sensitivity (~10-100 genomic equivalents) and specificity, which may be used for 
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identification of either clinically infected or latently infected fish from both farms or wild 
sources (Dong et al., 2016a).  
d. Loop-mediated isothermal amplification (LAMP) 
Loop-mediated isothermal amplification (LAMP) is a simple, rapid, specific and cost-
effective nucleic acid amplification method. This technique employs a Bst DNA 
polymerase (optimal activity at 66 ºC), that originates from Bacillus stearothermophilus 
and has 5′–3′ DNA polymerase and strand displacement activities but lacks 5′ –3′ 
exonuclease activity, a set of four primers (two outer and two inner) and two optional loop 
primers designed to recognize a total of six different sequences in the target gene. 
Amplification by LAMP resulting in generation of multiple products of predictable sizes. 
The amplified products are stem-loop DNA structures with several inverted repeats of the 
target and cauliflower-like structures with multiple loops, yielding > 500 mg/mL of PCR 
products (Nagamine et al., 2001). A colorimetric LAMP assay was developed for 
screening milt, non-fertilized and fertilized eggs after crossing, different developmental 
stages of clinically healthy tilapia as well as water samples from rearing tanks to determine 
the presence of Fno. The assay could successfully detect the bacteria in all tested samples 
with detection limits as low as 1 fg of Fno gDNA (Pradeep et al., 2016). 
E. In situ hybridization (ISH) 
In situ hybridization techniques involve detection of specific nucleic acid sequences in 
morphologically preserved chromosomes, tissues or cell preparations using a labeled 
complementary DNA, RNA or modified nucleic acids strand (i.e., probe) (Kim et al., 
2017). In situ hybridization was successfully applied for identification of Fno in tilapia and 
other ornamental cichlids, where the 16S rRNA gene was targeted by a dioxigenin probe 
(DIG) in different tissues. The hybridization signals appeared as a purple precipitate in the 
target tissues representing binding of the labelled probe to the target molecules. The ISH 
demonstrated higher performance than conventional PCR in detection of Fno in infected 
tissue samples containing damaged DNA, where it was able to identify and localise the 
target agent with high specificity and sensitivity (Hsieh et al., 2006; 2007). The ISH was 
also useful for studying the developmental stages of granuloma formation within 





bacteria in the gills and intestinal epithelium suggesting their role as portals of entry (Dong 
et al., 2016b).    
F. Immunohistochemistry (IHC) 
Immunohistochemistry is a powerful diagnostic technique based on antigen-antibody 
interactions that can be used to detect and localize specific antigens ranging from amino 
acids and proteins to infectious agents and specific cellular populations within cells or 
tissue sections from formaline fixed parafine embedded (FFPE) tissues (Kim et al., 2017). 
A specific Fno-immunohistochemical (IHC) analysis was performed by Soto et al. (2012b) 
using formalin fixed paraffin embedded infected tissues collected from different fish from 
various locations, where the disease agent was initially diagnosed as Rickettsia-like 
organism. The test showed 45 positively stained tissues out of 68 after using mouse anti-
Fno serum. The Fno antigen was detected in different tissues including gill, gastric 
epithelium, liver, meninges, pericardium, but the strongest positive reaction was seen in 
spleen and kidney granulomatous tissues.  
1.1.4.11. Treatment of fish francisellosis with antibiotics 
The use of antimicrobial agents for controlling piscine francisellosis often proves 
ineffective. This can be attributed in part to the intracellular nature of this aquatic micro-
organism, its high infectivity, high transmissibility and the high morbidity of the disease. 
In addition, oral delivery of antimicrobials is not very practical as infected fish often 
exhibit poor feeding (Colquhoun and Duodu, 2011). The susceptibility of fish associated 
Francisella spp. to such antimicrobials has been extensively studied previously. The 
minimum inhibitory concentration (MIC) data obtained using Fnn isolated from Atlantic 
cod showed that there was high susceptibility to florfenicol (0.5 µg/mL), oxolinic acid 
(0.25 µg/mL), flumequine (0.25: 1 µg/mL) and rifampin (1 µg/mL) and low susceptible to 
oxytetracycline (64 µg/mL), trimethoprim/sulfadiazine (64: 128 µg/mL), ciprofloxacin (8 
µg/mL), streptomycin (32: 128 µg/mL) and erythromycin (16 µg/mL) (Isachsen et al., 
2012). Ramirez-Paredes et al. (2017b) tested 39 antibiotics against Fno, and reported 
sensitivity to enrofloxacin (<0.12 µg/mL), gentamicin (<0.5 µg/mL), neomycine (<2 
µg/mL) and streptomycine (<8 µg/mL) and low susceptible to sulphadimethoxine (128: 
256 µg/mL), trimethoprim/sulfamethoxazole (38 µg/mL), penicillin (4: >8 µg/mL), 
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tylosine tartarate (20: >20 µg/mL) and clindamycine (>4 µg/mL). Florfenicol was effective 
against Fno in infected tilapia when applied at a dose of 15 mg/kg of fish body weight for 
a period of 10 days (Soto et al., 2012d) and tetracycline was used at a concentration of 
0.38gm per kg of feed for 10 days treatment of francisellosis in hybrid striped bass 
(Ostland et al., 2006). In addition, oral administration of oxytetracycline medicated feed at 
a dose of 3 g/ 100 pounds of fish for 10 days resulted in a significant decrease in 
mortalities of Fno-infected grunts in Florida (Soto et al., 2014b). Moreover, F. halioticida 
isolated from abalone showed sensitivity to cefetazidime, ciprofloxacin, gentamycin and 
tetracycline, but was resistant to ampicillin, erythromycin, cefuroxime and penicillin 
(Brevik et al., 2011a).  
 Treatment of Fno by combinations of antibiotics with increased water temperature 
up to 30 ºC was reported to decrease mortalities in infected grunts. However, this approach 
did not give long lasting effects, as the mortality did not stop completely and screening of 
surviving fish by qPCR showed positive results for Fno, despite no growth of viable 
bacteria on CHAH (Soto et al., 2014b). These results highlight the urgent need for other 
reliable control and/ or prevention strategies such as vaccination against Fno.  
1.1.4.12. Vaccination against Fno in tilapia 
 A. History of fish vaccination 
Vaccines are an integral tool in any health management strategy applicable to 
economically important reared fish. They can greatly reduce the need for drugs and 
chemicals as they act by enhancing immunity against pathogens (Klesius et al., 2011). 
Vaccination plays an important role in combination with good management practices to 
increase resistance against subsequent infections by specific pathogens (Hill, 2005). The 
use of vaccines for the prevention of fish diseases remains an active area of study since the 
early findings of Snieszko et al. (1938) revealing increasing carp immunity after injection 
with killed Aeromonas hydrophila (Snieszko et al., 1938, 1970). Prior to this, Duff (1942) 
showed the efficacy of using feed containing chloroform killed Aeromonas salmonicida 
for the protection of trout against furunculosis. Furthermore, Goncharove (1951, 1971) 
first reported the use of a vaccine for prevention of viral diseases following his studies on 
spring viremia of carp (SVC). These early novel experiments paved the way for a break-
through in the fish vaccine industry that was continued later by Schaperclaus (1970; 1972) 





bacteria. The promising results achieved by the use of sulfa drug (e.g. sulphonamides) and 
antibiotics as potent therapeutic agents took the focus off vaccine development between 
the 1940s and 1950s, but this did not last due to the problems of antimicrobial resistance 
and the harmful impacts of such chemo-therapeutic agents (e.g. toxicity) on farmed 
animals and humans. This was a turning point for the revival of vaccine development in 
the 1960s (Ross et. al., 1956; Klontz et al., 1970). Since then, the field of successful fish 
vaccination has expanded and the process of producing safe, stable and protective vaccines 
against different fish pathogens remains an ongoing process.   
B-Development of vaccines against Fno 
Piscine francisellosis has been recognised as a major bacterial disease in fish in both 
aquaculture and in wild stocks from fresh, brackish and marine waters for more than 20 
years (Colquhoun and Duodu, 2011). However, the pathogenesis of this disease is not fully 
understood. Additionally, the development of safe, efficient and broad-spectrum licensed 
vaccines against fish francisellosis has not been successful to date. Thus, thorough 
investigations of Francisella pathogenesis and development of vaccines are urgently 
required. 
The first reported trial for vaccination against Francisella infection in tilapia was 
published by Soto et al. (2011b), where a mutant live attenuated vaccine was developed by 
a mutation in the iglC gene that is important for intracellular growth in macrophages. The 
newly developed vaccine was tested for its efficacy by immersion challenge with wild type 
Fno in tilapia fingerlings and adults. The vaccine was applied by immersion in two 
different administration times including 30 min and 180 min and the fish were challenged 
with high doses of the live bacteria (108 CFU/mL). The relative percents of survival (RPS) 
obtained from the vaccine were 68.75% and 87.5% after 30 min and 180 min immersion 
vaccination, respectively. Despite the significant serum and mucus antibody responses 
induced by this vaccine, it cannot currently be commercially used in tilapia farms because 
of safety issues, in particular, due to the concerns of reversion to virulence of the 
attenuated pathogen and the subsequent possibility of spreading the disease.  
Ramirez-Paredes (2015) successfully developed an autogenous formalin whole cell 
killed vaccine applied by i.p. injection. After i.p. challenging the fish with 4 ×103 CFU/mL 
of the vaccine strain, the relative percent of survival (RPS) was 100% and 40% in the 
vaccinated and adjuvant injected fish groups, respectively. In addition, a significantly 
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higher titer of antibodies measured after 45 days post vaccination (dpv) was obtained in 
vaccinated fish compared to the adjuvant or un-vaccinated control group as well as a lower 
granuloma score in the vaccinated fish (13.3%) than the non-vaccinated survivors (90%). 
A recent trial was performed by Brudal et al. (2015) using OMVs for i.p. vaccination of 
zebra fish followed by i.p. challenge 32 dpv with 108 CFU/mL of Fnn. Their results 
showed an induced immunity represented by high survival rates, decreased bacterial 
burden in the spleen, heart and head kidney and reduced granulomatous response in the 
affected tissues 28 days post-challenge (dpc) in vaccinated fish compared with the 
unvaccinated fish. In a similar study, Fno-derived OMVs were successfully used for i.p. 
vaccination of zebra fish against a lethal dose of Fno (1 × 106 CFU/mL). It demonstrated a 
significantly higher survival rate of 65% associated with high levels of serum IgM, 
significant expression of immune related genes and reduced granuloma formation in the 
spleen 28 dpc (Lagos et al., 2017). To-date, current vaccine developments for prevention 
of fish francisellosis in tilapia have not demonstrated the potential for cross-strain 
protection for Fno. Furthermore, the promising data achieved for the safe autogenous 
inactivated Fno vaccine reported by Ramirez-Paredes, (2015) requires further studies to 
ensure reproducible protection against experimental bacterial challenge. More studies need 
to be conducted for development of control strategies for such devastating diseases like 


















1.2 Aims of the study 
Fno is a serious pathogen that accounts for massive morbidities and mortalities in cultured 
tilapia spp. globally. Since its first discovery in 2006, the number of outbreaks has 
increased, however, studies contributing to the characterisation of Fno to identify the 
bacterial factors involved in pathogenicity and modulation of host immunity, development 
of rapid diagnostic tools and protective vaccines for this aquatic pathogen are limited. The 
overall aim of the current study was to establish effective control strategies for Fno 
infection in farmed tilapia based on rapid accurate diagnosis, development and application 
of protective vaccines and vaccination strategies.  
The main objectives of the study were: 
1- Comparison of the proteome and immunome of five clinical Fno isolates from diverse 
geographic origins. 
2- Isolation, characterisation and identification of the antigenic profile of the Fno outer 
membrane proteins (OMPs).  
3- Testing the efficacy of an injectable whole cell inactivated adjuvanted vaccine against 
heterologous Fno challenge in tilapia and investigation of immune-related genes 
expression post-immunisation.  
4- Testing the efficacy of an autogenous whole cell inactivated Fno immersion vaccine in 
tilapia fry. 
5- Development of a recombinase polymerase amplification assay (RPA) for rapid 
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Comparative analysis of the whole cell proteome and immunogenic profile of 








Francisella noatunensis subsp. orientalis is the causative agent of warm water 
francisellosis, a highly infectious granulomatous bacterial infection of fish (Duncan and 
Duodu, 2011). The disease has a wide host range, with tilapia being the most affected 
species, and outbreaks reported in various geographical locations including Europe, Asia, 
North, Central and South America (Kamaishi et al., 2005; Soto et al., 2009a; Lewish et al., 
2014; Nguyen et al., 2016; Ortega et al., 2016; Ramirez-Paredes, 2017b; Rodrigues et al., 
2017). The disease accounts for high economic losses and mortalities of up to 95% have 
been reported (Hsieh et al., 2006; Ortega et al., 2016). Previous genomics and proteomics 
studies have identified some potential Fno-pathogenicity determinants, including genes 
responsible for intracellular localization, survival and replication (Soto et al., 2013b; 
Lagos et al., 2017), however the functions of the conserved proteins derived from these 
genes are not fully-understood.  
The recent rise in francisellosis cases has led to an increase in Fno surveillance. 
Studies focusing on Fno adaptation and genetic diversity using geographically distinct 
isolates have reported a high degree of homogeneity between isolates based on their whole 
genome sequence, that reached up to 99%. Thus, these studies suggested that the Fno 
isolates from diverse origins express a unique clonal-like behaviour (Figueiredo et al., 
2016; Gonçalves et al., 2016; Ramirez-Paredes et al., 2017b). The reported similarities in 
genetic composition may have important implications for conserved Fno protein 
expression, virulence, pathogenesis, and more importantly vaccine-induced immunity. To 
this end, studies ascertaining divergence of Fno strain populations at the level of protein 
expression rather than at the bacterial genomic level could provide more insights into the 
increased spread of francisellosis globally.  
Traditional proteomic approaches have been implemented for characterisation of 
pathogenic micro-organisms, including sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) in combination with mass spectrometry for investigating 
total whole cell proteins or certain microbial protein fractions (West et al., 2012; Liu et al., 
2012; Watson et al., 2014). Moreover, the application of immuno-proteomics is useful for 
understanding the pathogenesis and virulence mechanisms of immune evasion and 
development of diagnostics and vaccines against etiological pathogens, especially when 
taking advantage of recent post-genomic technologies (Khan et al., 2006; Serruto and 
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Rappouli, 2006). These techniques were successfully applied for the discovery of novel 
immunogenic antigens in various clinically important pathogens, not only in human, such 
as Francisella tularensis (Janovska et al., 2007a; Kasap et al., 2017), Francisella novicida 
(Pierson et al., 2011), Francisella philomiragia (Pierson et al., 2011) and Neisseria 
meningitidis (Granoff, 2010), but also in fish including Streptococcus iniae (Shin et al., 
2007), Flavobacterium psychrophilum (Dumetz et al., 2008; LaFrentz et al., 2009), Vibrio 
harveyi (Pang et al., 2010), Aeromonas hydrophila (Poobalane et al., 2008), Aeromonas 
caviae , Aeromonas veronii and Aeromonas  jandaei (Peepim et al., 2016), Edwardsiella 
tarda (Kumar et al., 2010) and Francisella noatunensis subsp. noatunensis (Brudal et al., 
2015). 
In the current study, the whole cell protein profiles of 5 geographically distinct 
clinical Fno isolates, including 1 isolate that was previously used to produce an 
autogenous vaccine that gave 100% protection in Nile tilapia (Oreochromis niloticus, L) 
(Ramirez-Paredes, 2015), were comprehensively characterised using 1D and 2D PAGE. 
Additionally, investigation of the antigenic profiles of these diverse Fno isolates was 
performed using western blotting. The blots were screened with tilapia sera generated 
during an experimental Fno vaccine trial, using sera sampled post-vaccination and post-
challenge to identify putative immuno-dominant antigens using liquid chromatography 
electrospray ionization-tandem mass spectrometry (LC/ESI/MS/MS) and Matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF/MS). The 
current study provides useful information regarding the diversity and virulence 
mechanisms of Fno and lays the groundwork for improving Fno vaccine design.  
2.2. Materials and methods 
2.2.1. Bacterial isolates, culture media and growth conditions 
Five clinical Fno isolates were used in this study (Table 2.1). All the strains were stored as 
a master seed stock in Modified Muller Hinton broth (MMHB) (Difco, USA) with 2% 
IsoVitaleX (Becton Dickenson BBL, USA) and 0.1% glucose (Baker et al., 1985) 
containing 20% sterile glycerol (Sigma-Aldrich, UK). A cryo-tube aliquot of the master 
seed stock was thawed and 50 µL was used to inoculate cysteine hear agar media (Difco, 
USA) with 1% bovine haemoglobin (Becton Dickenson BBL, USA) (CHAH) and 
incubated for 72 h at 28°C. A loopful of the bacteria was inoculated into 15 mL MMHB 





incubator (Kuhner, Germany). The incubation conditions were the same for all the strains 
to avoid any growth-related differences in their proteome profiles.  
Table 2.1. Bacterial isolates used in the study  
Isolate name ID Source Origin and 
isolation year 
Fno UK isolate STIR-GUS-
F2f7 












Fno Austrian isolate NVI-9449 Malawi cichlids  Austria  
(2013) 
Fno Costa Rican 
isolate 





DSMZ: The German collection of Microorganisms and Cell Cultures, NVI: Norwegian Veterinary 
Institute, Oslo, Norway. T: Type strain.   
Following bacteria growth, cells were harvested by centrifugation at 5,000 × g at 
4°C for 15 min. The pellets were washed twice with 15 mL sterile PBS (pH 7.0) then the 
optical density (OD600nm) was adjusted to 0.4 ( ~1.2 × 109 CFU/mL) using 1X sterile PBS 
(pH 7.0) and suspension was aliquoted and kept in -70°C till used. 
2.2.2. Preparation of whole cell protein extract   
2.2.2.1.  Extraction of the whole cell lysate 
Extraction of whole-cell proteins from Fno isolates was performed according to Coelho et 
al. (2004), with some modifications. In brief, the bacterial cells were harvested by 
centrifugation of the bacterial suspension (OD600 = 0.4) at 5,000 × g at 4°C for 15 min. The 
pellets were resuspended in 1 mL lysis buffer (Appendix 1) containing 1% (v/v) of 
nuclease mix and 0.1% (v/v) of protease inhibitor mix (GE Healthcare, Uppsala, Sweden). 
The cell suspension was incubated on ice for 2 h, and insoluble cellular debris was 
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removed by centrifugation at 15,000 × g at 4°C for 60 min, and the clear supernatants were 
aliquoted and kept at - 70°C until use. 
2.2.2.2.  Cleaning, concentration, and quantification of proteins 
The protein samples were cleaned using a Clean-up kit (GE Healthcare, USA) following 
the manufacturer’s instructions. Briefly, 100 µL of each sample was transferred to 1.5 mL 
microcentrifuge tubes (Eppendorf, USA), 300 µL of precipitant solution was added then 
contents were quickly mixed on a vortex mixer (TopMix FB15024, Fisher scientific, UK) 
for 30 s. The tubes were incubated on ice for 15 min then 300 µL of co-precipitant solution 
was added and the tubes were inverted 5 times and mixed by vortexing for 30 s. The 
samples were then centrifuged at 15,000 × g at 4°C for 5 min after which the supernatant 
was removed and the pellet re-suspended in 40 µL of co-precipitant solution and incubated 
on ice for 5 min. Centrifugation was repeated at 15,000 × g at 4°C for 5 min and pellets 
were re-suspended in 25 µL milli-Q (MQ) water  and mixed by vortexing for 30 s, before 
adding 1 mL of ice-cold wash buffer together with 5 µL of wash additive and mixed by 
vortexing for 1 min. Tubes were kept at -20°C for 30 min with quick vortexing for 30 s 
every 10 min. Tubes were centrifuged at 15,000 × g at 4°C for 5 min and the pellets were 
left to air dry for 4- 5 min. The pellets were re-suspended in a mix of 500 µL of lysis 
buffer (Appendix 1) containing 1% (v/v) of nuclease mix and 0.1% (v/v) of protease 
inhibitor mix, then vortexed for 30 s. After centrifugation at 15,000 × g at 4°C for 5 min, 
the cleared supernatant was transferred to fresh low protein binding microcentrifuge tubes 
and stored at -70°C.  
The cleaned protein extracts were quantified using a 2-D Quant kit (GE Healthcare, 
USA) according to the manufacturer’s instructions. In brief, a standard curve was prepared 
using 2 mg/mL of bovine serum albumin (BSA) standard solution at 6 concentrations: 0, 
10, 20, 30, 40 and 50 µg. For the protein samples, 25 µL from each of the corresponding 
Fno protein samples were transferred to low protein binding 1.5 mL microcentrifuge tubes 
and 500 µL of precipitant solution were added to all the tubes, including the standard 
curve tubes. The tubes were mixed by vortexing for 30 s then incubated at room 
temperature (~ 22°C) for 3 min. 500 µL of co-precipitant was added and mixed by 
inverting tubes 10 times then by vortexing for 30 s. Tubes were then centrifuged for 





and 400 µL of Milli-Q water before quickly mixing by vortexing until the protein pellet 
was dissolved. 1 mL of colour reagent mix was added to each tube and the tubes were then 
incubated for 20 min at room temperature. After incubation, 300 µL from each sample was 
transferred to a 96 well microtiter plate (ThermoFisher Scientific, UK), each sample was 
added in triplicate, then the absorbance was measured using a microtiter plate reader 
(Bioteck, Synergy HT, USA) at a wave length of 480 nm. The standard curve was 
generated by plotting the absorbance of the standards against the quantity of proteins in the 
respective wells. The concentrations of protein samples were obtained after comparing the 
values at OD480 to the standard curve values. The concentration of samples was optimised 
to 50 µg using Milli-Q water, aliquoted and kept at -70°C until further use. 
2.2.3. 1D SDS-PAGE (1-DE) 
The bacterial protein suspension was thawed on ice from -70°C and mixed with 2X protein 
sample buffer (National Diagnostics, USA) at a ratio 1:1, then incubated in a Grant digital 
heat block (Thomas Scientific, USA) at 90°C for 10 min. The samples were centrifuged 
for 3 min at 17,000 × g, then 10 µL of each sample and 5 µL from a precision protein dual 
colour standard (Bio-Rad, USA) were loaded into a 4-15%, 12-well comb, 20 µL Mini-
PROTEANâ TGXä precast gel (Bio-Rad, USA). Two technical replicates per sample 
were prepared to ensure reproducibility. The gels were electrophoresed in 1X Lamelli SDS 
electrophoresis buffer (Appendix 1) using a mini-PROTEANâ tetra cell (Bio-Rad, USA) 
at 100 v for 90 min and then stained with SimplyBlue™ Safe Coomassie stain 
(ThermoFisher Scientific, UK) and a ProteoSilver™ plus silver stain kit (Sigma-Aldrich, 
UK) following the manufacturer’s instructions for each stain. For the Coomassie stain, the 
gels were washed three times with distilled water after electrophoresis, five min each, then 
stained with the safe blue stain for 1 h with continuous shaking on a Gyro-rocker (Stuart 
Scientific, UK). De-staining was performed using distilled water for 3 successive hours 
with water changes each 1 h. For silver staining, gels were fixed in 100 mL of fixing 
solution (Appendix 1) overnight on a rocking platform. The fixative was discarded, and 
gels were washed with 100 mL ethanol wash solution (Appendix 1) for 10 min. Gels were 
washed with 200 mL of ultrapure water for 10 min. Water was decanted and 100 mL of 
sensitizer solution (Appendix 1) was added with shaking on the rocker for 10 min. Washes 
were preformed twice as before then 100 mL of silver solution (Appendix 1) was added 
                                                                                                                          Chapter Two 
 
 
  43 
with shaking for 10 min. Following washing for 1 min as mentioned before, 100 mL of 
developer solution (Appendix 1) were added with shaking for 4 min until protein bands 
were developed. The reaction was then stopped by adding 5 mL of proteosilver stop 
solution with shaking for 5 min. The stop solution was decanted, and the gels were washed 
with 200 mL of ultrapure water for 5 min. After staining, the gels were scanned using an 
Epson expression 1680 artist scanner (Epson, USA). The image obtained was evaluated 
using Irfanview software (http://www.irfanview.com). 
For investigation of presence of polysaccharides and/or lipopolysaccharides within 
the proteome of the Fno whole cell lysate, proteinase-K digestion was performed 
following the method described by Kay et al. (2006) with some modifications. Briefly, 
Fno suspension (OD600 0.4) was incubated with 2X sample buffer (1:1) as mentioned 
above, cooled at room temperature (RT) (22°C) for 5 min then mixed with 10% (v/v) 
proteinase-K (1mg/mL) (ThermoFisher Scientific, UK) and incubated at 60°C overnight 
followed by another incubation at 100°C for 10 min to inactivate the enzyme and stop 
digestion. The digested proteins were centrifuged for 10,000 × g at 4°C for 5 min and 
transferred to new set of tubes. 15 µL of the digested protein samples were resolved on 
SDS PAGE, stained with Coomassie blue and silver stain and gel images analysed as 
mentioned previously. Non-digested protein samples were included as controls.  
2.2.4. 2D SDS-PAGE (2-DE) 
Fifty µg of each cleaned and quantified protein sample were mixed with 125 µL of 
rehydration buffer (Appendix 1) containing 0.5% (v/v) IPG buffer pH 4-7 (GE Health 
care, Sweden) followed by a quick mix on vortex. The samples were used to passively 
rehydrate Immobilized pH gradient strips (IPG strips) (7 cm, pH 4-7, Bio-Rad, USA) in an 
IPG Box (GE Health care, Sweden) for 20 h at room temperature (22°C).  
 The first-dimensional isoelectric focusing (IEF) and second-dimensional SDS-gel 
electrophoresis were performed according to the Amersham Biosciences manual (Berkel-
man and Stenstedt, 1998). Separation of proteins in the first-dimension was performed 
using an IPGphor Ettan isoelectric focusing system (Amersham, Pharmacia, Biotech, 
USA) in an Ettan IPGphor cup loading manifold (GE Health care biosciences, AB). The 
manifold was placed on the focusing unit first then 9 mL/well of immobilline drystrip 





up in each well then 2 wicks pre-wet with 150 µL of distilled water were placed 
overlapping the 2 ends of the strips. The electrodes were placed on the top of the wicks 
and their locks were closed. The IPG strips were run at a constant temperature of 20°C 
through a stepwise incremental voltage program consisted of 300 v for 30 min (step-on-
hold), 1000 v for 30 min (gradient), 5000 v for 90 min (gradient) and 5000 v for 25 min 
(gradient) with constant electric current of 50 mA/strip. After the IEF, the strips were 
washed twice with ultrapure water then equilibrated by a two-step-equilibration on a 
rocking platform for 15 min. Initially, strips were equilibrated in equilibration buffer I 
(DDT-equilibration buffer) (Appendix 1) followed by a washing step with ultrapure water 
then a second equilibration was performed by equilibration buffer II (Iodacetamide-
equilibration buffer) (Appendix 1). The second-dimension protein separation was done 
using 12% (non-gradient) IPG/prep-well Mini-Protean TGX™ Precast gels (Bio-Rad, 
USA). The gels were assembled in the same electrophoresis system used in the 1D PAGE 
step then 150 µL of agarose sealing solution (Appendix 1), pre-heated at 89°C in heat 
block, was placed on top of the gels followed by placement of IPG strips. A filter paper 
soaked with 5 µL of precision protein dual colour molecular weight standard (Bio-Rad, 
USA) was added on the anodic (positive) end of the strip. An extra 100 µL of the agarose 
sealing solution was added to fix the strip and the filter paper with the marker in tight 
contact with the gel. Electrophoresis and gel staining were performed as mentioned in 
Section 2.2.3. Following staining, gels were scanned with Image scanner III (GE 
Healthcare, Sweden) using lab scan software and the images were viewed using Irfan view 
image viewer software. Three technical replicate gels were used for analysis.  
2.2.5. Image analysis and statistical significance  
The gel images were analysed using ImageMaster™ 2D Platinum 7 (GE Healthcare, UK). 
The outer edges of the images were identically cropped using the automated crop tool. 
Stain background were filtered and the standardised areas of interest from all gels were 
matched and wrapped. Matching of gel images was performed using the software and by 
visual inspection as well. Density of each protein spot was normalised by linear regression 
model and statistical significance of protein spot expression was determined using 
ANOVA in the ImageMaster™ 2D Platinum 7 software package, where statistical 
significance level was set at p < 0.05. Gel spots showing highly significant different 
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abundance between isolates were excised from the gel using EXQuest Spot cutter (Bio-
Rad, USA) to be used for protein identification.  
2.2.6. Immunoblotting  
2.2.6.1. Fish serum  
Archived hyper immune serum samples collected from red Nile tilapia (12 ± 0.2 g), 
following an intraperitoneal (i.p.) vaccination and challenge were used in this experiment. 
The fish were stocked in triplicate static 15 L tanks with 20 fish each,  i.p. injected with 
0.1 mL of adjuvanted inactivated vaccine produced using Fno UK isolate (STIR-GUS-
F2f7) at a concentration of 1×109 CFU/mL at 28 ± 2°C, then i.p. challenged at 23± 2°C 
with 0.1 mL of lethal dose (LD70) of Fno UK (1×106  CFU/mL), Fno Mexican (3.1 ×104 
CFU/mL), Fno Austrian (3.1 ×105 CFU/mL) or Fno Costa Rican (3.1 ×104 CFU/mL) 
isolates. The individual serum samples were obtained at 30 days post-vaccination (dpv) 
from vaccinated and mock vaccinated fish (PBS only) and at 15 days-post challenge (dpc) 
from survivor fish in all the challenged groups. Anti-Fno UK IgM were measured by 
indirect ELISA and serum samples with high levels were used for performing western 





Table 2.2. Summary of tilapia vaccination experiment.  
Fish serum OD 450 of Anti-Fno IgM measured by ELISA  





 Fish 1 Fish 2 Fish 3 Fish 4 Fish 5   
Vaccinated (30 dpv) 0.690 0.557 0.643 0.0575 0.079 ------- -------- 
PBS control (30 dpv) 0.126 0.0614 0.201 0.128 0.215 ------- -------- 
Vaccinated and Fno UK challenged (15 dpc) 1.21 1.09 1.23 1.14 0.9035 50% 47% 
Vaccinated and Fno Mexico challenged (15 dpc) 1.01 1.12 0.96 0.849 1.078 83.3% 11.7% 
Vaccinated and Fno Austria challenged (15 dpc) 1.06 0.969 1.095 0.9545 1.15 83.3% 11.7% 
Vaccinated and Fno Costa Rica challenged (15 dpc) 1 1.13 0.93 0.925 1.025 80% 12.6% 
Non-vaccinated (PBS only) and Fno UK challenged  
(15 dpc) 
1.06 0.89 0.98 0.993 1.13 94.4% -------- 
Non-vaccinated (PBS only) and Fno Mexico challenged  
(15 dpc) 
0.861 0.918 0.829 0.815 0.902 94.4% -------- 
Non-vaccinated (PBS only) and Fno Austria challenged  
(15 dpc) 
1.13 0.92 0.95 0.97 0.876 94.4% -------- 
Non-vaccinated (PBS only) and Fno Costa Rica challenged  
(15 dpc) 
0.752 0.90 0.892 0.532 0.91 91.6% -------- 
* OD450 readings of serum IgM are average of 2 parallel wells. CPM: Cumulative percent mortality, RPS: Relative percent of survival.
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2.2.6.2. 1D Western blotting  
Immunoblotting was performed to detect the antigenic protein bands in the Fno whole cell 
lysate of the different isolates using pooled hyper-immune sera (n= 3) collected from 
survivor tilapia 15 dpc with 106 CFU/mL (LD60) of Fno STIR-GUS-F2f7 isolate as 
described in Section 2.2.6.1. Individual sera used in the pool had high levels of specific 
anti-Fno-IgM, as measured by indirect ELISA (Table 2.2). Pooled sera (n=3) from mock 
vaccinated tilapia (PBS only) was used as a negative control.  
The whole cell lysates of the five Fno isolates were resolved on a 12% NuPAGETM 
Novex® Bis-Tris gel (NuPAGETM , Invitrogen, USA) in NuPAGETM MES-SDS running 
buffer (ThermoFisher Scientific, UK) at 200 V (constant) for 45 min. Folllwoing 
electrophoresis, the separated proteins were transferred to a nitrocellulose membrane 
(Invitrogen, USA) at 30 V (constant) for 45 min using 1X NuPAGETM Transfer buffer 
(ThermoFisher Scientific, UK). Two separate membranes were used in this experiment, 
one for blotting with the Fno UK infected fish sera pool while the other was used for the 
control fish sera pool. Following transfer, the membranes were washed for 5 min in Tris-
buffer saline (TBS) (Appendix 1) and blocked overnight at 4°C in TBS with 5% (w/v) 
dried skimmed milk (Marvel, Premier Foods Group Ltd, UK). After washing 3 times with 
TBST (Appendix 1) for 10 min on each wash, the membranes were incubated for 3 h at RT 
(~22oC) with continuous agitation on a Gyro-rocker (Stuart Scientific, UK) with 5 mL of 
1:50 diluted convalescent or control pooled fish sera in TBS with 1% (w/v) BSA (Sigma-
Aldrich, UK), respectively. Washing was repeated as described before, then 5 ml of 1:50 
mouse anti-tilapia IgM monoclonal antibody (Mab) (Fo4, Aquatic Diagnostics Ltd, UK) in 
TBS was added to each membrane and incubated with continuous shaking at RT for 1 h. 
Following washing, 5 mL of 1:200 goat anti-mouse HRP MAb (Sigma-Aldrich, UK) in 
TBS was added to each membrane with incubation for 1 h at RT. The membranes were 
then washed 3 times with TBST and once with TBS for 5 min, before the reaction was 
developed by adding 5 mL of ImmPACT DAB peroxidase substrate (Vector laboratories 
Ltd, USA) to the membranes with incubation for 2 min. The reaction was stopped by 
addition of 5 mL of distilled water. Membranes were left to dry then scanned using an 
Epson expression 1680 artist scanner (Epson, USA). Two technical replicate immuno-blots 





2.2.6.3. 2D Western blotting  
2D-immunoblotting was only preformed for the Fno UK isolate as this isolate was used 
previously for vaccine formulation (Ramirez-Paredes, 2015). 2D-PAGE of the Fno UK 
was done as described in Section 2.2.4 and western blot was performed as described in 1D 
blotting in Section 2.2.6.2. Four blots were prepared in this experiment, the first was 
blotted with pooled vaccinated fish sera 30 dpv (n= 3), the second was blotted with pooled 
control (PBS only) fish sera (n= 3), the third membrane was blotted with pooled sera from 
vaccinated fish which survived challenge with 106 CFU/mL (LD60) of Fno UK isolate 15 
dpc (n= 3) and the fourth membrane was blotted with pooled sera obtained from survivor 
non-vaccinated fish (n= 3) after challenge with 106 CFU/mL (LD60) of Fno UK isolate. 
Membranes were left to dry, scanned as described in Section 2.2.6.2, then matched using 
the image analysis software (ImageMaster™ 2D Platinum 7) followed by a manual 
inspection for the spot detected by the software.  
2.2.7.  Identification of proteins of interest  
2.2.7.1. In-gel tryptic digestion and identification of antigenic proteins on 1D-gel by 
liquid chromatography electrospray ionisation mass spectrometry (LC-ESI-MS/MS) 
Gel band on whole cell lysate corresponding to the immuno-dominant band on the 1D blot 
was excised and sliced horizontally from top to bottom to yield a series of equal slices of 
2.5 mm deep. Each of the resulting gel slices was then subjected to standard in-gel 
destaining, reduction, alkylation and trypsinolysis procedures as previously described by 
Shevchenko et al. (1996), with some modifications. Briefly, the gel slices were destained 
in 100 µL destaining solution (Appendix 1) at RT (~22°C) for 45 min on a KZ-variable 
speed vortex mixer (Cole-Parmer, UK) with removal of the destaining solution each 15 
min. 100 µL of dehydration solution (Appendix 1) was added and mixing was done as 
before for 30 min with removal of solution every 10 min. Gel pieces were spun down at 
2,000 × g for 30 s and all liquid was removed. Reduction was done by adding 100 µL of 
reduction solution (Appendix 1) followed by incubation at 50°C for 30 min then the liquid 
was removed by centrifugation as described above. 100 µL of alkylation solution 
(Appendix 1) was added followed by 30 min incubation at RT in the dark and liquid was 
removed by centrifugation  at 2,000 × g for 20 min. Rehydration was repeated for 10 min 
and the gel pieces were dried in a SpeedVac centrifuge (Eppendorff, USA) for 30 min. 
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Digestion buffer (Appendix 1) at afinal concentration of 20 ng/ µL was added followed by 
incubation for 16 h at 37°C. The peptides were collected by centrifugation, dried in the 
SpeedVac centrifuge and resuspended in 0.1 % trifluoroacetic acid (Sigma-Aldrich, UK). 
The samples were transferred to HPLC sample vials and stored at 4°C until required for 
LC-ESI-MS/MS analysis. Liquid chromatography (LC) was performed following the 
protocol described by Batycka et al. (2006) using a Dionex Ultimate 3000 nano-HPLC 
system (ThermoFisher Scientific, Hemel Hempstead, UK) comprising a WPS-3000 well-
plate micro auto sampler, a FLM- 3000 flow manager and column compartment, a UVD-
3000 UV detector, an LPG-3600 dual-gradient micro-pump and an SRD- 3600 solvent 
rack controlled by Chromeleon chromatography software 
(www.thermoscientific.com/dionex). Briefly, a micro-pump flow rate of 246 µL/min was 
used in combination with a cap-flow splitter cartridge, affording a 1/82 flow split and a 
final flow rate of 3 µL/min through a 5 cm × 200 µm I.D. monolithic reversed phase 
column (ThermoFisher Scientific, UK) maintained at 50°C. Samples of 4 µL were applied 
to the column by direct injection. Peptides were eluted by the application of a 15 min 
linear gradient from 8% to 45% solvent (80% acetonitrile, 0.1% (v/v) formic acid) and 
directed through a 3 nL UV detector flow cell. LC system was interfaced directly with a 3-
D high capacity ion trap mass spectrometer (Esquire HCTplusTM, Bruker Daltonics, 
Bremen, Germany) via a low volume (50 µL/min maximum) stainless steel nebuliser 
(G1946-20260 Agilent Technologies, Wokingham, UK) and ESI. Parameters for tandem 
MS analysis were set as previously described (Batycka et al., 2006) including the 
following conditions: spray voltage 4500 V; ion charge control 300–1700 (standard–
enhanced); MS/MS scan (m/z) 200-2000 (ultrascan); precursor numbers = 4; active 
exlusions 0.5–0.8/ min; averaging 2–5 r and neublizer power 15 psi. Technical controls 
included BSA standard and a blank gel slice. 
2.2.7.2. In-gel tryptic digestion and identification of antigenic protein spots on 2D gels 
by MALDI-TOF-MS.  
In-gel-digestion of the spots of interest was done using the same protocol described in 
Section 2.2.7.1. The digested concentrated peptides were applied to a steel MALDI sample 
target plate in a solution of 10 mg/mL a-cyano-4-hydroxycinnamic acid (CHCA) in 0.1 % 





were obtained using an Ultraflex II TOF/TOF instrument (Bruker Daltonics, USA) 
operated in the reflectron mode. The instrument was calibrated using known peptide 
standards (Bruker Daltonics PepMix 2, USA). Each spectrum was produced by 
accumulating data from 10 × 100 consecutive laser shots.  
2.2.8. Data analysis and database mining 
Deconvoluted MS/MS data in Mascot generic format (mgf) was imported into 
ProteinScape™ V3.1 (Bruker Daltonics, USA) for downstream database mining of the 
available annotated cognate chromosomal and plasmid Fno protein database derived from 
genomic sequences available at the National Centre for Biotechnology Information 
(Genbank), (http://www.ncbi.nlm.nih.gov) (Table 2.3.) and the NCBInr Fno sub-database, 
utilising the Mascot™ V2.5.1 (Matrix Science, London, UK) search algorithm (Perkins et 
al., 1999). The protein content of the individual gel slices was established using the 
“Protein Search” and “Protein Compilation” features of the ProteinScape™ software. The 
separate compilation of the proteins contained in the gel slices of each of gel replicates 
was formed using the “protein extractor” feature of the software. Data was searched 
specifying Trypsin and Trypsin/P. Spectra used for protein identifications were re-
searched against the available database to ensure accurate peptide assignments. Mascot 
search parameters were set in accordance with published guidelines (Taylor and Goodlett, 
2005). To this end, fixed (carbamidomethyl “C”) and variable (oxidation “M” and 
deamidation “N,Q”) modifications were selected along with peptide (MS) and secondary 
fragmentation (MS/MS) tolerance values of 0.5 Da, whilst allowing for a single 13C 
isotope. Molecular weight search (MOWSE) scores attained for individual protein 
identifications were inspected manually and considered significant only if two or more 
peptides were matched for each protein, and each matched peptide contained an unbroken 
“b” or “y” ion series represented by a minimum of four contiguous amino acid residues.  
For the MALDI-TOF, peptides were identified by matching the measured 
monoisotopic masses to theoretical monoisotopic masses generated using MASCOT V 
2.5.1 search engine, peptide mass fingerprinting (PMF). The search parameters were 
maximum of one missed cleavage by trypsin, variable modification of oxidation of 
methionine (M), modification of cysteine by propionamidation and carbamidomethylation 
(C), peptide tolerance of ± 50 ppm, fragment mass tolerance of ± 0.2 Da and peptide 
charge of +1. The available Fno database (Table 2.3.) was used for downstream mining 
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and Mascot scores greater than 43 were considered significant (P <0.05). A minimum of 
two peptide fragmentation spectra, peptide z-score higher than six and p-value lower than 
106 were required for successful match achievement. 
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2.2.9. Bioinformatics Analysis  
The PSORTb algorithm (http://www.psort.org) was used to predict the subcellular location 
of identified proteins. The putative functional classification of the identified proteins was 
obtained by comparison of predicted proteins against clusters of orthologous groups of 
proteins (COGs) database using the EggNOG v4.5 server (http://eggnog.embl.de). 
Lipoproteins were identified using the LipoP 1.0 server 
(http://www.cbs.dtu.dk/services/LipoP-1.0/) and the presence of signal peptides sequence 







2.3.1. 1D PAGE, immunoblotting and identification of proteins by LC/ESI/MS/MS 
The resolved 1D gels showed a homogenous protein pattern in all the whole cell lysates of 
the five Fno isolates with both Coomassie safe blue stain (Figure 2.1A) and silver stain 
(Figure 2.1B). Immunoblotting with the hyper immune serum revealed a strong immuno-
dominant band corresponding to a protein band between 17-28 kDa and another faint band 
corresponding to a protein band between 49-62 kDa (Figure 2.2B). Blotting with the serum 
from control fish did not show any immunoreactivity with the whole cell lysate of any of 
the tested isolates (Figure 2.2C). The abundant immunoreactive protein band between 17-
28 kDa observed on the 1D- PAGE of the whole cell lysate of Fno UK isolate was selected 
for identification by LC/ESI/MS/MS. Analysis of this band revealed a total number of 47 
proteins, which were confidently identified and catalogued after downstream searching of 
the available Fno database. The identified proteins are listed in Table 2.4.  
The protein extracts digested with proteinase-K showed no protein bands when 
stained with Coomassie blue stain, while an abundant band between 20-37 kDa and 
another faint band between 15-20 kDa were observed when stained with Silver stain in all 
the isolates. The digested and non-digested Fno whole cell proteins resolved in the 1D gel 
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Figure 2.1. 4-15% gradient 1D-SDS PAGE showing the protein profile of the whole cell 
lysate of five Fno isolates. (A) 1D gel stained with SimplyBlue Safe Coomassie stain, (B) 
1D gel stained with ProteoSilver™ plus silver stain. Lanes: M: protein standard; 1: Fno 
UK isolate; 2: Fno Austrian isolate; 3: Fno Mexican isolate; 4: Fno Costa Rican isolate; 5: 
Fno Japanese isolate. Each gel is a representative of duplicate gels analysed. 
  
Æ 
















Figure 2.2. 1D Western blot of the different Fno isolates using tilapia hyper-immune 
serum. SimplyBlue Safe Coomassie stained 12% non-gradient 1D-SDS PAGE (Reference 
gel) (A) and representative immunoblots of whole cell lysate of 5 Fno isolates (B; C). A 
conserved strong immuno-dominant band between 17-28 kDa and faint antigenic band 
between 49-62 kDa were highlighted in all whole cell extracts when screened with 
hyperimmune serum (HIS) collected from surviving tilapia (B), while no 
immunoreactivity was observed with the control serum (C). Solid arrow refers to the 
immunogenic bands in the blots and dotted arrows refer to their corresponding protein 
bands in the reference 1D gel. M: protein standard; Lane 1: UK isolate; Lane 2: Austrian 
isolate; Lane 3: Mexican isolate; Lane 4: Costa Rican isolate; Lane 5: Japanese isolate. 
Each blot is a representative of duplicate blots. 
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Figure 2.3. Proteinase-K digestion of the whole cell lysate of five Fno isolates. 4-15% 
gradient 1D PAGE of whole cell lysate of different isolates of Fno stained with 
SimplyBlue Safe Coomassie stain (A) and ProteoSilver™ plus silver stain (B). M: Protein 
marker, UK+: Protienase-K digested Fno UK isolate, UK-: non-treated Fno UK isolate, 
CR+: Protienase-K digested Fno Costa Rican isolate, CR-: non-treated Fno Costa Rican 
isolate, MX+: Protienase-K digested Fno Mexican isolate, MX-: non-treated Fno Mexican 
isolate, AUS+: Protienase-K digested Fno Austrian isolate, AUS-: non-treated Fno 
Austrian isolate, JP+: Protienase-K digested Fno Japanese isolate, JP-: non-treated Fno 
Japanese isolate. Asterisks (black and white) refer to the original abundant band before 
proteinase-K treatment. Arrows refer to the observed bands on the digested protein 






















































[kDa] pI Scores Peptides 
SC 
[%] 
1 gi|300193842| IglC  22.1 5.3 1304.4  13 74.7 
3 gi|504528404| enoyl-ACP reductase I  27.7 5.5 422.3 8 49 
4 gi|564748870| 3-methyl-2-oxobutanoate hydroxymethyltransferase  28.1 5.6 789.7  14 60.0 
5 gi|386871721| Carbonate dehydratase  26.0 6.0 728.1  13 76.5 
6 gi|504527238| 50S ribosomal protein L5  20.0 9.7 651.7  14 65.9 
7 gi|505427577| 50S ribosomal protein L1  24.5 9.5 641.5  13 50.6 
8 gi|504527248| 30S ribosomal protein S4  23.2 10.4 618.2  13 53.9 
9 gi|386872019| Oxidoreductase, short-chain dehydrogenase family protein  26.0 5.3 603.9  10 49.6 
10 gi|386870855| Septum formation inhibitor protein 24.7 6.3 541.6  10 51.6 
11 gi|504527226| 50S ribosomal protein L3  22.1 9.5 498.8  8 48.6 
12 gi|504527828| IglA  20.4 8.6 494.2  9 47.2 
13 gi|386871670| Purine-nucleoside phosphorylase  26.9 5.2 486.7  9 43.8 
2 gi|504527915| AhpC/TSA family peroxiredoxin 21.8 5.0 472.4  15 65.9 
14 gi|504527815| Beta-ketoacyl-ACP reductase  26.3 9.6 460.0  7 48.2 
15 gi|386871074| Superoxide dismutase  22.0 5.7 453.5 8 51.0 
16 gi|504527224| 30S ribosomal protein S7  17.8 10.1 793.8 13 55.4 
17 gi|504527529| Succinate dehydrogenase iron-sulfur subunit  26.5 8.8 415.7  8 38.6 
18 gi|504527053| Chorismate mutase  20.3 9.2 238.2 4 16.7 
19 gi|504527242| 30S ribosomal protein S5  17.5 10.0 385.8 6 40.4 
20 gi|504527683| DNA-binding response regulator  25.5 6.2 368.4  5 32.0 
21 gi|504527216| 30S ribosomal protein S2  26.5 8.8 368.1  6 24.7 
22 gi|386871086| Triose-phosphate isomerase  27.6 5.0 347.5  6 42.3 
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Table 2.4.  continued      
23 gi|504527227| 50S ribosomal protein L4  22.5 10.0 333.7  6 35.7 
24 gi|752587925| SAM-dependent methyltransferase  24.7 9.0 322.1  5 26.5 
25 gi|855345305| Transcription antitermination/antitermination protein NusG  20.0 6.8 312.7  7 41.2 
26 gi|386870760| Ribosome recycling factor  20.6 5.4 282.7  5 32.4 
27 gi|504527082| Hypothetical protein_OOM_0066  25.3 5.6 177.2  4 27.6 
28 gi|504527834| Hypothetical protein  24.3 5.6 274.5  5 33.5 
29 gi|504528221| Acyl dehydratase  19.7 6.6 170.3  3 26.8 
30 gi|386871930| Deoxycytidine triphosphate deaminase  21.1 6.6 239.9  5 36.7 
31 gi|504527232| 30S ribosomal protein S3  24.5 10.0 411.1  8 44.4 
32 gi|504527329| OmpA family peptidoglycan-associated lipoprotein  23.4 4.8 233.4  5 32.5 
33 gi|386872073| Nucleoside-triphosphate-adenylate kinase  24.2 6.9 233.4 4 22.7 
34 gi|504527240| 50S ribosomal protein L6  19.2 9.7 229.1  4 23.0 
35 gi|386871705| Rhodanese-like family protein  27.9 5.0 205.3  6 26.5 
36 gi|386817600| Protein-L-isoaspartate O-methyltransferase 23.6 5.6 160.7  4 30.1 
37 gi|504527492| NADH-quinone oxidoreductase subunit-C  25.3 6.5 160.4  4 29.3 
38 gi|564748113| Activator of osmoprotectant transporter  27.6 9.0 137.0  4 24.6 
39 gi|386871417| 3-deoxy-D-manno-octulosonate 8-phosphate phosphatase  20.1 5.6 125.8  3 24.0 
40 gi|386870946| Chromosome partition protein A, ATPase  23.7 5.3 123.0  2 13.2 
41 gi|504527846| CBC domain pair protein  22.9 6.8 114.7  2 18.0 
42 gi|504527578| 50S ribosomal protein L10 18.7 9.1 110.8  2 20.3 
43 gi|504527806| Hypothetical protein OOM_0903  27.7 8.4 103.3  3 15.1 
44 gi|386871751| Isoprenoid biosynthesis protein  23.7 4.6 98.4  2 10.5 
45 gi|504527599| Hypothetical protein OOM_0658  23.7 6.1 96.8  2 10.4 
46 gi|386871418| Inorganic diphosphatase  19.5 4.8 71.6  2 15.6 
47 gi|386871579| Hypothetical protein OOM_1153  25.3 5.4 68.4  2 14.9 





2.3.2. 2D PAGE, immunoblotting and identification of proteins by MALDI-TOF/MS 
Following staining of the whole cell proteins of the five isolates, well resolved and 
reproducible 2D gels were produced as shown in Figure 2.4. Following the automated spot 
detection in the image analysis software (ImageMaster™), high similarity in distribution 
of the protein spots between the isolates and an average of 73 matched protein spots were 
detected unambiguously in all gels, while 2 protein spots (defined as 57, 58) were only 
detected in the 2D gels of Fno Japanese, Mexican, Austrian and Costa Rican isolates and 
absent in all gel replicates of the Fno UK isolate (Figure 2.5). Confirmation of the spot 
detection was done using the class analysis feature in ImageMaster™. Variations in the 
spot intensities were also detected after comparing the gels, where the abundance of 15 
protein spots were significantly different between isolates (p < 0.05) (Table 2.5). Three of 
these spots (56, 57 and 58) showed high significant difference in their intensities between 
the gels (p < 0.0001). Significantly higher abundance of 10/15 of these protein was 
observed in the Fno UK whole cell lysate, while significantly higher abundance of 2/15 
was observed in both the Japanese and Mexican Fno isolates and 1/15 was significantly 
higher in the Fno Costa Rican isolate. In addition, significantly lower abundance of two 
proteins were observed in the Austrian strain only compared to the other Fno isolates. 
Protein spots that were missing in the UK isolate or those showed highly significant 
differences in their intensity/abundance between the different isolates (spots 56; 57; 58) 
were subjected to identification by MALDI-TOF-MS. Analysis showed that all the three 
selected proteins were identified as “Aconitate hydrates” that also displayed multiple 
charge variants (Table 2.6). 
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Table 2.5. Abundance and statistical analyses of matched spots in 2-DE of 5 Fno isolates 













Density of spots Stats 
(ANOVA) 
1 5 0.094748 0.09716 0.124118 0.073305 0.090195 NS 
2 5 1.730390 1.99387­  1.835790 1.815881 1.720011 ** 
3 5 1.844110  1.72557 1.423520 1.473521 1.748050 NS 
4 5 0.147536 0.12490 0.171677 0.179181   0.126230 NS 
5 5 0.085782 0.07208 0.089223  0.054544 0.054112 NS 
6 5 0.175736  0.15078 0.169914 0.123109 0.141955 NS 
7 5 0.181725 0.20085  0.176306 0.194875 0.150568 NS 
8 5 8.259901  7.18432 6.267650 6.016310 7.423491 NS 
9 5 0.071566  0.05167 0.068959 0.054316 0.043227 NS 
10 5 2.705111 3.05892­ 2.513631 2.418775 2.727912 * 
11 5 0.105820  0.09210 0.103413 0.079054 0.077779 NS 
12 5 0.303575 0.37762  0.303154 0.293768 0.294687 NS 
13 5 0.575145  0.52014 0.463341 0.394732 0.501969 NS 
14 5 2.008650 1.80723 1.948122 2.132020  1.858382 NS 
15 5 0.898633 1.04252 0.935625 1.005761 1.042792 NS 
16 5 1.614191 1.46542 1.484113 1.734991  1.523023 NS 
17 5 1.172660 1.11321 1.366261 1.243210 1.335304 NS 
18 5 0.078258 0.09485  0.077931 0.069849 0.075794 NS 
19 5 0.894911 1.00091 0.906052 1.020090 0.960755 NS 
20 5 1.107091  1.07909 0.997563 0.978928 1.018751 NS 
21 5 1.090322 1.19339 1.248711 1.152131 1.262891  NS 
22 5 1.542191 1.31269 1.320961 1.592010 1.371970 NS 
23 5 0.150691  0.14423 0.143639 0.115394 0.121683 NS 
24 5 0.047792 0.06237  0.055938 0.048826 0.052949 NS 
25 5 2.320920 2.78374 2.358032 2.967091  2.624230 NS 
26 5 0.078137 0.18604­ 0.119553 0.099245 0.066148 * 
27 5 0.137551 0.24101­ 0.165299 0.151702 0.177732 * 
28 5 0.997432 1.04121 1.002712 0.990866 1.072699  NS 
29 5 0.033204  0.01661 0.020673 0.013254 0.027708 NS 
30 5 9.504591 8.28893 9.112441 10.24430  9.515443 NS 
31 5 0.391853 0.49900­ 0.414952 0.400841 0.382592 * 
32 5 0.810006 0.90209 0.879067 0.884858 0.928525  NS 
33 5 1.293972  1.16037 1.203241 1.266871 1.251276 NS 
34 5 0.686557 0.67391 0.800310 0.788019 0.862129  NS 
35 5 0.204072 0.21842  0.187659 0.207349 0.186918 NS 
36 5 0.791596 1.36584­ 0.888610 0.490198 0.542919 ** 
37 5 0.054599 0.10512­ 0.046862 0.039047 0.053033 * 
38 5 0.083494 0.11328 0.101476 0.120410  0.099811 NS 
39 5 0.071243 0.07283 0.116764  0.091799 0.102298 NS 
40 5 0.653177 0.86085  0.692062  0.726569 0.737331 NS 







Table 2.5. continued   
42 5 1.953331 2.29020­ 2.063331 2.100101  2.023337 * 
43 5 0.146421 0.12379  0.160965 0.148257 0.142921 NS 
44 5 0.115059 0.14466  0.128464 0.126525 0.129655 NS 
45 5 4.562882 4.38837 4.583931 4.547931 4.958848  NS 
46 5 0.520711 0.54139 0.541453  0.447709 0.513428 NS 
47 5 1.732472 1.90985  1.867571 1.899760 1.786410 NS 
48 5 1.220853 1.34472  1.325412 1.309510 1.240378 NS 
49 5 0.511506 0.42174 0.598469  0.531120 0.448811 NS 
50 5 7.209882  6.72228 6.302523 7.007221 6.818084 NS 
51 5 1.099221 1.07984 1.210241 1.208811 1.166955 NS 
52 5 0.462441 0.40849 0.505604  0.418394 0.404338 NS 
53 5 0.148147  0.12517 0.138391 0.130669 0.140828 NS 
54 5 0.705584 1.251801  1.12895­ 1.204057 0.906619 * 
55 5 0.388511  0.35147 0.248408 0.370275 0.336576 NS 
56a,b 5 0.140264 1.06201­ 0.110433 0.050706¯ 0.106453 **** 
57a 4 0.290101­ ----------- 0.210617 0.117562 0.248577 *** 
58a 4 0.192966­ ----------- 0.120511 0.051151¯ 0.147096 *** 
59 5 0.125754 0.139611  0.135714 0.11459 0.122522 NS 
60 5 0.229151 0.213641  0.211082 0.237551 0.203430 NS 
61 5 0.040560 0.022835 0.029111  0.044085 0.025373 NS 
62 5 0.807514 1.11421­ 0.923391 0.812479 0.925435 * 
63 5 0.147684 0.167319 0.169524 0.160156 0.167939 NS 
64 5 0.556329 0.776350  0.732561 0.737944 0.709743 NS 
65 5 0.281874 0.376215 0.306974 0.214808 0.449110­ * 
66 5 0.911887 0.895211 0.880191 0.936491 0.950006 NS 
67 5 0.531266 0.521372 0.544602 0.545505 0.567681  NS 
68 5 0.141887  0.125542 0.118363 0.131818 0.112381 NS 
69 5 1.803991 1.887670 1.990812 1.997391 1.865739 NS 
70 5 0.350011 0.371010 0.40660­ 0.362112 0.350201 ** 
71 5 0.215786 0.245720  0.244075 0.237604 0.210836 NS 
72 5 0.072622 0.070275 0.072901 0.090270  0.073948 NS 
73 5 0.063032 0.066752 0.059972 0.091471  0.064793 NS 
 
a Protein spots that were picked for analysis by MALDI-TOF-MS due to absence in some 
isolates. b Protein spots that were picked for analysis by MALDI-TOF-MS due to strong 
significantly greater abundance in spot intensity. Proteins spots with significantly different 
abundance are in bold. ­: High abundance, ¯: Low abundance. Asterisks denote 
significance difference. NS: not significant, significant difference is represented by stars 
(NS: p > 0.05, *: p < 0.05, **: p < 0.01, ***: p < 0.001, ****: p < 0.0001). All values are 
average of triplicate readings/spot.  
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Table 2.6. MALDI-TOF-MS analysis of selected spots in Fno isolates with highly 
significant different intensities between isolates. 
Fno isolate Spot no. Accession no. Protein ID. Mw [kDa] pI Scores SC [%] 
UK 56  gi|855345336| Aconitate hydratase  102.4 5.2 280.0  43.9 
Japanese 56  gi|855345336| Aconitate hydratase  102.4 5.2 119.0  20.0 
Japanese 57  gi|855345336| Aconitate hydratase  102.4 5.2 124.0  23.3 
Japanese 58  gi|855345336| Aconitate hydratase  102.4 5.2 86.8  21.9 
Austrian 56  gi|855345336| Aconitate hydratase  102.4 5.2 68.0 14.3 
Austrian 57  gi|855345336| Aconitate hydratase  102.4 5.2 100.0 26 
Austrian 58  gi|855345336| Aconitate hydratase  102.4 5.2 56.0 13.2 
Mexican 56  gi|855345336| Aconitate hydratase  102.4 5.2 110.0 25.1 
Mexican 57  gi|855345336| Aconitate hydratase  102.4 5.2 118.0 24.6 
Mexican 58  gi|855345336| Aconitate hydratase  102.4 5.2 81.0 22.5 
Costa Rican 56  gi|855345336| Aconitate hydratase  102.4 5.2 95.0 34 
Costa Rican 57  gi|855345336| Aconitate hydratase  102.4 5.2 115.0 28.6 
Costa Rican 58  gi|855345336| Aconitate hydratase  102.4 5.2 84.0 26.4 











































Figure 2.4. 2-DE of whole cell proteins of five different Fno isolates after focusing in 7-cm IPG strips, separation on 12% SDS-PAGE 
gels and staining with SimplyBlue™ Safe Coomassie stain. Molecular mass sizes (in kDa) are noted on the left side of each gel. Plates 
1-3: replicates of Fno UK isolate, plates 4-6: replicates of Fno Japanese isolate, plates 7-9: replicates of Fno Mexican isolate, plates 
10-12: replicates of Fno Austrian isolate, plates 13-15: replicates of Fno Costa Rican isolate. Labels in squares refer to spots with 
significantly different abundance between isolates. Stars mark the spots with the highest significantly different abundance between 
isolates. Dashed arrows indicate protein spots which are missing in the UK isolate. 











Figure 2.5. Close-up image of the protein spots with highest significant intensity difference between Fno isolates (56; 57; 58). These 
spots were further identified by MALDI-TOF. A: Fno UK isolate, B: Fno Japanese isolate, C: Fno Mexican isolate, D: Fno Austrian 
isolate, E: Fno Costa Rican isolate.  
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The 2D immunoblotting was performed with the resolved whole cell extract of the Fno 
UK isolate only. A total no. of 26, 31 and 30 immunoreactive spots were highlighted by 
pooled serum samples from vaccinated (Figure 2.6B), vaccinated and challenged (Figure 
2.6C) and non-vaccinated challenged tilapia (Figure 2.6D), respectively. No specific spots 
were recognised by the control fish serum pool (Figure 2.6E). The protein spots in the 
reference gel corresponding to the immuno-reactive proteins in the different blots were 
excised by spot cutter and subjected to MALDI-TOF-MS analysis.  
The application of MALDI-TOF-MS resulted in successful identification of 28 
proteins corresponding to 31 immunoreactive spots, as some of the proteins (n=3) 
occurred in multiple charge variants. The IDs of these protein spots are listed in Table 2.7 
and their positions are marked in the reference 2D gel (Fno UK) (Figure 2.6A). Analysis 
showed that the five proteins, which were not recognised by vaccinated non-challenged 
sera (26 spots/ 23 proteins) were identified as chaperone protein-DnaK (spot 42), 
dihydrolipoyllsine acetyle transferase (spot 48), outer membrane associated protein (spot 
45), chaperone Hsp-90 Heat shock protein (spot 46) and AhpC/TSA family peroxiredoxin 
(spot 29) (Figure 2.6B). One protein (spot 30) was not recognised by non-vaccinated 
challenged sera (30 spots/ 27 proteins) and was identified as glycerophosphoryl diesterase 
(Figure 2.6D). A summary of immunoreactivity by the serum pools from different 
treatments is shown in Table 2.8 and Figure 2.7.  
  
                                              Chapter Two                  


































































































































































































Figure 2.6. Screening of the Fno UK whole cell lysate by vaccinated, control, vaccinated 
challenged and non-vaccinated challenged sera. (A) 2D PAGE reference map of Fno UK 
proteins. (B-E) representative 2D blots showing immunoreactive proteins of Fno UK 
isolate in pH range of 4-7 recognised by serum from vaccinated fish 30 dpv (B), 
vaccinated challenged fish 15 dpc (C), non-vaccinated challenged fish 15 dpc (D) and PBS 
control fish (E). Identified immunoreactive protein spots are designated by numbers that 
refer to Table 2.7.  
  




Table 2.7. Identified proteins in the reference 2-DE gel of Fno UK whole cell lysate using MALDI-TOF-MS corresponding to the 
immunoreactive spots on the 2D blots. 
spot 
no.  Accession Protein ID Mw [kDa] pI Scores Peptides SC [%] 
2 gi|855345175| Hypothetical protein  51.8 5.7 145.0  23 54.2 
4 gi|300193833| Hypothetical lipoprotein  14.24 5.52 43.7  9 48.4 
6 gi|504527329| OmpA family peptidoglycan associated lipoprotein 23.4 4.8 150.0 20 44.2 
10 gi|855345037| Intracellular growth locus protein C  22.1 5.3 165.0  16 71.8 
11 gi|386870866| OmpA family protein  47.2 6.0 183.0  19 54.5 
12 gi|504527821| Type I glyceraldehyde-3-phosphate dehydrogenase  35.4 5.9 162.0  19 71.5 
13 gi|386870616| Universal stress protein 30.1 5.4 146.0  21 80.0 
26 gi|855344042| Cell division protein  39.3 4.6 119.0  17 63.4 
27 gi|504527123| aspartate--tRNA ligase  66.7 6.0 313.0  30 50.4 
29 gi|386871478| AhpC/TSA family peroxiredoxin  21.8 5.0 135.0  13 61.8 
30 gi|855361144| Glycerophosphoryl diester phosphodiestrase 35.1 5.4 126.0  11 53.2 
31 gi|855345307| Elongation factor Tu  43.3 5.0 254.0  28 74.1 
33 gi|855345110| DNA-directed RNA polymerase alpha subunit  35.1 4.9 49.9  8 22.7 
36 gi|855345251| Chaperonin protein, GroEL  57.1 4.9 294.0  38 60.8 
37 gi|504528561| ATP-dependent chaperone ClpB *  96.0 5.4 170.0  32 42.7 
39 gi|386871625| Catalse-peroxidase  82 5.7 64.8  12 21.1 
40 gi|855345348| Succinate dehydrogenase * 65.7 5.9 258.0  29 49.2 
41 gi|504528561| ATP-dependent chaperone ClpB * 96.0 5.4 155.0  33 45.2 
42 gi|855345003| Chaperone protein – DnaK  69.0 4.8 242.0  27 45.5 





      
Table 2.7. continued      
46 gi|386870797| Chaperone Hsp90, Heat shock protein HtpG  72.2 5.3 165.0  16 29.9 
47 gi|855344195| Fumarate hydratase, class I  54.8 5.1 130.0  23 49.0 
48 gi|504527658| Dihydrolipoyl lysine-residue acetyltransferase  49.0 5.9 48.0  11 22.3 
52 gi|855345336| Aconitate hydratase * 102.4 5.2 76.9  15 17.7 
55 gi|855344149| Hypothetical protein  45.4 5.7 143.0  17 44.8 
56 gi|855345336| Aconitate hydratase *  102.4 5.2 145.0  24 24.2 
62 gi|855344037| 30S ribosomal protein S1  61.5 5.2 349.0  37 72.3 
63 gi|855345348| Succinate dehydrogenase * 65.7 5.9 222.0  22 47.7 
65 gi|855350520| Pyruvate dehydrogenase complex, E2 component 80.6 5.3 320.0  39 59.4 
67 gi|504527659| Dihydrolipoamide dehydrogenase  50.3 5.9 60.3  12 32.8 
68 gi|855345345| 
Dihydrolipoamide succinyle transferase component of 2-
oxoglutarate dehydrogenase complex, E2 component  52.5 5.0 140.0  17 40.0 
Mw: Molecular weight, pI: Isoelectric focusing point, SC: Sequence coverage percent, * Proteins with multiple charge variant. 





Table 2.8. Comparative immunoreactivity of Fno UK whole cell protein lysate with serum pools from vaccinated, control, vaccinated 





Detection by tilapia antibodies 
 
  
PBS control sera 
(30 dpv) 
  









sera (15 dpc) 
2  Hypothetical protein **, §  - + + + 
4 Hypothetical lipoprotein ** - + + + 
6 OmpA family PAL** - + + + 
10  Intracellular growth locus protein C **, § - + + + 
11 OmpA family protein ** - + + + 
12 Type I glyceraldehyde-3-phosphate dehydrogenase  - + + + 
13 Universal stress protein - + + + 
26  Cell division protein **, §  - + + + 
27  Aspartate--tRNA ligase §  - + + + 
29 AhpC/TSA family peroxiredoxin ** - - + + 
30 Glycerophosphoryl diester phosphodiesterase ** - + + - 
31 Elongation factor Tu **, §  - + + + 
33 DNA-directed RNA polymerase alpha subunit  - + + + 
36  Chaperonin protein- GroEL **, §  - + + + 
37  ATP-dependent chaperone ClpB **, §  - + + + 





      
Table 2.8. continued    
40 Succinate dehydrogenase ** - + + + 
41 ATP-dependent chaperone ClpB **, §  - + + + 
42  Chaperone protein – DnaK **, §  - - + + 
45 Outer membrane associated protein ** - - + + 
46 Chaperone Hsp90, Heat shock protein HtpG ** - - + + 
47 Fumarate hydratase, class I - + + + 
48 Dihydrolipoyl lysine-residue acetyltransferase  - - + + 
52 Aconitate hydratase **  - + + + 
55 Hypothetical protein ** - + + + 
56  Aconitate hydratase **, §  - + + + 
62 30S ribosomal protein S1, §  - + + + 
63 Succinate dehydrogenase ** - + + + 
65  Pyruvate dehydrogenase complex, E2 component **, §  - + + + 
67 Dihydrolipoamide dehydrogenase ** - + + + 
68 
Dihydrolipoamide succinyle transferase component of 2-









(+) recognised by serum, (-) not recognised by serum, (**) immunoreactive proteins previously reported in F. tularensis LVS using serum from tularemic 
patients (Janovska et al., 2007a), (§) proteins with significantly different expressions between the 5 Fno isolates as shown in Figure 2.4, dpv: days post 
vaccination, dpc: days post challenge. 





























Figure 2.7. Venn diagram showing the immunoreactive proteins identified in the Fno UK 
whole cell lysate using vaccinated, vaccinated-challenged and non-vaccinated challenged 
sera. Numbers in circles refer to number of immuno-reactive proteins, (A) proteins 
highlighted by vaccinated (30 dpv), vaccinated challenged (15 dpc) and non-vaccinated 
challenged (15 dpc) sera, (B) proteins recognised by fish after challenge (vaccinated and 
non-vaccinated challenged fish sera), (C) proteins recognised by vaccinated non-
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2.3.3. Functional analysis of the identified proteins 
All Fno immunoreactive proteins were sorted into 9 functional categories using 
bioinformatics analysis. Prediction of functions, locations and cleavage by signal peptidase 
I or II are shown in Figure 2.8. The majority of the proteins were cytoplasmic (74%), 
however, 6% were cytoplasmic membrane proteins and 8% outer membrane proteins. 
Only 3% were peri-plasmic proteins, 6% were cytoplasmic membrane proteins, while the 
other 9% were with unknown localization (Figure 2.8A). Almost 1/3 of the total 
immunogenic proteins identified were found to be involved in energy production and 
conversion (33%) whilst 18% were involved in post-translational modification and protein 
turnover and 17% were associated with translation, ribosomal structure and biogenesis 
(Figure 2.8 B). Only 14 % of the identified proteins were lipoproteins of which 6% were 
found to be cleaved by signal peptidase enzyme I (SpI) and 8% were cleaved by signal 
peptidase II (SpII) (Figure 2.8C). 
  

























Figure 2.8. Bioinformatics analysis of identified antigenic proteins in the Fno UK whole 
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2.4. Discussion  
Francisella noatunensis subsp. orientalis is one of the most threatening pathogens to the 
tilapia industry, where as few as 23 CFU are capable of causing mortalities (Soto et al., 
2009b). Understanding the mechanisms involved in pathogenesis of Fno requires 
comprehensive knowledge of the proteins involved in the infection process. As with other 
pathogenic bacteria, Fno can employ different invasion mechanisms that may involve 
expression and post-transitional modification of their proteins, especially during host-
pathogen interaction (Ravikumar et al., 2015). Since Fno was first associated with 
extensive granulomatous inflammatory disease (Kamaishi et al., 2005), various studies 
have been conducted to understand the pathogenicity basis of this important aquatic 
pathogen. While genes for some potential pathogenicity factors had been previously 
identified in Fno including igl A, B, C, D (Soto et al., 2009b), the full array of 
pathogenicity determinants remain unknown. Understanding such information will 
improve development of therapeutics, diagnostics, and control strategies against Fno 
infection.     
In the current study, a comprehensive proteomic comparison between the whole 
cell lysate of five clinical isolates of Fno from distinct geographical locations was 
performed. The comparison using 1D PAGE showed a homogenous protein pattern for all 
tested isolates. The inability to detect a clear visual difference in the proteomic patterns 
between the tested Fno isolates may be attributed to the limitation of 1DE to separate 
single proteins during electrophoresis. Thus, 2D electrophoresis (2-DE) was performed to 
investigate any difference between these isolates. The 2-DE analysis provided higher 
resolution of the protein profiles of the clinical Fno isolates, where minor differences in 
the proteome patterns were observed between the isolates using image analyser. This was 
represented by 97% matching of the gel replicates with differences noted in comparison to 
the UK isolate, which was missing 2 spots in three gel replicates. This finding was similar 
to a recent proteomic study on three isolates of F. tularensis from human patients and the 
environment where they reported 96% matching of the resolved whole cell protein profiles 
of those strains despite their different sources and locations (Kasap et al., 2017). The 
similarity reported between the Fno isolates may be due to adaptation of the Fno isolates 
to the culture conditions in vitro, resulting in a similar milieu for protein expression. This 
might mask other variations in proteomic patterns. Different protein expressions have been 
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reported in various bacteria including F. tularensis when the bacteria are grown under a 
variety of culture conditions (e.g. in vivo vs. in vitro) (Hazlett et al., 2008) or after 
exposing to stressors like hydrogen peroxide (Janovska et. al., 2007a) or iron deprived 
medium (Lenco et al., 2007). Thus, further studies comparing the protein profiles of Fno 
isolates prepared under different culture conditions will give a clear idea about the 
proteome patterns of the different isolates. This may contribute to identification of the 
metabolic networks used by the bacteria in response to the various growth conditions or 
stressors and discovery of the identity and function of previously unidentified proteins.  
Fifteen differentially expressed proteins were identified by cluster analysis and 
there was a highly significant difference in abundance of 3 of these spots between isolates. 
Interestingly, identification of the three spots from the different Fno gels by MALDI-
TOF/MS revealed a similar protein identity which was “Aconitate hydratase”. Aconitate 
hydratase was previously identified as an abundant immunogenic protein in the F. 
tularensis live vaccine strain (LVS) and found to play a role in energy production 
(Janovska et al., 2007a). It was of note that this protein was expressed as 1 highly 
abundant spot (56) in the UK isolate, while it displayed 3 variably expressed spots (56; 57; 
58) in the other isolates (i.e. Japanese, Costa Rican, Mexican and Austrian Fno isolates). 
The reason for this difference is not clear, but this may be due to the occurrence of these 
proteins as multi charge variants. This finding was previously reported with different 
proteins in 2-DE of F. tularensis whole cell preparations, where proteins displayed multi 
charge and mass variants (Hubalek et al., 2004; Janovska et al., 2007a). In addition, the 
Fno UK isolate proteome profile displayed a higher number of these significantly 
abundant proteins compared to the other isolates examined in this study. Matching these 
differentially expressed proteins with the identified proteins in the 2D reference gel map of 
Fno UK isolate used for immunoblotting (Figure 2.6A) revealed that the majority of the 
aforementioned proteins have been involved in important functions including virulence 
and pathogenicity of Francisella such as IglC, GroEL, DnaK and ClpB proteins. Taken 
together with the results of the virulence study performed by Djainal, (2018), who reported 
that the Fno UK isolate was the most virulent isolate either in a Wax moth larva (Galleria 
mellonella) model or in tilapia when compared with the Japanese, Mexican, Austrian and 
Costa Rican isolates, may explain the reason for differences in the distribution and 
expression of some proteins in the Fno UK isolate. This finding was also in agreement 
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with the proteomic comparisons carried out between high and low virulent isolates of F. 
tularensis, where identification of more proteins and /or the abundance of the proteins with 
virulence-related functions (e.g. ClpB; Heat-shock protein-20; AcpA, PilP) were reported 
in the virulent strain F. tularensis subsp. tularensis compared to the less virulent species F. 
tularensis subsp. holarctica and F. tularensis subsp. mediaasiatica (Hubaleck et al., 2004; 
Konecna et al., 2010). The minor differences in protein abundance pattern between the 
Fno isolates used in the current study might explain the variation in profile and virulence 
between these isolates. However, more studies are required to investigate any post-
translational modification (PTMs) that may take place and include more isolates of Fno 
with comprehensive identification of the differentially expressed proteins for better 
understanding of this finding. Passage history of the used isolates may have an effect on 
their virulence and possibly their protein profile. Thus, performing virulence and 
proteomic studies using recent Fno isolates may contribute to our understanding of the 
basis of variation between Fno isolates. 
In this study, the immunoproteomic analysis in association with mass 
spectrophotometry led to confident identification of immunoreactive proteins of Fno UK 
isolate after 1-DE and 2-DE immunoblotting, respectively. Twenty-two of the proteins 
identified, highlighted in Table 2.8, have also been reported as immunogenic proteins in F. 
tularensis LVS (Janovska et al., 2007a). Bioinformatics analysis of the immunoreactive 
proteins revealed different categories of proteins with different functions, including 
chaperones, cell division proteins, outer membrane proteins, chromosome partitioning 
proteins, peroxidase/catalase proteins and transporters. Interestingly, the vast majority of 
the immunoreactive proteins are involved in essential functions, and notably 33% of these 
proteins are responsible for energy production and conversion including pyruvate 
dehydrogenase complex-component E2, dihydrolipoamide succinyle transferase 
component of 2-oxoglutarate dehydrogenase complex- E2 component, aconitate hydratase, 
fumarate hydratase I, dihydrolipoyl lysine residue acetyle transferase, dihydrolipoyl 
dehydrogenase, glycerophosphoryle diester phospho diestrase, succinate dehydrogenase 
and malate dehydrogenase. The abundance of energy production-related proteins was also 
reported in whole cell extracts of various human and environmental Francisella spp. 
including F. tularensis subsp. holarctica LVS (Janovska et al., 2007a; Kasap et al., 2017) 
and F. tularensis subsp. tularensis strain SCHU S4 (Hubalek et al., 2004). Moreover, the 
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immunoreactivity of these proteins against murine or human specific anti-Francisella 
tularensis LVS sera was previously described (Twine et al. 2006, 2010; Havalsova et al., 
2005; Eyles et al., 2007; Janovska et al. 2007a, b; Sundaresh et al., 2007). 
Glycerophosphoryl diester phosphodiestrase, that was identified only with vaccinated and 
vaccinated-challenged serum, is a secreted protein previously reported as an immunogenic 
antigen in different pathogenic bacteria including Staphylococcus aureus (Nakano et al., 
2002), F. tularensis LVS (Janovska et al., 2007a), Corynebacterium glutamicum (Ishige et 
al., 2003) and Bacillus subtilis (Antelmann et al., 2000). It is worth mentioning that a wide 
range of secerted proteins are involved in mediating host-pathogen interactions and have 
been identified as potential targets for development of novel vaccines, antimicrobial 
chemotherapy and diagnostic tools (Jungblut et al., 1999; Bumann et al., 2002; Bonin-
Debs et al., 2004). Thus, identification of this protein category as immunoreactive antigens 
in the Fno proteome may indicate a role in Fno pathogenicity.  
A number of chaperone proteins (ClpB; DnaK; HtpG; groEL) and stress proteins 
(AhpC/TSA protein; universal stress protein) were identified as antigenic in Fno whole 
cell extracts. Generally, bacterial pathogens produce a number of chaperone proteins to 
promote their survival in hostile environments or during changing environments and 
periods of stress (Neckers et al., 2008). In addition, some chaperone proteins have also 
been involved in bacterial virulence (Takaya et al., 2004). DnaK chaperone assists protein 
folding and interacts with ClpB in re-stimulation of aggregated proteins after heat shock 
processes (Lund, 2001). DnaK chaperone and ClpB have been shown to be involved in the 
invasion of epithelial cells and host intra-macrophage survival, promoting successful 
systemic infection in various pathogenic bacteria including F. tularensis (Meibom et al., 
2008), Listeria monocytogens (Chastanet et al., 2004) and Salmonella enterica (Lund, 
2001). Interestingly, DnaK was not detected by the non-challenged tilapia serum and was 
only detected after challenge with Fno by vaccinates and control tilapia sera, which may 
indicate its role in host-pathogenic interaction. LaFrentz et al. (2009) reported significant 
expression of ClpB, HtpG and universal stress protein in Flavobacterium psychrophilum 
during growth of the bacterium in vivo in fish and in iron-depleted media in vitro, and they 
suggested that those proteins may be important for in vivo survival and pathogenesis of F. 
psychrophilum. Moreover, GroEL and other relevant heat shock proteins (e.g. 
Hsp90/HtpG) identified in the Fno whole cell lysate in the current study were previously 
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reported as potential targets for the anti-tularemic antibodies and could induce significant 
cellular immune response, represented by stimulation of CD4+ and CD8+ a and b T-cells 
(Lee et al., 2006). Also, the surface-associated-GroEL was reported to be crucial for 
Legionella pneumophila to be able to invade HeLa cells (Garduno et al., 1998). 
AhpC/TSA assists host-pathogen interaction and upregulated expression of this protein 
was reported in F. tularensis LVS in association with conditions that mimic the hostile 
environment such as oxidative stress (Lenco et al., 2005) and iron depletion (Lenco et al., 
2007). 
The immunoreactive intracellular growth locus-C (IglC) protein, is one of the key 
elements of the pathogenicity-life style of different members of Francisella spp. required 
with the help of others factors including ClpB and transcriptional regulator -MglA proteins 
to allow the bacteria to grow in the hostile milieu (Gray et al., 2002; Bröms et al., 2010). It 
was commonly reported as a prominent immunogenic antigen in F. tularensis LVS 
(Havlasova et al., 2002, 2005; Janovska et al., 2007a), Fnn (Brudal et al., 2015) and Fno 
(Soto et al., 2009b; Lagos et al., 2017). Mutation of IglC gene resulted in a lack of growth 
of F. tularensis and Fno in mice and tilapia models, respectively (Santic et al., 2005; Soto 
et al., 2009b). It is worth mentioning that other virulence related proteins were highlighted 
by human tularemic serum in F. tularensis LVS, including intracellular growth locus A 
(IglA), which was also co-stimulated by MglA (Janovska et al., 2007a) and was reported 
to be crucial for intracellular growth and survival of F. tularensis and F. novicida in 
human and murine macrophages, and amoebae, respectively (Barons et al., 1998; Lauriano 
et al., 2004). It is of note that IglA was not detected in the current study. This may be 
attributed to using narrow range pH IPG strips (4-7) in the current study, while IglA (pI 
8.7) was detected in F. tularensis LVS when IPG strips of pH range of 6-11 were 
employed (Janovska et al., 2007a). Moreover, the whole cell of Fno used in this study is in 
essence a soluble protein lysate so, some of the proteins present may have lost their native 
conformational structure during sample preparation, leading to a lack of recognition of the 
epitopes by the serum antibodies and consequently, lower numbers of immunoreactive 
proteins may be recognised. In addition, cell division and chromosome partitioning 
proteins (cell division protein) identified in the current Fno, have been described as 
potential drug targets against clinically important bacterial pathogens as Mycobacterium 
tuberculosis (Nisa et al., 2010). Proteins involved in transcription, translation, synthesis 
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and metabolism, which were successfully identified in Fno whole cell lysate 
(peroxidase/catalase; elongation factor TU; 30s ribosomal protein S1, proline t-RNA 
ligase; Aspartate tRNA ligase, NADP-specific glutamate dehydrogenase; type I 
glyceraldhyde-3-phosphate dehydrogenase), are also well-known targets for inhibition of 
bacterial pathogens (Hong et al., 2014). Therefore, those proteins may serve as new drug 
targets for Fno, however, more studies are required to investigate their immunogenicity in 
depth. 
 The outer membrane proteins (outer membrane protein A, OmpA family protein; 
outer membrane associated proteins), outer membrane lipo-proteins (outer membrane 
protein peptidoglycan associated lipoproteins (PALs)) and lipoproteins (hypothetical 
lipoproteins; hypothetical protein FNO12_1528; hypothetical protein FNO12_0263; 
glycerolphosphoryl diester phosphophodiesterase) were found to be immunoreactive in the 
current study. This result is consistent with the reported immunogenicity of four peptidase-
II cleaved proteins (conserved hypothetical lipoproteins; OmpA family proteins; 
hypothetical membrane protein FTT1676; lipoprotein) and 2 peptidase-I cleaved proteins 
(hypothetical protein FTT1402; glycerolphosphoryl diester phosphophodiesterase protein) 
in resolved 2-DE whole cell extract of F. tularensis LVS (Janovska et al., 2007a). OMPs 
are integral constituent of Gram-negative bacteria that play an important role in the host-
pathogen interactions, pathogenicity and resisting host defence mechanisms (Lin et al., 
2002). In addition, OMPs have been shown to provide significant protection against 
various fish pathogens (Xiong et al., 2011). Moreover, OmpA was reported to be an 
excellent vaccine candidate, as it has abundant distribution on the bacterial cell surface, 
giving it the advantage of being easily accessible to various antibodies (Huntley et al., 
2007). The efficacy of OmpA as a protective vaccine candidate was tested by producing 
specific monoclonal antibodies that induced 40-50% and 80 % survival of mice infected 
with F. tularensis LVS (Savitt et al., 2009; Hickey et al., 2011). Also, the affinity of a 
recombinant OmpA protein (FopA) of F. tularensis to anti-tularemia serum antibodies was 
tested on an ELISA assay, which showed acceptable binding in comparison with the wild 
type F. tularensis LVS (Hickey et al., 2011). This may contribute to the development of a 
new generation of diagnostic and prophylactic assays against Fno. Interestingly, three of 
the proteins that were not recognised by the sera from the non-challenged vaccinated fish, 
were recognised by challenged vaccinated and non-vaccinated fish and were identified as 
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OmpA family protein and Omp PALs. This may reflect the role of OMP in the interaction 
of Fno with their host and indicate a potential role in their virulence. There is still little 
information on the OMP of Fno. Characterisation and cataloguing of proteins of the Fno 
OMP fraction, and more importanely, identification of its immunogenic antigens, will 
enhance our understanding of the importance of this group of proteins and may give 
insight to future applications in Fno diagnostics and/or prophylaxis.  
 Proteinase-K treatment of the Fno whole cell lysates revealed that the 
corresponding antigenic band in the 1D-immunoblot (20-37 kDa) is rich in glycoproteins 
or polysaccharides as determined by silver stain, which is more sensitive than Coomassie 
blue, especially for glycoprotein and polysaccharide staining. In a previous report by Kay 
et al. (2006), a heavily stained band of ~ 20 kDa and another low molecular band of ~ 10 
kDa were highlighted in a proteinase-K digested whole cell protein lysate of an isolate of 
Fno from tilapia, named as Francisella victoria, after immunoblotting with polyclonal 
antisera. Chemical and spectroscopy analyses identified these bands as lipo-
oligosaccharides and lipoprotein bands, respectively (Kay et al., 2006). In addition, 
screening whole cell lysate of Fnn with rabbit anti-Francisella serum or serum from 
Atlantic cod (Gadus morhua, L.) vaccinated with a monovalent Fnn vaccine or a 
multivalent Fnn and Vibrio anguillarum vaccine revealed an immunodominant band of 
~20 kDa (Schrøder et al., 2009). The LPS of Francisella spp. are characterised by 
unusually low biological activity and have been targeted as a potential constituent of 
tularemia vaccines (Fulop et al., 2001; Sjostedt, 2003; Isherwood et al., 2005). Also, LPS 
have been reported as protective antigens in many fish pathogens such Aeromonas 
hydrophila (Fernandez et al., 2014), Vibrio salmonicida, V. anguillarum (Bøgwald et al., 
1992) and V. alginolyticus (Li et al., 2016). This finding may help to explain the 
immunogenicity of the dominant protein band (~ 17-28 kDa) recognised by the anti-Fno 
hyperimmune sera, provide more insight to the importance of the proteins identified in this 
band in Fno virulence and highlight their potential use as drug or vaccine candidates 
against Francisella infection in tilapia or other susceptible species. Future study is 
required to test the anti-Fno tilapia immune sera against the proteinase-K digested Fno to 
see if the antibodies will recognise the carbohydrate moieties as opposed to the protein 
components shown in the current study.    
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 2.5. Conclusions 
The present study is one of the first to compare the proteome and antigenic patterns of 
different clinical isolates of Fno. The study demonstrated considerable degrees of protein 
profile homogeneity between the geographically distinct Fno isolates, however, variable 
expressions of proteins between the isolates did exist. The limited heterogeneity of the 
antigenic profile of the diverse Fno isolates shown by the anti-Fno UK hyperimmune sera 
and the significant abundance of the majority of the highly expressed proteins in Fno UK 
isolate, including some of the biologically important proteins, may provide a new 
biological basis for immune protection by this isolate. This will have a direct impact on 
improving vaccine design for francisellosis in tilapia. The identified immunoreactive 
antigens in Fno UK isolate will facilitate a better selection of protein candidates for the 
development of new generation of diagnostic or prophylactic tools. In addition, the current 
proteomic study highlights the importance of mass spectrometric analysis for identification 
of variable expressed proteins with virulence or immune related functions. Taken together, 
the methods used in this study could support currently available diagnostic methods for 
rapid strain characterisation and differentiation, diagnosis, treatment and/or prevention of 
Fno infection. It is worth noting that, analysis of the sub-immunoproteome of insoluble 
Fno protein preparations like outer membrane enriched fraction (OMPs) may decrease the 
complexity of the sample compared to the whole cell lysate, thus may facilitate better 
protein separation and yield significant differences between isolates that were poorly seen 
by the Fno whole cell proteome analysis. Therefore, a future study is needed for separation 
and characterisation of Fno outer membrane proteome with special consideration to 
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3.1. Introduction 
Outer membrane proteins (OMPs) are specific highly conserved components of Gram-
negative bacterial cells that including individual proteins associated with bacterial 
pathogenicity (Seltman and Holst, 2002), nutrient uptake (e.g. iron), antimicrobial peptide 
resistance and survival in the host environment (Koebnik et al., 2000). Their location on 
the surface of the bacteria facilitates interaction with the host immune system and thus 
antibodies raised against these proteins are likely to result in host generated neutralising 
activity against target microorganisms (Lin et al., 2002). The OMPs of a variety of fish-
pathogenic bacteria have previously been characterised, including those of Flavobacterium 
columnare (Liu et al., 2008; Luo et al., 2016), Streptococcus iniae (Cheng et al., 2010), 
Edwardisella tarda (Kumar et al., 2009; Sun et al., 2011), Edwarsiela ictaluri (Dumpala 
et al., 2009), Aeromonas hydrophila (Wang et al., 2013), Aeromonas salmonicida (Ebanks 
et al., 2005), Vibrio harveyi (Yu et al., 2013) and Vibrio alginolyticus (Qian et al., 2008). 
A more comprehensive characterisation of this vital group of proteins facilitated 
development of new generation of diagnostic and prophylactic tools for various bacterial 
diseases of economic importance to farmed and ornamental fish species such as A. 
hydrophila (Maji et al., 2006; Thangaviji et al., 2012; Divya et al., 2015), V. 
parahaemolyticus (Mao et al., 2007), V. harveyi (Li et al., 2008; Yu et al., 2013),  V. 
alginolyticus (Qian et al., 2007) and E. tarda (Maiti et al., 2011). 
Sub-immunoproteome analysis can reduce the sample complexity compared to 
whole cell preparation via better separation of proteins (Janovska et al., 2007a) and has 
enabled comprehensive identification of specific compartments in bacterial proteomes 
(Watson et al., 2014). In chapter 2, a proteomic study using the soluble whole cell 
proteome of Fno revealed minor differences between the whole cell lysate profile of 5 
clinical Fno isolates from diverse origins. Thus, investigation of more simple insoluble 
protein preparations, such as OMP, with a potential protective antigenicity may be a useful 
alternative approach. This may provide a deeper understanding of the pathogenicity of Fno 
and help identify new immuno-relevant antigens that would be useful for the development 
of novel drug targets, diagnostics or vaccines for warm water francisellosis, as with other 
pathogens (Hickey et al., 2011; Qian et al., 2008; Lu et al., 2016). To this end, the OMP 
profiles of the previously studied isolate panel were investigated. The OMP fraction of the 
vaccine strain (UK isolate / STIR-GUS-F2f7) were selected, catalogued and proteins 
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recognised by pooled hyperimmune sera collected from infected tilapia were identified 
using LC-ESI-MS/MS.   
3.2. Materials and methods 
3.2.1. Bacterial isolates and growth conditions 
The five Fno isolates previously described in Chapter 2 were used. Cultivation of the 
bacteria was performed as previously described in Section 2.2.1, Chapter 2. 
3.2.2. Extraction of OMPs 
OMPs were obtained by the method of Gauthier et al. (2003), with slight modifications. 
Briefly, bacterial cells of each of the 5 Fno isolates in 20 mL of liquid culture were 
harvested by centrifugation at 5,000 g for 15 min at 4°C, supernatant was discarded, and 
the cell pellet was washed three times with 10 mL of chilled 50 mM Tris HCl (pH 7.0) at 
3,000 × g for 10 min. The wash buffer was discarded, and the pellet re-suspended in 1 mL 
of 50 mM Tris HCl (pH 7.0) containing 20% (w/v) sucrose, 10 mM Na-EDTA, 10 µg/mL 
lysozyme (Sigma-Aldrich, UK) and 10 µL of protease inhibitor cocktail (Sigma-Aldrich, 
UK). The cell suspension was then transferred to 1.5 mL micro-centrifuge tubes 
(Eppendorf, Germany) containing 0.1 mL Zirconium silica beads (Thistle scientific, UK), 
and cells were disrupted in a FastPrep homogeniser B101011 (MP Biomedicals, USA) for 
6 ×30 s, with cooling on ice for 5 min between each cycle. The lysate was then transferred 
to a fresh 1.5 mL micro-centrifuge tube and cell debris was removed by centrifugation at 
16,000 × g for 2 min at 4°C. The insoluble material containing the membrane proteins was 
obtained by ultracentrifugation at 100,000 × g for 40 min at 4°C, the supernatant was 
discarded, and the pellet washed by addition of 1 mL of 10 mM Tris HCl (pH 7.0), without 
re-suspension, and incubation on ice for 1 min prior to discarding the supernatant once 
more. The cell pellet was then re-suspended in 1 mL of 10 mM Tris HCl (pH 7.0) 
containing 0.5% (w/v) N-lauryl-sarcosine (Sigma-Aldrich, UK) and centrifuged at 100,000 
× g for 40 min at 4°C. The supernatant was discarded, and the cell pellet was washed in 1 
mL of 10 mM Tris HCl (pH 7.0), as previously described, before the supernatant was 
discarded, and pellets were air dried at RT (22°C) for 30 s. Finally, the pellet was re-
suspended in 1 mL of 10 mM Tris HCl (pH 7.0) containing 0.5% (w/v) N-lauroylsarcosine 
and 0.1% (w/v) SDS (Sigma-Aldrich, UK) on a variable speed vortex mixer (Cole-parmer, 
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UK) for 30 s. The protein concentration of the OMP preparations was determined by BCA 
assay (Pierce BCA protein assay Kit; Thermo, USA) according to the manufacturer’s 
instructions. Briefly, a series of 6 proteins standard dilutions (250, 125, 50, 25, 5, 0 
µg/mL) using 2 mg/mL bovine serum albumin (BSA) was prepared in duplicate 1.5 mL 
centrifuge tubes (Eppendorff, Germany). 100 µL of the crude OMPs of each isolate extract 
was added to 2 mL of working reagent in 1.5 mL centrifuge tubes in duplicates followed 
by a quick mix on a vortex mixer (Cole-parmer, UK) for 30 s. Tubes were covered by 
aluminium foil and incubated in a heat block (Iso-temp 125D, Fisher scientific, UK) at 
60°C for 30 min followed by 5 min cooling at RT (~ 22°C). The absorbance of all samples 
and standards replicates was measured using a spectrophotometer (Cecil 2301, Buck 
scientific, USA) at OD562. The protein concentration of the OMPs samples was calculated 
from the prepared standard curve and standardised to 50 µg/µL using Milli-Q water 
(Thermo, UK). Aliquots of 20 µL were prepared and stored at -80°C until use.  
 3.2.3 1D SDS-PAGE 
One hundred µg sample of the OMPs was resolved on a 12% NuPAGETM Novex® Bis-Tris 
Gel (NuPAGE ™, Invitrogen, USA) in 20X NuPAGEÔ MES-SDS running buffer 
(ThermoFisher scientific, UK) at 200 V (constant voltage) for 45 min. After 
electrophoresis, the separated proteins were stained and scanned using same conditions 
previously described in Section 2.2.3, Chapter 2. Two technical replicates of SDS-PAGE 
were performed to ensure reproducibility. 
3.2.4 Western immunoblotting  
The immunoblotting was done following the protocol described in Section 2.2.6.2, Chapter 
2. Two technical replicates of immunoblots were prepared to ensure reproducibility. Hyper 
immune serum (HIS) and control serum samples pool (n= 5) previously used in 
immunoblotting of the whole cell lysate in Chapter 2 were also used to blot the OMPs 
derived from the Fno bacterial panel resolved in Section 3.2.3.  
3.2.5. LC-ESI-MS/MS identification, data interpretation and functional analyses  
The resolved OMPs of the Fno UK isolate (STIR-GUS-F2f7) was selected for LC-ESI-
MS/MS analysis. The entire gel lane was excised and sliced horizontally to 6 slices of ~ 
2.5 mm depth. Destaining, reduction, alkylation and trypsinolysis of the resulting gel 
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slices, data analysis and interpretation and functional analyses of the identified proteins 
were performed as described in Section 2.2.7.1 in Chapter 2.  
3.3. Results 
3.3.1. 1D PAGE and immunoblotting 
Following electrophoretic separation of OMPs of the five Fno isolates (Figure 3.1A), 
immunoblotting was performed using either convalescent immune sera from Fno-infected 
tilapia or control tilapia sera. The protein profile of the five OMP extracts appeared 
homogenous with identical distribution of bands on the gel. A conserved abundant protein 
band was observed between 17-28 kDa on the stained gel, and similarly, the pooled 
immune sera reacted with an equivalent size band on the western blot of the OMPs 
extracts of the different Fno isolates (Figure 3.1B). No immuno-reactivity was detected 
with the control fish pooled sera (Figure 3.1C). 
  










Figure 3.1. Safe blue stained 12% non-gradient 1D-PAGE showing outer membrane 
proteins (OMPs) profile of five clinical Francisella noatunensis subsp. orientalis isolates 
(A) and 2 representative immunoblots (B) and (C). Immunoreactivity was seen between 
the pooled anti-Fno UK sera from tilapia surviving infection and the OMPs of the five Fno 
isolates (B), while no reaction was observed with naïve tilapia sera (C). M: Protein 
standard, 1: Fno UK isolate, 2: Fno Costa Rican isolate, 3: Fno Mexican isolate, 4: Fno 
Austrian isolate, 5: Fno Japanese isolate. Black arrows refer to the immunoreactive band 
on blot and its corresponding protein band on the 1-DE gel. Gel and blots are 






































3.3.2. Protein identification by LC/ESI/MS/MS  
Mass spectrometric analysis facilitated the confident identification of a total of 239 
proteins in the OMP fraction, including 44 proteins in the immunoreactive band (17-28 
kDa) highlighted by the immune tilapia serum pool. The top 20 protein IDs of the Fno UK 
OMPs fraction and proteins identified in the immunodominant band (17-28 kDa) are listed 
in Tables 3.1 and 3.2. The full protein lists are presented in Tables S1 and S2 in Appendix 
2.  
Comparison between the proteins identified in the immunogenic band (17-28 kDa) 
of the OMP proteome of Fno UK isolate in the current experiment and those identified in 
the corresponding band in the whole cell lysate in Chapter 2, revealed 30 common proteins 
between both preparations, 17 unique proteins in whole cell lysate only and 14 unique 
proteins in the OMP fraction only (Tables 3.3- 3.5). The score of 17/30 proteins in the 
OMP was higher than their homologues in whole cell lysate, from which OmpA 
peptidoglycan-associated lipoprotein (PAL), IglC, IglA and AhpC were the most important 
identified proteins due to their role in Francisella virulence.  
3.3.3. Prediction of function, subcellular localisation and lipoproteins of the identified 
proteins  
EggNOG v4.5, PSORTbÒ v2.0, LipoP v1.0 servers were used to predict the function, 
subcellular location and lipo-protein nature of the 239 proteins identified in the OMPs of 
Fno UK isolate. Proteins associated with translation, ribosomal structure and biogenesis 
were the most abundant (42%), followed by those involved in energy production and 
conversion (31%), and those associated with cell wall biogenesis and post-translational 
modification (20%). The sub-cellular localisation of 82.8% of the Fno OMPs was 
putatively identified, where the majority of them were cytoplasmic proteins (62%). These 
were followed by cytoplasmic membrane proteins (8.8%), outer membrane proteins 
(5.8%), periplasmic proteins (2.5%) and extracellular proteins (0.8%). Lipoproteins 
represented 16.7% of Fno OMPs. Results of bioinformatics analysis of the top 20 protein 
IDs in the Fno UK OMPs are listed in Table 3.6 and Figure 3.2. The full data are shown in 
Table S3 in Appendix 2. 
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Table 3.1. List of top 20 proteins identified in the outer membrane proteome of the Fno UK isolate  
 
No. Accession no. Protein name Mw[kDa] pI Scores Peptides SC [%] 
1 gi|300193845| PdpD  139.9 6.2 4477.2  72 61.4 
2 gi|386872131| Chaperone ClpB  96.0 5.4 2588.9  49 57.7 
3 gi|169589436| PdpD  139.6 6.1 2478.8  39 52.1 
4 gi|300193842| IglC  22.1 5.3 2388.4  14 84.2 
5 gi|386871181| Chaperonin GroEL  57.1 4.9 1857.1  33 63.7 
6 gi|103012949| Ribosomal L29e protein family  126.8 8.9 1839.5 42 46.6 
7 gi|386870877| 
OmpA family peptidoglycan-associated 
Lipoprotein  23.4 4.8 1585.1 29 75.6 
8 gi|386872079| 
Bifunctional proline dehydrogenase/pyrroline-5-
carboxylate  149.5 7.8 1539.6 33 34.6 
9 gi|300193843| IglB  57.5 4.7 1526.5  30 59.9 
10 gi|386870689| 30S ribosomal protein S1  61.5 5.2 1389.2  26 58.1 
11 gi|386870694| Cell division protein FtsZ  39.3 4.6 1354.0  24 85.4 
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Table 3.1. continued. 
12 gi|386871696| Outer membrane associated protein  41.3 5.2 1307.4  22 42.8 
13 gi|300193831| PdpA  94.9 8.9 1244.6  15 47.8 
14 gi|386870866| OmpA family protein (FopA) 47.2 6.0 1090.3  30  62.1 
15 gi|169589422| PdpB  126.5 9.2 1046.8  24 44.6 
16 gi|386871950| Ribonuclease E  101.4 8.3 1036.3  19 27.4 
17 gi|300193844| IglA  20.4 8.6 1010.3  32 57.2 
18 gi|386871082| Alpha-ketoglutarate decarboxylase 105.5 6.1 1009.2  21  27.9 
19 gi|386870797| Heat shock protein 90  72.2 5.3 992.4  21 36.9 
20 gi|386871083| 
2-oxoglutarate dehydrogenase complex, E2 
component  52.5 5.0 991.1  18 45.6 
 
MW: Molecular weight; pI: Isoelectric point; SC %: Sequence coverage percent.  
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Table 3.2. List of the top 20 proteins identified in the immunoreactive band (17-28 kDa) of the OMPs of Fno UK isolate. 
No Accession Protein name MW [kDa] pI Scores Peptides SC [%] 
1 gi|300193842| IglC  22.1 5.3 2388.4  14 84.2 
2 gi|504527828| IglA  20.4 8.6 754.5  12 74.2 
3 gi|504527329| OmpA family peptidoglycan-associated lipoprotein  23.4 4.8 753.9  9 64.9 
4 gi|504527815| Beta-ketoacyl-ACP reductase  26.3 9.6 601.2  10 55.9 
5 gi|504527529| succinate dehydrogenase iron-sulfur subunit  26.5 8.8 540.4  11 54.9 
6 gi|504527238| 50S ribosomal protein L5  20.0 9.7 526.4 11 61.5 
7 gi|504527915| AhpC/TSA family peroxiredoxin  21.8 5.0 510.0  9 59.8 
8 gi|504528404| enoyl-ACP reductase  27.7 5.5 449  11 55.4 
9 gi|386871251| Hypothetical protein OOM-0776 22.5 9.8 388.6  9 41.3 
10 gi|504527834| Hypothetical protein  24.3 5.6 376.8  5 33.5 
11 gi|504527577| 50S ribosomal protein L1  24.5 9.5 374.1  9 39.4 
12 gi|504527226| 50S ribosomal protein L3 22.1 9.5 359.4  6 40.5 
13 gi|504527216| 30S ribosomal protein S2  26.5 8.8 333.7  5 21.3 
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Table 3.2.  continued 
14 gi|855345305| Transcription termination/antitermination protein nusG  20.0 6.8 333.1 7 41.2 
15 gi|855345177| Hypothetical protein  27.9 9.4 330.4  6 27.2 
16 gi|504527578| 50S ribosomal protein L10  18.7 9.1 274.5  8 45.3 
17 gi|504527053| Chorismiteate mutase 20.3 9.2 267.1  5 40.6 
18 gi|504527683| DNA-binding response regulator  25.5 6.2 261.9  5 32.9 
19 gi|504527248| 30S ribosomal protein S4  23.2 10.4 245.0 4 24.8 
20 gi|504527363| LemA-like protein  21.9 6.0 235.4  6 37.2 
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Table 3.3. Common proteins identified in immunoreactive band (~17-28 kDa) of outer membrane protein fraction (OMPs) and whole 
cel lysate (WC) of Fno UK isolate. 
No Protein name Accession no. Meta-score Peptide no. SC (%) 
  
 OMPs WC OMPs WC OMPs WC 
1 Hypothetical protein OM_0066 ** gi|504527082| 226.3 177.2 6 4 31.2 27.6 
2 AhpC/TSA family peroxiredoxin ** gi|386871478| 510 472.4 9 15 59.8 65.9 
3 IglA ** gi|300193844| 754.5 494.2 12 9 47.2 47.2 
4 50S ribosomal protein L1  gi|504527577| 374.1 641.5 9 13 39.4 50.6 
5 Beta-ketoacyl-ACP reductase ** gi|504527815| 601.2 460.0 10 7 55.9 48.2 
6 50S ribosomal protein L3  gi|386870769| 359.4 498.8 6 8 40.5 48.6 
7 50S ribosomal protein L5  gi|504527238| 526.4 651.7 11 14 61.5 65.9 
8 30S ribosomal protein S7  gi|504527224| 220.9 793.8 4 13 31.8 55.4 
9 Protein-L-isoaspartate O-methyltransferase ** gi|386871600| 179.2 160.7 3 4 23.3 30.1 
10 50S ribosomal protein L10  gi|386871131| 274.5 110.8 8 2 45.3 20.3 
11 30S ribosomal protein S4  gi|386870793| 245.0 618.2 4 13 24.8 53.9 
12 30S ribosomal protein S3  gi|386870775| 174.4 411.1 3 8 14.9 44.4 
13 50S ribosomal protein L4  gi|504527227| 225.7 333.7 5 6 31.9 35.7 
14 IglC ** gi|300193842| 2388.4 1304.4 25 13 89.9 74.7 
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Table 3.3. continued 
15 
OmpA family peptidoglycan-associated  
Lipoprotein ** 
 
gi|504527329| 753.9 233.4 9 5 64.9 32.5 
16 
Transcription termination/antitermination  
Protein nusG ** 
 
gi|752587918| 333.1 312.7 7 7 41.2 41.2 
17 Chorismate mutase ** gi|386870594| 267.1 238.2 5 4 40.6 16.7 
18 Hypothetical protein OOM_0903 ** gi|386871365| 212.1 103.3 5 3 22.7 15.1 
19 Acyl dehydratase ** gi|386871786| 197.2 170.3 5 3 35.1 26.8 
20 30S ribosomal protein S5  gi|504527242| 208.6 385.8 4 6 24.1 40.4 
21 Enoyl-ACP reductase I ** gi|504528404| 449 422.3 11 8 46.9 49 
22 Succinate dehydrogenase iron-sulfur subunit ** gi|504527529| 540.4 415.7 11 8 54.9 38.6 
23 DNA-binding response regulator  gi|504527683| 261.9 368.4 5 5 32.9 32.0 
24 50S ribosomal protein L6  gi|504527240| 197.0 229.1 4 4 51.1 23.0 
25 CBC domain pair protein ** gi|504527846| 138.7 114.7 3 2 28.0 18.0 
26 Hypothetical protein OOM_0658 ** gi|504527599| 193.9 96.8 4 2 22.2 10.4 
27 NADH-quinone oxidoreductase subunit-C **  gi|504527492| 226.1 160.4 5 4 34.9 29.3 
28 Hypothetical protein ** gi|504527834| 376.8 274.5 5 5 33.5 33.5 
29 30S ribosomal protein S2  gi|504527216| 333.7 368.1 5 6 21.3 24.7 
30 Septum formation inhibitor protein gi|386870855| 65.3 541.6 2 10 18.0 51.6 
WC: Fno whole cell lysate, OMPs: Fno outer membrane protein extract, ** Proteins with higher score in OMPs than in whoe cell lysate 
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Table 3.4. Proteins identified only in the immunoreactive band (~17-28 kDa) of the whole cell lysate of Fno UK isolate.  
No Protein name Accession no. Meta-score Peptide no. SC % 
   OMPs WC OMPs WC OMPs WC 
1 Chromosome partition protein A, ATPase  gi|386870946| 0.0 123.0 0 2 0.0 13.2 
2 Nucleoside-triphosph—e--adenylate kinase  gi|386872073| 0.0 233.4 0 4 0.0 22.7 





gi|564748870| 0.0 789.7 0 14 0.0 60.0 
5 Carbonate dehydratase gi|386871721| 0.0 728.1  0 13 0.0 76.5 
6 Deoxycytidine triphosphate deaminase  gi|386871930| 0.0 239.9 0 5 0.0 36.7 
7 
Isoprenoid biosynthesis protein with 
amidotransferase-like domain  
 
gi|386871751| 0.0 98.4 0 2 0.0 10.5 
8 Ribosome recycling factor  gi|386870760| 0.0 282.7 0 5 0.0 32.4 
9 SAM-dependent methyltransferase  gi|752587925| 0.0 322.1 0 5 0.0 26.5 
10 Purine-nucleoside phosphorylase  gi|386871670| 0.0 486.7 0 9 0.0 43.8 





gi|386871417| 0.0 125.8 0 3 0.0 24.0 
13 Hypothetical protein OOM_1153  gi|386871579| 0.0 68.4 0 2 0.0 14.9 
14 Oxidoreductase, short-chain dehydrogenase  gi|386871579| 0.0 603.9 0 10 0.0 49.6 
15 Triose-phosphate isomerase  gi|386871086| 0.0 347.5 0 6 0.0 42.3 
16 Activator of osmoprotectant transporter gi|386878113| 0.0 137.0 0 4 0.0 24.6 
17 Superoxide dismutase  gi|386871074| 0.0 453.5 0 8 0.0 51.0 
WC: Fno whole cell extract, OMP: Fno outer membrane protein extract, SC: Sequence coverage  
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Table 3.5. Proteins identified only in immunoreactive band (~17-28 kDa) of the OMP fraction of Fno UK isolate. 
No. Protein name Accession no. Meta-score Peptide no. SC % 





gi|386870968| 126.8 0.0 2 0 11.6 0.0 
2 Glutamine amidotransferase subunit PdxT  gi|504528036| 179.6 0.0 3 0 26.8 0.0 
3 Hypothetical protein OOM_0776  gi|386871251| 388.6 0.0 9 0 41.3 0.0 
4 Hypothetical protein  gi|504528150| 118.6 0.0 3 0 12.4 0.0 
5 LemA-like protein  gi|504527363| 235.4 0.0 6 0 37.2 0.0 
6 Hypothetical protein OOM_1699  gi|386872052| 129.5 0.0 5 0 22.1 0.0 
7 Hypothetical protein  gi|504528047| 117.3 0.0 3 0 18.7 0.0 
8 Hypothetical protein  gi|855345177| 330.4 0.0 6 0 27.2 0.0 
9 Acid phosphatase  gi|504528393| 118.4 0.0 3 0 16.7 0.0 
10 Shikimate kinase I  gi|504528505| 145.7 0.0 3 0 18.8 0.0 
11 Hypothetical protein  gi|504528150| 218.9 0.0 5 0 40.7 0.0 
12 Hypothetical protein OOM_0748  gi|504527673| 150.4 0.0 3 0 23.2 0.0 
13 Membrane protein  gi|504527668| 71.7 0.0 2 0 20.5 0.0 
14 ABC transporter ATP-binding protein  gi|504527852| 175.7 0.0 4 0 28.4 0.0 
WC: Fno whole cell extract, OMP: Fno outer membrane protein extract, SC: Sequence coverage 
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Table 3.6. Bioinformatics analysis of the top 20 proteins identified in the OMP fraction of Fno UK isolate. 
N. Protein  PSORTba COGsb  LipoPc SignalPd 
1 PdpD  Outer membrane S N N 
2 Chaperone ClpB  Cytoplasmic O N N 
3 PdpD  Outer membrane S N N 
4 IglC *  Unknown S N N 
5 Chaperonin GroEL  Cytoplasmic O N N 
6 Ribosomal L29e protein family  Outer membrane S N N 
7 OmpA family peptidoglycan-associated lipoprotein *  Outer membrane M Y Y (SpII) 
8 Bifunctional proline dehydrogenase  Cytoplasmic C N N 
9 IglB  Cytoplasmic S N N 
10 30S ribosomal protein S1  Cytoplasmic J N N 
11 Cell division protein FtsZ  Cytoplasmic D N N 
12 Outer membrane associated protein  Outer membrane M Y Y (SpI) 
13 PdpA  
Unknown/multiple 
localization 
S N N 
14 OmpA family protein  Outer membrane M Y Y (SpII) 
15 PdpB  Outer membrane M N N 
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Table 3.6. continued 
16 Ribonuclease E  Cytoplasmic E N N 
17 IglA * Cytoplasmic S N N 
18 Alpha-ketoglutarate decarboxylase  Cytoplasmic G N N 
19 Heat shock protein 90  Cytoplasmic O N N 
20 
2-oxoglutarate dehydrogenase complex, E2 
component  
Cytoplasmic C N N 
a Subcellular localization as predicted by PSORTb v. 2.0 (https://psort.org/).  
b Functional classification of the tentative proteins as predicted by EggNOG v. 4.5 server (https://eggnog.embl.de). The COGs 
functional categories are: C, energy production and conversion; D, Cell cycle control, cell division and chromosome partitioning; E, 
amino acid transport and metabolism; F,  Nucleotide transport and metabolism; G, carbohydrate transport and metabolism; H, 
Coenzyme transport and metabolism; I, lipid transport and metabolism; J, Translation, ribosomal structure and biogenesis; K, 
Transcription; L, replication, recombination and repair; M, cell wall/membrane biogenesis; O, Post-translational modification, protein 
turnover, and chaperones; P, Inorganic ion transport and metabolism; Q, Secondary metabolites biosynthesis, transport, and 
catabolism; S, Unknown function (includes Category R with general function and category N not in known COGs); T, Signal 
transduction mechanisms; U, Intracellular trafficking, secretion, and vesicular transport; V, Defence mechanisms. 
c Lipoproteins prediction by LipoP v. 1.0 (https://www.cbs.dtu.dk/services/Lipo/), Y: Yes, N: No 
d Signal peptide sequence prediction by SignalP v. 2.0 (https://cbs,dtu.dk/services/Signal P/), Y: Yes, N: No, SpI: Signal peptides 
cleave by signal peptidase I, SpII: Signal peptides cleaved by signal peptidase II. * Immuno-reactive proteins in the Fno-OMPs. 
















































Figure 3.2.  Summary of bioinformatics analysis of proteins identified in the OMP 
fraction of Fno UK isolate. Prediction of biological functions (A), subcellular localisation 
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3.4. Discussion  
Outer membrane proteins (OMPs) play an important role in the pathobiology of various 
bacteria by facilitating their adaptation to a wide range of different environments. Due to 
their prominence at the host-pathogen interface, the OMPs represent antigens with the 
potential to induce protective humoral and cellular immune responses in the host capable 
of inactivating the bacteria (Lin et al., 2002; Mukhopadhaya et al., 2006). Despite their 
potential importance, to date, no studies have been conducted on outer membrane proteins 
of Fno. In the current study, comparative analysis of the proteome of OMPs derived from 
five geographically distinct Fno isolates showed homogenous proteomic and antigenic 
profiles represented by a uniform distribution of protein bands by 1-DE and a conserved 
antigenic band on western blot of the different OMP preparations. The LC-ESI/MS/MS 
confidently identified a total of 239 Fno OMPs. Interestingly, many of these were 
observed to share similarities with proteins found in Fno-derived outer membrane vesicle 
(OMV) described by Lagos et al. (2017), where 52 % of the OMV proteins identified were 
predicted to be cytoplasmic, while the outer membrane and extracellular proteins were 5% 
and 1%, respectively, compared to 5.8% and 0.8% in the current study. 
The presence of cytoplasmic, periplasmic or inner membrane proteins in the 
current Fno-OMP preparation can be attributed to the fact that most bacterial outer 
membranes are involved in the transportation of substances between the intracellular and 
extracellular membranes. This may allow contact between the OMPs and other inner 
membrane proteins or the periplasmic proteins as an essential component of the membrane 
associated-enzyme complex (Vipond et al., 2006). Identification of different classes of 
non-outer membrane proteins in OMP preparations has been previously reported (Liu et 
al., 2008; Kumar et al., 2009; Watson et al., 2014). The reason for this is unknown, but as 
previously shown for other bacteria such as A. hydrophila, A. salmonicida, F. tularensis 
and S. agalctiae (Henderson and Martin, 2011), Fno may express non-classically 
associated outer membrane proteins known as “moonlighting proteins” on its surface, 
which are known to have more than one function both within the cytoplasm and 
extracellularly, and have been reported to perform various biological functions associated 
with bacterial virulence (Henderson and Martin, 2011). Definitive assignment of OMPs to 
specific subcellular locations within Gram-negative bacteria remains unclear. This may be 
due to OMPs spanning the three layers of the bacterial cell membrane as “b-barrel trans-




membrane proteins” for transportation of ions and other micro-molecules (Wimely, 2003; 
Pavkova et al., 2005). Alternatively, post-translational modification (PTMs) may enable 
the OMPs to associate with other proteins including lipoproteins and glycoproteins 
(Santoni et al., 2000). This may explain the high percentage of non-OMPs in the extracted 
Fno-OMPs preparation. Further studies are needed to confirm the identity and biological 
functions of these non-OMPs. In addition, the extraction method may have an effect on 
existence of other non-OMPs within the OMP fraction following bacterial cell lysis, as 
there may be some carry-over proteins that stick to the OMP extract and thus will be 
resolved together by electrophoresis. Therefore, optimisation of the extraction protocol for 
maximum recovery of OMP and reduce other proteins left-over is needed.      
Functional analysis of the proteins identified using EggNOG v. 4.5 revealed that 
most of the abundant proteins were involved in vital biological functions including energy 
production, cell wall/cell membrane formation, post-translational modification, and 
metabolism of various cellular components (including protein, carbohydrate and lipid 
metabolism), transcription and transport activities. It has already been reported that 
proteins responsible for translation/transcription, catalytic activity, and transporting 
activity are the most abundant proteins found in Fno-derived OMVs (Lagos et al., 2017). 
This highlights the diversity of biological functions associated with OMPs and may reflect 
the importance of the OMPs in the pathobiology of Fno.  
The presence of lipoproteins in the current Fno-OMPs was predicted using LipoP 
server v0.2 from which 24 were predicted to be cleaved by signal peptidase I and 16 were 
cleaved by signal peptidase II. In addition to their role in the acquisition of nutrients, it has 
been suggested that lipoproteins have the ability to switch-on the host’s immune response 
by interacting with Toll-like receptor 2 (Nguyen and Götz, 2016). Moreover, 31 ribosomal 
proteins, mainly 30s and 50s, were detected in the OMPs of Fno. The presence of 
ribosomal proteins has also been reported in OMPs preparations of other bacteria as F. 
tularensis (Janovska et al., 2007a), Flavobacterium columnare (Liu et al., 2008) and 
Pasteurella multocida (Boyce et al., 2006) and it was found that ribosomal proteins play 
an important role in the biogenesis and translocation of integral membrane proteins 
(Herskovits et al., 2002). Thus, they may be involved in bacterial pathogenesis.   
In this study, PdpD, IglA, IglB and IglC, outer membrane-A family protein 
(FopA), peptidoglycan associated lipoprotein (PAL), GroEl and ClpB displayed high 
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scores in comparison to the other proteins identified in the OMPs of Fno UK isolate. 
Interestingly, all of these proteins have already been detected in various protein 
preparations, including OMPs and OMVs, from different Francisella spp., including Fno 
(Lagos et al., 2017), F. novicida (Pierson et al., 2011) and Francisella tularensis (Ft) 
(Melillo et al., 2006; Huntley et al., 2007; Hickey et al., 2011). Homologues of some of 
the Fno OMPs identified in this study have previously been described as immunogenic in 
the F. tularensis live vaccine strain of (LVS), as demonstrated by immunoblotting using 
sera from tularemic patients (Janovska et al., 2007 a,b). Nevertheless, identification of the 
previously mentioned virulence-determinant proteins in our study suggests a possible role 
for OMPs in Fno virulence and its interaction with the fish immune system. 
The PdpA, PdpB, PdpD, IglA, IglB and IglC proteins represent the core elements 
of the Francisella pathogenicity island (FPI), which itself constitutes the major 
determinants associated with Francisella virulence and intracellular replication within host 
macrophages (Nano and Schmerk, 2007; Bröms et al., 2010). PdpA suppresses cell 
signalling by macrophages including growth factors, cytokines and adhesion ligands, thus 
suppressing the macrophages ability to recruit and stimulate other immune cells (Nano et 
al., 2004). Ludu et al. (2008) reported that PdpD protein is localised to the outer 
membrane of Francisella novicida and is involved in the extracellular virulence of the 
bacterium by affecting the localisation of other FPI proteins including IglA, IglB, IglC and 
T6SS. IglA and IglB are two cytoplasmic proteins that constitute an essential part of the 
type VI secretion system in F. novicida and both are required for intra-macrophage growth 
through stimulating secretion of effector molecules, that affect host cell processes (Barker 
et al., 2009). It has also been demonstrated that IglA is required for virulence and 
supporting the growth of the bacterium inside macrophages (de Bruin et et al., 2007).  
IglC protein, which was associated with the immunogenic band (17-28 kDa) of 
Fno OMP in the current study, is one of the important proteins upregulated during 
intracellular growth of Francisella spp. in macrophages (Golovliov et al., 1997, 2003). 
Earlier studies reported that IglC, with its regulator MglA, assist the ability of F. tularensis 
to modulate biogenesis of the phagosome, preventing the formation of the phagolysosome, 
and thus facilitating escape of the bacteria into the cytoplasm of the host cell following 
replication (Clemens et al., 2004; Santic et al., 2005). Furthermore, IglC has been reported 
to play a role in production of inflammatory cytokines (Telepnev et al., 2003) and 




subsequent induction of cell apoptosis (Lai et al., 2004). Mutations of this protein alter 
bacterial virulence and impair intracellular growth in human derived macrophages (Santic 
et al., 2005) as well as tilapia macrophages (Soto et al., 2009b).  
The Francisella outer membrane-A family protein (FopA), identified within the 
immunogenic band of the OMPs of  Fno UK, is the predominant outer membrane protein 
that is highly expressed on the cell surface and has been found to be highly immunogenic 
in F. tularensis (Fulop et al., 1996; Huntley et al., 2007). Readily accessible to different 
antibodies, it provided good protection when tested as a candidate subunit vaccine antigen 
against human tularemia in mice exposed to lethal intradermal and intranasal F. tularensis 
SchuS4 challenge (Hickey et al., 2011). The GroEL chaperone protein, is a heat shock 
protein which was found to be up-regulated in a mutant of F. tularensis LVS deficient in 
iron superoxide dismutase (sodBFt) that used for vaccinaction of mice against respiratory 
tularemia (Bakshi et al., 2008). It is also thought to induce long-lasting recall of CD4+ and 
CD8+ T cells in association with other heat shock proteins like DnaK and GroES by 
stimulating specific anti-tularemic antibodies (Havlasova et al., 2002; Lee et al., 2006). 
Peptido-glycan-associated lipoproteins (PALs) detected in OMPs of Fno in the current 
study, are ubiquitous proteins, found in many pathogenic Gram-negative bacteria including 
Escherichia coli (Hellman et al., 2002), Vibrio cholerae (Heilpern and Waldor, 2000) and 
F. novicida (McCaig et al., 2013). The PALs are thought to perform virulence-related 
functions and assist survival of pathogenic bacteria by modulating the host immune 
response and initiating the release of pro-inflammatory cytokines (Buwitt-Beckmann et al., 
2006; Oscarsson et al., 2008; Godlewska et al., 2009). The efficacy of PALs as potential 
subunit vaccine candidates has previously been tested for non-typeable Haemophilus 
influenza (Murphey et al. 2006), Campylobacter jeuni (Wyszynska et al., 2002) and 
Legionella pneumophilia (Yoon et al., 2002). Some of the proteins identified in the OMPs 
of Fno and other Francisella spp., such as IglB, IglC and PdpD have been tested as 
vaccine candidates in either mice (Tempel et al., 2006) or fish (Soto et al., 2011b). 
Mutations in the IglC gene of F. novicida and Fno have been used to develop live 
attenuated vaccines, resulting in survival levels (RPS) of 50% and 87.5% in mouse and 
tilapia, respectively (Pammit et al., 2006; Soto et al., 2011b). Also, vaccination of zebra 
fish (Danio rerio) with Fno-derived OMVs, that were shown to be rich with various 
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immunogenic proteins, gave an RPS of 65.5% after 28 days post-infection with Fno 
(Lagos et al., 2017).  
A previous genomic study performed by Sridhar et al., (2012) revealed major 
differences between human pathogenic F. tularensis (Ft) and fish pathogenic Fno 
genomes, especially in their pathogenicity island (FPI), where F. tularensis possess two 
copies of FPI, but Fno contains only one copy. More importantly, the number of protein 
coding genes are lower in Fno (n= 1595) than Ft (n= 1664) where pdpC, encoding one of 
the FPI proteins, was one of the most important genes missing in Fno and it was reported 
to be crucial for growing of Francisella spp. in mammalian cells (Hazlett and Cirillo, 
2009). Interestingly, the current proteomic study confirms the latter findings, where the 
PdpC protein was not detected. This highlights the importance of proteomic approaches in 
complementing genomic studies for establishing valid and definitive information about the 
microbial phenotype, especially in selection of candidates for therapeutic or diagnostic 
applications. 
When the OMP profile of the different Fno isolates were examined by 
immunoblotting using the hyper immune sera from convalescent tilapia, an 
immunoreactive region was observed between 17-28 kDa, while no immunoreactivity was 
seen with the control sera. A similar antigenic pattern of the current Fno OMP was 
obtained in the whole cell proteome analysis of Fno isolates described in Chapter two 
when screened with the same sera. In addition, this result was in agreement with that of 
Schrøder et al., (2009) who reported an immunoreactive band of 20 kDa after probing Fnn 
whole cell protein extract with serum from Atlantic cod (Gadus morhua, L) immunised 
with either a monovalent Fnn vaccine or a multivalent vaccine containing Fnn and V. 
anguillarum and the same immunoreactive band was also observed with a polyclonal 
rabbit antiserum raised against Francisella sp. In a separate study by Kay et al., (2006), 
polyclonal antisera raised against Francisella victoria, isolated from tilapia, recognised an 
immuno-dominant band of approximately 20 kDa in the large lipo-oligosaccharides 
fraction (LOS) of the proteinase-K treated whole cell protein lysate. Thus, presence of the 
immunoreactive band (~17-28 kDa) in the OMP fraction in the current study may support 
the results obtained in the previous studies. Enrichment of such immunodominant proteins 
by using a simple subcellular fraction as opposed to the complex whole cell makes it easier 
to identify immunogenic proteins previously reported in whole cell preparations of other 




fish pathogenic Francisella spp. More importantly, establishing the proteins present in the 
Fno OMPs fraction may enable a greater understanding of which proteins are involved in 
stimulating the fish immune system in response to Fno infection.      
Equally important, variation was observed in the protein profile of the antigenic 
band (17-28 kDa) between the Fno outer membrane proteome and whole cell (WC) lysate, 
where a set of unique proteins were identified in each preparation, including 14 in OMPs 
and 17 in the WC lysate. This was in agreement with results reported by McCaig et al. 
(2013), where they compared the proteome of whole cell extract, OMP, periplasmic 
proteins, secreted proteins, outer membrane vesicles (OMVs) and outer membrane tubes 
(OMTs) of F. novicida and found that each of these has a unique profile. Interestingly, the 
OMPs of Fno UK isolate showed a higher score of a group of important proteins compared 
to their analogous in the whole cell lysate. This included some of the well-known 
virulence related proteins, such as IglC and IglA (Soto et al., 2009b; Janovska et al., 
2007a), OmpA which was previously identified as immunoreactive antigen in other 
bacteria (Dabo et al., 2003; Janovska et al., 2007a) and the oxidative-stress related protein 
AhpC (Lenco et al., 2005; 2007). This finding highlights the importance of the insoluble 
fraction of Fno OMP with regards to better separation and /or concentration of proteins. 
These proteins, once identified and validated, could potentially serve as candidates for 
improved Fno vaccines.  
One of the key features of OMPs is that they are highly conserved among 
pathogens (Koebink et al., 2000). For instance, a 28 kDa OMP is a common antigen of V. 
anguillarum and V. parahaemolyticus (Dong et al., 2004); 36 kDa OMPs are conserved 
antigens between V. parahaemolyticous, V. anguillarum, V. icthyoenteri, V. alginolyticus, 
V. harveyi and V. vulnficus (Tang et al., 2009); the amino acid sequence of the 48 kDa 
OMP of A. caviae was reported to be similar to that of Aeromonas salmonicida, V. 
cholera, V. parahaemolyticuos, Salmonella enterica (Vázquez-Juárez et al., 2004), and 
four iron regulating OMPs (IR-OMPs) with molecular weights of 70, 77, 77 and 82 kDa 
were expressed in 18 strains of A. salmonicida (Hirst and Ellis, 1994). Thus, outer 
membrane conserved antigens in different strains of the same or different serotypes are 
most likely to induce cross-protection against infection by either heterologous strains or 
even related strains with similar or different serotypes. Kawai et al. (2004), reported that a 
conserved OMP of 37 kDa resulted in 50%, 65.5% and 70% protection in Japanese 
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flounder (Paralichthys olivaceus) against three E. tarda strains of different serotypes. A 40 
kDa major OMP (OM porin II) gave 70 % and 80 % protection against i.p challenge with 
lethal doses of A. salmonicida and A. hydrophila in rainbow trout (Oncorhynchus mykiss), 
respectively (Merino et al., 2005). In addition, a 43 kDA recombinant OMP induced 
87.5%, 75% and 44.4% protection in Three-spot Gourami (Trichogaster trichopterus) 
challenged with two strains with similar serotypes and one strain with a different serotype 
of A. hydrophila (Fang et al., 2004). Visualising the cross-reaction of the sera raised 
against Fno UK isolate with the OMP extract of the other isolates (Costa Rican, Japanese, 
Mexican and Austrian Fno isolates) in the current study, may suggest that these 
geographically distinct Fno isolates share a conserved OMP structure. Further proteomic 
and genomic analysis of the OMP of these isolates needs to be performed to reveal the 
protein distribution within this bacterial panel and highlight the conserved antigens that 
could be tested as candidates for a broad spectrum Fno-vaccine.  
To the best of knowledge, this is the first report describing identification of 
proteins comprising the OMP fraction of Fno. Interestingly, most of these proteins were 
previously reported to be immunogenic in F. tularensis (Havlasova et al., 2002; Lee et al., 
2006). When taken together, these results give more insight into the importance of Fno 
OMPs and highlight their potential use in future diagnostic and control of Fno infection in 
farmed tilapia. It is worth mentioning that, some of the pathogenicity-related proteins that 
showed high scores in the current Fno-OMP preparation, such as PdpD and FopA were not 
recognised by the sera from challenged tilapia. However, they were previously described 
as immunogenic antigens in F. tularensis using sera from tularemic patients (Hickey et al., 
2011; Huntly et al., 2007; Janovska et al., 2007 a). This anomaly may be attributed to the 
limited resolution offered by the 1D-SDS-PAGE and its inability to separate complex 
mixtures of proteins that co-migrate as a single band. To this end, the use of higher 
resolution 2-D gel electrophoresis together with immunoblotting and downstream mass 
spectrometry may facilitate a more precise characterisation of the protein complement of 
the Fno OMPs fraction. In summary, the data presented here offers a first insight into 
OMPs of Fno, which helps build our understanding of how this organism is able to cause 
disease.   





The current study provides the first describtion of the proteomic profile of Fno outer 
membrane proteins of isolates from geographically distinct origins. It has been 
demonstrated that these isolates share a homogenous proteomic and antigenic pattern. 
Further, OMPs of Fno UK isolate were successfully catalogued and characterised using 
immunoproteomics and LC-ESI/MS/MS. The analysis showed that OMPs of Fno 
contained known Francisella virulence-associated proteins that were more abundant than 
their corresponding proteins in the whole cell lysates. This finding broadly supports the 
advantage of using the insoluble OMP enriched fraction as a simple sub-immunoproteome 
for proteomic analysis rather than the complex whole cell lysate. Identification of such 
antigenic proteins in the Fno OMP fraction may provide preliminary data on Fno surface 
proteins that have potentiality to interact with the host immunity during infection and may 
offer an insight into their role in Fno pathogenesis. To follow up on the present study, 
future work will focus on the separation and identification of individual immuno-reactive 
proteins that co-migrate as single bands in low resolution 1-D gels. In addition, further 
study should be carried out to examine the possible vaccine candidate molecules in Fno 
OMP and to understand in depth the adaptive and innate immune responses of fish post- 
vaccination and post-challenge. As differences between the proteome of geographically 
diverse Fno isolates were highlighted in Chapter 2 and abundance of antigenic proteins 
recognised by tilapia anti-sera have been identified in Chapter 2 and 3, the protective 
antibody-mediated immune response should be investigated following challenge with 













Efficacy testing of an inactivated whole cell injection vaccine in Nile tilapia¸ 
Oreochromis niloticus (L), against multiple isolates of Francisella noatunensis 
subsp. orientalis from diverse geographical origins 
  





Francisella noatunensis subsp. orientalis (Fno) is a serious emerging bacterial pathogen 
affecting a wide range of ornamental and farm-raised cichlids globally (Colquhoun and 
Duodu, 2011). Due to its fastidious nature, high infectivity (~ 23 CFU can induce clinical 
disease), wide host range, transmission by both horizontal and vertical routes, capacity to 
survive in multiple environments and co-existence with other pathogens, it has been 
highlighted as one of the major threats to the tilapia industry where mortalities of >90% 
have been reported (Soto et al., 2012a). On tilapia farms, several strategies have been 
adopted to control francisellosis. Conventional practices of increasing the water 
temperature from 25 to 30°C have been used to inhibit the development of francisellosis in 
infected tilapia and other susceptible species of ornamental fish (Soto et al., 2012a; 
2014b). Moreover, treatment of Fno in fish with approved antibiotics like oxytetracycline 
(TerramycinÒ) and florfenicol (AquaflorÒ) has also been reported to be effective (Mauel 
et al., 2003; Soto et al., 2012d; Soto et al., 2014b). The latter can potentially improve fish 
health by significantly decreasing mortalities due to the disease (Soto et al., 2014b), 
however, using of antibiotics is not ideal as sick fish will not eat medicated feed and there 
is a risk of developing antibiotic resistance in the bacteria (Bruun et al., 2000; Soto and 
Hawke, 2017). In addition, Fno is an intracellular pathogen which limits the efficacy of 
antibiotic to completely clear-out of the bacteria from the infected fish. 
Currently no commercial therapeutics or prophylactic treatments are available for 
use against Fno in farmed fish. The emergence of Fno outbreaks in different countries has 
raised concerns of a potential francisellosis pandemic, thus efforts to develop protective 
vaccines against Fno are increasing. Ideally, the vaccine should confer high level of 
protection against all Fno isolates, be cost effective and easy to administer (Barnes, 2017). 
In a previous vaccination study in tilapia, the highest Relative Percent Survival (RPS) 
obtained was 87.5 % using a live attenuated immersion vaccine (Soto et al., 2011b). 
However, use of live attenuated mutants in vaccines is not acceptable in all countries due 
to the different regulations related to safety. Recently, Ramirez-Paredes (2015) developed 
an injectable whole cell adjuvanted bacterin vaccine against Fno in Nile tilapia. The 
vaccine in this study was developed using a virulent Fno isolate (UK isolate/ STIR-GUS-
F2f7) obtained from a diseased tilapia farmed in England (Ramirez-Paredes et al., 2017b). 
Following intraperitoneal (i.p.) administration and challenge with the homologous vaccine 
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isolate, the vaccine stimulated protective antibodies and resulted in high protection (RPS 
of 100%); however, cross protection against heterologous isolates still needs to be 
determined.  
 An adequate understanding of the innate and adaptive immune response of tilapia 
to Fno infection is a constraint to the development of an efficacious vaccine against Fno 
(Soto and Hawke, 2017). Jantrakajorn and Wongtavatchai (2016) reported significant 
expression of the pro-inflammatory genes, interleukin-1β (IL-1β) and tumor necrosis 
factor-α (TNF-α) within 24 h post-injection (hpi) till up to 96 hpi and down-regulation of 
the anti-inflammatory gene, transforming growth factor-β (TGF-β) 24 hpi in spleenic cells 
of juvenile Nile tilapia i.p. injected with 0.8 × 105 CFU/Fish of Fno. Recently, the immune 
response of adult zebra fish immunised with injectable Fno OMV-based vaccine was 
investigated, however similar studies on vaccinated tilapia, especially using inactivated 
whole cell vaccine, are lacking. Genotype and biotype diversity of the target pathogen 
represents another major challenge for vaccine development in fish (Munan’andu et al., 
2016). Recent studies of Fno genetic diversity using PCR-based typing or sequencing 
methods, revealed no discrimination among Fno iolates from different countries, thus 
demonstrating a clonal behavior pattern among these isolates (Leal et al., 2014; Figueiredo 
et al., 2016; Gonçalves et al., 2016; Ramirez-Paredes et al., 2017b). In addition, cross-
reactivity between anti-serum raised against Fno UK isolate and Fno isolates from distinct 
geographical regions, with minor antigenic differences between isolates has been 
highlighted in the proteomic study presented in Chapter 2. Hence, the similarity in 
antigenic profile of these isolates might suggest cross-protection between heterologous 
Fno isolates with the Fno vaccine described above. Based on the results of the proteomic 
studies in Chapter 2 and 3, a whole cell formaline killed adjuvanted vaccine was 
developed using Fno UK isolate. The present chapter aimed to investigate the efficacy of 
this formalin-killed vaccine to induce protection in Nile tilapia, Oreochromis niloticus, 
against i.p. challenge with Fno isolates obtained from different geographical regions. The 
specific IgM response in fish serum post-vaccination and post-challenge and the 
expression levels of four immune related genes (IgM, TNF-a, MHCIIβ and IL-1b) in 
response to vaccination were examined. In addition, cross-reactivity of serum raised 
against the vaccine isolate when screened against heterologous isolates of Fno using 




Western blotting was investigated and Fno load in surviving fish post-challenge was 
quantified using real-time qPCR.  
4.2. Materials and methods 
4.2.1. Fish  
4.2.1.1 Source and acclimatisation of fish 
Nile tilapia, O. niloticus (L.) with a mean weight 13 ± 0.8 g and an average length of 10 ± 
0.13 cm were obtained from a commercial tilapia farm in Petchaburi province, Thailand, a 
source with no previous history of Fno infection, and transported to the wet laboratory of 
Fish Vet Group Asia Ltd. (FVGAL), Chonburi, Thailand. Upon arrival, fish were 
acclimated for 2 weeks in 100 L tanks in a recirculation system (Fleuren and Nooijen, 
Netherlands) with dechlorinated water, aerated with air stones. The water quality 
parameters were as the following: temperature ~28°C, dissolved oxygen (DO) 6.5-7 mg/L, 
pH 7-7.5, free ammonia £0.1mg/L, nitrite £0.25 mg/L, nitrate £0.2 mg/L. The parameters 
were monitored throughout the day using a water quality sensor (Senseye® Reef V2, UK) 
which sends out alerts when any of the water parameters are outwith the specified range 
and the photoperiod was maintained at 12 h light :12 h dark. Fish were fed a commercial 
tilapia feed containing 30 % crude protein (CPF, Thailand) at a rate of 3% body weight per 
day. All experimental procedures with live fish were performed in accordance with the UK 
animals (Scientific Procedures) Act 1986 and associated guidelines (EU Directive 
2010/63/EU for animal experiments) and were approved by the Animal Welfare and 
Ethical Review Body (AWERB) of the Institute of Aquaculture, University of Stirling, 
UK.  
4.2.1.2. Confirmation of Fno free status  
Francisella genus specific PCR (Forsman et al. 1994) was used to confirm the Fno-free 
status of the fish proposed for the experiment. Six fish were euthanized by overdose of 
benzocaine (500 mg/L) (Sigma-Aldrich, UK) and head kidney and spleen were sampled 
and preserved in 95% ethanol (Sinopharm, China) for screening by PCR. Total DNA was 
extracted from pooled spleen and head kidney samples using DNeasy Blood and Tissues 
kit (QIAGEN, Germany) following the extraction protocol for tissues. Briefly, 20-30 mg 
of the tissue samples were lysed in lysis solution (180 µL of buffer ALT and 20 µL of 20 
µg/µL of proteinase-K). The tissues were homogenised and mixed thoroughly with the 
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lysis buffer on a vortex mixer (Clifton Cm-1, UK) for 30 s then incubated at 56°C 
overnight. After lysis, the samples were mixed for 15 s, then 200 µL of buffer AL in the 
kit and 200 µL of 100 % ethanol (Sigma, UK) were added and samples were mixed again 
for 10 s. The mixture was pipetted into DNeasy mini columns placed in 2 mL collection 
tubes and centrifugated at 6,000 × g for 1 min at 10°C in a refrigerated SIGMA 2-16K 
centrifuge (Sigma squib, UK). The collection tubes containing the flow-through were 
discarded. The membrane was washed using 500 µL of buffer AW1, tubes were 
centrifuged at 6,000 x g for 1 min and flow-through was discarded. Tubes were washed 
again with 500 µL of buffer AW2 and centrifugated at 20,000 × g for 3 min to dry the 
DNeasy membrane. The DNA was eluted by adding 200 µL of Buffer AE to each tube 
followed by centrifugation at 6,000 × g for 1 min. The concentration of the eluted DNA 
was measured using a Nanodrop ND-1000 Spectrophotometer (Thermo Fisher Scientific, 
UK). DNA samples were standardised to 100 ng/ µL with Milli-Q (M.Q.) water.    
PCR was performed in 25 µL reaction formed of 1X ReddyMix PCR Master Mix 
(Thermo Scientific, UK), 0.2 µM of each primer pair (F5: 5’-
CCTTTTTGAGTTTCGCTCC-3’, F11: 5’-TACCAGTTGGAAACGACTGT-3’) (MWG 
Eurofins, UK), 100 ng/ µL of DNA template and up to 25 µL M.Q. water. Cycling 
conditions consisted of an initial denaturation step of 2 min at 95°C, followed by 35 cycles 
of 1 min at 95°C, 1 min at 65°C and 1 min at 72°C, and a final extension step of 5 min at 
72°C in a Light CyclerTM 96 (Roche, Germany). Five µL of the amplification products 
were visualized on 1% (w/v) agarose gel containing 0.1 µg/mL EcoDye Ô DNA staining 
solution (SolGent, Bio fact Co. Ltd, Korea) in Tris-Acetate-EDTA (TAE) buffer 
(ThermoFisher Scientific, UK) after electrophoresis for 40 min at 80 volts. A 100 pb DNA 
ladder (GeneRuler Express DNA ladder, Fisher Scientific, UK) was used to confirm the 
presence of the Fno 16S rRNA gene amplicon of 1140 pb and 100 ng of Fno DNA and 
Milli-Q water were used as positive and non-template controls, respectively. The gel was 
visualized under a UV illuminator (Bio-Imaging, Syngene, UK). 
4.2.2. Preparation of the vaccine  
The vaccine was prepared as described by Ramirez-Paredes (2015). Briefly, an aliquot of 
the stock culture of Fno UK isolate (STIR-GUS-F2f7) maintained at -70°C in modified 
Mueller-Hinton II cation adjusted broth supplemented with 2% IsoVitaleX (Becton 




Dickenson BBL, USA) and 0.1% glucose (MMHB) with 20% glycerol (Fisher Scientific, 
UK) was defrosted and 30 µL was streaked onto cysteine heart agar supplemented with 
1% bovine hemoglobin (CHAH) (Becton Dickenson BBL, USA) for 72 h at 28°C. A 
single colony from the agar plate was inoculated into each of three 50 mL centrifuge tubes 
containing 15 mL MMHB with 2% IsoVitaleX and 0.1% glucose (Baker et al., 1985). 
Bacteria were grown as a primary culture overnight at 28°C in a shaker incubator (Biosan, 
Korea) at 175 rpm. After incubation, 50 µL from each bacterial culture was streaked onto 
CHAH to check purity and the remaining culture was added to each of three 500 mL screw 
capped bottles (Fisher, UK) containing 250 mL of MMHB with IsoVitaleX and glucose. 
Bottles were incubated in a shaker incubator at 28°C at 150 rpm for 18 h. Each bottle was 
divided into 6 × 50 mL centrifuge tubes. The tubes were centrifuged in an Eppendorf 
5417C centrifuge (Eppendorf, UK) at 4000 × g for 15 min at 4°C and the supernatants 
were discarded. Filtered sterile PBS (20 mL) was added to each tube and vortexed until the 
pellets were completely resuspended. Tubes were centrifuged as described above, and the 
supernatant was discarded. Washing was repeated 3 times and 5 mL of filtered sterile PBS 
was added to each tube and vortexed to re-suspend the bacterial pellets. All 6 tubes were 
combined into a sterile 250 mL bottle and the optical density (OD600) was adjusted to 0.4 
(~1.2 ×109 CFU/mL) using sterile PBS. The number of viable bacteria (CFU/mL) in the 
vaccine was confirmed by performing drop count. In brief, the bacterial suspension was 
adjusted to OD600 0.4 followed by ten-fold serial dilutions, and 20 µL from each dilution 
was pipetted onto five sections of a CHAH plate, which was incubated for 72 h at 28°C. 
The number of bacteria (CFU/mL) was calculated by multiplying the average number of 
colonies per drop by 50 and the dilution factor. The bacteria were then inactivated with 
0.5 % (v/v) of formalin 40 % (Formaldehyde 37 %, Sigma, UK) with gentle stirring on a 
magnetic stirrer (VWN, Korea) at 4°C for 96 h, then 1 % (v/v) of 15 % sodium 
metabisulfite (Sigma, UK) was added to neutralise the formalin with gentle stirring at 4°C 
for 48 h. The inactivated bacteria were aliquoted into 50 mL centrifuge tubes (40 mL each) 
and centrifuged at 3500 × g for 20 min, supernatants were discarded, and the pellets were 
washed 3 times for 20 min using 1X sterile PBS. The inactivated bacterial suspensions in 
all tubes were combined into one sterile 100 mL bottle and OD600 was adjusted using 
sterile PBS to 0.4 (1.2 ×109 CFU/mL). To confirm purity and inactivity, 30 µL of the 
bacterial suspension was streaked onto CHAH and incubated at 28°C for 72 h. The vaccine 
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was formulated by adding 33 mL of the concentrated killed bacteria at OD600 0.4 to 77 mL 
of a commercial adjuvant (Montanide ISA 763 A VG, Seppic, France) and emulsified 
using variable speed blender in 4 homogenisation steps including 4000 rpm for 3 min, 
5000 rpm for 30 s, 4000 rpm for 1 min and 5000 rpm for 30 sec, respectively. The vaccine 
was then stored at 4°C until used. The physical characteristics of the vaccine were 
evaluated as follows:  
A- Homogeneity and droplet size: 1 drop of the vaccine was put on a clean glass slide then 
gently covered by cover slip and examined under a light microscope using 40x lens. 
B- Stability: the vaccine was stored at 4°C for 24 h, 72 h and 1 week, respectively and the 
stability of the emulsion was checked by holding the bottle toward a light source and a 
drop test performed by transferring one drop of the vaccine to a beaker filled with water 
and observing the stability of the drop on the surface of the water.  
C- Syringability: 1 mL tuberculin syringe connected with 27G x1/2² hypodermic needle 
(NIPRO Europe N.V., Belgium) was filled with the vaccine. The ease and time required 
for releasing the vaccine from the syringe under a standard force was assessed.  
D- Safety:  10 fish (~14 g) were injected i.p. with 0.2 ml (i.e. twice the recommended 
dose) of the vaccine, held at 28°C, fed 3% body weight/day for 10 days and checked for 
any abnormalities, signs of toxicity or mortalities post-vaccination.  
 
4.2.3. Pre-challenge of un-vaccinated fish with multiple Fno isolates  
A pre-challenge was performed using three pathogenic Fno isolates from clinically 
infected tilapia from different geographical locations including 1 homologous isolate and 2 
heterologous isolates (Table 4.1). Bacterial isolates were injected i.p. to identify the 
bacterial dose resulting in 60-70 % mortalities (LD60-70) in naïve tilapia. One hundred and 
fifty fish (mean weight 18 ± 0.3 g) divided into 3 groups each consisting of 5 tanks were 











Table 4.1. Fno isolates used for the pre-challenge experiment.  
Isolate name ID Source  Origin 
Fno UK isolate STIR-GUS-F2f7 Red Nile Tilapia  England  
Fno Mexican isolate Fran-Cos1 Nile tilapia Mexico  
Fno Costa Rican isolate NVI-PQ1104 Nile tilapia Costa Rica  
The bacterial isolates were grown on CHAH and incubated at 28°C for 72 h in a 74 
L incubator with ventilation (Memmert IN 75, Germany). The cultures were transferred 
into 15 mL of MMHB (BD diagnostics) with 0.1% glucose (Sigma Aldrich) and 2% 
IsoVitaleX (BD diagnostics) then incubated in an orbital shaking incubator (ES-20 Biosan, 
Korea) at 150 rpm for 18 h. After incubation, the tubes were centrifuged at 4000 × g at 
4°C for 15 min. The pellets were washed twice with 15 mL of sterile PBS. The OD600 of 
the bacterial suspension was adjusted to 0.4 (~1.2 × 109 CFU/mL) and serially diluted to 
achieve five doses for performing the pre-challenge (Table 4.2). The doses used for 
injection were confirmed by performing drop counts as described in Section 4.2.2. After 
dose confirmation, fish were anaesthetized with benzocaine (Sigma-Aldrich, UK) (10% in 
100% ethanol) and each group was i.p. injected with 0.1 mL of each isolate of Fno at the 
different doses shown in Table 4.2, using 27 G ×1/2² hypodermic needle. 
Table 4.2. Doses of Fno isolates used in the pre-challenge experiment.  
Fno 
isolate 
Challenge dose (CFU/mL) 
Tank 1 Tank 2 Tank 3 Tank 4 Tank 5 
UK 1.1×108  1.3×107  1.25×106  1.4×105  1.2×104  
Mexico 1.15×108  1.19×107  1.2×106  1.1×105  1.35×104  
Costa Rica 1.25×108  1.15×107  1.3×106  1.25×105  1.3×104  
 
Fish were examined four times per day for 15 days, fed three times per day to 
satiation and the water temperature was maintained at 23 ± 2°C to mimic the natural 
conditions for the occurrence of francisellosis. Dead fish were removed, and moribund fish 
were euthanized, necropsied and examined by bacteriology after streaking spleen 
homogenates on CHAH and incubating at 28°C for 72 h. Molecular identification of Fno 
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was performed using the PCR protocol described in Section 4.2.1.2. After 15 days, the 
survivors were euthanized by an overdose of benzocaine to terminate the experiment.  
4.2.4. Fish vaccination  
Following acclimation for 2 weeks, fish (mean weight 15 ± 0.2 g) were divided into four 
groups, group 1: vaccination group (n= 260), group 2: adjuvant-alone group (n= 260), 
group 3: PBS control group (n= 260) and group 4: naïve group (n= 20). The fish were 
stocked in 100 L recirculation tanks filled with chlorine-free water. The vaccinated, 
adjuvant-alone and PBS control groups consisted of duplicate tanks (130 fish/tank), while 
the naïve group consisted of a single tank of 20 fish.  
Fish were starved for 24 h, anaesthetized with benzocaine and injected i.p. with 0.1 
mL of adjuvanted vaccine, adjuvant (30% sterile PBS (Sigma-Aldrich, UK) emulsified 
with 70% of adjuvant) or sterile PBS using a vaccination gun connected with multi-fit 
bottle, counter and adjustable self-refilling 23G x 4 mm short bevel needles (Kaycee for 
veterinary products, UK). The naïve group did not receive any treatments during the 
experiment. Fish were fed 3% of their body weight 3 times/day 24 h after injection, and 
water quality was monitored throughout the trial as described above. Fish were maintained 
at 28 ± 2°C for 30 days (840 degree days (dd)) and checked 3 times/day for any 
abnormalities.  
4.2.5. Fish challenge 
At 30 days post-vaccination (30 dpv) (840 dd), each of the three main groups (i.e. 
vaccinated, adjuvant-alone and PBS control), were subdivided into 3 sub-groups, each one 
consisted of 2 tanks holding 30 fish/tank. Fish were anaesthetized as described above and 
each two parallel tanks received i.p. injection of the LD60 (obtained from pre-challenge) of 
one of the three Fno isolates as shown in Table 4.3. (i.e. 2 tanks for Fno UK, 2 tanks for 
Fno Costa Rica and 2 tanks for Fno Mexico). Fish were maintained for 15 days at 23 ± 
2°C, examined 4 times per day and water quality monitored as described above. Fish 
received feed add libitum, mortalities were removed, and moribund fish were euthanized, 
necropsied and specific mortalities determined by bacteriology and PCR. The 
experimental design is shown in Figure 4.1.  
 
 




Table 4.3. Doses of Fno isolates used in the challenge experiment.  
Fno isolate Dilution 
UK 1.25 ×106 CFU/mL (1.25 ×105 CFU/fish) 
Costa Rica 1.2 ×106 CFU/mL (1. 2 ×105 CFU/fish) 





















Figure 4.1. Design of Fno vaccine efficacy experiment. UK: Fno UK isolate, CR: Fno 
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Fish were euthanized with an over dose of benzocaine (terminal anaesthia; 5 mL/L) 
at 6, 24 and 72 h postvaccination (hpv) and spleens were sampled for analysis of immune 
gene expression (n= 6). Spleen samples were stored in 1 mL of RNA later (Sigma, UK) at 
4°C overnight, then the RNA later was removed, and the tissues were stored at -80°C until 
used. Blood samples were collected by caudal vein puncture from five fish per tank under 
terminal anaesthia at day zero (D0), 30 days post-vaccination (30 dpv) and 15 days post-
challenge (15 dpc) from the surviving fish using a sterile ½ cc insulin syringe (Nipro®, 
Japan) with 27G needle (Termu®, Germany). Blood was transferred to microcentrifuge 
tubes, kept at 4°C overnight then centrifuged at 3000 × g for 10 min. Serum was collected, 
aliquoted into new tubes and kept at -20°C until used. The relative percent survival (RPS) 
in this experiment was calculated according to the following formula (Amend, 1981):  
 
                                  RPS = (1-	 %	#$	%#&'()*'+	*,	-(..*,('/0	$*12%	#$	%#&'()*'+	*,	,#,3-(..*,('/0	$*12) x100. 
 
4.2.7. Indirect enzyme-linked immunosorbent assay (ELISA) for determination of 
specific IgM in serum of tilapia 
An indirect ELISA was used to measure the specific antibody response in tilapia sera at 30 
dpv and 15 dpc to the three different Fno isolates. Briefly, 96-well ELISA plates 
(ImmulonÒ4 HBX-USA) were coated with 100 µL of 1% (w/v) poly - lysine in carbonate-
bicarbonate buffer (Sigma-Aldrich, UK) and incubated at room temperature (RT) (~22°C) 
for 1 h. The plates were then washed three times by 1X low salt wash buffer (LSWB, 
Appendix 1). One hundred µL of Fno UK isolate in PBS at OD600 0.4 (~1.2 ×109 
CFU/mL) was added to each well and plates were incubated at 4°C overnight. The 
bacterial suspension was prepared as described in Section 2.2.2. The plates were washed 
three times with LSWB and bacteria were fixed by adding 100 µL/well of 0.05% (v/v) 
glutaraldehyde (Sigma-Aldrich, UK) in LSWB and incubated for 20 min at RT. Plates 
were washed as before. Endogenous peroxidase activity was prevented by adding 100 
µL/well of 3% stock solution of hydrogen peroxide (Sigma-Aldrich, UK) and plates were 
incubated for 1 h at RT. Plates were washed three times as before and non-specific 




antibody binding sites were blocked by adding 250 µL/well of 5% (w/v) dried skimmed 
milk (Marvel, Premier Foods Group Ltd, UK) in distilled water for 3 h at RT. After 
washing plates three times by LSWB, 100 µL/well of serum from 10 fish from different 
groups (Day 0, 30 dpv and 15 dpc) at a dilution of 1:500 in LSWB with 1% bovine serum 
albumin (BSA) (Fisher scientific, UK) was added and plates were incubated overnight at 
4°C. Fno positive and Fno negative sera were included on each plate as assay controls at 
the same dilutions used in the tested serum samples. After incubation, the plates were 
washed 5 times by 1X high salt wash buffer (HSWB, Appendix 1) with a five min soak on 
the last wash to ensure removal of unbound antibodies. 100 µL/well of anti-tilapia IgM 
monoclonal antibody at dilution of 1/75 in PBS (Fo4, Aquatic Diagnostic Ltd, UK) was 
added and plates were incubated at RT for 1 h. Washing was repeated using HSWB as 
before and 100 µL/well of goat anti-mouse IgG labelled with horse radish peroxidase 
(HRP) (Sigma-Aldrich, UK) diluted to 1:3000 in LSWB with 1% BSA was added and 
plates incubated for 1 h at RT. Plates were washed once with HSWB to remove excess 
HRP and 100 µL/well of chromogen in substrate buffer (Appendix 1) was added and 
plates were incubated for up to 5 min at RT. The reaction was stopped by adding 50 
µL/well of 2M sulphuric acid (Sigma, UK) and the absorbance was measured at OD450 
using a micro-plate reader (Biotek Synergy HT, USA).  
4.2.8. Serum cross-reactivity 
The whole cell protein lysate of Fno UK (homologous vaccine isolate), Costa Rica and 
Mexican isolates (heterologous isolates) were resolved on 1D SDS-PAGE as previously 
described in Section 2.2.3, Chapter 2. Serum samples collected from fish at day zero (D0), 
30 dpv and 15 dpc from the different treatments were used to perform western blot. After 
transfer of the whole cell lysate of the different isolates, the nitrocellulose membrane was 
cut into strips containing the individual transferred protein of each Fno isolate and placed 
into an octaline disposable polypropylene tray (Pateof ApS, Denmark). Western blotting 
was carried out following the protocol described in Section 2.2.6.2. in Chapter 2. Fno 






4.2.9. Immune-genes expression 
4.2.9.1. RNA extraction 
RNA was extracted from 40-50 mg of spleen samples of three fish per tank, (n = 
6/group) at 6, 24, 72 h post vaccination (hpv) using TRI Reagent (Sigma, UK) following 
the manufacturer’s protocol. Briefly, tissues were transferred into a 1.5 mL skirted screw 
capped tube (Thermo, UK) containing 0.5 mL of TRI Reagent, followed by incubation for 
15 min on ice then homogenized for 60 s by a mini-beadbeater (BioSpec products, USA) 
until full disruption. Tubes were incubated at RT (~22°C) for 5 min then 50 µL of 1-
bromo-3-chloropropane (BCP) (Sigma, UK) was added into the disrupted tissues followed 
by a vigorous shaking for 15 s and incubation at RT for 15 min. The aqueous phase was 
separated by centrifugation at 20,000 × g for 15 min at 4°C in a refrigerated SIGMA 2-
16K Centrifuge (Sigma, UK) and transferred to a new 1.5 Eppendorf tube (Eppendorf, 
UK). RNA was precipitated by adding 75 µL of RNA precipitation solution 
(ThermoFisher Scientific, UK) then inverted gently 4-6 times, incubated at RT for 10 min 
and centrifugation was repeated for 10 min at 20,000 × g. The supernatant was removed, 
and the RNA pellet was washed for 15 min in 1 mL of 75% ethanol (Fluka, UK) at RT and 
centrifuged at 20,000 × g for 5 min. The resulting RNA pellet was air dried at RT for 5 
min to enable evaporation of any traces of ethanol, resuspended in 50 µL of RNase free 
water (ThermoFisher Scientific, UK) and incubated at RT for 30 min to enable full 
resuspension. The RNA samples were then stored at -70°C until use.  
The quality and quantity of RNA samples were evaluated using a Nanodrop ND-
1000 Spectrophotometer (ThermoFisher Scientific, UK). 1 % (v/v) agarose gel (Bioline, 
UK) containing 0.1 µg/mL ethidium bromide (Sigma, UK) in Tris-Acetate-EDTA (TAE) 
buffer (Sigma-Aldrich, UK) was used to check the integrity of the RNA. An aliquot of 
RNA (300-500 ng/µL) mixed with 6X loading dye (Thermo Fisher, UK) was incubated at 
65°C for 2 min in a thermoblock (Biometra T1, Germany) and incubated on ice for 1 min 
then run on an agarose gel. RNA was visualized after electrophoresis under a UV 
illuminator (Bio-Imaging, Syngene, UK).  
 4.2.9.2. DNase treatment 
The DNA in the RNA samples was removed using DNA-freeTM kit (Ambion, UK) 
following the manufacturer’s instructions. Firstly, the RNA concentration was adjusted to 




2 µg using nuclease free water (ThermoFisher Scientific, UK). A DNA digestion mix was 
prepared from 1 µL of 1X DNase I buffer, 0.25 µL of 2 U rDNase I and 10 µL of 2 µg 
RNA sample. Incubation of the mix was performed at 37°C for 30 min then 1 µL of 
DNase inactivation reagent was added, and the tubes incubated at RT (~ 22°C) for 2 min. 
Following a centrifugation at 10,000 × g for 90 s, the treated RNA was collected and 
transferred to new 1.5 mL Eppendorf tubes. The quantity and quality of the DNase treated-
RNA samples were checked as described in Section 4.2.9.1, the concentration of the 
DNAse-treated RNA samples was adjusted to 0.5 µg using Milli-Q water and stored at -
20°C till used. 
4.2.9.3. cDNA synthesis 
cDNA synthesis was performed using a High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystem, USA) following the manufacture’s protocol. In brief, 20 µL of 
reverse transcription (RT) master mix was formulated using 2 µL of 1X RT buffer, 0.8 µL 
of 4 mM dNTPs, 2 µL of primer mix (1.5 µL of 1X RT random primers and 0.5 µL of 0.5 
µM oligo dT (MWG Eurofins genomics, UK)), 1 µL of 50 U of MultiScribeTM Reverse 
Transcriptase, 1 µL of 20 U of RNase inhibitor (Applied Biosystem, UK), 10 µL of 0.5 µg 
DNAse-treated RNA sample and 3.2 µL Milli-Q water. Reverse transcription-PCR (RT-
PCR) amplification was performed in a thermocycler gradient (Biometra, Germany) using 
the following cycling conditions: 25°C for 10 min, 37°C for 120 min and 85°C for 5 min. 
A negative RT (RT-) control was prepared using a sample without MultiScribeTM Reverse 
Transcriptase in the RT master mix to check any residual contamination with genomic 
DNA in the prepared RNA samples. Following amplification, the resulting cDNA was 
diluted 10 times by nuclease free water (ThermoFisher Scientific, UK), aliquoted and kept 
at -20°C until further use.      
4.2.9.4. Reverse transcription quantitative real-time PCR (RT-qPCR) 
RT- qPCR reactions were performed using SYBR Green I master mix (ThermoFisher 
Scientific, UK) and primers (MWG Eurofins genomics, UK) listed in Table 4.4, in white 




Table 4.4. Primers used in the RT-qPCR.   
Gene Oligo sequence (5’ - 3’) Genbank accession no. Product Size (bp) Annealing temperature (°C) Reference 
b-actin F: CCACACAGTGCCCATACTACGA 
R: CCACGCTCTGTCAGGATCTTCA 
XM_003443127 144 60°C Liu et al. (2011) 
EF-1a F: GCACGCTCTGCTGGCCTTT 
R: GCGCTCAATCTTCCATCCC 
NM_001279647 250 57°C Wang et al. (2015)  
IgM F: GGGAAGATGAGGAAGGAAATGA 
R: GTTTTACCCCCCTGGTCCAT 
KC708223 120 57°C Wang et al. (2015)  
TNF-a F: CTTCCCATAGACTCTGAGTAGCG 
R: GAGGCCAACAAAATCATCATCCC 
NM_001279533 161 60°C Liu et al. (2011) 
IL-1b F: TGCACTGTCACTGACAGCCAA 
R: ATGTTCAGGTGCACTTTGCGG 
XM_019365844 113 57°C Liu et al. (2011) 
MHC-II  F: ACTGACTGGGACCCGTCCAT 
R: ACAGGAAGCAGCCGCTTTTA 
XM_003459253 204 57°C Pang et al. (2013) 
 




The RT-qPCR was performed in 20 µL reaction mix consisted of 10 µL 1X 
SYBR® Green I buffer, 0.6 µL of 0.3 µM forward and reverse primers, 5 µL of ten-fold 
diluted cDNA and 3.8 µL Milli-Q water. The cycling conditions were 94°C for 15 s, 40 
cycles of denaturation at 95°C for 30 s, annealing at the optimal temperature of each 
primer as indicated in Table 4.4. for 30 s and a final extension at 72°C for 1 min. Melting 
curve analysis included amplification at 60°C to 90°C with 0.1°C increments per second to 
evaluate the qPCR products specificity. Samples were run in duplicate and each qPCR run 
included RT negative (RT-) and non-template controls (NTC) (Milli-Q water only). Serial 
dilutions of a pool of all cDNA samples were prepared in nuclease free water 
(ThermoFisher Scientific, UK) including seven dilutions at 1:10, 1:20, 1:50, 1:100, 1:500, 
1:1000 and 1:10000. The threshold cycle (Ct) values of these dilutions were plotted versus 
log concentration to generate a standard curve in the realplex software V2.2 (Eppendorf, 
UK). The quality of the generated standard curve was evaluated using the slope curve and 
the correlation co-efficient (R2). The efficiency of the amplification of the qPCR targets 
was judged by the line slope following the equation, E= (10-1/slope) -1. All the primers used 
in this study were analysed for self-annealing using NCBI Blast sequence analyser 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch).  
4.2.10. Quantification of Fno load in survivor fish by quantitative real-time PCR 
(qPCR)   
Ten spleen samples were randomly collected from surviving fish in the different 
treatments 15 dpc and preserved in 95% ethanol (Sinopharm, China) for quantification of 
Fno load using quantitative real-time PCR (qPCR). DNA was extracted from 20 mg of 
spleen tissues using DNeasy blood and tissue kit (Qiagen, UK) as described in Section 
4.2.1.2. After extraction, the DNA concentration was measured using a nanodrop ND-1000 
Spectrophotometer (ThermoFisher scientific, UK) and standardised to 100 ng/µL by Milli-
Q water (Thermo, UK). 1 µL of each DNA sample was visualised by UV illuminator (Bio 
Imaging, Syngene) after electrophoresis on 1.0 % (w/v) agarose gel containing 0.1 µg/mL 
ethidium bromide (Sigma, UK) in Tris-acetate EDTA (TAE) buffer (ThermoFisher 
Scientific, UK). Real time qPCR was performed to quantify the Fno genomic load in copy 
numbers using a dilution range of 107: 101 copies/ µL of DNA plasmid standard containing 
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a unique gene (Hypothetical protein gene, Genbank accession no. JQ780323) previously 
identified in Fno strains only (Duodu et al., 2012). The assay was performed using a 
LightCycler® 2.0 (ROCHE) in a 20 µL reaction volume consists of 0.6 µL of 0.3 µM 
primers (F: 5’-CAT GGG AAA CAA ATT CAA AAG GA-3’ and R: 5’- GGA GAG ATT 
TCT TTT TTA GAG GAG CT-3’) (MWG Eurofins genomics, UK), 10 µL of 1X 
Luminaris color HiGreen™ qPCR master mix (ThermoFisher Scientific, UK), 1 µL DNA 
template and nuclease free water (ThermoFisher Scientific, UK) up to 20 µL. The qPCR 
cycling conditions were adopted from Duodu et al. (2012) as following: 50°C for 2 min 
for uracil-DNA glycosylase enzyme activity, 95°C for 10 min to start denaturing the UNG 
enzyme and activate the DNA polymerase enzyme then 45 cycles at 95°C for 15 s and 
60°C for 1 min. Melting curve analysis formed of 1 cycle at 95°C for 30 s, 55°C for 30 s 
and 95°C for 30 s. All samples were run in triplicate. After the run, analysis was 
performed using the default calculation of the threshold fluorescence (Ct value).  
4.2.11. Statistical Analysis 
Data processing was performed using Microsoft Excel 2013, while GraphPad prism 
version 7 (GraphPad software Inc., Sand Diego, CA, USA) was used to conduct pairwise 
Kaplan-Meier survival analyses with subsequent Mantel-Cox log-rank test applied to the 
mortality data to calculate the survival probabilities and to compare the survival 
distributions of fish in each experimental group (Kaplan and Meier, 1958). Normality of 
the data from serum antibody responses and Fno load in spleen samples was tested using 
Komogorov-Smirnov test. One-way ANOVA with a Tukey post hoc test was performed to 
analyse the differences in optical density (OD450) values representing antibody responses 
in serum samples and Fno load between the different treatments (vaccinated, adjuvant and 
PBS control groups). In all cases a p-value of < 0.05 was considered significant. 
The expression of the target genes in this study was normalised to the expression of 
b-actin and EF-1a. The fold change in the expression of the target genes in spleen samples 
of vaccinated and adjuvanted fish compared to the unvaccinated-control samples was 
calculated following the 2-DDCT method (Livak and Schmittgen, 2001) using the Relative 
Expression (REST©) Software (Pfaffl et al., 2002). The expression of the target genes in 
both vaccinated and adjuvanted samples was considered significantly different from that of 
the control samples when a p-value <0.05 was obtained.    




4.3. Results  
4.3.1. Confirmation of Fno free status of fish 
PCR results showed that spleen and head kidney samples of the tested naïve fish (n= 6) 
were all negative for Fno (Figure 4.2). 
 
 








Figure 4.2. 16S rRNA PCR for screening tilapia for the presence of Fno before 
vaccination. 1% agarose gel showing negative results for Fno in tested fish. M: 100bp 
Molecular marker, Lane 1-6 head kidney and spleen pool of 6 naïve tilapia, Lane 7: 
Positive control, Lane 8: negative control (Milli-Q water only). 
4.3.2. Assessment of the physical characteristics and safety of the vaccine 
4.3.2.1. Homogeneity and droplet size   
A homogenous distribution of the continuous and dispersed phases of the mixture 
(vaccine-adjuvant) and thin emulsion with particles size of ~ 1-2 µm were observed after 
microscopical examination of a drop of the produced vaccine.  
4.3.2.2. Stability and drop test   
The stability of the emulsion was tested after 24 h, 48 h and 1 week after the 
emulsification. Observations indicated that there was no separation of the liquid phases of 
the solution, no creaming, breakage, sedimentation or releasing of oil on the surface. Thus, 
the emulsification of the vaccine had resulted in a stable solution that could be used for 
fish vaccination. The drop test showed that the vaccine droplet stayed on the surface. This 
reflects the stability of the vaccine creating a linear drop where the oily component stayed 
in the superficial layer and a major portion of the drop stayed on the surface.  







4.3.2.3. Syringability   
By applying of a standard force, the vaccine drops diffused smoothly from the needle and 
no obstruction was observed. Also, during i.p. injection of the fish, no pressure was 
required to release the vaccine into their abdominal cavity. 
4.3.2.4. Safety  
No mortalities were recorded in any of the injected fish. The fish appeared normal and 
upon dissection, deposition of vaccine was observed in the abdominal cavity either below 
the swim bladder or distributed through the cavity. 
4.3.3. Pre-challenge of un-vaccinated tilapia  
Necropsy of either recently dead or moribund fish showed typical signs of francisellosis 
including enlarged spleen and kidney with multiple white nodules on the surface and 
massively enlarged gall bladder (Figures 4.3 and 4.4). The pre-challenge with the different 
bacterial doses revealed that doses of 104 and 105 CFU/mL caused low mortalities (0%; 20-
30%, respectively), while 107 and 108 CFU/mL induced higher mortalities (>90%) with all 
isolates used for the challenge. A dose of 106 CFU/mL of the three Fno isolates used was 
able to induce ~ 60% mortality, therefore this dose was chosen to challenge the fish at 30 





































Figure 4.3. Splenomegaly (solid arrow) and enlarged gall bladder (dashed arrow) after 











Figure 4.4. Fno-infected Nile tilapia showing enlargement of head kidney (dashed arrow) 








                                
                          











                   
 





Figure 4.5. Percentage mortality following i.p. injection of five doses of Fno UK (A), 








4.3.4. Fish vaccination and challenge 
Observation of fish in vaccinated, adjuvant-alone or PBS control groups showed slight 
differences in their behaviour after the challenge. The challenged vaccinated fish appeared 
more active, had good appetite and were well distributed in the tanks. The other groups of 
fish appeared lethargic, gathered toward the sides of the tanks and had reduced appetite. 
The moribund fish showed abnormal swimming with a distended abdomen. Mortalities 
started at day 6-8 post-challenge (pc) in the vaccinated group and at day 3- 4 pc in both 
adjuvant-alone and the PBS groups. Upon necropsy of the mortalities and moribund fish, 
signs of Fno infection were evident, including the presence of ascites and enlargement of 
the spleen and head kidney, with white or creamy nodules covering their surfaces (Figure 
4.6). Detection of Fno was confirmed by bacteriology from swab taken from the spleen of 















Figure 4.6. Clinical signs of francisellosis in moribund (A) and recently dead (B) tilapia after heterologous i.p. challenge with three 
Fno isolates. (A) Ascites (dashed arrow), (B) enlargement of spleen (SP) and head kidney (HK) with appearance of white nodules on 













Figure 4.7. Grey, semi translucent and mucoid Fno colonies retrieved from spleen 
homogenate of moribund tilapia after i.p. challenge with Fno UK (A), Costa Rica (B) and 







Figure 4.8. Francisella genus specific PCR (16S rRNA) for detection of Fno in moribund 
fish and recent mortalities post-challenge with three different Fno isolates. 1% agarose gel 
showed amplicon of 1140 bp. M: DNA ladder, Lanes 1 – 6: spleen of representative 
moribund fish (1-3) and recent mortalities (4-6) post the heterologous challenge with Fno 
UK (Lanes 1,4), Costa Rica (Lanes 2,5) and Mexico (Lanes 3,6). Lane 7: positive control, 
Lane 8: Negative control (Milli-Q water only).   








 The non-vaccinated fish (PBS group) showed the highest mortality at 15 dpc with 
the different Fno isolates. Fish injected with the adjuvant alone had higher survival rates 
than the PBS control, however these were not significant (p>0.05). The vaccinated fish 
demonstrated the lowest mortalities following challenge and survival was significantly 
higher than adjuvant-alone and non-vaccinated tilapia post-challenge (p< 0.001) (Table 4.5 
and Figure 4.9). 
Table 4.5. Accumulated mortality in the different groups of fish after challenge (Average 
mortality % ± SD of 2 parallel tanks holding 30 fish/tank/challenge group) 
 
Fno isolate Cumulative mortality 
in vaccinated fish 
15 dpc (n= 60) 
Cumulative mortality in 
adjuvant-alone fish  
15 dpc (n= 60) 
Cumulative mortality 
in PBS control fish  
15 dpc (n= 60) 
UK  13.3% (± 0.49) 63.3% (± 1.33) 75% (± 1.8) 
Mexico  25 % (± 0.82) 60% (± 1.68) 73.3% (± 1.26) 
Costa Rica  21.7 % (± 0.56) 56.7% (± 1.5) 71.7 % (± 1.74) 
       n: number of fish per challenge group  
 
  



























Figure 4.9. Mortalities in vaccinated, adjuvant-alone and control fish after i.p. challenge 
with Fno UK (A), Mexico (B) and Costa Rica (C) isolates. Each line displays the average 
mortality of 2 parallel tanks with 30 fish /tank/challenge group. Groups that do not share 















The vaccinated fish had RPS levels of 82.3%, 69.8% and 65.9%, while the 
adjuvant-alone groups had RPS levels of 15.6%, 20.9% and 18.2% after challenge with 
Fno UK, Mexico and Costa Rica Fno isolates, respectively. Significantly higher survival 
(p< 0.05) was observed in all vaccinated groups after challenge with the three different 
Fno isolates compared to the adjuvant-alone and unvaccinated control fish. No significant 
difference (p> 0.05) was observed in survival of fish after challenge with the homologous 
isolate (UK Fno) or the heterologous isolates (Mexico and Costa Rican Fnos) in the 
adjuvant-alone or non-vaccinated groups. However, in the vaccinated group, fish 
challenged with the homologous isolate displayed significantly higher survival (p< 0.05) 
than fish challenged with heterologous isolates which showed non-significant difference 
between their survival rates (p> 0.05). In addition, in the adjuvant-only treatment, fish 
challenged with Costa Rican isolate was the only group that showed significantly higher 
survival (p< 0.05) to non-vaccinated fish challenged with either the UK or the Mexican 
isolates (Figure 4.10). 
4.3.5. Antibody response after vaccination and challenge 
Serum IgM response measured by ELISA showed that vaccinated fish produced 
significantly higher Fno specific IgM levels (OD450 at 1:500 dilution) than the adjuvant 
injected and unvaccinated control fish at 840 dd after immunization. No specific immune 
response was detected at day 0 in any of the treatment groups. Analysing the IgM levels 
after vaccination and challenge with the three different Fno isolates (15 dpc) showed that 
the vaccinated fish in the different treatment groups had significantly higher antibody 
responses (p<0.05) compared to the adjuvant-alone and unvaccinated control fish (Figure 
4.11). In addition, the IgM level in the Fno UK challenged fish was significantly higher 
(p<0.05) than that of fish challenged with either the Mexican or Costa Rican isolates.  
  




















Figure 4.10. Kaplan-Meir (Log-rank Mantel Cox) representation of cumulative survival of 
tilapia fingerlings 15 dpc with 106 CFU/mL of Fno UK, Mexico and Costa Rica isolates. 
Each curve represents the average results of 2 parallel tanks holding 30 fish/tank/challenge 
group. The non-vaccinated, non-challenged curve represents data from 1 tank with 20 fish. 
Asterisks refer to the overall significant differences in survival rates between the different 
treatments (p < 0.0001). Groups that do not share similar symbols are significantly 


































Figure 4.11. Serum IgM response (Mean of OD450 ± SD) of tilapia following i.p. injection 
of vaccine, adjuvant-alone and PBS at 30 dpv (840 dd) and 15 dpc with three Fno isolates. 
UK: Fno UK isolate, CR: Fno Costa Rica isolate, MEX: Fno Mexico isolate, dpv: days 
post vaccination, dpc: days post challenge. Each bar represents average of IgM at OD450 of 
10 fish/ treatment. The dashed line represents the cut-off (three times the absorbance of the 
negative control (PBS)). Groups that do not share letters are significantly different 
(p<0.05). Serum dilution was 1:500.  
  




4.3.6. Serum cross-reactivity 
When subjected to 1D SDS-PAGE, the whole cell lysate of the Fno isolates from the three 
geographical regions showed a similar protein banding pattern as seen in Figure 4.12A. 
Coomassie Blue and Silver staining revealed a conserved abundant band between 20-37 
kDa. This band showed immunoreactivity whith sera obtained from pre-challenged 
vaccinated fish at 30 dpv (Figure 4.12A). Considerable variability was observed in 
intensity of the immunoreactive band in the blots between the different Fno isolates, where 
the UK isolate showed the highest intensity. No immunoreactivity was seen with the day 
zero (D0) fish sera, pre-challenged adjuvant-alone or non-vaccinated control fish serum 
samples 30 dpv. The same band was also observed with a stronger intensity when the 
whole cell lysate of the vaccine isolate (Fno UK) was blotted with sera of surviving fish 




























































Figure 4.12. Western blot showing immunoreactivity of serum of vaccinated, adjuvant-
alone and control tilapia 30 dpv against homologous and heterologous Fno isolates (A) 
and immunoreactivity of serum of survivor tilapia 15 dpc with the different Fno isolates in 
vaccinated, adjuvant-alone and control groups against Fno UK (vaccine isolate) (B). The 
antigenic band on the blots (b, d) is indicated by black arrows and its corresponding 
protein band on the reference gels (a, c) is indicated by brackets. M: marker, UK: Fno UK 
whole cell lysate, CR: Costa Rica isolate whole cell lysate, MX: Fno Mexico isolate whole 
cell lysate. a Fno UK: anti-serum raised against Fno UK isolate, a Fno CR: anti-serum 
raised against Fno Costa Rican isolate, a Fno MX: anti-serum raised against Fno Mexican 
isolate, PC: Fno-positive tilapia serum, NC: Fno-negative tilapia serum, TBS: Internal 








































































































































































































4.3.7. Analysis of immune genes expression by RT-qPCR 
The integrity of the RNA extracted from spleen samples was checked by electrophoresis 
on a 1.0% agarose gel as shown on Figure 4.13, before performing DNase treatment. The 
relative expression of the target genes IgM, IL-1b, TNF-a, MHCII was normalized against 
b-actin and EF-1a. The relative fold change in expression of these genes in spleen 
samples from vaccinated and adjuvant-alone groups of tilapia was compared to the 
expression in control fish and is summarized in Table 4.6. At 6 hpv, a significant up-
regulation of IL-1b  was seen in both treatments with significantly higher expression in 
vaccinated groups (p < 0.001) than adjuvant-alone (p <0.01). In addition, a significant up-
regulation of TNF-a (p <0.001) and MHCII (p <0.01) was seen in the vaccinated group 
only. At 24 hpv a significantly higher expression of IL-1b and TNF-a was observed in 
vaccinated fish (p <0.001) when compared to the fish given adjuvant-alone (p < 0.01 and p 
< 0.05, respectively). MHCII was significantly upregulated in vaccinated fish (p < 0.01), 
while it was significantly down-regulated in the adjuvant-alone group (p <0.01). At 72 
hpv, a significant up-regulation of IgM, IL-1b, TNF-a and MHCII (p <0.01) was observed 























Figure 4.13. Agarose gel electrophoresis showing integrity of RNA in 1% agarose 
gel. (A) RNA from spleen samples in adjuvant-alone treatment (Lanes 1-18), (B) 
RNA from spleen samples in PBS control treatment (Lanes 19-36), (C) RNA from 
spleen samples in vaccine treatment (Lanes 37-54). 
1       2       3        4        5       6       7        8      9        10     11     12     13      14      15     16   17      18        
19    20      21     22     23      24      25    26     27     28      29     30     31      32      33    34      35      36  















Table 4.6. Relative expression of pro-inflammatory and immune related genes in spleen samples of vaccinated and adjuvant-alone 
groups of tilapia at 6 h, 24 h and 72 h post-vaccination compared to the non-vaccinated control group. (↑ or ↓), (↑↑ or ↓↓) and (↑↑↑ or 





Gene Treatment 6 hpv 24 hpv 72 hpv 
  Expression SE Expression SE Expression SE 
IgM Vaccinated 2.306 0.261-22.013 3.077 1.248-7.406 4.956 ↑↑ 2.384 - 11.362 
Adjuvanted 1.443 0.403-4.624 2.800 0.694 - 14.70 0.777 0.274 - 3.188 
IL-1b Vaccinated  7.884 ↑↑↑ 3.685 - 12.028 5.811 ↑↑↑ 1.911 - 11.435 4.977 ↑↑ 3.319 - 9.852 
Adjuvanted 5.761 ↑↑ 1.728 - 37.970 4.404 ↑↑ 1.713 - 11.199 4.269 ↑ 0.951 - 28.387 
TNF-a Vaccinated 2.467 ↑↑↑ 1.949 - 3.108 2.991 ↑↑↑ 2.164 - 3.998 4.539 ↑↑ 2.543 - 12.118 
Adjuvanted 1.188 0.876 - 1.659 1.473 ↑ 1.112 - 2.199 1.692 0.895 - 4.483 
MHCII Vaccinated 3.409 ↑↑ 1.854 - 4.927 4.190 ↑↑ 2.048 - 7.672 4.506 ↑↑ 2.815 - 6.063 
Adjuvanted 0.770 0.414 - 1.428 0.627 ↓↓ 0.435 - 0.861 0.395 ↓↓ 0.267 - 0.587 
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4.3.8. Fno load in the spleen of survivor fish post-challenge  
Quantification of the bacterial burden (copies/µL) in the spleen samples from the different fish 
treatments showed significantly higher Fno loads (p<0.05) in the un-vaccinated control and the 
adjuvant-alone groups than vaccinated group after challenge with Fno UK, Costa Rica and 
Mexico isolates, respectively (Figure 4.14). No significant difference was seen in the bacterial 
burden measured in spleen samples from fish challenged with different Fno isolates within the 


















Figure 4.14. Fno load (Log10 of mean copies/µL±SD) quantified by qPCR in spleen of survivors 
after i.p. challenge with Fno UK, Costa Rica (CR) and Mexico (MEX) isolates in the different 
treatment groups. Each bar represents average of Fno load of 10 spleen samples/treatment. 
Groups that do not share letters are significantly different (p < 0.05). 
 




4.4. Discussion  
Vaccination is the most widely accepted and effective strategy for prevention of infectious 
diseases in aquaculture. Tilapia farming has been established in many countries due to the 
high demand of the fish amongst consumers (Pretto-Giordano et al., 2010). With the 
emergence of piscine francisellosis outbreaks in different countries around the world, high 
mortality and serious economic losses are being reported in farm-raised tilapia due to 
infection with Fno. Therefore, efforts to develop potent, safe, cost-effective vaccines 
against Fno have become a priority.  
 In the current study, the efficacy against three clinical Fno isolates including one 
homologous and two heterologous isolates with distinct geographical origins was 
demonstrated in Nile tilapia fingerlings following immunisation with an inactivated 
injectable whole cell oil-based vaccine. In addition, the fish immune response was 
examined by serology post-vaccination and post-challenge and analysis of expression of 
pro-inflammatory and immune related genes post-vaccination. The vaccine tested in this 
study conferred significant protection against challenge with a homologous as well as two 
heterologous Fno isolates in tilapia fingerlings (~15 g), compared to fish that received the 
adjuvant-alone or were mock vaccinated with PBS (Figure 4.10, p < 0.05). The 
significantly higher RPS values (p< 0.05) in the vaccinated fish in the present study 
(82.3 %; 69.8 %; 65.9 %) as opposed to adjuvant injected fish (15.6 %; 20.9 %; 18.2 %), 
post-challenge with the homologous isolate (UK Fno) and the two heterologous isolates 
(Mexican and Costa Rican Fno isolates, respectively) are in agreement with results 
reported by Ramirez-Paredes, (2015) using the same vaccine, which induced significant 
protection in tilapia, demonstrated by RPS value of 100% compared to 46.6% in the 
adjuvant-alone group post-challenge with the same vaccine isolate. Furthermore, the RPS 
values in the current vaccinated tilapia were similar to those obtained in tilapia fingerlings 
vaccinated with a live-attenuated Fno vaccine after immersion challenge with a self-
genotype Fno isolate that resulted in RPS of 68.75%: 87.5% (Soto et al., 2011b). 
Interestingly, the survival rates in the current study were higher than that obtained in 
zebrafish, Danio rerio, i.p. immunised with a Fno-outer membrane vesicle (OMV)-derived 
vaccine and i.p. challenged with the homologous Fno vaccine isolate, where a survival rate 
of 65.5 % was reported 28 dpc (Lagos et al., 2017). This suggests a weaker stimulation of 
the zebrafish immune system by OMVs when compared with the adjuvanted whole cell 
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vaccine developed in the current study, although differential susceptibility to Fno between 
tilapia and zebrafish is likely to be a major influential factor.  
Analysing different vaccine efficacy experiments, it could be observed that several 
factors can affect the efficacy of these vaccines, including, antigenicity of the master seed, 
vaccine composition and use of adjuvants, concentration of the vaccine, route of 
administration, fish size, temperature of the water, fish species, stocking densities, 
husbandry, rearing system (recirculation vs flow through) or difference in the bacterial 
batch used for vaccine production and/or challenges (Pridgen and Klesius, 2013; Evans et 
al., 2004, Liu et al., 2016; Munang’andu et al., 2016). The difference in the level of 
protection observed against the homologous isolate (i.e. Fno UK isolate) obtained in the 
current study (RPS 82.3 %) and the study of Ramirez-Paredes, (2015) mentioned above 
may be attributed to the variability in the genetic make-up and susceptibility of the fish 
that were used in the experiment. The fish used in the current study were of the wild type 
Nile tilapia obtained from a commercial farm and therefore may have been exposed to 
other stressors commonly present in the farm environment, while the autogenous vaccine 
experiment of Ramirez-Paredes, (2015) included indoor raised-hybrid red tilapia obtained 
from the in-house aquatic research facility that maintains its own tilapia seed without using 
fish from any external sources. Moreover, different concentrations of inoculum were used 
for the fish challenges in the two experiments to achieve specific mortalities. A bacterial 
dose of 105 CFU/Fish used to achieve 70 % mortality (LD70) in the current study, while 
103 CFU/Fish and 105 CFU/Fish were required to achieve the same mortality level in 
tilapia and zebrafish, respectively (Ramirez-Paredes, 2015; Lagos et al, 2017) which may 
have influenced the RPS observed following vaccination in the different studies.  
Immersion vaccines target the natural routes of pathogen entry including fish gills 
and skin (Soto et al., 2011b). However, immersion vaccines are mainly used for smaller 
fish (<10 g) and have been found to stimulate the mucosal immune system of the fish 
leading to enhanced production of specific B-cells located in gills and skin epithelium with 
a minor effect on the systemic immunity of the fish (Barnes, 2017). Therefore, protection 
may be short lived and vaccinated fish are likely to require a booster vaccination. 
Moreover, live vaccines are well known to induce a strong cell-mediated response in 
addition to humoral immune memory, which is the commonly stimulated immune arm 
post injection immunisation (Barnes, 2017). Thus, a higher level of protection is frequently 




obtained by live attenuated vaccines. Whilst the live attenuated vaccine may seem more 
effective than the inactivated vaccines, there are concerns related to potential reversion to 
virulence in fish under stress in the field and release of the live genetically modified 
organisms (GMOs) into the environment (Muanang’andu et al., 2016), costs and 
complexity of production (Barnes. 2017), which limit their marketability and regulatory 
acceptability in fish farms in some countries.  
  Adjuvants play an important role in modulating the intrinsic immunogenicity of the 
vaccine antigens and stimulation of non-specific defence mechanisms which can induce 
protection against a wide range of pathogens (Guy, 2007). Generally, adjuvants can 
promote induction of both cellular and humoral immune responses in fish mediated by 
downstream activation of natural killer cells (NKc), phagocytes including macrophages 
and a distinct subset of T-helper cells (Th cells) (Schijns and Tangerås, 2005; Jiao et al., 
2010; Tafalla et al., 2013). Montanide or oil based-adjuvants have been widely used in the 
formulation of fish vaccines aiming to improve their efficacy and stability (Tafalla et al., 
2013). The slow release of the antigen incorporated in the adjuvant (W/O emulsion) can 
contribute to a highly effective and long-lasting protection against the target pathogen 
(Brudeseth et al., 2013). An oil-based adjuvant (MontanideÔ ISA 763 A VG) has been 
demonstrated to improve the efficacy of the developed Fno vaccine in the current study. 
When mixed with the inactivated Fno and i.p. injected, the vaccine conferred the fish with 
a high degree of resistance to Fno infection. This result was in agreement with that 
reported by Ramirez-Paredes, (2015), where RPS of 46.6 % was obtained in fish given the 
adjuvant-alone and challanged with the vaccine isolate. The non-mineral oil adjuvant 
Montanide ISA 763 A VG used in the current study was successfully used in other 
commercial and lab-based vaccines for tilapia including a whole cell-inactivated vaccine 
(AQUAVACÒ Strep Sa) and a recombinant vaccine against S. agalactiae (Liu et al., 
2016). Comparison of the efficacy of tilapia vaccines with and without adjuvant was also 
reported. Firdaus-Nawi et al. (2013) observed that a survival rate of 100% was obtained 
using a feed-based vaccine containing Freund’s complete adjuvant in tilapia post-challenge 
with S. agalactiae, compared to a lower survival rate of 57% when the vaccine was 
administrated alone without the adjuvant. In rainbow trout, Oncorhynchus mykiss, 
immunisation against Yersinia ruckeri resulted in survival rates of 97.5%, 87% and 60% 
post-injection of adjuvanted vaccine, vaccine alone and adjuvant alone (Montanide ISA 
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763 A VG), respectively, compared to 100 % mortality in the control fish (Jaafar et al., 
2015).  
A widely used parameter to predict vaccine efficacy in fish and other higher 
vertebrates is assessment of the resulting antibody responses and its correlation with 
protection (Plotkin, 2008; 2010; Munang’andu et al., 2016). A strong correlation between 
specific antibody production and the level of protection was observed in the current study. 
At 30 dpv, a relatively weak antibody response was observed in vaccinates, although it 
was significantly higher (p< 0.05) than both adjuvant-alone and PBS control group fish. 
This corroborates previous results with this vaccine (Ramirez-Paredes, 2015), but was in 
contrast to weak and non-significant mucosal or serum antibody responses to a non-
adjuvanted live attenuated Fno immersion vaccine 4 weeks post-vaccination (wpv) in 
tilapia and an OMV-derived Fno injectable vaccine trialled in zebrafish 3 wpv, 
respectively (Soto et al., 2011b; Lagos et al., 2017). The reason for the lower antibody 
responses in these studies may be attributed to the difference in the vaccine composition 
(i.e. addition of adjuvant), the method of vaccine delivery, the vaccine inoculum dose, or 
the fish species used in the experiment. Elevated specific serum IgM levels were detected 
in all treatments 15 dpc with the different isolates with significantly higher IgM values in 
the vaccinated fish. More importantly, significantly higher IgM responses were detected, 
which correlated with higher survival rates (RPS) in the vaccinated fish challenged with 
the Fno UK (homologous/vaccine isolate) than fish challenged with other Fno isolates 
(e.g. Fno Costa Rican and Mexican isolates).   
The protective mechanism of immunity against piscine francisellosis is yet to be 
determned. However, previous results of correlation between the survival in vaccinated 
fish and the antibody levels in serum or mucus post-challenge in tilapia (Soto et al., 
2011b) and zebrafish (Lagos et al., 2017) can corroborate the importance of the antibody-
mediated immunity in protection against Fno infection. A similar pattern was reported 
with other bacterial pathogens of tilapia including Streptococcus iniae (Shelby et al., 
2002), S. agalactiae (Pasnik et al., 2005) and Flavobacterium columnare (Grabowski et 
al., 2004), where the humoral immune response has been paramount for protection against 
these pathogens. Moreover, the specific antibody produced in response to vaccination/or 
infection with the majority of Gram-negative bacteria act synergistically with the 




complement system leading to a direct bactericidal effect on the invading bacteria or can 
assist phagocytic cell activity. Stimulation of phagocytosis is mainly facilitated by the 
effect of antibodies on Fc receptor bearing macrophage-like cells and NK cells to destroy 
the engulfed bacterial cells including intracellular bacteria (Soto et al., 2011b). This was 
previously demonstrated by the ability of antibodies in the serum obtained from tilapia 
immunised with live attenuated Fno vaccine to co-stimulate phagocytosis of Fno by head 
kidney derived macrophages (HKDM) while neither the heat inactivated, nor normal sera 
obtained from adult tilapia damage the bacteria in vitro (Soto et al., 2011b). Thus, further 
in vitro studies analyzing the role of the antibodies produced in serum obtained from 
vaccinated or adjuvant-alone fish post-challenge with the multiple Fno isolates to mediate 
phagocytic uptake of Fno may enhance our understanding of the role of the antibody-
mediated response in protection against piscine francisellosis in tilapia.    
There is a lack of information regarding the role of cellular immunity against 
piscine francisellosis and most present understanding is based on results from vaccine 
experiments with Francisella tularensis. It was reported that F. tularensis has the ability to 
trigger T-cell mediated immune responses, mainly antigen-specific IFN-γ recall responses, 
besides humoral mediated immunity (Huntely et al., 2008; Cong et al., 2009) and a strong 
cell-mediated immune response was suggested to prevent Francisella spp. infection in 
other vertebrates (Kirimanjeswara et al., 2008; Chou et al., 2013). IFN-γ, is a well-known 
Th1 marker that plays an important role in response to microbial infection via triggering 
effective innate and adaptive immune response (Vilcek, 2003). IFN-γ has been cloned in 
teleost fish and was reported to be a powerful stimulator of macrophages and can boost a 
strong MHC-I and II expression, suggesting a role in antigen presentation (Zou et al., 
2005), beside modulation of genes responsible for induction of microbicidal activity 
(Martin et al., 2007). In a recent study by Lagos et al. (2017) a significant up-regulation of 
IFN-γ-1 transcription was reported in zebrafish 24 h post-immunization with Fno-derived 
OMVs vaccine that continued until 21 dpv. These authors suggested a similar role for IFN- 
γ in zebrafish by preventing the escape of Fno from the phagosome. Taking into account 
the complexity of the IFN-γ machinery in teleosts as opposed to the mammalian analogue 
in terms of types, levels of ligands, receptors and the variability in the recruited cell 
populations, we can expect diverse expression ranges of this gene in different teleost 
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species. In addition, high expression of the p40 subunit of IL-12 and IL-17 in Atlantic cod 
indicated that Fnn infection could drive a stronger immune response towards effective T 
cell proliferation (Bakkemo et al., 2011). Thus, more studies are required to investigate the 
role of cell-mediated immunity in protection of tilapia against Fno infection at the 
molecular level (i.e. genes associated with immune cell stimulation). 
The antigenicity of the vaccine master seed may constitute a major factor in the 
efficacy of the vaccine against heterologous bacterial isolates (Pretto-Giordano et al., 
2010). The proteomic and antigenic pattern of the five isolates from diverse geographical 
locations, including the isolates used in the current study, were successfully characterised 
in Chapter 2 and 3. The proteomic study showed only minor differences in their antigenic 
profile and the previous molecular-genotyping studies suggested that these Fno isolates are 
clonally-related (Leal et al., 2014; Figueiredo et al., 2016; Gonçalves et al., 2016; 
Ramirez-Paredes et al., 2017b). However, it is unknown whether the inclusion of one 
isolate in the current vaccine would cross protect against isolates from different origins. 
Immunoblotting with sera obtained from vaccinated tilapia before the challenge or sera 
from tilapia post-challenge with either the homologous or the heterologous Fno isolates 
revealed a cross-isolate antigenicity. Taken together with the induced high survival rates 
(i.e RPS) post-challenge with the different Fno isolates, cross-protection ability of the 
developed vaccine against challenge with heterologous Fno isolates may be highlighted. 
Further studies using other geographically distinct Fno isolates will give us more insights 
into the efficacy, and in particular, establishment of the cross-protectivity of the developed 
vaccine. Future work could also include development and efficacy testing of a vaccine 
containing more than one Fno isolate (i.e. bivalent or polyvalent vaccine). 
In order to investigate the effect of the developed vaccine on tilapia immune 
response at the molecular level, expression of some genes associated with innate and 
adaptive immunity were analysed. Efficient antigen recognition and presentation by the 
host immune cells is a paramount step in the success of vaccination, which primarily 
involves Major Histocompatibility Complex (MHC) molecules (MHC-I and MHC-II) 
located on the surface of the antigen presenting cells (APCs) (Secombes and Belmonte, 
2017). MHC-II is restricted to the so-called “professional APCs” which are the immune 
cells able to internalize extracellular pathogens or proteins including macrophages, 
dendritic cells and B cells (Secombes and Belmonte, 2017). MHC-II plays an important 




role in modulation of the adaptive immune response following vaccination, where 
interaction of the vaccine antigen-MHC-II complex with the T-cell receptor (TCR) will 
mount a T-helper cell activation. The later step is crucial in adaptive immunity (Secombes 
and Belmonte, 2017). In the current study, the transcription of MHCII was significantly 
up-regulated in the spleen of vaccinated fish 6 hpv and at 24 - 72 hpv represented by ~ 4.5 
times fold change, while a significant down-regulation was observed in the adjuvant-alone 
group. This finding suggests the successful recognition of Fno antigens in the vaccine and 
presentation of these antigens by the fish APCs, which is a key step in triggering of a 
subsequent adaptive immune response.  
The rapid activation of pro-inflammatory cytokines in response to the vaccine in 
the current study was evidenced by an early (6 hpv) significant up-regulation of IL-1β and 
TNF-a , which is produced by the activated macrophages in spleen tissue (Zhu et al., 
2013). Interleukin 1β (IL-1β) is one of the earliest pro-inflammatory cytokines to be 
expressed in a prompt response to infection via triggering of a cascade of reactions, 
including up or down-regulation of expression of other cytokines and chemokines. It is 
mainly involved in lymphocyte activation, leukocyte migration, phagocytosis and diverse 
bactericidal activities (Ryes-Cerpa et al., 2013). The finding in the current study is in 
agreement with a previous study by Lagos et al. (2017), where a significantly higher IL-1b 
expression was seen in kidney of adult zebra fish vaccinated with Fno-derived OMVs at 1 
dpv compared to control fish. Moreover, IL-1b expression was up-regulated in splenic 
tissue of Nile tilapia 24-96 h post-challenge with Fno (Jantrakajorn and Wongtavatchai, 
2016). TNF-a is a well-known pro-inflammatory cytokine that has been identified in 
various fish species and is expressed in multiple isoforms (Zou et al., 2002; Saeji et al., 
2003). It is mainly involved in killing of infected cells, inhibiting intracellular pathogen 
replication, apoptosis, up-regulation of transcription of various immune-related genes and 
recruiting leukocytes to the site of inflammation (Reyes-Cerpa et al., 2013). In contrast to 
the significant up-regulation of TNF-a 6-72 hpv in the current study, TNF-a transcription 
in the head kidney of zebra fish adults vaccinated with Fno-derived OMVs exhibited 
down-regulation 1-21 dpv (Lagos et al., 2017). While challenge with Fno successfully 
induced up-regulation of TNF-a at 6-96 hpc in tilapia and 1 dpc and 48 hpc in zebra fish 
adults and larvae, respectively (Brudal et al., 2014; Jantrakajorn and Wongtavatchai, 2016; 
Lagos et al., 2017).  
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Despite an observed upregulation of the aforementioned cytokines in the adjuvant 
alone group, the fold change of their transcription was lower and of shorter duration than 
that obtained by the vaccine at 6, 24 and 72 hpv. Notably, the TNF-a upregulation started 
earlier at 6 hpv in the vaccinated samples than in the adjuvant-alone group in which TNF-
a was significantly up-regulated only at 24 hpv. The ability to enhance expression of 
genes associated with innate and adaptive immune responses was previously reported with 
other adjuvants, where injection of flagellin in Atlantic salmon triggered up-regulation of 
TNF-a, IL-1β, IL-6, IL-8, however, this immune response is primarily “non-specific” and 
lacks the ability to produce specific and or protective antibodies against the target antigen 
(Hynes et al., 2001). This finding was corroborated by the ELISA and western blot 
analyses in the current study, where sera obtained from the adjuvant-alone groups 30 dpv 
demonstrated significantly lower anti-Fno IgM compared to the vaccinated group and 
these sera did not recognize any specific bands on western blots.  
Generally, fish vaccination aims to trigger a specific antibody response that is 
paramount for protection when subsequent infections occur (LaFrentz, et al., 2002). This 
protective adaptive immune response is mainly based upon a massive proliferation of 
multiple classes of T and B-lymphocytes, where the later constitutes the main repertoire of 
antibodies in fish. In teleost fish, it was thought, until recently, that IgM was the only well 
characterised immunoglobulin, but recent researches has demonstrated the presence of 
other classes including IgT and IgD (Zhang et al., 2010; Xu et al., 2013; Castro and 
Tafalla, 2015). However, IgM is the dominant circulating antibody that can be detected in 
blood, skin, gut, gill mucus and bile (Morrison and Nowak, 2002) suggesting a potential 
role in both systemic and mucosal immunity with a direct correlation to protection against 
pathogens and/or immunogens of various origins (Solem and Stenvik, 2006; Castro and 
Tafalla, 2015). In the present study, a significant up-regulation of IgM transcription was 
noted in the spleen of immunised tilapia at 72 hpv. This indicates the activation of B cells 
in response to the vaccine antigen that can be also correlated to the increased serum IgM 
detected at 30 dpv. These results are consistent with the finding of Lagos et al. (2017) who 
reported an up-regulation of IgM at 7 dpv that was maintained to 21 dpv following i.p. 
immunisation of zebra fish adults by Fno-derived OMVs. It is worth mentioning that, in 
the current study only spleen samples post-vaccination were analysed, which were also 




collected at early time points following initial immunisation (6, 24, 72 hpv). Hence, further 
analyses of other tissue samples (e.g. kidney, gills, liver), collected at different time points 
(i.e. early and late sampling) either post-vaccination or post-challenge would give more 
insights into the immune responses triggered by the vaccine. More importantly, 
investigation of the innate/non-specific immune-related factors including antimicrobial 
peptides, alternative complement and lysozymes, lectins, hemolysins, agglutinins, 
proteolytic enzymes and phagocytosis activity in the serum of vaccinated fish would 
improve our understanding of the protective mechanisms induced by injection vaccination 
against Fno in tilapia. 
Furthermore, study of the bacterial burden showed that vaccinated fish did become 
infected, albeit with fewer bacteria than adjuvant-alone and control fish. However, this 
bacterial load was significantly lower (p< 0.05) in comparisons to that detected in adjuvant 
and the control groups 15 dpc with the different Fno isolates. Thus, the protection 
provided by the developed vaccine may be associated with the ability to enhance clearance 
and/or limit dissemination of the infection, probably by recruiting activated phagocytes 
that were found to be the most abundant cell type post Francisella infection and identified 
as the favorable niche for both piscine and mammalian Francisella spp. (Clemens et al., 
2004; Bakkemo et al., 2011; Soto et al., 2011b; Celli and Zahrt, 2013; Lagos et al., 2017). 
This finding may support the advantage of using bacterial load quantification as one of the 
vaccine efficacy assessment approaches. Future histological studies investigating the 
inflammatory and tissue-associated damage post-challenge between vaccinated and control 
tilapia would allow greater insights into the protection mechanisms of the developed 
vaccine at the tissue level. Synergism between antibodies, immune-related cytokines, 
phagocytes and activated complement system has been suggested to be crucial in clearance 
of intracellular pathogens (Soto et al., 2011b). Interestingly, stimulation of the majority of 
the aforementioned components was observed in this study that may contribute to the 
efficacy of the produced vaccine against Fno infection.  
4.5. Conclusions  
The current study represents the first report of the efficacy of an oil-based 
inactivated injectable vaccine against different isolates of Fno from diverse geographical 
origins in Nile tilapia fingerlings. The developed vaccine successfully induced a 
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significantly high RPS against the different Fno isolates which was correlated with 
significantly higher specific antibody responses in vaccinated tilapia than adjuvant-
injected or control fish suggesting the importance of antibody-mediated immune responses 
in the control of Fno infection in tilapia. In addition, the potential cross-protection of the 
vaccine was highlighted by inter-isolate cross-reactivity shown by immunoblotting that 
was also supported with a significantly lower Fno burden detected in spleen samples from 
vaccinated tilapia compared to other treatments following challenge with isolates from 
different geographical locations. Furthermore, the significantly higher expression of IgM, 
IL-1b, TNF-a and MHCII transcripts 72 hpv in the spleen of the vaccinated tilapia 
provides further evidence of the ability of the vaccine to trigger an effective immune 
response that contributes to the significant protection of tilapia against Fno infection. 
However, more studies are required to investigate the role of cell-mediated immunity in 
depth and dissect the relationship between the different immune cell populations (i.e. B 
cells and T cells) and protection. Considering the short production cycle of tilapia in most 
tropical countries (~ 4-6 months), a desirable vaccine must induce a significant long-term 
protection against Fno. Thus, more studies are needed to investigate the duration of 
protection induced by the developed vaccine and test the efficacy under field conditions by 
performing a field vaccination trial. Moreover, future work should investigate the broad-
spectrum protection of the vaccine against more Fno isolates. To this end, the whole-cell 
inactivated vaccine described in the present study may provide the benchmark for 
developing a broad-spectrum highly protective injectable vaccine against emerging Fno 
outbreaks. Testing the inactivated Fno vaccine in immersion trial is required to evalaute 




















Development and efficacy of a whole cell inactivated immersion vaccine 





Piscine francisellosis is a significant bacterial disease of fish and molluscs grown in both 
the wild and aquaculture (Colquhoun and Duodu, 2011; Soto et al., 2014b). In tilapia and 
other warm water species, the disease is caused by the Gram-negative fastidious 
intracellular aquatic pathogen, Francisella noatunensis subsp. orientalis (Fno), that has 
been detected in different geographical locations (Kamishi et al., 2005; Kamishi et al., 
2010; Hseih et al., 2006; Mauel et al., 2007; Soto et al., 2009a; Lewish et al., 2016; 
Nguyen et al., 2016; Ortega et al., 2016). Fno induces systemic granulomatosis with high 
morbidity and variable mortalities up to 95 % have been recorded in all stages of fish 
(Colquhoun and Duodu, 2011); however, fingerlings (3-30 g) and juveniles (150-500 g) 
were previously found to be the most affected groups (Sebastião et al., 2017). 
 Transmission of the disease is associated with the aquatic environment (Colquhoun 
and Duodu, 2011), however, the portal of entry is still to be defined. Both horizontal and 
vertical transmission routes have been recorded (Mauel et al., 2003; Soto et al., 2009a; 
Jeffery et al., 2010; Pradeep et al., 2016) and cases of asymptomatic carriers of tilapia and 
other susceptible ornamental species were previously reported (Pradeep et al. 2016; Soto 
et al., 2014b). Thus, more research on development of control strategies against Fno 
infection in fish is warranted. The development of vaccines and other strategies to prevent 
or control piscine francisellosis must take into account the epizootiology of the disease and 
pathogenesis of Fno. Curently there is no commercially available vaccine against 
francisellosis in tilapia in spite of the serious losses caused by this disease. Various 
experimental vaccines against Fno have been developed to date with variable degree of 
success. Live attenuated immersion vaccine produced by Fno strain with an insertional 
mutantion in the iglC gene (ΔiglC) induced high protection (RPS 87.5%) in tilapia against 
immersion challenge with high dose (LD80) of wild type Fno (Soto et al., 2011b). Injection 
vaccines were also developed against Fno infection in fish including an autogenous 
inactivated oil-adjuvanted injectable vaccine (RPS 100%, Ramirez-Paredes, 2015), the 
injection vaccine tested against heterologous Fno isolates in tilapia in Chapter 4 (RPS 
65.9, 69.8 and 82.3%) and Fno-derived outer membrane vesicle (OMV) vaccine in zebra 
fish (RPS 65.5%, Lagos et al., 2017). In comparison to the whole cell inactivated or the 
OMVs-based vaccines, the live attenuated Fno vaccine may offer longer-lasting 
protection. However, safety issue represents a significant concern when live vaccines are 
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used in farms and stringent policies should be used in order to provide the safest product 
for the fish, humans and the environment (Soto and Hawke, 2017). Moreover, the 
developed Fno injection vacciones are not suitable for vaccination of small sized tilapia (< 
10 g). Thus, development of an effective vaccination strategy for protection of small fish 
against Fno infection on farms is urgently needed.    
Immersion vaccination is one of the first strategies used for immunisation of fish in 
farms and continues to be used globally (Sudheesh and Cain, 2017). It represents a natural 
route of antigen entry that has advantages over other means of vaccination including, not 
only stimulation of the mucosal immunity (Munang’andu et al., 2015a), but also low 
labour costs, reduced stress on the fish and convenience of vaccinating a large number of 
different sizes of fish at one time (Nakanishi and Ototake, 1997; Moore et al., 1998). 
Immersion has been successfully implemented in farms as a primary vaccination 
procedure to protect fish that are too small to vaccinate during hatchery rearing, and this 
has contributed to reduction and/or prevention of many threatening infectious diseases in 
farmed fish (Barnes, 2017). Tilapia are mainly reared in intensive breeding systems to 
increase production, however these high stocking densities provide a suitable environment 
for the occurrence of various infectious diseases including francisellosis, where fry are at 
their most vulnerable stage (Sebastião et al., 2017). The aim of this research was to 
develop and test the efficacy of an immersion bacterin against Fno infection in tilapia fry. 
5.2. Materials and methods 
5.2.1. Fish 
5.2.1.1. Source and acclimation of fish 
Healthy tilapia fry, O. niloticus (L.) with a mean weight of 5 ± 0.8 g were obtained from a 
commercial tilapia farm in Chachoengsao province, Thailand, a source believed to be free 
of francisellosis, and were transported to the wet laboratory of Fish Vet Group Asia Ltd. 
(FVGAL), Chonburi, Thailand. Fish were acclimated for 10 days in 100 L recirculation 
glass aquaria (Fleuren & Nooijen, Netherlands) with continuous aeration supplied with 
dechlorinated municipal water. The water parameters were maintained as described in 
Section 4.2.1.1, Chapter 4. Fish were fed at a rate of 3% body weight per day with a 
commercial tilapia feed containing 40% crude protein (CPF, Thailand). All experimental 
procedures with live fish were carried out in accordance with the UK animals (Scientific 
Procedures) Act 1986 and associated guidelines (EU Directive 2010/63/EU for animal 
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experiments) and were approved by the Animal Welfare and Ethical Review Body 
(AWERB) of the Institute of Aquaculture, University of Stirling, UK. 
5.2.1.2. Screening tilapia fry for previous exposure to Fno infection  
 Six fish were randomly collected and euthanized with 5 mL/L of benzocaine 10% (w/v) in 
ethanol (Sigma-Aldrich, UK) and head kidney and spleen were sampled, preserved in 95% 
ethanol (Sinopharm, China) and checked by Francisella genus specific PCR to confirm 
they were free from Fno before the experiment following the protocol published by 
Forsman et al. (1994) as described in Section 4.2.1.2, Chapter 4.  
5.2.2. Vaccine preparation 
The Fno UK isolate, that was used to produce the injection vaccine in Chapter 4, was also 
used for preparation of the current immersion vaccine. The bacterial cells were prepared, 
formaline inactivated, checked for sterility and the concentration of the inactivated Fno 
was adjusted to a final OD600 of 0.4 (~1.2×109 CFU\mL) using sterile 1X PBS as described 
in Section 4.2.2, Chapter 4. No adjuvants were used in the current immersion vaccine and 
after OD adjustment, the prepared vaccine was kept at 4°C till use.     
5.2.3. Pre-challenge  
The aim of the pre-challenge trial was to determine the bacterial dose that caused 60-70 % 
mortality in the control group. A total of 50 fish of mean weight 7 ± 0.6 g were used for 
the pre-challenge. The fish were distributed between 5 tanks containing 100 L of 
recirculating chlorine-free water and each tank had 10 fish. The vaccine isolate (Fno UK 
or STIR-GUS-F2f7) was used for the pre-challenge trial. The bacteria were prepared and 
the viable number of Fno cells (CFU/mL) was confirmed as described in Section 4.2.2, 
Chapter 4. Fish were then placed in a bathing solution of 2 L of live Fno-UK isolate at 
1.2×103, 1.2×104, 1.2×105, 1.2×106 or 1.2×107 CFU/mL in a static condition at a 
temperature of 23 ± 2°C with aeration for 3 h. Fish were then moved to 100 L recirculation 
tanks and kept for 15 days at 23±2°C. Daily mortalities in the different treatments were 
recorded. Moribund fish or mortalities were removed and sampled by streaking head 
kidney or spleen on CHAH to confirm specific mortality. A sub-sample of colonies 
recovered were analysed by PCR for detection of Fno as described in section 4.2.1.2, 
Chapter 4. 
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5.2.4. Immersion vaccination  
After acclimatization of fish, 160 fish (6± 0.2 g) were divided into three groups: 
vaccinated group (n= 70), non-vaccinated group (MMHB-vaccinated/control group) (n= 
70) and naïve group (n= 20). The fish were stocked in 100 L recirculation tanks filled with 
chlorine-free water. Vaccination and control groups were divided into duplicate tanks with 
35 fish per tank, while the naïve group included 1 tank of 20 fish. The formalin-inactivated 
vaccine was diluted 1:10 in tank water to a final concentration of 1 × 108 CFU/mL. The 
fish in the vaccination group were dipped in the vaccine for 30 s, while the non-vaccinated 
fry were mock vaccinated by dipping in sterile MMHB mixed with tank water for 30 s 
(1:10 dilution) (Figure 5.1). The naïve fish remained untreated throughout the experiment. 
Fish were fed 3% of their body weight 3 times/day and water temperature was maintained 
at 28°C. Water quality was monitored through a Seneye monitoring system (Seneye®, 
UK) as described in Chapter 4. At day zero (D0) and 30-days post vaccination (dpv), blood 
samples were collected from five fish per tank and processed as described in Section 4.2.5. 



































Figure 5.1. Immersion vaccination of tilapia fry. (A) immersion vaccination of tilapia fry 
in vaccine diluted in tanks water (1:10; final concentration 1×108 CFU/mL) for 30 s, (B) 
mock vaccination of fish by dipping into solution of sterile MMHB diluted in tank water 
(1:10), (C) and (D) are holding tanks for vaccinated and control groups after bath 




Chapter Five                                                                                                      Chapter Five 
161 
 
5.2.5. Immersion challenge 
The bacterial suspension was prepared following the same procedures as described in 
Section 4.2.2, Chapter 4. Thirty dpv, 50 fish (~ 9 ± 0.3 g) (duplicate tanks of 25 each) from 
vaccinated and control groups were used for the challenge. Fish were starved for 48 h 
before the challenge. Vaccinated (n = 50) and non-vaccinated fry (n = 50) were immersed 
into a static bath of 6 L of live Fno UK isolate at 1 × 108 CFU/ mL with aeration for 3 h. 
After the challenge, the fish were then placed back into the holding tanks from which they 
had originated and were maintained at 23± 2°C for 20 days. Daily mortalities in the 
different treatments were recorded. Moribund fish or recent mortalities (<6 h) were 
sampled and subjected to bacteriological culture and screening using the PCR for Fno as 
described in Section 4.2.1.2, Chapter 4. At 20 dpc, the survivors of the different groups 
were euthanized, and blood was sampled, serum was collected as described in Section 
4.2.5, Chapter 4, and preserved at -20°C for measuring IgM by ELISA following the 
protocol described in Section 4.2.7., Chapter 4. 
5.2.6. Statistical analyses 
Cumulative percent mortality (CPM) of each treatment (vaccinated challenged; non-
vaccinated challenged) at 20 dpc was calculated. The relative percentage survival (RPS) of 
fish in the vaccinated group was calculated using the following formula described in 
Section 4.2.6, Chapter 4. All data were arranged using Excel 2016. GraphPad prism® v7 
(GraphPad, San Diego, CA, USA) was used for statistical analysis and generating graphs. 
Kaplan-Meier survival analysis with subsequent Mantel-Cox log-rank test was applied to 
the mortality data to calculate the survival probabilities and to compare the survival 
distributions of the two groups (Kaplan and Meier, 1958). Normality of the data from 
serum antibody responses was tested using Komogorov-Smirnov test. Significant 
differences between vaccinated and control groups was analysed by a Kruskal-Wallis test 
(Non-parametric One-way ANOVA). If the difference was significant, a Dunn’s multiple 
comparison post-hoc test was performed to determine which groups were significantly 
different.    
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5.3. Results  
5.3.1. Screening of tilapia fry for previous Fno infection 
Initial screening of a sub-sample of tilapia by conventional PCR prior to vaccination gave 
negative results for all tested spleen and kidney tissues, confirming the Fno free status of 















Figure 5.2. Screening of tilapia fry for presence of Fno before vaccination by Francisella 
genus specific PCR. 1% agarose gel showing negative results for Fno in tested fish. M: 
100 bp Molecular marker, Lane 1: Positive control, Lane 2: Negative control, Lane 3-8: 
head kidney and spleen pool of six naïve tilapia. 
 5.3.2 Pre-challenge 
The cumulative percentage mortalities from the dose response trial were 0 %, 0 %, 10 %, 
30 % and 40 % with doses of 103, 104, 105, 106, 107 CFU/mL, respectively (Figure 5.3). As 
none of the tested doses achieved the LD60-70, a higher dose of 1×108 CFU/mL was used in 























Figure 5.3. Cumulative percentage mortalities of Nile tilapia fry after immersion 
challenge with five doses of Fno UK isolate. Each curve represents the total mortality 




5.3.3. Vaccine efficacy 
Following immersion immunisation of the tilapia fry, fish were behaving and eating 
normally, and no mortalities were recorded, indicating safety of the vaccine. Following 
challenge, the non-vaccinated fish appeared lethargic, gathered towards the sides of the 
tanks, and showed reduced appetite and abnormal swimming. The moribund fish showed 
abnormal swimming behaviour with distended abdomens. White nodules in the spleen and 
head kidney with remarkable enlargement of most of the visceral organs and ascetic fluid 
in the abdominal cavity were also observed in moribund and dead fish post-challenge 
(Figure 5.4). The bacteriological investigation using spleen and head kidney from 
moribund fish showed growth of grey, semi translucent and mucoid colonies after 
streaking on CHAH and incubating for 72 h at 28°C (Figure 5.5A). These fish were also 
positive by Francisella genus-specific PCR (Figure 5.5B).   












Figure 5.4. Clinical signs of francisellosis in tilapia fry after immersion challenge with 
Fno UK isolate. (A) Enlargement of spleen and visceral adhesions (white arrow), (B) 






Figure 5.5. Confirmation of Fno-specific mortality in tilapia fry post immersion challenge 
with Fno UK by bacteriology and PCR. (A) Grey, semi translucent and mucoid colonies 
on CHAH retrieved from spleen homogenate of moribund tilapia. (B) 16S rRNA PCR for 
detection of Francisella spp. in moribund and dead tilapia. 1% agarose gel showed 
amplicon of 1140 bp. M: DNA ladder, Lanes 1 – 6: spleen of representative moribund fish 
(1-3) and recent mortalities (4-6) post-immersion challenge with 1.2 × 108 CFU/mL of 
Fno UK, Lane 7: positive control (Fno DNA), Lane 8: Negative control (Milli-Q water 
only).   
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Mortality started at day 5 post-challenge in the non-vaccinated fry, while it started 
at day 7 post-challenge in vaccinated fry. The mean cumulative percentage mortalities 
(CPM) were 64 % (± 26.19) and 36 % (±15.3) in non-vaccinated and vaccinated groups, 
respectively (Table 5.1). The survival analysis showed a significant difference between the 
survival rates in the vaccinated and the non-vaccinated control groups post-challenge 
(p<0.001). The survival rates from both treatments are presented as a Kaplan-Meier plot in 
Figure 5.6. The RPS in vaccinated tilapia fry was 43.7 % at 20 dpc. 
 
Table 5.1. Mortalities of vaccinated and non-vaccinated tilapia fry after immersion 
challenge with 1x108 CFU/mL of Fno (n: number of fish; SD: standard deviation) 
Group Replicate n % mortality (n) Cummulative Percent 
mortality (CPM) ± SD 
Non-vaccinated 1 25 76 % (19)  
      64 % (±26.19) 2 25 52 % (13) 
Vaccinated 1 25 44 % (11)  














Figure 5.6. Kaplan-meier representation of cumulative survival of vaccinated (n=50) and 
non-vaccinated tilapia fry (n=50) after immersion challenge with 1.2 × 108 CFU/mL of 
Fno UK isolate. Each curve displays the average results for two replicate tanks (n=25 
/tank) per treatment group. Asterisks denotes significant differences between treatment 
pairs (p<0.001) 
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5.3.4. Specific immune response by ELISA 
Levels of specific IgM (OD450, 1:500) in sera of immersion vaccinated fry were above the 
positive/negative cut-off level in seven out of ten fry at 30 dpv, although the mean OD450 
value was only just above the cut-off. Similarly following challenge, although the IgM 
levels in vaccinated fish were higher than in control fish, this difference was not 






















Figure 5.7. Serum IgM responses (Mean ± SD) of vaccinated (n =10) and non-vaccinated 
(control) (n= 10) tilapia fry at day 0, 30 dpv and 20 dpc. Groups that don’t share letters are 
significantly different (p<0.05) (Kruskal-Wallis test with Dunn’s multiple comparison 
test). The dashed line represents the cut-off as determined by three times the absorbance of 
the negative control (PBS). The blue line represents mean OD450 value of each group. dpv: 
days post-vaccination, dpc: days post-challenge. Serum dilution was at 1:500. 
Chapter Five 
 168 
5.4. Discussion  
Francisellosis is an important bacterial disease affecting tilapia farming causing high 
mortalities in different developmental stages, including fry and fingerlings. In the current 
study, a whole cell-inactivated immersion vaccine was developed using a virulent isolate 
of Fno (Fno UK isolate). The efficacy of this immersion vaccine was investigated by 
measuring the RPS following immersion immunisation and immersion challenge in tilapia 
fry. The results showed that the experimental vaccine gave an RPS of 43.7 % in 6 g tilapia 
after immersion challenge with a homologous Fno isolate. 
It is of note that the RPS in this study was lower than that previously reported by 
other vaccines developed against Fno. A live attenuated vaccine that was produced by a 
mutation in the IglC locus in Fno was reported to induce a protective immune response in 
tilapia (average weight ~ 6.4 g) and the highest RPS value obtained was 87.5% following 
immersion vaccination for 180 min and challenging with 1 × 108 CFU/ mL (Soto et al., 
2011b). It is not surprising to get a high level of protection with live attenuated vaccines as 
they are likely to elicit a stronger immune response than a bacterin vaccine. Many studies 
have investigated the use of live attenuated vaccines against tilapia pathogens such as 
Streptococcus agalactaie (Pridgeon and Klesius, 2013; Li et al., 2015). However, the use 
of live vaccines is not approved in most countries due to safety concerns. In addition, 
preparation of live-attenuated vaccines is often costly, thus it may not be cost-effective for, 
a relatively low-priced fish such as tilapia. An alternative/additional explanation for the 
low RPS in the current efficacy trial compared to the trial by Soto et al. (2011) is the 
duration of vaccination. Tilapia fry in the previous study were immersed for 180 min in the 
vaccine comparing to 30 s in this study. However, this long administration time would be 
impractical under a field vaccination process and most of the commercial immersion 
vaccines recommend a short time for dipping the fish ranging from 30 to 60 s (Adams et 
al., 1988; Deshmukh et al., 2012). In addition, Sudheesh et al. (2016) reported that 
administration of an immersion vaccine for more than 3 min in rainbow trout fry did not 
give any advantage and these authors mentioned that this strategy can be considered only 
if the vaccine dose was low. It is of note that most recommendations regarding vaccine 
administration in fish are based on trials with salmonids which are anatomically and 
physiologically different from tilapia (e.g. tilapia have thicker skin and more tolerance to 
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oxygen depletion as well as changes in water temperature). Thus, trials need to be 
conducted to determine the optimal delivery time for the developed vaccine in tilapia. 
 Route of administration of vaccines has a great influence on the nature, length and 
magnitude of the host adaptive immune response (Salinas, 2015). A previous trial using an 
injectable vaccine prepared with the same Fno isolate as in this study was shown to give 
100 % RPS in vaccinated tilapia of a mean weight of 15 g after a homologous challenge at 
690 dd (Ramirez-Paredes, 2015). Also, in a very recent study in a zebra fish model (Danio 
rerio), a Fno-OMVs derived injectable vaccine gave RPS of 65% (Lagos et al., 2017). A 
similar survival variability was observed in vaccines produced against Streptococcus 
agalactiae in Nile tilapia. A microwave killed S. agalactiae vaccine produced RPS of 74% 
and 24-40% in Nile tilapia with a mean weight of 5.6 ± 1.55 g by i.p injection vaccination 
and bath immersion (BI), respectively (Pasnik et al., 2014). In addition, a live attenuated S. 
agalactiae resulted in RPS of 93.61%, 60.58% and 53.16% in Nile tilapia with a mean 
weight of 30.15± 1.55 g when administrated by i.p. injection, bath immersion and oral 
routes, respectively (Li et al., 2015).   
In general, injection vaccines confer more protection than mucosal vaccines in fish, 
including immersion vaccines (Munang’andu et al., 2015a). This is due to the rapid uptake 
of the injection vaccine after administration inside the fish that causes a quicker and 
stronger systemic immune response compared to the immersion vaccines that require more 
time to cross-mucosal barriers before gaining entry to the fish’s systemic milieu 
(Munang’andu et al., 2016). In addition, the injectable vaccine produced by Ramirez-
Paredes, (2015) was formulated with an adjuvant, which is well-known to effectively 
stimulate the adaptive arm of the immune system and contributes to improving the 
immune-availability of the vaccine antigen (Tafalla et al., 2013). Taken together, this may 
explain the superior protection of the previously mentioned injection vaccines (Ramirez-
Paredes, 2015; Lagos et al., 2017) compared with the bacterin vaccine described here. 
Triggering of an immune response in fish following mucosal immunisation 
depends mainly on either local response in the mucosal surfaces or uptake of antigens from 
the external surfaces and/or the gut lumen for systemic distribution to head kidney and/or 
spleen (Evensen, 2017). The high exposure of the fish mucosal surfaces to various 
pathogens present in their environment can adversely affects the immune response 
following immersion vaccination (Salinas, 2015). Thus, mucosal adjuvants are required to 
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enhance the immunogenicity of immersion vaccines and improve the fish mucosal immune 
status to achieve a high level of protection (Kim et al., 2012; Munang’andu et al., 2015b). 
Use of mucosal adjuvants was previously reported in the formulation of immersion 
vaccines for fish. An immersion adjuvanted vaccine against Yersinia ruckeri was 
formulated by addition of Polyethylenimine (PEI), a polycation with a potent mucosal and 
systemic adjuvant activity, to a commercial Y. ruckeri immersion vaccine. Immersion 
vaccination of rainbow trout by this vaccine showed an increased serum antibody response 
6, 8 and 10 weeks post-vaccination, however, no evidence of enhancement of the pro-
inflammatory genes expression in gills or skin was detected (Heidari, et al., 2016). In 
addition, olive flounder, Paralichthys olivaceus, was immersion vaccinated against viral 
haemorrhagic septicaemia (VHS) with a heat killed vaccine containing Montanide IMS 
1312 VG. This induced higher RPS levels than that observed in fish vaccinated with the 
vaccine without the adjuvant (Hwang et al., 2017). There is no available information for 
using mucosal adjuvants so far in tilapia. Therefore, more studies need to be performed to 
test the potential use of adjuvants in formulating immersion vaccines against Fno and test 
their effect on the immune response of tilapia post-vaccination and post-challenge. 
One of the key factors in fish vaccination is the size of the fish to be vaccinated. In 
tilapia, the development of the immune system has been reported to start at two days post- 
fertilisation and differentiation of thymus cortex and medulla has been observed in Nile 
tilapia (O. niloticus) larvae at the age of 20 days (Cao et al., 2017). In addition, detection 
of changes in an IgM-like protein were detected in Oreochromis mosambicus larvae at 14 
days post-hatch (Takemura, 1993) and the age of immune-competency in tilapia is 
believed to be at approximately 21 days (Evans et al., 2004). Thus, fish of ~ 6 g will 
apparently be suitable for vaccination. However, in a previous experiment, 10 g tilapia 
fingerlings were shown to produce a significantly higher protective immune response 
against Fno infection than 5 g fry (Soto et al., 2014a). This in part, may explain the 
increased RPS and protection in the vaccinated fingerlings (~10 g or more) after challenge. 
More studies are required for optimisation of the size and/or age at first vaccination in 
tilapia to identify optimal vaccination regimen for this species.  
Onset of mortality post-challenge was delayed in vaccinated fry (7th dpc) when 
compared with control fry (5th dpc). Similar finding has been reported in a previous study, 
where mock vaccinated Nile tilapia died at 7 dpc after immersion challenge with dose of 
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1×108 CFU/mL of Fno (Soto et al., 2011b). In contrast, the first mortality in zebra fish in 
both vaccinated and control fish was recorded on the 2nd day after i.p. challenge with Fno, 
however mortality continued in the controls where only 20 % of the fish were left after 7 
dpc. This variation may be attributed to difference in susceptibility of the different fish 
species to Fno, the bacterial strain virulence and route of challenge (i.p. versus 
immersion).  
The mean specific serum IgM levels in the immersion vaccinated fry 30 dpv were 
considered to be negative when compared with the positive/negative threshold level. This 
can be attributed to the limited ability of immersion vaccination to stimulate a systemic 
antibody response in contrast to injection vaccination, although protection against Y. 
ruckeri in immersion vaccinated trout was shown to be strongly associated with plasma 
IgM levels (Raida et al., 2011). This stimulation of IgM responses by the immersion route 
in trout could be pathogen specific (Hoare et al., 2017). In the current work, there was high 
variability in the immune response of the vaccinated fry with IgM levels in serum of 3 of 
10 fish considered negative (i.e. below the threshold), while 7 fish had IgM levels above 
the threshold level. The reason for the variability between fish is not clear but may be 
attributed to the genetic make-up of the fish. Similar results were reported by Hoare et al. 
(2017), where immersion vaccination against Flavobacterium psychrophilum in rainbow 
trout fry induced high protection, however, levels of specific serum IgM of 2/5 fish were 
below the threshold 6 weeks post-vaccination. At 20 dpc with Fno, a higher serum IgM 
response was detected in both vaccinated and control fry, although there were no 
significant differences between these levels in both groups. This result is in contrast to that 
previously obtained by Soto et al. (2011b) who reported a significantly higher secondary 
antibody response 8- 10 weeks post-immunisation using an immersion mutant Fno vaccine 
in serum and mucus of vaccinated tilapia compared to mock-vaccinated tilapia post-
challenge with 1 × 108 CFU/mL. This again could be attributed to the superior effect of the 
live attenuated Fno vaccine compared to the formalin killed vaccine in triggering a 
stronger immune response.   
Measurement of antibody levels post-vaccination and post-challenge is a widely 
used correlate of protection in many vaccines including fish vaccines (Munang’andu and 
Evensen, 2018). In the current study, higher survival rates and higher, but non-significant, 
serum IgM levels were detected in the immersion vaccinated fry compared to the PBS 
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control fish post-challenge. However, protection induced by the immersion vaccine was 
more likely to be due to triggering mucosal immune response (e.g. IgT) along with 
contribution of non-specific immune mechanisms. In general, immersion vaccination has a 
strong effect on mucosal immunity, with specific antibody secreting cells (B-cells) 
detected mostly in skin epithelium and gills following immersion vaccination (Barnes, 
2017). Both IgT and IgM were previously detected in all mucosal associated lymphoid 
tissues (MALT) (Salinas, 2015). However, IgT is the major isotype in mucosal organs 
(Zhang et al., 2010; Salinas et al., 2011) and it was reported to play a role in preventing 
attachment and localisation of pathogens, using a mechanism equivalent to the IgA in 
mammals (Munang’andu et al., 2015; Salinas, 2015). In a previous study, immersion 
vaccination against F. psychrophilum in rainbow trout induced high RPS of 84 % that was 
associated with high serum IgT and proliferation of IgT positive cells in spleen and head 
kidney 6 weeks post-vaccination (Hoare et al., 2017). There is little information about the 
role of IgT in mucosal immunity in tilapia. In addition, there is no so far available anti-
tilapia IgT which presents a challenge to use IgT to evaluate efficacy of mucosal vaccines 
in tilapia. Thus, further studies are required to develop assays for quantification of IgT in 
mucus of tilapia. Moreover, there is also need for studies to investigate the level of specific 
immunoglobulin in skin mucus or gills. This will give us more insight to the interaction of 
the developed immersion vaccine with the mucosal immune system and will enable 
establishing a more reliable correlate to the protection induced by the Fno immersion 
vaccine. 
The interaction of antibody-mediated immunity with other innate immune factors 
for protecting fish against Fno was previously reported by Soto et al. (2010b), where 
serum from tilapia vaccinated by immersion with live attenuated vaccine enhanced 
phagocytosis of Fno in head kidney derived-macrophages. Furthermore, the cellular 
immune response has been reported to be fundamental in controlling various fish 
pathogenic bacteria such as Aeromonas salmonicida and Renibacterium salmoninarum 
(Ellis, 2001). To this end, investigating the expression of immune-cell markers (e.g. CD4, 
CD8) post-immersion vaccination against Fno in tilapia in conjugation with both humoral 
and mucosal antibody levels may elucidate the the role of cellular mediated immunity in 
protection against Fno in tilapia. Further research is required to identify cellular immune 
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response induced by immersion vaccination and elucidate the mechanism of interaction 
between antibody mediated and cellular mediated responses for controlling Fno in tilapia.  
5.5. Conclusions 
The whole-cell bacterin immersion vaccine developed in this study induced a moderate 
level of protection against Fno infection that was evident by significantly lower mortality 
and an RPS of 43.7 % in vaccinated tilapia fry compared to the non-vaccinated fry 
following challenge with a high dose of Fno. The protection against immersion challenge 
with Fno is likely to be due to induction of mucosal immune response, however, the levels 
of specific antibodies, in particular IgT, in mucus of the immersion vaccinated fish need to 
be evaluated. In addition, further research is required to increase the efficacy of the Fno 
immersion vaccine by optimising delivery time, delivery dose, vaccine formulation by 
including mucosal adjuvants, booster applications, and investigate duration of immunity 
and cross-protection against other heterologous Fno isolates. In addition, further 
investigation is needed to understand the mechanism of protection and the expression of 
immune-related genes following immersion vaccination. What is clear is that vaccines 
developed in Chapter 4 and 5 have demonstrated potentials to protect tilapia against Fno 
infection. Application of such vaccines in association with convenient, rapid, sensitive, 
specific and cost-effective diagnostic tool will facilitate controlling of francisellosis in 












Development of a recombinase polymerase amplification assay for rapid 








Francisella noatunensis subsp. orientalis (Fno) is the causative agent of piscine 
francisellosis in warm water fish including tilapia. The disease induces chronic 
granulomatous inflammation with high morbidity and can result in high mortality. Early 
and specific detection of Fno is crucial for initiation of appropriate outbreak control 
measures in tilapia farms. Diagnosis of fish Francisella is a challenging issue due to its 
nature as a fastidious intracellular microorganism and the insufficient availability of 
sensitive and specific detection methods for this aquatic pathogen (Soto et al., 2010a; Soto 
and Hawke, 2017). Conventional diagnosis of fish francisellosis via bacterial isolation in 
culture media has many constrains as it takes several days to grow and is often overgrown 
by concomitant bacteria (Duodu et al., 2012; Assis et al., 2016). Furthermore, affected 
tissue samples need homogenisation for maximum bacterial recovery. Antibody-based 
immunological assays such as enzyme-linked immunosorbent assay (ELISA) and 
immunohistochemistry (IHC), have also been used for diagnosis of francisellosis in fish 
(Soto et al. 2011a), but they were reported to have low sensitivity and limited throughput 
(Ottem et al., 2008).  
Nucleic acid-based methods have been applied for detection of fish pathogenic 
Francisella, including a conventional Francisella genus-specific polymerase chain 
reaction (PCR) (Nguyen et al., 2016; Hsieh et al., 2006; Ramirez-Paredez et al., 2017b), 
quantitative real-time PCR (qPCR) (Soto et al., 2010a; Duodu et al., 2012; Assis et al., 
2016; Ortega et al., 2016; Sebastião et al., 2017), duplex PCR, in situ hybridisation (Dong 
et al., 2016a) and loop mediated isothermal amplification (LAMP) (Pradeep et al., 2016). 
Despite the fact that these techniques have their own points of interest, downsides make 
them more challenging to use for pond-site diagnosis, for instance, they can be time 
consuming (Dudou et al., 2012; Assis et al., 2016), labour intensive, there is a prerequisite 
need for skilled staff, some tests are prone to show false negatives or false positives 
because of low sensitivity or low specificity liability (Soto et al., 2010a), highly influenced 
by reaction inhibitors (Rodrigues et al., 2012; Hall et al., 2013) and requirement of 
complex design (Pradeep et al., 2016).  
The isothermal amplification technology recombinase polymerase amplification 
(RPA) has been successfully used for field diagnostics of various pathogens. The 
technique has been widely used recently due to its affordable price (~ 4.5 USD per test), 
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sensitivity (limits of detection as low as 1 copy), short reaction time (results can be 
obtained in less than 10 min), robustness and simplicity as only minimum equipment and 
hands-on manipulation are required (Daher et al., 2016).  
The RPA performs DNA amplification at a constant temperature between 37 and 
42 °C by employing phage-derived recombinase (UvsX), single-strand binding protein 
(SSB) and strand-displacing Staphylococcus aureus-derived-DNA polymerase (Sau). The 
recombinase protein promotes binding of the primers to their homologous target sequence 
in the double stranded DNA (dsDNA) after invasion and displacement of the non-template 
strand by Sau enzyme, which is assisted by reaction stabilisation by SSB proteins 
(Pipenburg et al., 2006). By the end of the reaction, complementary dsDNA containing the 
target sequence will be synthesised following the same strategy as PCR, however, all RPA 
steps are run at lower temperatures, giving a minimal chance for generating undesired 
products that could oppose target amplification (Sharma et al., 2014). 
Since its first introduction in 2006, RPA has been widely used in diagnosis of 
various pathogens of clinical importance in human medicine including Methicilline-
resistant Staphylococcus aureus  (Pipenburg et al., 2006), Francisella tularensis (Euler et 
al., 2012a and 2013), Middle East respiratory syndrome coronavirus (Abd El Wahed et al., 
2013a), Ebola virus (Faye et al., 2015), Sudan virus (Euler et al., 2013), Dengue virus 
(Toeh et al., 2015), Bacillus anthracis (Euler et al., 2013), Zika virus (Abd El Wahed et 
al., 2017), Noro viruses (Moore and Jaykus, 2017) and Mycobacterium tuberculosis 
complex (Ma et al., 2017). RPA was also used in diagnosis of animal diseases such as Rift 
Valley Fever virus (Euler et al., 2012b), Foot-and-mouth disease virus (Abd El Wahed et 
al., 2013b), Bovine viral diarrhoea virus (Aebischer et al., 2014), lumpy skin disease virus 
(Shalaby et al., 2016) and Feline herpes virus (Wang et al., 2017) ), avian diseases such as 
Influenza A H7N9 (Abd El Wahed et al., 2015) and plant diseases like little cherry virus 2 
(Mekuria et al., 2014) and plum pox virus (Zhang et al., 2014). In the aquatic veterinary 
field, RPA has recently been developed for Penaeus stylirostris densovirus (Jaroenram and 
Owens, 2014), shrimp white spot syndrome virus (Xia et al., 2014), and infectious 
hypodermal and hematopoietic necrosis virus (Xia et al., 2015), Cyprinid Herpes virus 3 
(Prescott et al., 2016; Soliman and El-Matbouli, 2018), Abalone Herpes-like virus and red-
spotted grouper nervous necrosis virus (Gao et al., 2017) and Carp edema virus (Soliman 
and El-Matbouli, 2018).  
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While vaccines are important for developing preventative measures to control Fno 
induced francisellosis, development of tools to detect outbreaks of this emerging pathogen 
is necessary to prevent its spread. The aim of the current study was to develop and validate 
a real-time RPA for a rapid and specific detection of Fno to be applied as a point-of-care 
diagnostic tool for monitoring and preventing the spread of francisellosis.  
6.2. Material and methods 
6.2.1. Bacterial isolates and DNA extraction   
In this study isolates of Fno and other bacteria, including closely related Francisella spp. 
and other non-related bacteria, were used to test the specificity of the RPA. The bacterial 
isolates used are listed in Table 6.1. All Francisella strains including Francisella 
noatunensis subsp. orientalis (Fno), F. noatunensis subsp. noatunensis (Fnn) and F. 
philomiragia (Fp) were cultured from stock cultures on cysteine heart agar with 2% 
bovine haemoglobin (CHAH; BD, Oxford, UK). The agar plates were incubated at 28°C 
for 3 days for Fno isolates, 22°C for 5 days for Fnn isolates and 28°C for 24 h for Fp 
isolates. After incubation, growth and purity of the colonies were checked then a loop-full 
of bacteria from each plate was inoculated into modified Mueller Hinton broth (MMHB) 
with 2% IsoVitaleX and 0.1% glucose (Difco, BD, USA) and incubated in a shaking 
incubator (Kühner, Switzerland) at 28°C, 150 rpm for 20 h. Colonies of Aeromonas 
hydrophila, Streptococcus agalactiae, Streptococcus iniae, Escherichia coli, Yersinia 
ruckeri and Pseudomonas sp. were grown on Tryptic Soy agar (Sigma-Aldrich, UK) at 
28°C for 48 h, then inoculated into tryptic soy broth (Sigma-Aldrich, UK) and incubated 
for 24 h. Strains of Vibrio anguillarum and Photobacterium damselae were cultured on 
marine agar at 28°C for 48 h (Difco, USA) then inoculated into tryptic soy broth (Sigma-
Aldrich, UK) with 2% salt (Sigma-Aldrich, UK) and incubated for 24 h at 28°C.  
The genomic DNA from the different bacterial cultures was extracted using a real 
pure extraction kit (RBMEG01, Real Laboratory, Valencia, Spain) following the protocol 
for extraction of genomic DNA from bacterial cells with slight modifications. Briefly, 1.5 
mL of overnight bacterial culture was centrifuged at 14,000 × g for 30 s then the 
supernatant was removed, and the bacterial pellets were re-suspended in 300 µL of lysis 
solution and 5 µL of proteinase-K (10 mg/µL) then incubated at 55 °C overnight. For S. 
agalactiae and S. iniae, the pellets were re-suspended in 500 µL of 50 mM EDTA 
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contained 60 µL of lysozyme (10 mg/mL) first then samples were incubated at 37 ºC for 
60 min followed by centrifugation at 14,000 × g for 2 min. Supernatants were removed 
and cells were lysed as described above. Samples were left to cool at room temperature 
(RT) (~ 22 ºC) for 5 min then 3 µL of RNAse (10 mg/µL) was added followed by a quick 
mix using vortex for 30 s and incubation at 37°C for 1 h. Samples were left to cool at RT 
for 5 min, then 200 µL of protein precipitation solution was added followed by mix on 
vortex (1010, VNWR, China) at high speed for 30 s and incubation at 4°C for 15 min. 
Samples were centrifuged at 14,000 × g for 5 mins and the clear supernatant was 
transferred to fresh Eppendorf tubes (Eppendorf, UK). 600 µL of isopropanol (Sigma-
Aldrich, UK) was added to the tubes containing the DNA and mixed by inversion 10 times 
followed by centrifugation for 5 min at 14,000 × g. All traces of isopropanol were 
removed by pipetting then bacterial DNA pellet were re-suspended in 1 mL of 70 % 
ethanol (Sigma-Aldrich, UK) and mixed for 1 h on a paddle mixer (VNW, China). After 
ethanol washing, samples were centrifuged for 5 min at 14000 × g and pellets were left to 
be air dried for 3 min. The DNA pellets were resuspended in 50 µL rehydration solution 
and properly mixed by vortexing then left for overnight rehydration. The concentration of 
DNA samples was measured using a nanodrop (Nanodrop 1000, ThermoFisher Scientific, 
UK). Each DNA sample was standardised to 100 ng/µL and stored at -20°C until used.  
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Table 6.1. Bacterial strains used in the assay.  
Bacterial species            Strain ID         Source 
F. noatunensis subsp. orientalis* STIR-GUS F2f7 Tilapia (UK) 
F. noatunensis subsp. orientalis# NVI-PQ1104 Tilapia (Costa Rica) 
F. noatunensis subsp. orientalis # DSMZ21254T Three-line grunt (Japan) 
F. noatunensis subsp. orientalis# NVI-9449 Malawi cichlids (Austria) 
F. noatunensis subsp. orientalis* Fran-Cos1 Tilapia (Mexico) 
F. noatunensis subsp. orientalis*  STIR-HON1 Tilapia (Central America) 
F. noatunensis subsp. noatunensis#  NCIMB 14265 T Atlantic Cod (Norway) 
F. noatunensis subsp. noatunensis # NVI-7601 Atlantic Cod (Ireland) 
F. noatunensis subsp. noatunensis# PQ1106 Atlantic Salmon (Chile) 
F. philomiragia# ATCC® 25015T Muskrat (USA) 
F. philomiragia# ATCC® 25017 Water (USA) 
F. philomiragia# CCUG 12603 Human abscess (Sweden) 
Aeromonas hydrophila*  ATCC® 7966T Milk with fish odour (USA) 
Streptococcus agalactiae§ ATCC® 51487T Tilapia (Israel) 
Streptococcus iniae§ ATCC® 29178T Amazon fresh water dolphin 
Vibrio anguillarum* ATCC® 19264T Atlantic Cod (UK) 
Photobacterium damselae 
subsp. piscicida § 
 
ATCC® 51736 T 
 
Yellow tail fish (Japan) 
Escherichia coli* ATCC® 11775T Urine (Sweden) 
Yersinia ruckeri* ATCC® 29473T Rainbow trout (USA) 
Pseudomonas spp.* STIR-Ps17 Lump sucker (UK) 
 
(T) Type strains, DSMZ: The German Collection of Microorganisms and Cell Cultures, 
NVI: The Norwegian Veterinary Institute, NCIMB: The National Collection of 
Industrial Food and Marine Bacteria, ATCC: American Type Culture Collection. 
*Bacterial strains provided by aquatic vaccine unit, Stirling University; § bacterial 
strains kindly provided by Dr. Kim Thompson, Aquatic Research Group, Moredun 
Research institute, UK; # bacterial strain kindly donated by Dr. Duncan Colquhoun, 




6.2.2. Field samples  
Samples of spleen (n=78), head kidney (n= 78) and water (n= 5) were used in the current 
study. The tissue samples were obtained from 78 moribund and clinically healthy Nile 
tilapia that were randomly collected from two different geographical locations including 
38 fish from three tilapia farms in the UK (Farm one (Lincolinshire): 10 fish / 40 ± 0.6 g; 
Farm two (Lincolinshire): 10 fish /45 ± 0.4 g; Farm three (London): 18 fish / 12 ± 0.3 g) 
and 40 fish from a commercial tilapia farm in central Thailand (10 ± 0.6 g). A history of 
natural outbreak of francisellosis was reported in the first and second UK farms during 
2011-2012 (Ramirez-Paredes et al., 2017b) and in 2008, 2013-2016 in the Thai farm 
(Pradeep et al., 2016). The third UK farm had no history of francisellosis, but it supplied 
red tilapia fry to an aquaponics farm in London, UK, where a natural outbreak of 
francisellosis occurred during spring 2017 (Ramirez-Paredes personal communication). 
The fish showed non-specific clinical signs including loss of scales and eroded fins. On 
necropsy, some of the examined fish displayed creamy/white nodules on spleen and head 
kidney and pale liver. Five water samples of 500 mL were collected from different 
sections at the infected aquaponics farm that received fish from the third UK farm 
including one sample from UV filter unit, two samples from bio-filter tanks and two 
samples from individual fish holding tanks.  
Isolation of Fno was attempted from spleen samples from the first and second UK 
farms and the Thai farm using CHAH supplemented with Polymixin B (100 units/mL, 
Sigma, UK) and plates were incubated as described above. DNA from all the collected 
spleen and head kidney samples was extracted using the kit used for extraction of bacterial 
gDNA, as described in Section 6.2.1. DNA from 350 mL of each water sample was 
extracted using DNeasy Blood and Tissue Kit (QIAGEN, Germany) as described by 
Renshaw et al. (2015) with slight modifications. In brief, 350 mL of the water samples 
were filtrated using 0.45-µm filter (Millipore-Merck, Germany). After filtration, the filter 
paper was removed from the filtration unit and inserted into 2 mL micro-centrifuge tube 
then 576 µL of buffer ALT from the kit and 60 µL proteinase-K were added. The tubes 
containing the filter paper were briefly mixed for 30 s then incubated in a heat block 
(QBD, Grant, Thomas Scientific, USA) at 65°C for 3 h. After incubation, 630 µL of buffer 
AL from the kit and 630 µL of 100% ethanol (Sigma, UK) were added then the whole tube 
content was transferred into DNeasy Mini spin columns placed in 2 mL collection tubes 
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followed by centrifugation at 10,000 × g using a refrigerated centrifuge (SIGMA 2-16K 
Centrifuge, Sci-quib Ltd., UK) for 1 min. The DNeasy spin columns were transferred to 
new 2 mL collection tubes and 500 µL of buffer AW1 added and centrifugation repeated 
as described before. The spin columns were transferred again to new collection tubes and 
500 µL of buffer AW2 were added followed by centrifugation at 20,000 × g for 3 min and 
the flow-through with the collection tube were discarded. Following transfer of the spin 
columns to 1.5 mL Eppendorf tubes, 150 µL of buffer AE were used to elute the DNA 
then incubation was done for 2 min at RT. Centrifugation was performed for 2 min at 8000 
× g and spin columns were discarded. The concentration of the eluted DNA was then 
measured by nanodrop as described previously. All the extracted DNA samples were 
standardised to 100 ng/µL and stored at -20°C until used.  
6.2.3. Preparation of plasmid DNA standard containing the Francisella noatunensis 
subsp. orientalis hypothetical protein gene  
6.2.3.1. Plasmid DNA description  
A specific DNA sequence unique to Fno, previously identified by Duodu et al., (2012), 
representing the hypothetical protein gene (Genbank accession no. JQ780323.1) was 
synthesised and ligated into vector backbone pENTR221 (Geneart, Life Technologies Ltd, 
Paisely, United Kingdom). The resulting Fno-standard plasmid was transformed into an E. 
coli vector (OmniMAX™ 2 T1R) and purified from transformed bacteria using QIAprep8 
Miniprep Kit (QIAGEN, UK) (Figure 6.1.). The final construct was verified by sequencing 








Figure 6.1. Fno plasmid standard containing the hypothetical protein gene (JQ780323.1) 
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6.2.3.2. Restriction, concentration and quantification of the Fno-plasmid standard 
 A total of 6 µL of the Fno-plasmid standard DNA was used for extraction in a 60 µL 
reaction containing 3 µL of Eco-RV restriction enzyme (R01955 NEB, New England 
laboratories, UK), 6 µL of 10X buffer 3.1 (B72035 NBE, New England laboratories, UK) 
and 45 µL of RNAse free water (ThermoFisher Scientific, UK). The mix was incubated in 
a heat block at 37°C for 1 h. After digestion, the plasmid DNA was run on a 1% agarose 
gel with non-restricted plasmid DNA to confirm restriction for 40 min at 85 volts. The 













Figure 6.2. Visulaisation of the restricted Fno plasmid DNA containing the hypothetical 
protein gene on 1% agarose gel. A1-A3: restricted Fno plasmid DNA; B: non-restricted 
Fno plasmid DNA; M: DNA marker; pb: Base pair. 
 
The restricted plasmid bands were cut using a sterile scalpel and transferred to 1.5 
mL Eppendorf tubes. The bands were cleaned and concentrated using Qia Ex II Gel 
extraction kit (Qiagen) following the manufacturers protocol. Briefly, the weight of the 
bands was calculated then a volume of QX1 buffer equal to 3X of the band weight was 
added followed by quick vortex for 30s to re-suspend the bands. 10 µL of Qia EX II buffer 
were added to the mix to solubilise any extra agarose and bind to the DNA followed by 
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briefly for 30 s and supernatant was discarded. 500 µL of QX1 buffer was added to wash 
the DNA pellet followed by quick vortex then centrifugation for 30 s and supernatant was 
discarded. 500 µL of buffer BE were added followed by centrifugation for 30 s and the 
supernatant discarded. The last step was repeated twice for proper washing of the product. 
The pellet was left to air dry for 10 min then 20 µL of 10 mM Tris-HCl (ThermoFisher, 
Scientific, UK) was added followed by 5 min incubation at RT (~22°C). The pellet was 
centrifuged for 30 s and the clear supernatant was transferred to new tube that was kept at -
20°C till being used.     
Quantification of the Fno-plasmid DNA was done using Quant-iT™ PicoGreen® 
dsDNA kit (Molecular Probes, ThermoFisher Scientific, UK) following the manufacturer’s 
protocol. In brief, a five-point high-range standard curve was prepared from a stock 
solution of 2 μg/mL Lambda dsDNA standard in 1X Tris-EDTA buffer (TE buffer, Sigma-
Aldrich, UK) including 1µg/mL; 100 ng/mL; 10 ng/mL; 1ng/mL and a blank. The Fno-
plasmid DNA was diluted in 1X TE buffer to a final volume of 1 mL. 1 mL of the aqueous 
working solution of Quant-iTTM PicoGreen® reagent was added to the standard curve 
dilutions and and the Fno plamisd DNA followed by incubation at RT (~ 22°C) for 5 min 
in the dark. 100 µL of the standard curve dilutions and the plasmid was added to a black 
flat bottom 96 well plate (Sigma-Aldrich, UK) and the fluorescence (excitation = 480 nm 
and emission = 520 nm) was measured using a plate reader (BioTek, Synergy HT). The 
fluorescence value of the reagent blank was substracted from that of each of the samples 
and the corrected data was used to generate a standard curve of fluorescence versus DNA 
concentration and the concentration of Fno-plasmid DNA in nanogram/mL (ng/mL) was 
calculated from the generated standard curve. The results were used to calculate the 
number of copies of the Fno-plasmid DNA based on the following equation:  
                     Number of copies/µL = 
M x 6.02 x	1023x	10-6
n x 660
 
where (M) is the amount of DNA in nanogram (ng/mL), (n) is the number of nucleotides 
in the plasmid in base pair and 660 Da is the average weight of one base pair. Following 
calculation of the copy number of the Fno-plasmid DNA, a quantitative plasmid standard 




6.2.4. Real-time qPCR for the Fno-plasmid standard   
Real-time qPCR was performed using the primers listed in Table 6.2. The assay 
was performed on a LightCycler® 2.0 (ROCHE, Germany) in a 20 µL reaction volume 
consisting of 0.3 µM from each primer (Eurofins Genomics, UK), 1X Luminaris color 
HiGreen™ qPCR master mix (ThermoFisher Scientific, UK), 1 µL Fno Plasmid DNA 
template and nuclease free water (ThermoFisher Scientific, UK) up to 20 µL total volume. 
The PCR cycling conditions were adopted from Duodu et al. (2012) as following, 50°C for 
2 min for activation of uracil-DNA glycosylase enzyme, 95°C for 10 min to start 
denaturing the UNG enzyme and activate the DNA polymerase enzyme then 45 cycles at 
95°C for 15 s and 60°C for 1 min. Melting curve analysis was formed of 1 cycle at 95°C 
for 30 s, 55°C for 30 s and 95°C for 30 s. All samples were run in duplicates and each run 
included non-template control (Milli-Q water only). A standard curve was created from the 
data of three independent runs (n=3).  
Table 6.2. List of primers and probe used in the experiment  
Name                                        Sequence (5’ – 3’) Amplicon 
size 
Reference 
RPA (F1) ATGAGATATGTGTTAATTTGGCTGTTCCTGTACGA 153 bp This 
study RPA (R2) TAGTTGTATCAGTAATAGGCGTAACTCCTTTTAGC 
RPA (P) GTATAATCTTTTCGTTCTAACTGAGATTGAXTXFTT
CTAGGAAGCTAA-PH 
qPCR (F) CATGGGAAACAAATTCAAAAGGA 85 bp Duodu et 
al. (2012) qPCR (R) GGAGAGATTTCTTTTTTAGAGGAGCT 
PCR (F5) CCTTTTTGAGTTTCGCTCC 1140 bp Forsman 
et al. 
(1994) 
PCR (F11) TACCAGTTGGAAACGACTG 
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6.2.5. Real-time RPA for the Fno plasmid standard  
6.2.5.1. Fno-RPA primers and probe design    
Two primers and a probe for RPA were designed  using Primer ExpressTM, V.3.0.1 
(ThermoFisher Scientific, UK) following the manufacturer’s instructions 
(http://www.twistdx.co.uk/images/uploads/docs/Appendix.pdf) using the target sequence 
(GenBank Accession no. JQ780323) representing the hypothetical protein gene (456 pb) 
and all available genome sequences for fish pathogenic Fno, Fnn, as well as the human 
pathogenic and environmental Fp strains (Sridhar et al., 2012; Sjodin et al., 2012; Johnson 
et al., 2015; Goncalves et al., 2016; Ramirez-Paredez et al., 2017a) (Table 6.3 and Figure 
6.3) to exclude cross detection by RPA. 
 
Table 6.3. Francisella genomes used in this study. 
Bacteria Strain ID Genbank 
accession no. 
Reference 
Fno STIR-GUS-F2f7 LTD00000000.1 Ramirez-Paredes et al. 
 (2017a). 
Fno FNO01 CP012153 Figueiredo et al. (2016) 
Fno FNO12 CP011921 Gonçalves et al. (2016) 
Fno FNO24 CP011922 Gonçalves et al. (2016) 
Fno FNO90 CP011923 Gonçalves et al. (2016) 
Fno LADL--07-285A CP006875 Un-published 
Fno F1 CP018051 Un-published 
Fno LADL--07-285A NC_023029 Un-published 
Fno Toba 04 CP003402 Sridhar et al. (2012) 
Fno Toba 04 NC_017909 Sridhar et al. (2012) 
Fnn FSC772 CP022207 Sjodin et al., (2012) 
Fp GA01-2801 CP009444 Johnson et al. (2015) 
Fp O#319-036  CP009442 Johnson et al. (2015) 
Fp GA01-2794 CP009440 Johnson et al. (2015) 
Fno: Francisella noatunensis subsp. orientalis, Fnn: Francisella noatunensis subsp. 
























Figure 6.3. Alignment of RPA target region in the hypothetical protein gene. (A) Fno unique sequence (JQ780232) at the top, 
followed by Fno sequences, RPA-primers (F: FNO RPA-P1, R: FNO RPA-P2) and probe (FNO RPA-P1) sequences and F. 
philomiragia sequences at the bottom. The Fno target gene JQ780323 (shown) is 100% conserved and present in Fno genomes and Fp 
genomes, but not in Fnn. (B) Nucleotides mismatching with Fp sequences at the Fno-RPA probe (n = 3) and the RPA forward primer 
(n= 2) are marked by yellow. Underlined neucleotide refers to mismatch at the 3’ end of RPA-FP. NNN represents the tetrahydrofuran 
bridge of the probe. Positions are given in relation to Fno genome (CP006875) and Fp genomes (CP009444, CP009442, CP009440).  
[A] 
[B] 
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The primers and the probe for RPA were synthesised by TIB Molbiol (Berlin, 
Germany). The probe contained a tetrahydrofuran spacer (THF) with a 3’ quencher 
(BHQ1-dT; thymidine nucleotide carrying Blackhole quencher) and 5’ fluorescence 
reporter (FAM-dT; thymidine nucleotide carrying 6 carboxy-flourescein). The sequences 
of the final primers and probe used in this study are listed in Table 6.2. 
6.2.5.2. Fno-RPA reaction    
The RPA reaction was performed in a 50 µL volume using a TwistAmp™ exo lyophilized 
kit (TwistDX, Cambridge, United Kingdom). The reaction mixture included 420 nM of 
each primer, 120 nM FAM-tagged RPA probe, 14 mM magnesium acetate, 1X rehydration 
buffer and 1 µL of template. All the reagents except the template and Mg acetate were 
prepared in a master mix which was distributed into 0.2 mL tubes (Eppendorf, Germany). 
Four µL of Mg acetate were pipetted into the lid of the reaction tubes containing the dried 
reaction-pellet. One µL of the template was added to the mixture aliquots and quickly 
centrifuged using a mini-spin centrifuge (MCF 2360, LMS Co-Ltd., Korea) then 
transferred to the reaction tubes and lids were closed carefully. The tubes were vigorously 
mixed by inversion 10 times and centrifuged for 20 s. The tubes were immediately placed 
in an ESE Quant Tube Scanner device (Qiagen Lake Constance, Stockach, Germany). The 
tubes were incubated at 42°C for 20 min where the fluorescence measurement including 
excitation at 470 nm and detection at 520 nm for FAM channel was performed. After four 
min, the tubes were taken out of the ESE Quant Tube Scanner device for a quick spin then 
returned to complete the scanning. The ESE Quant scanner software enabled threshold 
validation including evaluation of fluorescence by increasing the fluorescence above three 
standard deviations over the background detected in the first minute of the reaction. In 
addition, the curve slope represented in mV/time can be utilised (slope adaptable) and a 
second derivative window for calculation of the turning point of the upward fluorescence 
development can be used for verifying curves with a very low slope. 
6.2.6. Analytical sensitivity and specificity of Fno-RPA reaction 
The quantitative Fno-plasmid DNA standard was used to evaluate the sensitivity of 
the RPA and qPCR reactions using 1 µL of a dilution range of 107 to 101 copies/µL. Both 
RPA and qPCR were repeated 10 times using 10 individual master mixes, each run 
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included duplicate reactions and non-template control (Milli-Q water only). To evaluate 
the specificity of the RPA reaction, the assay was tested using 1 µL of gDNA (100 ng/µL) 
from the different bacterial strains listed in Table 6.1.  
6.2.7. Clinical testing of the Fno-RPA   
DNA extracted from fish tissues (78 spleen and 78 head kidney samples) and water 
samples (n= 5) were used to test the developed RPA. The tissue and water samples were 
firstly tested by both conventional PCR using previously published Francisella genus-
specific primers (Table 6.2; Forsman et al., 1994) and qPCR using Fno-specific primers 
(Table 6.2; Duodu et al., 2012) targeting a region slightly downstream from the region 
used for RPA amplicon design as previously described in sections 4.2.1.2 and 4.2.10 in 
Chapter 4. One µL from the total DNA (100 ng/µL) was amplified using RPA and results 
were compared with data obtained from qPCR. All positive RPA results were additionally 
verified by secondary derivative analysis as implemented in the analysis software. Samples 
tested negative by qPCR and positive by RPA were further diluted to 1:10 and 1:100 
dilutions and re-tested to investigate potential inhibition of qPCR. The diagnostic 
performance of the developed RPA was evaluated by calculation of sensitivity, specificity, 
positive predictive value (PPV) and negative predictive value (NPV) using free statistical 
calculators “Diagnostic Test Evaluation Calculator” 
(https://www.medcalc.org/calc/diagnostic_test.php) and results were presented as a 
percentage. 
6.2.8. Evaluation of the effect of reaction temperature on the Fno-RPA amplification 
To evaluate the temperature ranges at which the developed RPA can be performed, 10 
copies of the plasmid standard DNA and a non-template negative control (Milli-Q water) 
were used to run the RPA assay at 42°C, 39°C, 37°C and 35°C for 20 min and 
amplification results and time were recorded.  
6.2.9. Statistical analysis 
Microsoft Excel 2016 was used to arrange the data for analysis. GraphPad® prism v.6 
(GraphPad, San Diego, CA, USA) was used to calculate a semi-log regression of the data 
set of 10 runs of Fno-RPA and qPCR by blotting the threshold time in minutes (Tt) for 
RPA or the cycle threshold (Ct) for qPCR against the molecules detected of the Fno-
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plasmid standard DNA dilutions (107: 101 copies/µL). A probit regression analysis was 
performed in Minitab® v.17 (Minitab Ltd., UK) to calculate limits of detection (LOD) in 
95 % of the cases following both assays.  
6.3. Results 
6.3.1. Analytical sensitivity  
To determine the analytical sensitivity, the Fno-DNA plasmid standard was used for both 
qPCR and RPA. RPA needed approximately 6 min (6.2± 0.22 min) to reach the detection 
limit (Figure 6.4A) while the qPCR required about 90 min (Ct 35.2 ± 0.6) (Figure 6.4B). 
The highest detection sensitivity of both qPCR and RPA was 10 copies (Figure 6.5). Probit 
analysis showed that, the limits of detection with 95% probability were 15 molecules and 





























Figure 6.4. Performance of RPA and qPCR using dilutions of Fno-plasmid DNA standard.  
Representatives amplification curves from three runs of both RPA (A) and qPCR (B) 
(n=3) showing the fluorescence development over time in both assays using a dilution 


























































Figure 6.5. Reproducibility of RPA and qPCR assays in detection of dilutions of Fno-
plasmid standard. The semi-log regression generated by 10 data sets of RPA (A) and 
qPCR (B). Threshold time (Tt in RPA) and cycle threshold (Ct in qPCR) were represented 
as a mean ± standard deviation (±SD).  
Molecules detected (Copy number of plasmid standard / µL) 





     







         
    
 















Figure 6.6. Probit analysis of data set of 10 runs of RPA and qPCR. The black triangle 
indicates limits of detection at 95% probability which were 15 and 11 copies/reaction of 
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6.3.2. Analytical specificity  
The RPA developed was highly specific as results showed that it only detected the gDNA 
of the Fno isolates and did not detect the gDNA of either the closely related Francisella 
spp. (Fnn and Fp) or the other bacterial species used in the study (Table 6.4 and Figure 
6.7). 
 
Table 6.4. Analytical specificity of Fno-RPA  
Bacterial species  Strain Detection by RPA 
F. noatunensis subsp. orientalis STIR-GUS F2f7  + 
F. noatunensis subsp. orientalis NVI-PQ1104 + 
F. noatunensis subsp. orientalis  DSMZ21254T + 
F. noatunensis subsp. orientalis NVI-9449 + 
F. noatunensis subsp. orientalis Fran-Cos1 + 
F. noatunensis subsp. orientalis  STIR-HON1 + 
F. noatunensis subsp. noatunensis  NCIMB 14265 T  - 
F. noatunensis subsp. noatunensis  NVI-7601 - 
F. noatunensis subsp. noatunensis PQ1106 - 
F. philomiragia  ATCC® 25015 T  - 
F. philomiragia   ATCC® 25017  - 
F. philomiragia CCUG 12603  - 
A. hydrophila  ATCC® 7966 T - 
S. agalactiae ATCC® 51487 T - 
S. iniae ATCC® 29178 T - 
V. anguillarum ATCC® 19264 T - 
Photobacterium damselae 
subsp. piscicida 
ATCC® 51736 T - 
E. coli  ATCC® 11775 T - 
Y. ruckeri ATCC® 29473 T - 
Pseudomonas Spp. STIR-Ps17 - 
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Figure 6.7. Analytical specificity of Fno-RPA. Positive amplification only with Fno 
isolates [A], while negative results were obtained with Fnn, Fp and non-Francisella 
isolates [B and C]. A1 (violet line), B1 (Blue line) and C1 (blue line):  Positive control , 
A2: Negative control (dark green line) , A3: A8 : Fno isolates (A3: Fno UK isolate (black 
line), A4: Fno Costa Rican isolate (red line), A5: Fno  Japanese isolate (green line), A6: 
Fno Austrian isolate (orange line),  A7: Fno Mexican isolate (pink line), A8: Fno  Central 
American isolate (brown line), B2: B7 : Fnn isolates (B2: Fnn Norwegian isolate (black 
line), B3: Fnn Irish isolate (red line), B4: Fnn Swedish isolate (green line), Fp isolates 
(B5: Fp from muskrat (orange line) , B6: Fp from water (pink line), B7: Fp  human 
(brown line) and B8: A. hydrophila (dark green line). C2: S. agalactiae (black line), C3: S. 
iniae (red line), C4: V. anguilarum (green line), C5: P. damselae subsp. piscicida (orange 
line), C6: E. coli (pink line), C7: Y. ruckeri (brown line), C8:  Pseudomonas spp. (dark 
green line). 
6.3.3. Evaluation of clinical sensitivity of Fno-RPA with field samples  
The collected fish were tested by bacteriological tests, PCR, qPCR and RPA. Fno was 
successfully recovered on CHAH from spleen samples of 7/10, 3/10 and 14/40 from the 
first and second UK and the Thai tilapia, respectively. Fno was successfully detected by 
conventional PCR (38/78 spleens; 33/78 head kidneys), by qPCR (46/78 spleens; 42/78 
head kidneys) and by RPA (47/78 spleens, 47/78 head kidneys). Screening of water 
samples showed that all samples were negative by PCR and qPCR, while they were 
positive by RPA (Table 6.5 and Figure 6.8). The clinical sensitivity and specificity of the 
developed RPA assay were 100 % (95 % CI: 95.89 % to 100 %) and 84.93 % (95 % CI: 
74.64 % to 962.23 %), respectively (Table 6.6). The crude DNA extracts of 1 spleen, 5 
head kidneys and the 5 water samples that had tested negative by qPCR (Ct>40) and 
positive by RPA, were diluted to 1:10 and 1:100 dilutions and retested by qPCR. One 
spleen sample and three head kidney samples (HK 2, 7, and 10) tested positive at 1:10 and 
1:100 dilutions, one head kidney sample (HK16) was positive only at 1:100 dilution, 1 
sample (HK11) was negative at both dilutions. In addition, 3 samples of water (UV filter; 
Bio-filter tank1; Fish tank1) tested positive at 1:10 and 1:100 dilutions, while the other two 























Figure 6.8. PCR results of 156 tissue samples from tilapia and 5 water samples collected from UK and Thai farms after electrophoresis 
on a 1% agarose gel. M: 100Pb DNA marker, S: spleen, K: Head kidney, UV: ultraviolet filter, B1: Bio-filter tank 1, B2: Bio-filter 
tank 2, T1: Fish tank 1, T2: Fish tank2, PC: Positive control (Fno gDNA), NTC: Negative control (Milli-Q water).    M 
 
 




Table 6.5. Screening of field samples (tilapia tissues and water samples) by bacteriology, conventional PCR, qPCR and RPA.  
Sample ID.  Sample type Bacterial 
isolation 
Conventional PCR qPCR Cycles threshold (Ct) RPA threshold time (Tt) in 
minutes 
Fish 1 Spleen  - + 30.06 + 3.7 + 
Head Kidney  + 36.97 + 5.7 + 
Fish 2 Spleen  - - - - - - 
Head Kidney  - - - 5.7 + 
Fish 3 Spleen  + + 30.8 + 5.7 + 
Head Kidney  + 25.1 + 3.3 + 
Fish 4 Spleen  + + 29.44 + 5.7 + 
Head Kidney  + 32.3 + 3.7 + 
Fish 5 Spleen  + + 27.45 + 3.3 + 
Head Kidney        + (w) 31.07 + 5.7 + 
Fish 6 Spleen  + + - - 5.7 + 
Head Kidney  + 27.68 + 3.7 + 
Fish 7 Spleen  + + 32.38 + 5.7 + 
Head Kidney  - - - 5.7 + 
Fish 8 Spleen  - - - - - - 
Head Kidney  - 34.86 + 5.7 + 
Fish 9 Spleen  + + 38.82 + 5.7 + 
Head Kidney  + 30.16 + 5.7 + 
Fish 10 Spleen  + + 28.1 + 3.3 + 
Head Kidney  - - - 5.7 + 
Fish 11 Spleen  - - - - - - 







        
Table 6.5.  continued      
Fish 12 Spleen  - + 30.83 + 3.7 + 
Head Kidney  - - - - - 
Fish 13 Spleen  - - - - - - 
Head Kidney  - - - - - 
Fish 14 Spleen   + 23.42 + 3.0 + 
Head Kidney - - - - - 
Fish 15 Spleen  + + 27.98 + 2.7 + 
Head Kidney  + 25.14 + 3.3 + 
Fish 16 Spleen  - - 32.53 + 5.7 + 
Head Kidney  - - - 5.7 + 
Fish 17 Spleen  + + 28.19 + 3.0 + 
Head Kidney  - - - - - 
Fish 18 Spleen  + + 23.66 + 3.0 + 
Head Kidney        + (w) 35.21 + 5.7 + 
Fish 19 Spleen  - - - - - - 
Head Kidney  - - - - - 
Fish 20 Spleen  - - - - - - 
Head Kidney  - - - - - 
Fish 21 Spleen  + + 23.94 + 5.7 + 
Head Kidney  + 21.24 + 4 + 
Fish 22 Spleen  - - 23.49 + 5.7 + 
Head Kidney  - 23.30 + 3.7 + 
Fish 23 Spleen  + + 23.57 + 5.7 + 
 Head Kidney   + 20.51 + 3.3 + 
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Table 6.5.  continued      
Fish 24 Spleen  - + 21.88 + 5.7 + 
Head Kidney        + (w) 23.67 + 5.7 + 
Fish 25 Spleen  + + 22.19 + 5.7 + 
Head Kidney  + 22.34 + 3.7 + 
Fish 26 Spleen  + + 21.67 + 5.7 + 
Head Kidney  + 21.28 + 3.3 + 
Fish 27 Spleen  - + 22.91 + 5.7 + 
Head Kidney  + 19.49 + 5.7 + 
Fish 28 Spleen  - + 18.04 + 3.3 + 
Head Kidney  + 21.01 + 3.7 + 
Fish 29 Spleen  - - 19.99 + 5.7 + 
Head Kidney  - 22.33 + 3.7 + 
Fish 30 Spleen  + + 23.71 + 5.7 + 
Head Kidney  + 25.76 + 5.7 + 
Fish 31 Spleen  + + 21.81 + 3.7 + 
Head Kidney        + (w) 30.94 + 5.7 + 
Fish 32 Spleen  - + 22.04 + 5.7 + 
Head Kidney         + (w) 23.70 + 3.7 + 
Fish 33 Spleen  + + 24.41 + 3.7 + 
Head Kidney  + 21.85 + 3 + 
Fish 34 Spleen  - - 22.09 + 3.7 + 
Head Kidney  - 25.93 + 3.7 + 
Fish 35 Spleen  + + 24.66 + 3.7 + 




Table 6.5. continued      
Fish 36 Spleen  - + 20.84 + 4 + 
 
Head Kidney  
 
+ 20.56 + 3 + 
Fish 37 Spleen  - - 21.78 + 3 + 
Head Kidney  - 26.36 + 5.7 + 
Fish 38 Spleen  - - 18.15 + 3 + 
Head Kidney  - 21.60 + 3.3 + 
Fish 39 Spleen  + + 24.65 + 5.7 + 
Head Kidney  + 22.90 + 4.7 + 
Fish 40 Spleen  + + 24 + 5.3 + 
Head Kidney  + 20.72 + 3.3 + 
Fish 41 Spleen  + + 20.81 + 3.3 + 
Head Kidney  + 21.14 + 3.7 + 
Fish 42 Spleen  - + 24.74 + 5.7 + 
Head Kidney  + 20.58 + 3 + 
Fish 43 Spleen  - - 29.67 + 5.7 + 
Head Kidney  - 22.37 + 3.3 + 
Fish 44 Spleen  + + 23.05 + 3.7 + 
Head Kidney  + 35.20 + 6 + 
Fish 45 Spleen  - + 29.06 + 5.7 + 
Head Kidney  + 21.52 + 3.3 + 
Fish 46 Spleen  - + 23.97 + 3.7 + 
Head Kidney  + 23.32 + 3.3 + 
Fish 47 Spleen  + + 20.32 + 3 + 
Head Kidney  + 22.73 + 3.3 + 
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Table 6.5. continued       
Fish 48 Spleen  - - 26.20 + 5.7 + 
 
Head Kidney  
 
- 24.67 + 3.7 + 
Fish 49 Spleen  - + 22.54 + 3.7 + 
Head Kidney  + 21.96 + 3.3 + 
Fish 50 Spleen  - + 20.1 + 3 + 
Head Kidney  + 21.29 + 3 + 
Fish 51 Spleen  - + 21.59 + 3.3 + 
Head Kidney  + 18.75 + 3 + 
Fish 52 Spleen  + + 28.09 + 5.7 + 
Head Kidney  + 23.85 + 3.7 + 
Fish 53 Spleen  - - - - - - 
Head Kidney  - - - - - 
Fish 54 Spleen  - - - - - - 
Head Kidney  - - - - - 
Fish 55 Spleen  - - 34.53 + 5.7 + 
Head Kidney  - 33.9 + 5.7 + 
Fish 56 Spleen  - - - - - - 
Head Kidney  - - - - - 
Fish 57 Spleen  - - - - - - 
Head Kidney  - - - - - 
Fish 58 Spleen  - - - - - - 
Head Kidney  - - - - - 
Fish 59 Spleen  - - - - - - 
Head Kidney  - - - - - 




Table 6.5.  continued.  
      
 
Head Kidney  
 
- - - - - 
Fish 61 Spleen  N/A - - - - - 
 Head Kidney   - - - - - 
Fish 62 Spleen  N/A - - - - - 
 Head Kidney   - - - - - 
Fish 63 Spleen  N/A - - - - - 
 Head Kidney   - - - - - 
Fish 64 Spleen  N/A - - - - - 
 Head Kidney   - - - - - 
Fish 65 Spleen  N/A - - - - - 
 Head Kidney   - - - - - 
Fish 66 Spleen  N/A - - - - - 
 Head Kidney   - - - - - 
Fish 67 Spleen  N/A - - - - - 
 Head Kidney   - - - - - 
Fish 68 Spleen  N/A - - - - - 
 Head Kidney   - - - - - 
Fish 69 Spleen  N/A - - - - - 
 Head Kidney   - - - - - 
Fish 70 Spleen  N/A - - - - - 
 Head Kidney   - - - - - 
Fish 71 Spleen  N/A - - - - - 
 Head Kidney   - - - - - 
Fish 72 Spleen  N/A - - - - - 
 Head Kidney   - - - - - 
Fish 73 Spleen  N/A - - - - - 
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Table 6.5. continued      
 Head Kidney   - - - - - 
Fish 74 Spleen  N/A - - - - - 
 Head Kidney   - - - - - 
Fish 75 Spleen  N/A - - - - - 
 Head Kidney   - - - - - 
Fish 76 Spleen  N/A - - - - - 
 Head Kidney   - - - - - 
Fish 77 Spleen  N/A - - - - - 
 Head Kidney   - - - - - 
Fish 78 Spleen  N/A - - - - - 
 Head Kidney   - - - - - 
Water 
Samples 
UV filter N/A - - - 5.7 + 
Bio-filter 1 N/A - - - 5.7 + 
Bio-filter 2 N/A - - - 3.7 + 
Tank 1 N/A - - - 6 + 
Tank 2 N/A - - - 5.7 + 




Table 6.6. Diagnostic performance of the Fno-RPA using field samples  
                                           Real-tim qPCR  Performance characteristics (%) 
                            Positive Negative  Sensitivity Specificity PPV NPV 
RPA Positive 88 11  100% 84.93% 88.89% 100% 
Negative 0 62  
  
(PPV: Positive predictive value, NPV: Negative predictive value) 
 
 
Table 6.7. Results of testing diluted crude DNA preparations from fish tissues and water 
samples by qPCR.  
      Sample Crude DNA  1:10 dilution 1:100 dilution 
 Ct value Results*   Ct value Results* Ct Value Results* 
Spleen 6 >40.0      - 26.95 + 30.04 + 
Head Kidney 2 >40.0      - 29.50 + 32.88 + 
Head Kidney 7 >40.0      - 30.20 + 34.30 + 
Head Kidney 10  >40.0      - 31.14 + 33.54 + 
Head Kidney 11 >40.0      - >40.0 - >40.0 - 
Head Kidney 16 >40.0      - >40.0 - >34.04 + 
UV filter water >40.0      - 34.88 + 37.02 + 
Bio-filter 1 water >40.0      - >40 - >40 - 
Bio-filter 2 water >40.0      - 34.99 + 36.72 + 
Tank 1 water >40.0      - 36.80 + 39.9 + 
Tank 2 water >40.0      - >40 - >40.0 - 
 
      (+) Positive, (-) Negative, (Ct) cycle threshold.  * All results are mean of duplicate reactions. 
 
 
6.3.4. Evaluation of the effect of reaction temperature on the Fno-RPA  
Running Fno-RPA at temperature range of 35-42°C showed positive amplification of Fno 
at all temperatures used but at different reaction time (Table 6.8). 
 
Table 6.8. Results of RPA amplification of Fno DNA at different reaction temperatures 
Temperature (°C) Threshold time (Min) 
42°C 6 min 
39°C 7.3 min 
37°C 8.7 min 
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6.4. Discussion  
 Francisellosis is one of the most serious bacterial pathogens affecting tilapia 
industry worldwide. Mortality rates of up to 95% were documented in cultured tilapia in 
Taiwan (Chen et al., 1994; Chern and Chao, 1994) and recently mortalities up to 40% in 
broodstock in Mexico (Ortega et al., 2016) and 5-50% in fingerlings and juveniles in 
Brazil (Sebastião et al., 2017). Application of rapid, sensitive and robust monitoring 
represents the most reliable strategy for early identification of outbreaks and initiation of 
control measures to prevent spreading of the disease outbreak. In the current study, a rapid 
isothermal RPA assay targeting the unique hypothetical protein gene which is present only 
in Fno and not in the very closely related fish pathogen Fnn was developed (Duodu et al., 
2012). Fno specific qPCR targeting this gene could detect up to 20 fg (~10 genome copies) 
of the genomic DNA of Fno in a previous experiment (Duodu et al., 2012). Three recently 
published sequences of Fp isolates (Accession numbers CP009444; CP009442; 
CP009440; Johnson et al., 2015) containing the hypothetical protein gene like sequence, 
which were not available at the time of the qPCR assay development, were included in the 
alignment in the current study. These genome sequences were derived from Fp isolates 
recovered from water and two human clinical samples. In a previous cross detection 
experiment, the published qPCR did not pick up any Fp strains tested (Dudou et al., 2012). 
Sequence alignment in the current study now confirms that this is due to 3 mismatches in 
the Fp target region for the Fno-RPA probe and one mismatch on the 3`-end of the 
designed RPA forward primer (Figure 6.3). 
Additionally, the cold-water fish pathogen Francisella noatunensis subsp. 
noatunensis used in the current cross-detection study, was found to be a genetically, 
biochemically and morphologically distinct sub species from Fno (Ottem et al., 2007). 
Alignments of the existing genome sequences showed that Fnn was lacking the 
hypothetical protein gene sequence. This finding is now confirmed as neither the 
developed RPA assay nor the previously published qPCR (Duodu et al., 2012) could 
detect it. By using the principles of the amplification refractory mutation system (ARMS) 
concept, that stated that oligonucleotides with a mismatched 3'-residue will not function as 
primers in the PCR under appropriate conditions (Newton et al., 1989), and including a 
mismatch at position 3 from the 3’-end of the RPA forward primer (Figure 6.3), detection 
of Fp was avoided as confirmed by the cross-detection assays (Table 6.4). Thus, even in 
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the case of environmental contamination, false positive results due to of Fp are excluded 
when RPA is used.   
In this study, a rapid RPA was developed which showed high performance in 
detection of Fno. The analytical sensitivity of the developed RPA was highly comparable 
to the published qPCR (Dudou et al., 2012), as the limits of detection were determined at 
15 molecules of Fno target gene for RPA and sensitivity of the published qPCR at 11 
molecules was confirmed. However, there was a contrast in the time required to reach the 
limits of detection in both assays, where qPCR required 90 min, while the RPA could 
achieve that in 6 min, needing only 2.7- 3 min to determine the Fno in clinical samples. 
The short time of detection in RPA makes it an attractive tool for an on-site detection and 
monitoring strategy for francisellosis especially on large farms. Also, the quick turnaround 
of RPA would likewise be of advantage in a standard research facility set-up empowering 
high-throughput testing. The RPA was performed at a relatively low temperature with 
isothermal conditions (42°C) and real-time monitoring was performed using an ESE-
Quant tube scanner which is less expensive than a mobile cycler. This tube scanner is very 
convenient with a footprint of 17.5 × 19 cm and an approximate weight of 2 Kg including 
the attached laptop. Other readers are commercially available such as the Axxin TSO-ISO 
reader (Axxin. http://www.axxin.com/Molecular-T8.php) or the Genie III (Optigene. 
http://www.optigene.co.uk/instruments/instrument-genie-iii/). These devices or others 
currently being developed, such as hand-held detection devices, can contribute to the 
development of mobile pond-side or point-of-care diagnosis of Fno in tilapia farms. 
The developed RPA assay was highly specific and only detected gDNA of Fno 
isolates and did not cross detect the closely related Fnn nor Fp or any other bacteria tested. 
Moreover, results showed that the crude DNA extracts of 11 clinical samples (1 spleen and 
5 head kidneys and 5 water samples) were positive by RPA while they were negative by 
conventional PCR or qPCR. Calculating the sensitivity and specificity in comparison to 
qPCR, RPA showed a sensitivity and specificity of 100% and 84.93%, respectively. The 
lower specificity was due to the RPA scoring 11 samples which the qPCR failed to detect. 
The qPCR assay used here also gave false positive results. This was demonstrated by 
achieving positive qPCR results upon diluting the crude DNA extracts which indicates the 
presence of reaction inhibitors in the DNA extracts that affected qPCR performance but 
not the RPA. 
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The robustness of the RPA when crude clinical specimens are used is often featured 
as benefit of this technique. The developed RPA was found to be more robust than the 
published qPCR in detection of Fno when clinical samples were used. In previous studies, 
RPA was performed with nucleic acid extracted from various samples including blood 
(Aebischer et al., 2014), serum (Teoh et al., 2015), plasma (Euler et al., 2013), stool 
(Crannell et al., 2014), nasal swabs (Boyle et al., 2014), vaginal swabs (Daher et al., 
2014), milk (Santiago-Felip et al., 2015), urine (Krolove et al., 2014), sputum and 
respiratory wash (Ma et al., 2017), foodstuff (Santiago-Felip et al., 2014a), animal tissues 
(Xia et al., 2014) and plant tissues (Zhang et al., 2014). This is due to the tolerance of the 
RPA to common PCR inhibitors (Daher et al., 2016). Additionally, it was shown that RPA 
can work in presence of 15-25% of milk, 50 g/L haemoglobin, 4% (v/v) ethanol and 0.5 U 
of heparin, all of which have an inhibitory effect on PCR. In an experimental trial, 103 
copies of gDNA of S. agalactiae could be detected in the presence of up to 5 µL of stool 
sample (Daher et al., 2014). This finding highlights the robustness of the developed Fno-
RPA for detection of nucleic acids in different crude biological samples if the appropriate 
extraction protocol is carried out. Other isothermal assays have been adopted for diagnosis 
of francisellosis in tilapia including LAMP that was successfully used for detection of Fno 
with LOD at 1 fg (Pradeep et al., 2016). However, LAMP has many drawbacks in 
comparison with RPA, as it depends on turbidity index measurement with a Loopamp® 
Realtime Turbidimeter that weighs ~ 5 Kg, uses a complex-design of 6 oligonucleotides 
targeting four target sequences, requires a high temperature of 60 °C, and has a longer 
reaction time (~ 45 min). Thus, the recent findings ultimately favour the usage of RPA 
instead of LAMP for mobile isothermal detection of Fno.    
The RPA assay developed in this study could detect Fno-DNA across wide 
temperature range (35- 42°C) with minimum effect of temperature fluctuation on the 
amplification results. These findings provide more flexibility and feasibility for the RPA 
assay over the conventional PCR and qPCR which require a thermocycler and other 
sophisticated equipment for reliable amplification. Therefore, the developed RPA assay 
could potentially be used by people with minimal training for on-site diagnosis of 
francisellosis which will contribute to the decrease and/or prevention of spread of the 
disease by minimising the movement of potentially infected tilapia. One of the main 
benefits of the RPA is the convenience of the assay, as the kit used (TwistAmp Exo kit, 
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Twist DX, UK) is commercially available in the form of dried pellets accompanied with 
the rehydration buffer and reagents required for the reaction mixture. The only step 
required is the addition of primers, probe and template DNA. In addition, the detection is 
performed with an ESE-Quant tube scanner that is very compact. Nevertheless, a major 
constraint of using the RPA in field is ability to extract good quality nucleic acids to 
perform the test. However, there are many commercially available DNA extraction 
methods at present which are simple, cheap and suitable for field application, including 
magnetic bead-based technology, heated NaOH method (Xing et al., 2017) and mobile 
extraction devices like QuickGene-Mini80 (Autogen®, USA) (Pereira et al., 2011; Shipley 
et al., 2012). Using any of these methods will considerably reduce the cost of the assay 
and provide more flexibility to use RPA in the field conditions.  
 Recently, RPA assays were used in combination with other tools including lateral 
flow dip sticks (LFD) (Xing et al., 2017; Guimin et al., 2017; Hou et al., 2017; Tu et al., 
2017), ELISA (Santiago-Felipe et al., 2014b), aptamer-based bio-barcodes (ABC) (Loo et 
al., 2013), and hybridisation in microarray format (Kersting et al., 2014). These tools have 
enhanced the performance of the RPA assay and elucidated its significance as a versatile 
next-generation molecular diagnostic test. Overall, the RPA developed in the current study 
can be considered a potential user-friendly method for the simple, accurate and rapid 
detection of Fno that can be applied for field screening of tilapia for francisellosis. 
6.5. Conclusions 
A novel real time Fno-RPA was developed for the rapid and accurate detection of 
Fno that showed high analytical sensitivity and specificity. The sensitivity, specificity and 
reproducibility were highly comparable to the published qPCR with better tolerance to 
amplification inhibitors in clinical samples. The RPA assay with the mobile tube scanner 
and proper fast DNA extraction protocol could be used as a promising “pen test” to be 
applied on fish farms for the rapid detection of Fno. Such specific and sensitive diagnostic 
tools are imperative to development of successful control and management strategies for 



























7.1. General discussion 
Tilapia is one of the oldest fish species to be farmed around the world. The high consumer 
demand, the fast growth rate, short production cycle and adaptability to various culture 
conditions, makes tilapia one of the leading farmed fish species. Tilapia is ranked as the 
third most important finfish aquaculture species after carp (Cyprinus carpio) and salmon 
(Salmo salar) (Munang’andu et al., 2016). At present, tilapia farming is carried out in 
more than 135 countries worldwide, with 72% of the production taking place in Asia, 19% 
in Africa and 9% in North and South America (FAO, 2017). Tilapia is also produced in 
Europe, but on a very minor scale that is estimated to be about 0.05% of the total 
production (Falch, 2013). Despite the rapid development of global tilapia farming, the 
intensification of production using high stocking densities, aimed at increasing production 
outputs, has been associated with great challenges for the industry due to the increased 
incidence of various diseases. Francisellosis, caused by Francisella noatunensis subsp. 
orientalis (Fno), is a significant bacterial disease affecting tilapia production globally. The 
disease has been reported in Asia, Europe, and North, Central and South America over the 
past 13 years, resulting in massive losses in farms ranging between 5-95% (Soto et al., 
2009a; 2012b; 2014b). Up till now, there is no commercially available prophylactic 
treatment against piscine francisellosis for use on tilapia farms. Therefore, the 
development of an effective vaccine, that protects against current Fno isolates globally is 
crucial to the tilapia aquaculture industry. 
While Fno outbreaks in tilapia are increasing, there have been few studies 
examining the diversity of Fno isolates recovered from tilapia published in the literature 
(Figueiredo et al., 2016; Gonçalves et al., 2016; Ramirez-Paredes et al., 2017b). In 
Chapter 2, the proteomic and antigenic profiles of the whole cell proteome of five Fno 
isolates from diverse geographical locations were described using a combination of 
immunoproteomic and mass-spectrometric methods. Although some of these isolates 
showed a high degree of homogeneity in a previous study based on phenotypic and 
genomic comparisons, in addition to antimicrobial susceptibility scheme (Ramirez-
Paredes, et al., 2017), the study in Chapter 2 showed minor, but significant differences 
between the isolates, represented by difference in the abundance of 15 proteins between 
the different isolates. This finding broadly supports the presence of a “clonal-like 
behaviour” between Fno isolates from wide spread origins as reported in previous studies 
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(Figueiredo et al., 2016; Gonçalves et al., 2016; Ramirez-Paredes et al., 2017b). Limited 
studies have been performed linking the virulence of Fno isolates with francisellosis 
severity in fish farms. Djainal, (2018) showed that the Fno UK isolate was more virulent 
than isolates from Costa Rica, Mexico, Austria or Japan in both tilapia and wax moth 
larvae models. Differences in abundance of virulence-associated proteins between the Fno 
isolates were examined in Chapter 2, and the UK isolate displayed a significantly higher 
abundance of some of these proteins (e.g. iglC, GroEL, DnaK, ClpB). This may help to 
explain the findings of Djainal, (2018), and may provide insight into our understanding of 
the basis of difference in the virulence between the circulating Fno isolates. A combination 
of proteomics (1-DE and 2-DE) and mass spectrophotometry methods (LC-EDI-MS/MS 
and MALDI-TOF/MS) was employed in Chapter 2 to characterise the Fno proteome and 
create a data base of the proteins identified. This database is potentially useful for 
determining which proteins can be used for typing and/or diagnosis of Fno as previously 
shown for F. tularensis (Hubalek et al., 2003). More importantly, identification of proteins 
that are related to virulence or pathogenicity in the Fno proteome is a key step to 
understanding the molecular basis of pathogenicity of this significant pathogen, which in 
turn will help the development of therapeutics, diagnostics, and prophylactic tools against 
francisellosis in tilapia.  
Bacterial culture is a valuable experimental tool for studying growth characteristics 
of Fno in vitro, however, it is not a true reflection of the conditions present in the host 
when the bacteria is growing in vivo. This may have limited the information on Fno 
virulence obtained with the proteomic analysis performed. Thus, Fno isolates grown in the 
host environment may have different growth and protein expression kinetics in vivo 
compared to the lab adapted growth in culture media, as was reported for Aeromonas 
hydrophila (Poobalane et al., 2008). Therefore, future proteomic studies comparing the 
protein profiles of Fno isolates grown under different conditions (e.g in vivo vs in vitro or 
in media lacking essential elements like iron) are required. This will help provide 
information on the metabolic networks involving the different Fno proteins when grown 
under different culture conditions, and will enhance genome annotations of Fno, which are 
frequently based on bioinformatics predictions and discovery of uncharacterised proteins 
classified as hypothetical proteins.     
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While analysis of the whole cell lysate identifies proteins in the soluble portion of 
the Fno bacterial proteome, the outer membrane (OMPs) reflects the proteins in the non-
soluble fraction of the bacterium. In Chapter 3, the sub-cellular fraction of Fno OMPs 
displayed a mixture of proteins involved in important biological functions, especially those 
putatively associated with pathogenicity and host-pathogen interactions. Notably, the 
majority of the pathogenicity-related proteins were more abundant in the OMPs of Fno 
than in the whole cell preparation, supporting the importance of OMPs in Fno 
pathogenesis. Identification and characterisation of proteins present in the OMP fraction is 
useful for the development of new generation prophylactic tools such as recombinant 
OMPs based nano-particles that have been recently reported to provide high levels of 
protection in Rohu (Labeo rohita) and Fringed-lipped Peninsula Carp (Labeo fimbriatus) 
against A. hydrophila and Edwardisella tarda, respectively (Dubey et al., 2016 a,b). More 
importantly, simplifying the protein sample preparation using emriched OMPs fraction has 
contributed to successful identification of the proteins of Fno proteome.  
One of the key findings in Chapters 2 and 3 was that the antigenic profile of the 
different Fno isolates appeared very homogenous, with the presence of a dominant 
immuno-reactive protein band (~ 17-28 kDa) present in all isolates, as shown by 1D-
western blotting of both whole cell and OMPs preparations. Interestingly, this antigenic 
protein band has also been reported in other Francisella studies, including Fno (Kay et al., 
2006) and Fnn (Schrøder et al., 2009). The ability of the tilapia serum antibodies raised 
against the Fno UK isolate to cross-react with the other Fno isolates, supported the 
hypothesis of the potential cross-protection of the Fno UK isolate (vaccine isolate) against 
other heterologous isolates from different geographical locations. Equally important, 
identified and validated proteins that showed immunoreactivity against anti-Fno antibodies 
could be used as potential candidates for an improved Fno vaccine. Silver staining of the 
whole cell proteinase-K digest of the five Fno isolates used in Chapter 2, revealed an 
abundant band that was similar to the immunodominant lipo-oligo-polysaccharide band 
identified in F. victoria isolated from tilapia in a previous research study (Kay et al., 
2006). Further work is required to investigate the immuno-reactivity of the tilapia anti-Fno 
hyper immune serum against this abundant band in the proteinase-K digested proteins by 
western blot to show if these antibodies will have a similar affinity to the carbohydrate rich 
component as opposed to the proteins in the present study. In addition, performing 2D-
                                                                                                                          Chapter Seven 
213 
 
SDS-PAGE and 2D western blot analyses for the OMPs of different Fno isolates is 
necessary to improve the protein resolution and to confidently identify the immunogenic 
proteins within this fraction. Determining similarity in the antigenic profile of Fno isolates 
investigated in Chapters 2 and 3, with only minor difference in their proteomic profile, and 
the significant abundance of an important set of proteins in the Fno UK isolate, that are 
involved in pathogenicty and/or virulence, energy production and other high biological 
activities, were results that formed a benchmark to design the vaccination experiments 
performed in Chapters 4 and 5.   
In the absence of a commercial vaccine against Fno, the traditional method of 
raising water temperature to 30°C and/or using prolonged antibiotic treatment for up to 10 
days are the current practices for controlling Fno outbreaks (Soto et al., 2012d; 2014 a,b). 
Although antimicrobials showed an effect on Fno in tilapia and other susceptible 
ornamental species, antibiotics do not control the disease and there are increasing concerns 
regarding the development of antimicrobial resistance by Fno (Soto and Hawke, 2017). 
Vaccination is one of the most effective measures for preventing diseases in farmed fish, 
contributing to a sustainable aquaculture industry with low use of antimicrobials (Gudding, 
2014). Unlike salmonids, vaccination in tilapia is still in its infancy and there are only few 
available commercial vaccines for use in tilapia farms, such as AQUAVACâ Sa for S. 
agalactiae serotype lb, AQUAVACâ Sa1 for S. agalactiae serotypes la and III, 
AQUAVACâ Si for S. iniae and AQUAVACâ IridoV for Irido virus. Thus, more research 
is required to develop effective vaccines against other infectious diseases in tilapia, 
including francisellosis. Based on the immuno-proteomic study using a diverse selection of 
Fno isolates in Chapter 2 and 3, an injectable whole-cell, formalin killed adjuvanted 
vaccine against Fno was developed using the Fno UK isolate. The cross-reactivity of 
serum raised against heterologous Fno isolates would be expected to confer a broad-
spectrum protection against Fno infection. The protective efficacy of this vaccine in Nile 
tilapia (mean weight 15 ± 0.2 g) after i.p. challenge with either homologous or 
heterologous Fno isolates, was investigated in Chapter 4. Immunisation of tilapia with this 
vaccine by i.p. administration, resulted in significant protection against the homologous 
isolate (RPS 82.3%) and the heterologous isolates (RPS 69.8% and 65.9%). The results of 
this study were comparable to a previous study using an autogenous immersion live 
attenuated vaccine (RPS of 68.75 % to 87.5%, Soto et al., 2011b). The use of live 
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attenuated vaccines on farms, despite promising results, have safety constrains due to 
concerns of the bacteria regaining virulence under certain biological and environmental 
conditions (Munang’andu et al., 2016) and generally unacceptable in most countries. As 
tilapia is one of the most widely farmed fish globally, any live attenuated vaccine used in 
farmed tilapia must be safe, not only for tilapia, but also for other aquatic organisms. Thus, 
a killed vaccine would be more acceptable if it provides desirable level of protection 
against francisellosis in tilapia. The RPS obtained with the vaccine developed in Chapter 4 
was higher than that obtained with the injectable OMVs-based vaccine administrated in 
zebrafish (RPS 65.5%, Lagos et al., 2017). This could be due to the use of adjuvant in the 
current vaccine study or the weak stimulation of the immune system by the OMVs-
vaccine. It is of note that cross-protection against heterologous Fno isolates has not been 
studied previously (Soto et al., 2011b; Lagos et al., 2017), which highlights the importance 
of the study in Chapter 4 by providing valuable information towards the establishing of 
control strategies against the circulating Fno isolates.  
Fish vaccination is generally targeted toward stimulation of antibody responses to 
provide protection against subsequent infection with the pathogens (LaFrentz et al., 2012). 
In the current study, the serum antibody level 30 days post initial vaccination was 
significantly higher in the vaccinated fish than the adjuvant-alone or the PBS control fish. 
This finding was similar to that reported by Ramirez-Paredes (2015), but contrasted with 
other reports, where no significant difference of the serum antibody response between 
vaccinated and control groups before challenge were observed (Soto et al., 2011b; Lagos 
et al., 2017). The reason for these differences in antibody induction is unclear, but could 
involve the vaccine formulation (e.g. addition of adjuvant), route of administration of the 
vaccine, size and species of the fish used. A significant increase in serum antibody 
response in vaccinated fish was observed after challenge, in agreement with other studies 
(Soto et al., 2011b; Ramirez-Paredes, 2015; Lagos et al., 2017), but the most important 
observation was that, higher specific IgM levels were also found against the heterologous 
isolates as well as the vaccine isolate. In addition, serum sampled from vaccinated fish 30 
dpv reacted with the different Fno antigens, highlighting an immunogenic band similar to 
that observed in the proteomic studies in Chapters 2 and 3, which was also seen when anti-
sera raised against the different Fno isolates 15 dpc reacted with the vaccine isolate. The 
significantly higher survival rates and serum IgM levels observed in the vaccinated fish 
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compared to adjuvant-alone and PBS control fish, in addition to observation of cross-
reactivity with the different Fno antigens, may provide strong evidence to support the 
efficacy of this vaccine. It also suggests the potential of the vaccine to confer broad 
ranging protection against heterologous Fno isolates. Association between the increased 
IgM levels and the high survival rate in the vaccinated fish after challenge, may indicate 
that humoral immunity significantly contributes to protection against Fno infection in 
tilapia. It is not surprising that significantly higher survival and serum IgM levels were 
observed in the homologous challenge group compared to the heterologous challenge 
groups, however, these isolates exhibited homologous antigenic profiles with the 
antiserum raised against the vaccine isolate. This may be attributed to the abundance of 
important virulence-related proteins in the Fno UK isolate (the vaccine isolate) in contrast 
to the other isolates as observed in the 2-DE analysis in Chapter 2. Thus, larger challenge 
experiments involving other Fno isolates from a broader geographical distribution may 
explain these findings by comparing the IgM and survival levels post-challenge with the 
diverse Fno isolates. 
The expression levels of selected immune-related genes (MHCII; IL-1b; TNF-a; 
IgM) in the spleen samples of tilapia fingerlings in response to the i.p. vaccination was 
examined to investigate the effect of the vaccine on the fish immune system at the 
molecular level. The significant up-regulation of MHCII in the spleen samples of 
vaccinated fish 6-72 hpv indicates a successful stimulation of the immune response in 
vaccinated fish (i.e. contact of the inactivated Fno cells in the vaccine with TCR and 
uptake of Fno cells/antigens by APCs which in turn triggered a cascade of adaptive 
immune responses) (Castro and Carolina, 2015). Future study to quantify the number of 
macrophages in the spleen of tilapia following vaccination may validate this result. An 
early pro-inflammatory response (6-72 hpv) was observed in vaccinated fish, indicated by 
significantly up-regulated levels of IL-1b and TNF-a genes, providing an evidence of the 
immune priming and migration of the inflammatory cells to the systemic environment of 
the fish and stimulation of the fish’s innate immune system in response to vaccination. 
Previous study reported down-regulations or late up-regulation of the IL-1b and TNF-a 
transcripts after vaccinations against Fno in zebra fish (Lagos et al., 2017). The reason for 
this finding is not clear, but may be attributed to difference in the composition of the 
vaccine, dose of vaccine, route of vaccination and fish species used in the trial. 
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Furthermore, the significant up-regulation of IgM transcripts in spleen samples that 
correlated with the significantly higher levels of serum IgM in vaccinated fish, points to a 
successful triggering of the humoral immune system post-vaccination against Fno. More 
importantly, it supports the role of humoral immunity in protection of tilapia against 
subsequent Fno infection. In the current study, only spleen samples were analysed post-
vaccination. Further studies should be conducted to investigate the immune response in 
other tissues (e.g. liver, head kidney, gills, gut) at different time points (i.e. pre-
vaccination, post-vaccination and post-challenge) to establish the effect of the vaccine on 
immune gene expression, not only in the systemic organs, but also the mucosal organs 
would be useful. This will help to improve our understanding of molecular mechanism of 
induction of immunity by i.p. vaccination against Fno infection. In addition, cellular 
immunity was reported to play an important role against F. tularensis in mammals (Celli 
and Zahrt, 2013). Therefore, further studies are required to examine immune cell markers 
such as CD8 and CD4 expression in order to investigate the importance of cell-mediated 
immunity in protection of tilapia against Fno infection.  
Quantification of the bacterial load by qPCR proved to be a very useful approach in 
Chapter 4, where it indicated the ability of the vaccine to reduce bacterial replication in 
comparison to the relatively higher load observed in the adjuvant-alone and non-
vaccinated fish post-challenge. This finding demonstrated that vaccination against Fno 
appears to be more advantageous than antimicrobials, which demonstrated a limited ability 
to reduce the bacterial replication and spread in the infected fish tissues, as previously 
reported by Soto et al. (2012d; 2014b). It can also be used to determine the optimal dose of 
the vaccine that is able to induce protection, while preventing colonisation of the invading 
bacteria on mucosal surfaces and penetration to the systemic milieu within the vaccinated 
fish. Additional histopathological studies are required to investigate the extent of tissue 
damage post-challenge in vaccinated fish, which can then be used as a correlate of vaccine 
efficacy in association with the other parameters (e.g. IgM levels, RPS, quantification of 
bacterial burden).  
The use of adjuvant was shown to be beneficial in the vaccine study performed in 
Chapter 4. The role of adjuvants in assisting the efficacy of injectable vaccines and 
inducing long-lasting protection in fish has been reported, and previous studies showed 
lower survival rates with non-adjuvanted vaccines compared to adjuvanted vaccines 
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(Firdaus-Nawi et al. 2013; Jaafar et al., 2015). It is important to consider the short life 
cycle of tilapia (~ 4-6 months) when developing vaccines for this fish species. Thus, a 
suitable vaccine for Fno in tilapia should confer long-life immunity against the diseases 
without the need for a booster vaccination that would increase the cost of vaccination for 
this relatively inexpensive fish. In the present study, vaccination was performed 30 days 
prior to challenging the fish for 15 days. It would be informative to perform a potency test 
for the vaccine, by evaluating antibody response over a longer period of vaccination 
followed by challenge, so that the duration of immunity elicited by the developed Fno 
vaccine can be predicted.  
While the injectable vaccine developed in Chapter 4 showed potential efficacy and 
cross-protection against heterologous Fno in tilapia fingerlings, from a practical point of 
view it cannot be used in fish less than 10 g. Thus, another Fno vaccine efficacy trial was 
performed in Chapter 5 with an immersion vaccine for smaller sized tilapia (~ 6 g). The 
immersion vaccine was developed using the same isolate as used in the injectable vaccine 
and was administered by dip immersion without adjuvant. Although a relatively moderate 
level of protection was obtained with this immersion vaccine (RPS of 43.7%), this level 
was lower than that obtained with both the current i.p. vaccination described in chapter 4 
(RPS 65.9 – 82.3 %) and other recent autogenous i.p. Fno vaccine study (RPS 100%, 
Ramirez-Paredes, 2015). In addition, the RPS induced by this immersion vaccine was 
lower than that reported for a live attenuated immersion vaccine (RPS 68.75% - 87.5%, 
Soto et al., 2011b). It is still unclear as to the best parameters to use for vaccination of 
tilapia fry against Fno (e.g. optimum vaccine dose, time of vaccination and fish size at the 
time of vaccination). Therefore, more studies are required to optimise these factors, taking 
into account the nature of tilapia’s physiology and anatomy. This may enable 
establishment of an efficient vaccination regimen for tilapia fry against subsequent 
infection with Fno.  
Evaluation of serum IgM level was the only parameter studied after immersion 
vaccination of tilapia in the present study. Notably, the IgM levels of 30% of the 
immersion vaccinated fish were below the threshold at 30 dpv and serum IgM levels were 
not-significantly different between immersion vaccinated and non-vaccinated fry 20 dpc, 
although the average IgM level in the immersion vaccinated and challenged fry was higher 
compared to the non-vaccinated and challenged fry. It was not surprising to detect a low 
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serum IgM response in the immersion vaccinated fish. This may be attributed to the 
limited ability of the immersion vaccination to trigger systemic immune response (i.e. 
serum IgM response) and the greater effect is more likely to be observed on the level of 
mucosal surfaces. Thus, performing other investigations including analysing of mucus 
IgM, and perhaps more importantly IgT levels, will provide more information regarding 
the effect of the immersion vaccine on the mucosal immunity of tilapia. Triggering of 
mucosal immunity was reported to be important against Fno infection (Soto et al., 2011b). 
In addition, further studies with different Fno vaccine formulations (e.g. bivalent, 
polyvalent vaccines, OMVs or OMPs derived vaccines) are required. Use of mucosal 
adjuvants to enhance the efficacy of the Fno immersion vaccine should be also 
investigated. Analysis of immune gene expression in mucosal and systemic organs at 
different time points pre-challenge and post-challenge should also be performed to 
elucidate the mechanism of interaction of the Fno immersion vaccine with the tilapia 
immune system.   
One of the challenges for controlling piscine francisellosis is the nature of the 
causative agent, which is a fastidious, intracellular organism that can also form biofilms 
(Soto et al., 2015) and exists in a viable but non-culturable state (Duodu and Colquhoun, 
2010). Development of control measures for Fno on tilapia farms is urgently needed, but 
Fno is more difficult to isolate and detect than other common bacterial pathogens found 
during clinical disease outbreaks in tilapia. Thus, having a diagnostic tool that would 
enable early and accurate detection of the pathogen in the diseased/carrier fish or its 
surrounding environment would benefit the tilapia industry. In Chapter 6, a novel 
isothermal recombinase polymerase amplification assay (RPA) was developed and 
validated for rapid and accurate detection of Fno. Comparing the Fno-RPA with bacterial 
isolation, conventional PCR and the previously published Fno-specific qPCR (Duodu et 
al., 2012), which considered to be the gold standard molecular test in diagnostic labs, 
showed that RPA can provide more benefits to detection of Fno. The Fno-RPA displayed 
a faster reaction time of 6 min to reach a detection limit of 15 molecules of a DNA plasmid 
standard, prepared using the Fno-unique hypothetical protein gene (JQ780323), in contrast 
to 90 min required by qPCR to achieve a detection limit of 11 molecules. Furthermore, the 
RPA showed high specificity, where it only detected the DNA of Fno isolates without 
cross-detection of DNA from the other fish, human and environmental pathogenic 
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Francisella spp. (Fnn; Fp) or other common fish bacterial pathogens used in this study. 
More importantly, the Fno-RPA demonstrated a greater performance than qPCR using 
field samples including tissue samples (spleen, head kidney) and water samples. The 
tolerance of Fno-RPA to reaction inhibitors was evident by 100 % clinical sensitivity and 
84.89 % clinical specificity. This enabled detection of Fno in 47/78 spleen, 47/78 kidney 
and 5/5 water samples, in contrast to qPCR that failed to initially detect Fno in the crude 
DNA of 6 tissues samples and 5 water samples, but after dilution of the DNA to 1:10 and 
1:100, it detected the bacteria in 2/6 and 3/5 of these samples. The robustness of Fno-RPA 
with field samples was in agreement with previous reports of RPA (Daher et al., 2014; 
2016; Bonney et al., 2017). The cost effectiveness of RPA, convenience of performing the 
assay using very simple equipment without the requirement for skilled personnel, the 
ability to perform the reaction at a relatively wide range of temperatures (37- 42°C) along 
with the high diagnostic performance, make the RPA a highly recommended diagnostic 
assay for Fno, especially in a poorly equipped diagnostic laboratory. This will provide 
high throughput, sensitive, specific, affordable, fast, user friendly molecular detection of 
Fno, avoiding the disadvantages of other previously reported diagnostic tools (e.g. 
bacteriology; immunological assays (ELISA, IHC); nucleic acid-based assays (ISH; PCR; 
duplex-PCR; qPCR) (Soto et al., 2009b, 2010a, 2012c; Duodu et al., 2012; Assis et al., 
2016; Rodrigues et al., 2016; Sebastião et al., 2017; Dong et al., 2016a; Ramirez-Paredes 
et al.,2017b). Future studies are required to test and optimise different protocols for DNA 
extraction and coupling the RPA with other quick detection assays (e.g. Lateral flow dip 
stick). This will contribute to decreasing costs and enhancing the performance of the RPA 
to be applied as a pen-side test for detection of Fno on fish farms.  
7.2. Final conclusions  
Piscine francisellosis is recognised as one of the most significant emergent diseases in 
farmed tilapia. The fastidious nature of Fno, the high infectivity, ability to survive in a 
wide range of environments and its world-wide distribution, highlight the importance of 
this aquatic pathogen, yet we know very little about it. Fno diversity, pathogenesis and 
mechanisms of interaction with its host, require further investigation. Prophylactic 
measures and accurate diagnostic tools are needed for controlling this important disease. 
Observation of minor differences in the protein profile of geographically diverse 
Fno isolates, exhibiting a largely homogenous antigenic profile, provides a valuable 
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information about the diversity of Fno and supports the hypothesis of the genomic-based 
studies of existence of “clonal-like characteristics” between the different Fno isolates.  
Identification of various virulence-related proteins in the OMP fraction of Fno 
reveals the importance of this simple protein fraction in the pathogenic life-style of Fno 
and its role in host-pathogenic interactions. Furthermore, identification of the immuno-
reactive proteins within the Fno proteome will help in future development of a new 
generation of diagnostic and prophylactic tools (e.g. recombinant vaccines).  
The whole cell Fno vaccine stimulated the expression of genes related to innate 
and adaptive immunity post-vaccination and provided promising protection not only 
against the homologous Fno isolate, but also against heterologous isolates in tilapia 
fingerlings. Significantly higher IgM levels and significantly lower bacterial burden 
following i.p. vaccination and challenge correlated with protection, suggesting a protective 
role of antibody-mediated immunity against Fno in tilapia. Taken together, the results 
from this study provide a benchmark to develop a broad-spectrum vaccine for protection 
against diverse Fno isolates in tilapia.  
Immersion vaccination provided tilapia fry a relatively moderate level of protection 
(RPS of 43.7%). Therefore, further optimisation is required to enhance the efficacy of this 
vaccine (e.g. optimisation of delivery time, vaccine composition and using immersion 
adjuvants). Understanding molecular mechanism of protection induced by immersion 
vaccination against Fno in tilapia fry also requires further research.    
Finally, a novel isothermal RPA was developed for cost-effective, fast, accurate, 
sensitive, specific and user-friendly diagnosis of Fno. The short reaction time, with high 
robustness in detection of Fno from clinical samples, make the RPA a suitable diagnostic 
assay for Fno with special consideration to be applied in poor-setting diagnostic labs and 
in field-diagnostics if accompanied with a proper extraction protocol. 
In general, the current study provides an insight into our understanding of the 
diversity and virulence mechanisms of the pathogenic Fno isolates affecting fish. It also 
lays the groundwork for improving Fno vaccine design and aids in enabling surveillance 
strategies for future Fno outbreaks. 
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7.3. Future prospects  
The results obtained in this thesis pave the way to additional research for future studies. 
This includes, but is not restricted to:  
1- Comparing the expression of proteins of Fno grown under certain conditions that mimic 
the host environment such as stress conditions (i.e. iron restricted media) to normal culture 
conditions or in vivo versus in vitro.    
2- Performing 2D-SDS-PAGE for the OMPs of Fno to have a better separation of the 
proteins that co-migrated in a single band in the 1D-SDS-PAGE. 
3- Performing 1D and 2D-SDS-PAGE with more Fno isolates from other geographical 
locations. 
4- Cloning of proteins with promising immunoreactivity and testing their efficacy as 
recombinant vaccines or coupling them with nanoparticles to formulate nano-based 
vaccines against Fno in tilapia.   
5- Testing the performance of the developed injection vaccine under field conditions and 
investigation of the duration of immunity provided by this vaccine. 
6- Optimising of dose, duration and suitable fish size for immersion vaccination of tilapia 
fry and more importantly, investigation of the age of immunocompetency of tilapia that is 
currently unknown. 
7- Investigation of the role of cell mediated immunity in protection of tilapia against Fno 
following i.p and immersion vaccinations. 
8- Testing different DNA extraction protocols and optimising rapid, cheap and effective 
methods to enable the use of Fno-RPA in the field and enhance Fno detection using recent 
tools such as the lateral flow dip stick. Other possibilities include set-up of two separate 
mobile suitcases, one for sample preparation and another for detection of Fno. This will 
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Appendix 1: Media, buffers and chemicals  
Bacteriological media  
Cystein heart agar media enriched with hemoglobine (1% v/v) (1 L) 
Cystein heart agar       51 g 
Bovine haenoglobine      10 g 
Distilled water                  up to 1L 
Modified Muller Hinton broth with 0.1 % (w/v) glucose and 2% (v/v) IsoVitaleX (1L) 
Modified Muller Hinton powder    22 g 
Glucose       1 gb 
IsoVitaleX       20 µL 
Distilled water                                        up to 1L 
 
Buffers used for proteomics experiments  
Lysis buffer for extraction of whole cell lysate (stored at -20 ºC) 
(7M Urea, 2M thiourea, 4% CHAPS, 40 mM DDT, 25 mL) 
Urea (7 M)                      10.5 g 
Thiourea (2 M)                 3.8 g 
CHAPS (4% (w/v))                             1 g 
DDT (40 mM)                                                                        154 mg 
Double-distilled water                                                             Up to 25 mL  
Nuclease mix (1% (v/v))                                                         250 µL   
Protease inhibitor (0.1 % (v/v))                                              25 µL                                                             
Thiourea rehydration solution (stored at -20 ºC) 
(7M Urea, 2M thiourea, 2% CHAPS, 0.002% bromophenole blue, 2% IPG buffer, 25 mL) 
Urea (7 M)                      10.5 g 
Thiourea (2 M)                 3.8 g 
CHAPS (2% (w/v))                             0.5 g 
IPG buffer pH 4-7 (0.5% (v/v))                                             125 µL 
1% Bromophenole blue stock solution (0.002%)                   50 µL  
DDT                                                                                       70 g   
Double-distilled water                                                            Up to 25 mL                                                             
Bromophenol blue stock solution (stored at room temeprature) 
Bromophenol blue (1%)                     100 mg 
Tris-base (50 mM)                            60 mg 





10X Lamelli SDS electrophoresis buffer (250mM Tris base, 1.92M glycine, 1% SDS, 10L) 
Tris base (250 M)           303 g 
Glycine (1.92 M)       3.8 g 
SDS (1% (w/v))                              100 g 
Double-distilled water                                                              Up to 10 mL  
Equilibration buffer I (6M urea, 75mM Tris-HCl, pH 8.8, 29.3% glycerol, 2% SDS,  
0.002% bromophenol blue, DDT 1% (w/v), 200 mL) 
Urea (6 M)                              72.1 g 
Tris-HCl, pH 8.8 (75 mM)                            10 mL 
Glycerol (29.3%)                              69 mL 
SDS (2% (w/v))                              4 g 
1% Bromophenole blue stock solution (0.002%)                    400 µL  
DDT (1% (w/v)) *                                                                   2 g 
Double-distilled water                                                             Up to 200 mL  
* add before equilibration 
Equilibration buffer II (6M urea, 75mM Tris-HCl, pH 8.8, 29.3% glycerol, 2% SDS,  
0.002% bromophenol blue, iodacetamide 2.5% (w/v), 200 mL) 
Urea (6 M)                              72.1 g 
Tris-HCl, pH 8.8 (75 mM)                            10 mL 
Glycerol (29.3%)                              69 mL 
SDS (2% (w/v))                              4 g 
1% Bromophenole blue stock solution (0.002%)                    400 µL  
Iodacetamide (2.5% (w/v)) *                                                   5 g 
Double-distilled water                                                              Up to 200 mL  
* add before equilibration 
Agarose sealing solution (25 mM Tris base, 192 mM glycine, 0.1% SDS, 0.5% agarose, 
0.002% bromophenol blue, 100 mL) 
1X Lamelli SDS electrophoresis buffer          100 mL 
Agarose                                                    0.5 g 
1% Bromophenole blue stock solution (0.002%)                    200 µL  
Coomassie blue stain fixing solution (1 L) 
Methanol (40% (v/v))                              400 mL 
Glacial acetic acid (10% (v/v))                                               100 mL    
Double-distilled water (50% (v/v))                500 mL 
Silver stain fixing solution (1 L) 
Absolute ethanol (50% (v/v))                 500 mL 
Glacial acetic acid (10% (v/v))                                               100 mL    
Double-distilled water (40% (v/v))               400 mL 
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Ethanol wash solution (1 L) 
Absolute ethanol (30% (v/v))                 300 mL 
Double-distilled water (70% (v/v))               700 mL 
Sensitizer solution (100 mL) 
Proteosilver sensitizer                                     1 mL 
Double-distilled water                               99 mL 
Silver solution (100 mL) 
Proteosilver solution                                     1 mL 
Double-distilled water                               99 mL 
Silver stain developer solution (100 mL) 
Proteosilver developer solution 1                                           5 mL 
Proteosilver developer solution 2                                           100 µL 
Double-distilled water                               95 mL 
Protein destaining solution (1:1 (v/v) Acetonitrile (ACN): 50 mM NH4HCO3) 
Ammonium bicarbonate (NH4HCO3)                                    79.06 mg 
Double-distilled water                               20 mL 
Acetonitrile (ACN)                                                                 20 mL 
Protein dehydration solution (2:1 (v/v) Acetonitrile (ACN): 50 mM NH4HCO3) 
Ammonium bicarbonate (NH4HCO3)                                    79.06 mg 
Double-distilled water                               20 mL 
Acetonitrile (ACN)                                                                 40 mL 
Protein reduction solution (10 mM DDT in 100 mM NH4HCO3) 
DDT                                                                                        7.7 mg 
NH4HCO3 (50 mM (79.06 mg in 20 mL DW))              5 mL 
Protein alkylation solution (55 mM iodacetamide in 50 mM NH4HCO3) 
Iodacetamide                                                                          10.16 mg 
NH4HCO3 (50 mM (79.06 mg in 20 mL DW))             1 mL 
Protein digestion solution (Trypsin solution) (20 ng/ µL) 
Trypsin lypholized powder                                                           20 µg 
HCl (1 mM)                                                                            100 µL 
NH4HCO3 (50 mM (79.06 mg in 20 mL DW))                   900 µL 
 
Buffers used for ELISA 
Coating buffer (1% (w/v) poly-lysine in carbonate bi-carbonate buffer) 
Carbonate-bicarbonate buffer  
(1 capsule of carbonate-bicarbonate in 100 mL DW)                    99 mL                                                                   
Poly-lysine buffer              1 mL 
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Low salt wash buffer (LSWB), 10X, pH 7.3 
Tris-Base (0.2 M)              24.2 g 
NaCl (3.8 M)               222.2 g 
Tween-20                5 mL 
Distilled water               up to 1L 
High salt wash buffer (HSWB), 10X, pH 7.7 
Tris-Base (0.2 M)              24.2 g 
NaCl (5M)               292.2 g 
Tween-20                10 mL 
Distilled water               up to 1L 
Blocking buffer (5% w/v marvel in distilled water)  
Marvel                 5 g 
Milli-Q water                 100 mL 
Phosphate Buffer Saline (PBS) 10x (1L), pH 7.4. 
NaCl                 80 g 
Na2HPO4                14.4 g 
NaH2PO4                 2.4 g 
Milli-Q water                 up to 1L 
Antibody buffer 
LSWB                  100 mL 
BSA                  1 g 
Substrate buffer (pH 5.4) (Stored at -4 ºC) 
Citric acid (0.1 M)                21 g 
Na acitate (0.1 M)                2 g 
Distilled water                            Up to 1 L 
Chromogen solution (Stored at -4 ºC) 
3’3’5’5’-Tetramethylbenidine dihydrochloride (42 mM)              0.07896 g 
Acetic acid: distelled water                         6 mL 
Chromogen in substrate buffer (Stored at -4 ºC) 
Substrate buffer                                                15 mL 
Chromogen solution                                          150 µL 
H2O2                                                                  5 µL 
 
Buffers used for Western blot 
Tris-buffered saline (TBS) (pH 7.5) 
Tris-base (0.02 M)              2.42 g 
NaCl                                      29.24 g 
Distilled water                                                                                Up to 1 L 
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Tris-buffered saline with Tween-20 (TBST)  
Tris-base (0.02 M)              2.42 g 
NaCl                                      29.24 g 
Distilled water                                                                                Up to 1 L 
Tween-20                          1 mL 
 
Francisella genus specific conventional PCR mixture (25 µL reaction) 
1X ReddyMix PCR master mix                  12.5 µL 
Forward Primer (0.2 µM)              1 µL 
Reverse Primer (0.2 µM)              1 µL 
DNA template (100 ng/ µL)              1 µL 
Milli-Q water                 9.5 µL 
 
Francisella noatunensis subsp. orientalis qPCR mixture (20 µL reaction) 
1X Luminaris color HiGreen qPCR master mix           10 µL 
Forward Primer (0.3 µM)             0.6 µL 
Reverse Primer (0.3 µM)             0.6 µL 
DNA template (100 ng/ µL)             1 µL 
Milli-Q water                           7.8 µL 
 
Francisella noatunensis subsp. orientalis RPA mixture (50 µL reaction) 
1X Rehydration buffer                          29.5 µL 
Forward Primer (10 µM)                        2.1 µL 
Reverse Primer (10 µM)                        2.1 µL 
Probe (10 µM)                                    0.6 µL 
DNA template (100 ng/ µL)             1 µL 
Milli-Q water                10.7 µL 




Appendix 2:  
Table S1. Proteins identified in the OMPs of Fno UK isolate. 
No. Accession no. Protein name Mw[kDa] pI Scores Peptides SC [%] 
1 gi|300193845| PdpD  139.9 6.2 4477.2  72 61.4 
2 gi|386872131| Chaperone ClpB  96.0 5.4 2588.9  49 57.7 
3 gi|169589436| PdpD  139.6 6.1 2478.8  39 52.1 
4 gi|300193842| IglC  22.1 5.3 2388.4  14 84.2 
5 gi|386871181| Chaperonin GroEL  57.1 4.9 1857.1  33 63.7 
6 gi|103012949| Ribosomal L29e protein family  126.8 8.9 1839.5 42 46.6 
7 gi|386870877| OmpA family peptidoglycan-associated lipoprotein  23.4 4.8 1585.1 29 75.6 
8 gi|386872079| 
Bifunctional proline dehydrogenase/pyrroline-5-
carboxylate  149.5 7.8 1539.6 33 34.6 
9 gi|300193843| IglB  57.5 4.7 1526.5  30 59.9 
10 gi|386870689| 30S ribosomal protein S1  61.5 5.2 1389.2  26 58.1 
11 gi|386870694| Cell division protein FtsZ  39.3 4.6 1354.0  24 85.4 
12 gi|386871696| Outer membrane associated protein  41.3 5.2 1307.4  22 42.8 
13 gi|300193831| PdpA  94.9 8.9 1244.6  15 47.8 
14 gi|386870866| OmpA family protein (FopA) 47.2 6.0 1090.3  30  62.1 
15 gi|169589422| PdpB  126.5 9.2 1046.8  24 44.6 
16 gi|386871950| Ribonuclease E  101.4 8.3 1036.3  19 27.4 
17 gi|300193844| IglA  20.4 8.6 1010.3  32 57.2 
18 gi|386871082| Alpha-ketoglutarate decarboxylase 105.5 6.1 1009.2  21  27.9 
19 gi|386870797| Heat shock protein 90  72.2 5.3 992.4  21 36.9 
20 gi|386871083| 2-oxoglutarate dehydrogenase complex, E2 component  52.5 5.0 991.1  18 45.6 
21 gi|359325479| Succinate dehydrogenase  65.7 5.9 978.2  18 40.4 
22 gi|386871045| NADH dehydrogenase subunit G  87.2 5.3 969.6  16 34.8 
23 gi|564749340| Hypothetical protein M973_05085  154.4 5.6 961.0 53 23.2 
24 gi|386871702| Putative cyanophycin synthetase  103.8 5.7 909.0  20 26.6 
25 gi|386872051| 4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase  43.4 7.6 907.0  16 55.6 
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26 gi|386871615| Enolase  49.4 4.8 890.7  18 56.5 
27 gi|386871214| Pyruvate dehydrogenase subunit E1  100.3 5.7 869.3  19 30.0 
28 gi|386871625| Peroxidase/catalase  82.1 5.7 859.1  17 36.8 
29 gi|386870767| Elongation factor G  77.7 4.8 851.8  16 35.7 
30 gi|386871057| Translation initiation factor IF-2 91.8 8.9 818.4  17 27.4 
31 gi|386871419| Serine-type D-Ala-D-Ala carboxypeptidase  48.2 9.0 802.8  15 46.8 
32 gi|386871186| Glutamate dehydrogenase  49.0 6.4 782.8  15 43.7 
33 gi|386870911| LemA-like protein 21.9 6.0 754.5  17 66 
34 gi|386871126| Elongation factor  43.3 5.0 735.9  36 46.9 
35 gi|386870580| Carbamoyl phosphate synthase large subunit  120.4 5.0 740.9  16 22.1 
36 gi|860224409| Non-ribosomal peptide synthetase  249.4 5.2 734.6  27 18.2 
37 gi|386871071| ATP synthase subunit beta  49.8 4.9 689.2  15 49.3 
38 gi|386870999| DnaK, molecular chaperone  69.0 4.8 669.8  11 28.7 
39 gi|386871203| tRNA adenyle transferase  35.2 6.8 665.2  11 41.9 
40 gi|752588110| Murein transglycosylase  77.2 9.0 661.9  14 28.5 
41 gi|386870616| Universal stress protein  30.1 5.4 645.3  10 48.2 
42 gi|386871260| DTDP-4-dehydrorhamnose 3,5-epimerase  83.4 9.0 637.2  11 20.1 
43 gi|386871056|  Transcription elongation factor NusA  55.3 4.5 629.9  12 29.7 
44 gi|386871375| Beta-ketoacyl-ACP reductase  26.3 9.6 617.3  10 55.9 
45 gi|386871595| Uncharacterized protein OOM_1173  64.6 10.2 614.3  9 20.2 
46 gi|855345043| Pyruvate kinase  51.7 8.4 614.1  11 32.8 
47 gi|386871457| DsbA_Com1_like, DsbA family, Com1-like subfamily  40.4 4.7 608.2  17 46.6 
48 gi|564748617| Peptidyl-prolyl cis-trans isomerase DNA-directed 29.6 9.1 594.0  9 44.5 
49 gi|386871134| RNA polymerase, b’ta' subunit/160 kD subunit  157.2 6.2 590.9  12 13.1 
50 gi|564749241| Hypothetical protein M973_02230  15.1 7.7 576.0  8 47.1 
51 gi|386870783| 30S ribosomal protein S8  14.4 9.2 563.2  9 61.4 
52 gi|386871081| Succinate dehydrogenase iron-sulfur subunit  26.5 8.8 555.8  12 54.9 
53 gi|386870794| DNA-directed RNA polymerase subunit alpha  35.3 4.9 550.2  11 49.2 
54 gi|386871259| Putative glucose-1-phosphate thymidyl transferase  100.5 5.3 537.2  13 22.1 
55 gi|386870813| Sel1-like protein  45.4 5.7 533.6  11 36.2 
56 gi|386870781| 50S ribosomal protein L5  20.0 9.7 526.4  11 61.5 
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57 gi|386870724| Cytochrome ubiquinol oxidase subunit I  63.7 6.0 519.4  8 13.7 
58 gi|386870758| Elongation factor Ts  30.9 5.2 495.8  9 41.5 
59 gi|386871568| Acetyl-CoA carboxylase, biotin carboxylase subunit  49.8 6.9 477.2  10 37.0 
60 gi|386870942| Hypothetical protein OOM_0413  15.7 9.2 471.3  8 48.3 
61 gi|386871669| Microtubule-severing ATPase  70.8 5.4 470.0  10 25.0 
62 gi|386871478| AhpC/TSA family peroxiredoxin  21.8 5.0 510.0  9 59.8 
63 gi|386871972| Enoyl-ACP reductase I  27.7 5.5 449.0  11 55.4 
64 gi|386870822| Putative lipoprotein  18.0 8.8 419.0  6 51.9 
65 gi|386871594| Succinyl-CoA synthetase subunit beta  41.5 5.2 398.0  7 28.9 
66 gi|386870957| Hypothetical protein OOM_0430  58.1 4.4 395.5  7 12.3 
67 gi|386871251| Hypothetical protein OOM-0776  22.5 9.8 388.6  9 41.3 
68 gi|386871449| Alanyl-tRNA synthetase  96.1 5.7 377.0  5 8.7 
69 gi|300193838| Hypothetical protein  24.3 5.6 376.8  5 33.5 
70 gi|386870607| Membrane protein of unknown function  62.1 7.7 374.3  6 13.6 
71 gi|386871130| 50S ribosomal protein L1  24.5 9.5 374.1  9 39.4 
72 gi|386871311| Phosphomannomutase  54.5 5.2 372.7  7 15.6 
73 gi|386870601| Pyruvate phosphate dikinase  97.7 5.4 371.1  7 12.7 
74 gi|386871607| Polynucleotide phosphorylase/polyadenylase  75.4 5.8 364.3  9 20.4 
75 gi|386871122| Glycerol-3-phosphate dehydrogenase  58.0 8.6 362.3  7 16.3 
76 gi|386871423| RNA polymerase sigma-70 factor  67.4 5.3 361.4  9 22.2 
77 gi|386870769| 50S ribosomal protein L3  22.1 9.5 359.4  6 40.5 
78 gi|386871866| Amino acid adenylation  396.7 5.9 357.6  10 4.6 
79 gi|386871131| 50S ribosomal protein L10  18.7 9.1 351.8  10 55.2 
80 gi|386871651| Phosphoglyceromutase  57.6 5.6 349.9  5 12.1 
81 gi|386871129| 50S ribosomal protein L11  15.4 9.8 347.8  7 46.2 
82 gi|386871662| Leucyl aminopeptidase  51.7 5.2 347.7  8 22.5 
83 gi|752587925| SAM-dependent methyltransferase  24.7 9.0 346.8  7 39.5 
84 gi|386871735| HflC protein  34.4 9.2 342.5  8 32.1 
85 gi|386870644| Riboflavin synthase  16.3 7.7 341.4  6 54.4 
86 gi|386872152| Putative ABC transporter ATP-binding protein  63.0 5.2 341.2  8 20.6 
87 gi|386870642| Hypothetical protein OOM_0085  35.1 6.7 340.2  5 22.4 
88 gi|386870664| Aspartyl-tRNA synthetase  66.7 6.0 339.4  7 16.3 
89 gi|386870854| Septum formation inhibitor-activating ATPase  30.0 7.6 338.8  8 44.7 
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90 gi|386870693| Cell division protein FtsA  44.9 4.9 334.8  7 24.3 
91 gi|386871293| AMP-dependent synthetase/ligase  58.6 5.2 334.5  7 20.2 
92 gi|386870757| 30S ribosomal protein S2  26.5 8.8 333.7 5 21.3 
93 gi|752587918| Transcription termination/antitermination factor NusG  20.3 6.8 333.1  7 40.8 
94 gi|386872038| Gamma-glutamyltransferase 62.2 8.1 333.1  6 18.9 
95 gi|386871665| Glucose-6-phosphate isomerase  60.6 5.7 331.3  8 22.2 
96 gi|855345177| Hypothetical protein OOM_1530  27.9 9.4 330.4  6 27.2 
97 gi|564748853| Phosphoglycerate kinase  41.9 5.2 324.3  6 31.1 
98 gi|386870979| Putative cystathionine beta-synthase  34.5 9.0 318.0  11 39.7 
99 gi|386871715| Hypothetical protein OOM_1308  18.6 9.4 316.2  6 40.7 
100 gi|386871133| DNA-directed RNA polymerase subunit beta  151.3 5.6 309.5  9 10.7 
101 gi|386871154| Pyrrolo-quinoline quinone repeat protein  55.7 5.6 309.2  8 24.7 
102 gi|386871439| 50S ribosomal protein L9  16.0 5.1 303.6  5 47.7 
103 gi|386870820| Hypothetical protein OOM_0272  33.3 6.7 303.3  5 21.6 
104 gi|386871446| Transaldolase B  36.3 9.2 300.5  6 24.0 
105 gi|564748023| ABC transporter substrate-binding protein  34.1 5.5 300.2  6 37.3 
106 gi|386870940| Oligopeptidase A  76.6 5.4 286.7  3 6.7 
107 gi|386870846| VacJ like lipoprotein  40.0 4.3 286.4  5 20.2 
108 gi|386870587| Alpha/beta fold family hydrolase  32.6 5.3 279.7  7 36.6 
109 gi|386871343| Prolyl-tRNA synthetase  64.0 5.4 275.9  6 13.6 
110 gi|564749152| NADH dehydrogenase subunit D  47.4 6.1 274.1  6 19.4 
111 gi|386871593| Succinyl-CoA synthetase, alpha subunit  29.9 5.9 273.2  7 38.3 
112 gi|386870594| Chorismate mutase  20.3 9.2 267.1  5 40.6 
113 gi|386870793| 30S ribosomal protein S4  23.2 10.4 265.0  4 24.8 
114 gi|386871240| DNA-binding response regulator  25.5 6.2 261.9  5 32.9 
115 gi|195973818| DNA-directed RNA polymerase subunit beta 145.2 5.5 258.0  6 6.7 
116 gi|386872012| Ribose-5-phosphate isomerase A  24.5 6.2 254.6  4 37.1 
117 gi|386871889| Chorismate binding family protein  120.0 5.6 253.9  26 31.3 
118 gi|386871827| DEAD-box subfamily ATP-dependent helicase  65.8 9.1 247.8  4 10.1 
119 gi|386871215| Dihydrolipoamide acetyltransferase  56.0 5.1 247.6  5 11.1 
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120 gi|386870623| Hypothetical protein OOM_0066  25.3 5.6 246.1  7 34.9 
121 gi|386870770| 50S ribosomal protein L4  22.5 10.0 242.5  5 31.9 
122 gi|386872041| 
GTP binding translational elongation factor Tu and G 
family protein  67.5 5.2 240.7  6 14.5 
123 gi|386870647| Pyrimidine reductase/pyrimidine deaminase  39.4 9.7 240.6  5 21.9 
124 gi|386872101| Malate dehydrogenase  34.0 6.1 238.6  6 27.3 
125 gi|300193839| Hypothetical protein  46.0 4.5 236.1  5 22.9 
126 gi|386871026| Adenylosuccinate lyase  49.3 6.0 235.9  5 11.1 
127 gi|300193833| Lipoprotein  14.3 6.2 232.5  4 40.0 
128 gi|386871069| ATP synthase subunit alpha 55.5 4.9 230.1  4 9.7 
129 gi|386870956| Malate dehydrogenase  67.0 5.5 227.8  6 18.7 
130 gi|386871411| GMP synthase  57.6 5.7 227.1  7 19.4 
131 gi|386870640| GTP-binding protein LepA  65.6 5.5 227.1  5 12.6 
132 gi|504527492| NADH-quinone oxidoreductase subunit C 25.3 6.5 226.1  5 34.9 
133 gi|386871562| Organic solvent tolerance protein, OstA  98.9 4.9 223.0  6 10.3 
134 gi|386870766| 30S ribosomal protein S7  17.8 10.1 220.9  4 31.8 
135 gi|386871067| ATP synthase subunit B  17.4 7.7 215.2  4 23.1 
136 gi|386871365| Hypothetical protein OOM_0903  27.7 8.4 212.1  5 22.7 
137 gi|386871865| ATP binding protein 48.4 6.9 211.5  4 13.0 
138 gi|386870786| 30S ribosomal protein S5 17.5 10.0 208.6  4 24.1 
139 gi|752595689| Trigger factor  49.6 5.0 207.3  6 19.9 
140 gi|386870792| 30S ribosomal protein S11  13.7 11.5 202.7 6 62.8 
141 gi|386871489| 
UDP-N-acetylglucosamine 
pyrophosphorylase/glucosamine-1-phosphate  49.1 6.7 202.2  5 14.3 
142 gi|386871068| ATP synthase subunit delta  19.3 4.6 200.3  5 38.5 
143 gi|386871786| Acyl dehydratase  19.7 6.6 197.2  5 35.1 
144 gi|386870784| 50S ribosomal protein L6 19.2 9.7 197.0  4 51.1 
145 gi|386871937| Phenylalanyl-tRNA synthetase subunit beta 87.8 5.0 194.9  4 7.1 
146 gi|386871155| Hypothetical protein OOM_0658 23.7 6.1 193.9  4 22.2 
147 gi|386871627| Glycerophosphoryl diester phosphodiesterase 38.7 5.3 191.0  5 21.1 
148 gi|386870788| 50S ribosomal protein L15  15.2 10.4 189.6  3 27.3 
149 gi|386871348| Hypothetical protein OOM_0882  40.1 5.1 186.6  5 24.1 
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150 gi|564749116| Succinate dehydrogenase  13.4 7.7 185.9  3 17.9 
151 gi|386871908| Phospho-2-dehydro-3-deoxyheptonate aldolase  41.0 6.2 185.1  4 14.1 
152 gi|386870831| Fructose 1,6-bisphosphatase II  34.6 4.9 182.2  4 12.5 
153 gi|386871600| Glutamine amidotransferase subunit PdxT  20.0 5.3 179.6  3 26.8 
154 gi|386871020| Protein-L-isoaspartate O-methyltransferase  23.6 5.6 179.2  3 23.3 
155 gi|386871414| ABC transporter, ATP-binding protein  27.1 8.5 175.7  4 28.4 
156 gi|386871725| ATP-dependent protease ATP-binding subunit ClpX  45.9 8.9 174.4  4 13.0 
157 gi|386870775| 30S ribosomal protein S3  24.5 10.0 174.4  3 14.9 
158 gi|386870861| Fumarate hydratase, class I  54.8 5.1 172.1  4 14.1 
159 gi|386872053| M24 family peptidase  69.1 6.8 170.8  5 8.6 
160 gi|386871801| UTP-glucose-1-phosphate uridylyltransferase  31.9 6.2 169.4  4 18.1 
161 gi|386871216| 
Pyruvate dehydrogenase complex, E3 component, 
dihydrolipoamide  50.3 5.9 164.6  5 21.5 
162 gi|386870687| Membrane protein of unknown function 21.1 8.9 164.1  3 16.3 
163 gi|386870772| 50S ribosomal protein L2  30.4 11.4 161.7  3 13.5 
164 gi|386871673| Preprotein translocase subunit SecA  103.3 5.3 159.8  5 8.2 
165 gi|386871652| D-lactate dehydrogenase (cytochrome)  114.3 9.6 157.6  4 6.3 
166 gi|386871878| Glutamate-1-semialdehyde-2,1-aminomutase  47.7 5.3 156.7  3 11.3 
167 gi|386872072| D-lactate dehydrogenase (cytochrome)  102.2 9.2 156.5  6 9.6 
168 gi|386871268| Hypothetical protein OOM_0777  43.1 5.5 156.2  4 16.6 
169 gi|386870654| Rhodanese-related sulfurtransferase  15.8 9.4 153.1  3 30.7 
170 gi|386871000| Heat shock protein DnaJ  41.5 7.9 151.0  3 10.5 
171 gi|386871230| Hypothetical protein OOM_0748  22.3 6.7 150.4  3 23.2 
172 gi|386870703| Hypothetical protein OOM_0151  20.2 6.6 149.7  3 18.9 
173 gi|386870771| 50S ribosomal protein L23 11.1 9.8 146.0  3 40.4 
174 gi|386872075| Shikimate kinase I  19.7 5.4 145.7  3 18.8 
175 gi|386871947| D-3-phosphoglycerate dehydrogenase  45.0 6.0 145.2  5 16.1 
176 gi|386871549| Phosphoenolpyruvate carboxykinase  60.6 8.7 144.3  3 7.0 
177 gi|386872099| 
Bifunctional gluaredoxin/ribonucleoside-diphosphate 
reductase subunit  47.2 5.1 143.4  3 8.1 
178 gi|386871490| Glucosam—e--fructose-6-phosphate aminotransferase  67.5 5.7 142.6  5 12.1 
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179 gi|386870951| Hypothetical protein OOM_0424  18.0 7.6 140.4  3 19.4 
180 gi|386871408| CBS domain pair protein  22.9 6.8 138.7  3 28.0 
181 gi|386871933| Lipoprotein  37.2 5.9 137.3  4 10.4 
182 gi|386871680| Polyamine transporter, ABC transporter 42.2 7.8 133.9  3 17.7 
183 gi|386870652| S49 family peptidase 34.2 8.6 131.8  3 17.9 
184 gi|386872052| Hypothetical protein OOM_1699  27.1 8.4 129.5  5 22.1 
185 gi|386870779| 50S ribosomal protein L14  13.3 10.4 127.3 3 29.5 
186 gi|386870645| GTP cyclohydrolase II  44.5 6.5 126.9  3 8.9 
187 gi|386870968| Ubiquinone/menaquinone biosynthesis methyltransferase  28.1 9.5 126.8  2 11.6 
188 gi|855345336| aconitate hydratase  99.1 5.1 126.4  3 4.2 
189 gi|386871238| HAM1 protein  21.5 8.5 124.3  3 20.3 
190 gi|386871225| Outer membrane protein OmpH  18.5 9.0 122.6  3 28.9 
191 gi|386871909| Signal recognition particle protein  50.5 9.5 119.9  4 14.8 
192 gi|386871569| Hypothetical protein OOM_1143  24.8 5.1 119.8  3 20.5 
193 gi|386871016| Competence lipoprotein ComL  30.2 7.6 118.6  4 23.6 
194 gi|504527146| Membrane protein  55.7 5.4 118.6  3 11.9 
195 gi|386871961| Acid phosphatase  26.3 8.6 118.4  3 16.7 
196 gi|386871612| Hypothetical protein OOM_1191  20.6 8.6 117.3  3 18.7 
197 gi|386871734| HflK-HflC membrane protein complex, HflK  40.3 9.4 116.3  2 8.7 
198 gi|386872049| 2-alkenal reductase  49.4 8.8 115.3  3 7.4 
199 gi|752587895| 30S ribosomal protein S9  14.7 10.5 114.7  3 36.4 
200 gi|564748965| Hypothetical protein M973_08435  36.2 8.5 114.5  4 19.0 
201 gi|386870994| 50S ribosomal protein L13  16.0 9.9 112.4  3 22.5 
202 gi|386871084| Adenine phosphoribosyltransferase  19.1 5.9 111.5  3 23.4 
203 gi|639195041| 30S ribosomal protein S10  11.7 9.8 110.5  2 23.3 
204 gi|386871775| ATP-dependent protease peptidase subunit 19.8 5.6 110.0  2 19.7 
205 gi|386871712| Preprotein translocase family protein  12.8 9.6 107.3  2 22.0 
206 gi|386871004| Membrane fusion protein  38.4 9.3 107.3  2 9.8 
207 gi|386871727| DNA-binding protein HU-beta  9.4 9.8 107.2  2 17.8 
208 gi|386870776| 50S ribosomal protein L16  15.7 11.5 107.1  2 16.8 
209 gi|386870925| Superoxide dismutase (Cu-Zn) precursor  20.2 5.2 106.8  3 38.4 
210 gi|386870591| Hypothetical protein OOM_0024  15.2 7.8 102.2  2 24.4 
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211 gi|386871516| Phosphoglucomutase  59.4 5.3 102.0  3 10.1 
212 gi|386870765| 30S ribosomal protein S12  13.7 12.2 101.2  3 18.5 
213 gi|386872008| 50S ribosomal protein L20  13.3 11.0 100.2  3 8.5 
208 gi|386870776| 50S ribosomal protein L16  15.7 11.5 107.1  2 16.8 
214 gi|386871066| ATP synthase subunit gamma  10.1 4.9 99.5  3 10.9 
215 gi|386871976| Arabinose-5-phosphate isomerase  34.4 5.8 98.3  2 3.8 
216 gi|386871463| Glutaredoxin like protein  9.7 8.9 97.8  2 31.3 
217 gi|386871114| Type IV pili, pilus assembly protein  48.6 4.6 97.8  2 8.3 
218 gi|386872007| 50S ribosomal protein L35  7.3 11.8 96.4  3 46.2 
219 gi|386870656| Recombinase A  38.6 5.6 96.0  3 12.7 
220 gi|564749085| Peptide chain release factor 3  59.3 5.7 95.0  2 6.5 
221 gi|386871466| Chorismate mutase type II  10.6 7.1 94.2  3 48.9 
222 gi|564748402| 50S ribosomal protein L21  11.7 10.0 94.0  2 26.9 
223 gi|386871713| Preprotein translocase subunit SecD  69.8 8.7 93.9  2 5.7 
224 gi|386870870| CDP-alcohol phosphatidyltransferase  30.2 7.6 93.7  2 3.7 
225 gi|386871051| NADH dehydrogenase (quinone)  57.8 8.4 93.6  3 4.3 
226 gi|386870933| Phosphoribosylaminoimidazole synthetase  37.9 5.0 90.5  3 15.3 
227 gi|386871726| Endopeptidase La 86.1 8.8 89.0  3 4.4 
228 gi|386871258| GDP-D-mannose dehydratase  41.7 6.1 85.7  2 10.6 
229 gi|386871928| Rare lipoprotein B family protein  20.3 9.6 85.2  2 16.4 
230 gi|386870969| Glucokinase  37.8 6.0 80.6  2 9.7 
231 gi|386870782| 30S ribosomal protein S9 14.7 10.4 80.4  2 30.7 
232 gi|386871763| Ribose-phosphate diphosphokinase  35.0 5.8 73.3  2 8.1 
233 gi|752588102| Beta-ketoacyl-[acyl-carrier-protein] synthase II  44.0 5.9 72.8  2 7.4 
234 gi|386870604| Membrane protein  18.5 9 71.7  2 24.1 
235 gi|386871142| 50S ribosomal protein L19  13.3 10.7 68.2  2 30.4 
236 gi|386870855| Septum formation inhibitor  24.7 6.3 65.3  2 18.0 
237 gi|386870819| Hypothetical protein OOM_0271  17.1 8.9 65.3  2 8.1 
238 gi|198417057| DnaA, partial  49.0 7.7 62.5  2 5.5 
239 gi|386871047| NADH dehydrogenase subunit I  18.8 6.8 60.4  2 16.0 




Table S2. Proteins identified in the immunoreactive band (17-28 kDa) of the OMPs of the Fno UK isolate 
No. Accession Protein name MW [kDa] pI Scores Peptides SC [%] 
1 gi|300193842| IglC  22.1 5.3 2388.4  14 84.2 
2 gi|504527828| IglA  20.4 8.6 754.5  12 74.2 
3 gi|504527329| OmpA family peptidoglycan-associated lipoprotein  23.4 4.8 753.9  9 64.9 
4 gi|504527815| beta-ketoacyl-ACP reductase  26.3 9.6 601.2  10 55.9 
5 gi|504527529| succinate dehydrogenase iron-sulfur subunit  26.5 8.8 540.4  11 54.9 
6 gi|504527238| 50S ribosomal protein L5  20.0 9.7 526.4 11 61.5 
7 gi|504527915| AhpC/TSA family peroxiredoxin  21.8 5.0 510.0  9 59.8 
8 gi|504528404| enoyl-ACP reductase  27.7 5.5 449  11 55.4 
9 gi|386871251| Hypothetical protein OOM-0776 22.5 9.8 388.6  9 41.3 
10 gi|504527834| hypothetical protein  24.3 5.6 376.8  5 33.5 
11 gi|504527577| 50S ribosomal protein L1  24.5 9.5 374.1  9 39.4 
12 gi|504527226| 50S ribosomal protein L3 22.1 9.5 359.4  6 40.5 
13 gi|504527216| 30S ribosomal protein S2  26.5 8.8 333.7  5 21.3 
14 gi|855345305| Transcription termination/antitermination protein nusG  20.0 6.8 333.1 7 41.2 
15 gi|855345177| Hypothetical protein  27.9 9.4 330.4  6 27.2 
16 gi|504527578| 50S ribosomal protein L10  18.7 9.1 274.5  8 45.3 
17 gi|504527053| Chorismiteate mutase 20.3 9.2 267.1  5 40.6 
18 gi|504527683| DNA-binding response regulator  25.5 6.2 261.9  5 32.9 
19 gi|504527248| 30S ribosomal protein S4  23.2 10.4 245.0 4 24.8 
20 gi|504527363| LemA-like protein  21.9 6.0 235.4  6 37.2 
21 gi|504527082| hypothetical protein OOM_0066 25.3 5.6 226.3  6 31.2 
22 gi|504527492| NADH-quinone oxidoreductase subunit C 25.3 6.5 226.1  5 34.9 
23 gi|504527227| 50S ribosomal protein L4  22.5 10.0 225.7  5 31.9 
24 gi|504527224| 30S ribosomal protein S7  17.8 10.1 220.9  4 31.8 
25 gi|504528150| hypothetical protein  18.6 9.4 218.9  5 40.7 
26 gi|504527806| hypothetical protein OOM_0903  27.7 8.4 212.1  5 22.7 
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27 gi|504527242| 30S ribosomal protein S5  17.5 10.0 208.6  4 24.1 
28 gi|504528221| Acyl dehydratase  19.7 6.6 197.2  5 35.1 
29 gi|504527240| 50S ribosomal protein L6  19.2 9.7 197.0  4 51.1 
30 gi|504527599| hypothetical protein OOM_0658   23.7 6.1 193.9  4 22.2 
31 gi|504528036| Glutamine amidotransferase subunit PdxT  20.0 5.3 179.6  3 26.8 
32 gi|386871600| protein-L-isoaspartate O-methyltransferase  23.6 5.6 179.2  3 23.3 
33 gi|504527852| Polyamine transporter, ABC transporter ATP-binding  27.1 8.5 175.7  4 28.4 
34 gi|504527232| 30S ribosomal protein S3  24.5 10.0 174.4  3 14.9 
35 gi|504527673| Hypothetical protein OOM_0748 22.3 6.7 150.4  3 23.2 
36 gi|504528505| shikimate kinase I  19.7 5.4 145.7  3 18.8 
37 gi|504527846| CBC domain pair protein  22.9 6.8 138.7  3 28.0 
38 gi|386872052| hypothetical protein OOM_1699 27.1 8.4 129.5 5 22.1 
39 gi|386870968| Ubiquinone/menaquinone biosynthesis methyltransferase  28.1 9.5 126.8  2 11.6 
40 gi|504527146| hypothetical protein 21.1 8.9 118.6  2 12.4 
41 gi|504528393| acid phosphatase  26.3 8.6 118.4  3 16.7 
42 gi|504528047| hypothetical protein  20.6 8.6 117.3  3 18.7 
43 gi|504527668| membrane protein  18.5 9.0 71.7  2 20.5 




Table S3. Bioinformatics analyses of the protein identified in the OMPs of the Fno UK isolate 
No. Protein  PSORTba COGsb  LipoPc SignalPd 
1 PdpD  Outer membrane S N N 
2 Chaperone ClpB  Cytoplasmic O N N 
3 PdpD  Outer membrane S N N 
4 IglC *  Unknown S N N 
5 Chaperonin GroEL  Cytoplasmic O N N 
6 Ribosomal L29e protein family  Outer membrane S N N 
7 OmpA family peptidoglycan-associated lipoprotein *  Outer membrane M Y Y (SpII) 
8 Bifunctional proline dehydrogenase  Cytoplasmic C N N 
9 IglB  Cytoplasmic S N N 
10 30S ribosomal protein S1  Cytoplasmic J N N 
11 Cell division protein FtsZ  Cytoplasmic D N N 
12 Outer membrane associated protein  Outer membrane M Y Y (SpI) 
13 PdpA  Unknown/multiple localization S N N 
14 OmpA family protein  Outer membrane M Y Y (SpII) 
15 PdpB  Outer membrane M N N 
16 Ribonuclease E  Cytoplasmic E N N 
17 IglA * Cytoplasmic S N N 
18 Alpha-ketoglutarate decarboxylase  Cytoplasmic G N N 
19 Heat shock protein 90  Cytoplasmic O N N 
20 2-oxoglutarate dehydrogenase complex, E2 component  Cytoplasmic C N N 
21 Succinate dehydrogenase  Cytoplasmic membrane C N N 
22 NADH dehydrogenase subunit G  Cytoplasmic  C N N 
23 Hypothetical protein M973_05085  Unknown Q N N 
24 Putative cyanophycin synthetase  Cytoplasmic M N N 
25 4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase  Cytoplasmic I N N 
26 Enolase  Cytoplasmic G N N 
27 Pyruvate dehydrogenase subunit E1  Cytoplasmic C N N 
28 Peroxidase/catalase  Unknown/multiple localization P Y Y (SpI) 
29 Elongation factor G  Cytoplasmic J N N 
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30 Translation initiation factor IF-2 Cytoplasmic J N N 
31 Serine-type D-Ala-D-Ala carboxypeptidase  Unknown/multiple localization M Y Y (SpI) 
32 Glutamate dehydrogenase  Unknown/multiple localization E N N 
33 LemA-like protein * Cytoplasmic S N N 
34 Elongation factor  Cytoplasmic J N N 
35 Carbamoyl phosphate synthase large subunit  Unknown/multiple localization F N N 
36 Non-ribosomal peptide synthetase  Cytoplasmic I N N 
37 ATP synthase subunit beta  Cytoplasmic/ multiple localization C N N 
38 DnaK, molecular chaperone  Cytoplasmic O N N 
39 tRNA adenyle transferase  Cytoplasmic I N N 
40 Murein transglycosylase  Periplasmic M Y Y (SpI) 
41 Universal stress protein  Cytoplasmic T N N 
42 DTDP-4-dehydrorhamNse 3,5-epimerase  Unknown I N N 
43 Transcription elongation factor NusA Cytoplasmic K N N 
44 Beta-ketoacyl-ACP reductase * Cytoplasmic I N N 
45 Uncharacterized protein OOM_1173  Cytoplasmic membrane S N N 
46 Pyruvate kinase  Cytoplasmic G N N 
47 DsbA_Com1_like, DsbA family, Com1-like subfamily  Unknown O Y Y (SpII) 
48 Peptidyl-prolyl cis-trans isomerase  Outer membrane O Y Y (SpII) 
49 
DNA-directed RNA polymerase, b’ta' subunit/160 kD 
subunit  
Cytoplasmic K N N 
50 Hypothetical protein M973_02230  Unknown S Y Y (SpI) 
51 30S ribosomal protein S8  Cytoplasmic J N N 
52 Succinate dehydrogenase iron-sulfur subunit *  Cytoplasmic Membrane C N N 
53 DNA-directed RNA polymerase subunit alpha  Cytoplasmic K N N 
54 Putative glucose-1-phosphate thymidyl transferase  Cytoplasmic I N N 
55 Sel1-like protein  Unknown S Y Y (SpI) 
56 50S ribosomal protein L5 * Cytoplasmic J N N 
57 Cytochrome-D ubiquinol oxidase subunit I  Cytoplasmic Membrane C N N 
58 Elongation factor Ts  Cytoplasmic J N N 
59 Acetyl-CoA carboxylase, biotin carboxylase subunit  Cytoplasmic I N N 
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60 Hypothetical protein OOM_0413 * Outer membrane S Y Y (SpII) 
61 Microtubule-severing ATPase  Cytoplasmic O N N 
62 AhpC/TSA family peroxiredoxin * Cytoplasmic O N N 
63 Enoyl-ACP reductase I * Cytoplasmic membrane I N N 
64 Putative lipoprotein  Unknown C Y Y (SpII) 
65 Succinyl-CoA synthetase subunit beta  Cytoplasmic C N N 
66 Hypothetical protein OOM_0430  Unknown/multiple localization S Y Y (SpI) 
67 Hypothetical protein OOM_0776 * Unknown/multiple localization S Y Y (SpI) 
68 Alanyl-tRNA synthetase  Cytoplasmic J N N 
69 Hypothetical protein * Cytoplasmic S N N 
70 Membrane protein of Unknown function *  Cytoplasmic membrane U Y Y (SpI) 
71 50S ribosomal protein L1 * Cytoplasmic J N N 
72 Phosphor-mannomutase  Cytoplasmic G N N 
73 Pyruvate phosphate dikinase  Cytoplasmic G N N 
74 Polynucleotide phosphorylase/polyadenylase  Cytoplasmic J N N 
75 Glycerol-3-phosphate dehydrogenase  Unknown/multiple localization C N N 
76 RNA polymerase sigma-70 factor  Cytoplasmic K N N 
77 50S ribosomal protein L3 * Cytoplasmic J N N 
78 Amino acid adenylation  Unknown/multiple localization Q N N 
79 50S ribosomal protein L10 * Cytoplasmic J N N 
80 Phosphoglyceromutase  Cytoplasmic G N N 
81 50S ribosomal protein L11  Cytoplasmic J N N 
82 Leucyl aminopeptidase  Cytoplasmic E N N 
83 SAM-dependent methyltransferase  Unknown Q N N 
84 HflC protein  Cytoplasmic O N N 
85 Riboflavin synthase  Cytoplasmic H N N 
86 Putative ABC transporter ATP-binding protein  Cytoplasmic S N N 
87 Hypothetical protein OOM_0085  Unknown/multiple localization S Y Y (SpII) 
88 Aspartyl-tRNA synthetase  Cytoplasmic J N N 
89 Septum formation inhibitor-activating ATPase  Cytoplasmic/multiple localization D N N 
90 Cell division protein FtsA  Cytoplasmic D N N 
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91 AMP-dependent synthetase/ligase  Cytoplasmic Q N N 
92 30S ribosomal protein S2 * Cytoplasmic J N N 
93 
Transcription termination/anti termination factor 
NusG * 
Cytoplasmic K N N 
94 Gamma-glutamyl transferase Periplasmic E Y Y (SpI) 
95 Glucose-6-phosphate isomerase  Cytoplasmic G N N 
96 Hypothetical protein_1530 * Outer membrane S Y Y (SpI) 
97 Phosphoglycerate kinase  Cytoplasmic G N N 
98 Putative cystathionine beta-synthase  Cytoplasmic E N N 
99 Hypothetical protein OOM_1308 * Unknown S Y Y (SpI) 
100 DNA-directed RNA polymerase subunit beta  Cytoplasmic K N  
101 Pyrrolo-quinoline quinone repeat protein  Unknown/multiple localization M Y Y (SpII) 
102 50S ribosomal protein L9  Cytoplasmic J N N 
103 Hypothetical protein OOM_0272  Cytoplasmic O N N 
104 Transaldolase B  Cytoplasmic G N N 
105 ABC transporter substrate-binding protein  Unknown P Y Y (SpI) 
106 Oligopeptidase A  Cytoplasmic E N N 
107 VacJ like lipoprotein  Outer membrane M Y Y (SpII) 
108 Alpha/beta fold family hydrolase  Cytoplasmic C N N 
109 Prolyl-tRNA synthetase  Cytoplasmic J N N 
110 NADH dehydrogenase subunit D  Cytoplasmic/multiple localization C N N 
111 Succinyl-CoA synthetase, alpha subunit  Cytoplasmic C N N 
112 Chorismate mutase*  Unknown/multiple localization E Y Y (SpI) 
113 30S ribosomal protein S4 * Cytoplasmic J N N 
114 DNA-binding response regulator * Cytoplasmic T N N 
115 DNA-directed RNA polymerase subunit beta Cytoplasmic K N N 
116 Ribose-5-phosphate isomerase A  Cytoplasmic G N N 
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117 Chorismate binding family protein  Cytoplasmic J N N 
118 DEAD-box subfamily ATP-dependent helicase  Cytoplasmic L N N 
119 Dihydrolipoamide acetyltransferase  Cytoplasmic C N N 
120 Hypothetical protein OOM_0066  Cytoplasmic P N N 
121 50S ribosomal protein L4 * Cytoplasmic J Y Y (SpI) 
122 GTP binding translational elongation factor Tu  Cytoplasmic membrane J N N 
123 Pyrimidine reductase/pyrimidine deaminase  Cytoplasmic H N N 
124 Malate dehydrogenase  Cytoplasmic C N N 
125 Hypothetical protein * Cytoplasmic S N N 
126 Adenyl succinate lyase  Cytoplasmic F N N 
127 Lipoprotein  Unknown S Y Y (SpII) 
128 ATP synthase subunit alpha Cytoplasmic C N N 
129 Malate dehydrogenase  Cytoplasmic C N N 
130 GMP synthase  Cytoplasmic E N N 
131 GTP-binding protein LepA  Cytoplasmic membrane M N N 
132 NADH-quinone oxidoreductase subunit C * Cytoplasmic/multiple localization C N N 
133 Organic solvent tolerance protein, OstA  Outer membrane M Y Y (SpI) 
128 ATP synthase subunit alpha Cytoplasmic C N N 
129 Malate dehydrogenase  Cytoplasmic C N N 
130 GMP synthase  Cytoplasmic E N N 
131 GTP-binding protein LepA  Cytoplasmic membrane M N N 
132 NADH-quinone oxidoreductase subunit C * Cytoplasmic/multiple localization C N N 
133 Organic solvent tolerance protein, OstA  Outer membrane M Y Y (SpI) 
134 30S ribosomal protein S7 * Cytoplasmic J N N 
135 ATP synthase subunit B  Cytoplasmic membrane C N N 
136 Hypothetical protein OOM_0903 * Unknown S N N 
137 ATP binding protein Cytoplasmic S N N 
138 30S ribosomal protein S5 * Cytoplasmic J N N 
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139 Trigger factor  Cytoplasmic O N N 
140 30S ribosomal protein S11  Cytoplasmic J N N 
141 
UDP-N-acetylglucosamine pyrophosphorylase  
/glucosamine-1-phosphate  
Cytoplasmic M N N 
142 ATP synthase subunit delta  Cytoplasmic  C N N 
143 Acyl dehydratase * Unknown I N N 
144 50S ribosomal protein L6 * Cytoplasmic J Y Y (SpI) 
145 Phenylalanyl-tRNA synthetase subunit beta Cytoplasmic J N N 
146 Hypothetical protein OOM_0658 * Extracellular S N N 
147 Glycerophosphoryl diester phosphodiesterase Periplasmic C Y Y (SpI) 
148 50S ribosomal protein L15  Cytoplasmic J N N 
149 Hypothetical protein OOM_0882  Unknown S N N 
150 Succinate dehydrogenase  Cytoplasmic membrane C N N 
151 Phospho-2-dehydro-3-deoxyheptonate aldolase  Cytoplasmic E N N 
152 Fructose 1,6-bisphosphatase II  Cytoplasmic G N N 
153 Glutamine amidotransferase subunit PdxT * Unknown E N N 
154 Protein-L-isoaspartate O-methyltransferase * Cytoplasmic O N N 
155 ABC transporter, ATP-binding protein * Cytoplasmic/multiple localization S N N 
156 ATP-dependent protease ATP-binding subunit ClpX  Cytoplasmic O N N 
157 30S ribosomal protein S3 * Cytoplasmic O N N 
158 Fumarate hydratase, class I  Cytoplasmic C N N 
159 M24 family peptidase  Cytoplasmic E N N 
160 UTP-glucose-1-phosphate uridylyltransferase  Cytoplasmic M N N 
161 
Pyruvate dehydrogenase complex, E3 component, 
dihydrolipoamide  
Cytoplasmic C N N 
162 Membrane protein of Unknown function * Cytoplasmic membrane S N N 
163 50S ribosomal protein L2  Cytoplasmic J N N 
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164 Preprotein translocase subunit SecA  Cytoplasmic/multiple localization U N N 
165 D-lactate dehydrogenase (cytochrome)  Cytoplasmic C N N 
166 Glutamate-1-semialdehyde-2,1-amiNmutase  Cytoplasmic H N N 
167 D-lactate dehydrogenase (cytochrome)  Cytoplasmic C N N 
168 Hypothetical protein OOM_0777  Cytoplasmic M N N 
169 Rhodanese-related sulfur transferase  Unknown P N N 
170 Heat shock protein DnaJ  Cytoplasmic O N N 
171 Hypothetical protein OOM_0748  Unknown S N N 
172 Hypothetical protein OOM_0151  Cytoplasmic membrane L N N 
173 50S ribosomal protein L23 Cytoplasmic J N N 
174 Shikimate kinase I * Cytoplasmic E N N 
175 D-3-phosphoglycerate dehydrogenase  Cytoplasmic E N N 
176 Phosphoenolpyruvate carboxykinase  Cytoplasmic  C N N 
177 
Bifunctional gluaredoxin/ribonucleoside-diphosphate 
reductase subunit  
Cytoplasmic F N N 
178 Glucosamine--fructose-6-phosphate aminotransferase  Cytoplasmic M N N 
179 Hypothetical protein OOM_0424 * Unknown S Y Y (SpII) 
180 CBS domain pair protein * Cytoplasmic S N N 
181 Lipoprotein  Unknown S Y Y (SpII) 
182 ABC transporter, ATP-binding protein Cytoplasmic membrane E N N 
183 S49 family peptidase Cytoplasmic membrane O N N 
184 hypothetical protein OOM_1699 * Cytoplasmic S N N 
185 50S ribosomal protein L14  Cytoplasmic J N N 




Cytoplasmic H N N 
188 Aconitate hydratase  Cytoplasmic  C N N 
189 HAM1 protein  Cytoplasmic F N N 
190 Outer membrane protein OmpH  Periplasmic M Y Y (SpI) 
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191 Signal recognition particle protein  Cytoplasmic membrane U N N 
192 Hypothetical protein OOM_1143 * Unknown S N N 
193 Competence lipoprotein ComL  Outer membrane M N N 
194 Membrane protein  Outer membrane M N N 
195 Acid phosphatase * Periplasmic I Y Y (SpI) 
196 Hypothetical protein  Unknown S Y Y (SpI) 
197 HflK-HflC membrane protein complex, HflK  Cytoplasmic O N N 
198 2-alkenal reductase  Cytoplasmic membrane G N N 
199 30S ribosomal protein S9  Cytoplasmic J N N 
200 Hypothetical protein M973_08435  Unknown S Y Y (SpI) 
201 50S ribosomal protein L13  Cytoplasmic J N N  
202 Adenine phosphoribosyltransferase  Cytoplasmic F N N 
203 30S ribosomal protein S10  Cytoplasmic J N N 
204 ATP-dependent protease peptidase subunit Cytoplasmic O N N 
205 Preprotein translocase family protein  Cytoplasmic membrane U Y Y (SpI) 
206 Membrane fusion protein  Unknown/multiple localization V N N 
207 DNA-binding protein HU-beta  Cytoplasmic L N N 
208 50S ribosomal protein L16  Cytoplasmic J N N 
209 Superoxide dismutase (Cu-Zn) precursor  Periplasmic P Y Y (SpII) 
210 Hypothetical protein OOM_0024  Unknown S Y Y (SpII) 
211 Phosphoglucomutase  Unknown G N N 
212 30S ribosomal protein S12  Cytoplasmic J N N 
213 50S ribosomal protein L20  Cytoplasmic J N N 
214 ATP synthase subunit gamma  Cytoplasmic membrane C N N 
215 ArabiNse-5-phosphate isomerase  Cytoplasmic M N N 
216 Glutaredoxin like protein  Unknown O N N 
217 Type IV pili, pilus assembly protein  Unknown S Y Y (SpI) 
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218 50S ribosomal protein L35  Cytoplasmic J N N 
219 Recombinase A  Cytoplasmic L N N 
220 Peptide chain release factor 3  Cytoplasmic J N N 
221 Chorismate mutase type II  Unknown S N N 
222 50S ribosomal protein L21  Cytoplasmic J N N 
223 Preprotein translocase subunit SecD  Cytoplasmic membrane U N N 
224 CDP-alcohol phosphatidyltransferase  Cytoplasmic membrane I N N 
225 NADH dehydrogenase (quinone)  Cytoplasmic membrane C N N 
226 PhosphoribosylamiNimidazole synthetase  Cytoplasmic F N N 
227 Endopeptidase La Cytoplasmic O N N 
228 GDP-D-mannose dehydratase  Cytoplasmic I N N 
229 Rare lipoprotein B family protein  Unknown M Y Y (SpII) 
230 Glucokinase  Cytoplasmic G N N 
231 30S ribosomal protein S9 * Cytoplasmic J N N 
232 Ribose-phosphate diphosphokinase  Cytoplasmic F N N 
233 Beta-ketoacyl-[acyl-carrier-protein] synthase II  Cytoplasmic I N N 
234 Membrane protein * Extracellular U N N 
235 50S ribosomal protein L19 * Cytoplasmic J N N 
236 septum formation inhibitor protein * Cytoplasmic D N N 
237 Hypothetical protein OOM_0271  Unknown S Y Y (SpII) 
238 DnaA, partial  Cytoplasmic L N N 
239 NADH dehydrogenase subunit I  Cytoplasmic/multiple localization C N N 
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